{"title":"Medicines and Sprays for Colds and Stuffed Noses","description":"\u003cp\u003eEverything for stuffy noses and colds: decongestant sprays, physiological and hypertonic solutions for nasal washing, sachets to dissolve for cold symptoms, balsamic ointments to inhale and nasal plasters. For adults, children and babies. Fast shipping in 24\/48 hours.\u003c\/p\u003e","products":[{"product_id":"propoli-spray-forte-tintura-madre-propoli-30ml-dr-tili","title":"Propolis Spray Strong propolis mother tincture 30ml Dr.Tili","description":"\u003cp data-mce-fragment=\"1\"\u003e\u003cimg height=\"125\" width=\"125\" alt=\"Supplement made in Italy\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" style=\"float: none;\" data-mce-style=\"float: none;\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" alt=\"gluten-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" alt=\"lactose-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" alt=\"vegan supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e  \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003ePropolis spray Forte is a highly titrated phytotherapeutic extract obtained from \u003cstrong\u003efresh mother tincture of propolis\u003c\/strong\u003e with the addition of \u003cstrong\u003eeucalyptus essential oil\u003c\/strong\u003e which enhances its activity. Useful in case of \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003eseasonal flu and inflammation of the oral cavity\u003c\/strong\u003e. The particular formulation of Propoli Spray Forte guarantees the stability of the active ingredient over time. His \u003cstrong\u003eparticular density\u003c\/strong\u003e \u003cstrong\u003eimproves adhesion\u003c\/strong\u003e of the substance \u003cstrong\u003eto the mucous membranes\u003c\/strong\u003e for a prolonged action. Propolis strong spray contains alcohol and eucalyptus essential oil, which make it \u003cstrong\u003ealso useful in case of canker sores, gingivitis and abscesses\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003epropolis\u003c\/strong\u003e it is a natural substance produced by bees to insulate hive cells. It thus limits the entry of air, water, bacteria, viruses and pathogens. It appears as a gummy, sticky and water-insoluble resin. It can be made up of over 200 different compounds including resins, wax, essential oils, pollen, flavonoids, organic compounds, mineral salts, vitamins and other elements. Its composition depends on the type of vegetation from which the bees obtain the starting material to synthesize it.\u003c\/p\u003e\n\u003cp\u003eProperties are attributed to propolis \u003cstrong\u003enatural antiviral and antibacterial\u003c\/strong\u003e, anti-inflammatory and immunostimulant. These are due in particular to the presence of \u003cstrong\u003eflavonoids\u003c\/strong\u003e (Galangina and Pinocembrina). Propolis is traditionally \u003cstrong\u003econsidered a natural antibiotic\u003c\/strong\u003e. It can inhibit the ability of bacteria to reproduce and naturally disinfect the mucous membranes and oral cavity. It is useful in case of burning throat and inflammation of the upper respiratory tract such as pharyngitis, laryngitis. Propolis is also a natural antiviral useful against \u003cstrong\u003eviruses that cause the common flu\u003c\/strong\u003e seasonal.\u003cbr\u003eIndicated in case of: sore throat, flu, cold, canker sores, abscesses, gingivitis, pharyngitis, laryngitis, burning throat.\u003c\/p\u003e\n\u003cp\u003eThe\u003cstrong\u003eeucalyptus essential oil\u003c\/strong\u003e extracted from eucalyptus leaves it is rich in \u003cstrong\u003eeucalyptol\u003c\/strong\u003e, to which strong natural germicidal properties are attributed. Eucalyptol helps in case of pain and inflammation of the mucous membranes of the oral cavity with its \u003cstrong\u003ebalsamic power,\u003c\/strong\u003e also due to \u003cstrong\u003ecanker sores and abscesses\u003c\/strong\u003e. Thanks to its balsamic and antiseptic properties, eucalyptus essential oil is an excellent ally for dealing with sore throats. In fact, when the first symptoms of pharyngitis or laryngitis appear, eucalyptus takes advantage of its \u003cstrong\u003edecongestant and emollient power\u003c\/strong\u003e to counteract infection by viruses or bacteria.\u003cbr\u003eIndicated in case of: fever, flu, aphthous stomatitis, bronchitis, sinusitis\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Propoli Spray Forte propolis mother tincture 30ml Dr.Tili? What is it for?\u003c\/h3\u003e\u003cp\u003eHighly titrated phytotherapeutic extract from the propolis mother tincture with eucalyptus essential oil, useful in case of sore throat, colds, seasonal flu and inflammation of the oral cavity, including canker sores and gingivitis.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Propolis Spray Forte propolis mother tincture 30ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003eWaterfall. Glycerol. Propolis hydroalcoholic extract (45% vol. alc.). Sweetener: fructose. Flavoring: eucalyptus essential oil, mint essential oil\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Propoli Spray Forte propolis mother tincture 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e2 sprays of Propolis Spray Forte propolis mother tincture 3 times a day. Any sediments are considered normal. Shake well before use.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Propoli Spray Forte propolis mother tincture 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eDo not exceed the indicated intake quantities. Supplements are not intended as substitutes for a varied, balanced diet and a healthy lifestyle. The product is contraindicated in subjects predisposed to allergies, in particular to pollen and bee products, and in atopic or asthmatic subjects. Do not use during pregnancy. Keep out of reach of children under 3 years.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Propoli Spray Forte propolis mother tincture 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e30ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207819669619,"sku":"975044241","price":11.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/tilab-srl-propoli-spray-forte-tintura-madre-propoli-30ml-dr-tili-farmacia-dottor-tili-1213792869.jpg?v=1767123851"},{"product_id":"propoli-spray-hd-fragola-30ml-dr-tili","title":"Propolis Spray HD Strawberry 30ml Dr.Tili","description":"\u003cp data-mce-fragment=\"1\"\u003e\u003cimg height=\"125\" width=\"125\" alt=\"Supplement made in Italy\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" style=\"float: none;\" data-mce-style=\"float: none;\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" alt=\"gluten-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" alt=\"lactose-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" alt=\"vegan supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e  \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003ePropoli Spray HD Strawberry is a supplement based on highly titrated phytotherapeutic extract of propolis. Useful in case of \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003eseasonal flu symptoms\u003c\/strong\u003e e \u003cstrong\u003einflammation of the oral cavity\u003c\/strong\u003e. The particular formulation of Propolis Spray guarantees the stability of the active ingredient over time. His \u003cstrong\u003eparticular density\u003c\/strong\u003e improves the\u003cstrong\u003eadhesion of the substance to the mucous membranes\u003c\/strong\u003e for a prolonged action. Its excellent \u003cstrong\u003estrawberry flavour\u003c\/strong\u003e and the \u003cstrong\u003ealcohol-free formulation\u003c\/strong\u003e they make it \u003cstrong\u003esuitable for children\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003epropolis\u003c\/strong\u003e it is a natural substance produced by bees to insulate hive cells. It thus limits the entry of air, water, bacteria, viruses and pathogens. It appears as a gummy, sticky and water-insoluble resin. It can be made up of over 200 different compounds including \u003cstrong\u003eresins, wax, essential oils, pollen, flavonoids, organic compounds, mineral salts, vitamins\u003c\/strong\u003e and other elements. Its composition depends on the type of vegetation from which the bees obtain the starting material to synthesize it.\u003c\/p\u003e\n\u003cp\u003eProperties are attributed to propolis \u003cstrong\u003enatural antiviral and antibacterial\u003c\/strong\u003e, anti-inflammatory and immunostimulant, due in particular to the presence of \u003cstrong\u003eflavonoids\u003c\/strong\u003e (Galangina and Pinocembrina). Propolis is traditionally considered a \u003cstrong\u003enatural antibiotic\u003c\/strong\u003e which can inhibit the ability of bacteria to reproduce e \u003cstrong\u003enaturally disinfect the mucous membranes and oral cavity\u003c\/strong\u003e. It proves useful in case of \u003cstrong\u003eburning in the throat\u003c\/strong\u003e and inflammation of the upper respiratory tract such as pharyngitis, laryngitis. Propolis is also a \u003cstrong\u003enatural antiviral\u003c\/strong\u003e useful against viruses that cause the common seasonal flu.\u003cbr\u003eIndicated in case of: sore throat, flu, cold, pharyngitis, laryngitis, burning throat.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Propolis Spray HD Strawberry 30ml Dr.Tili? What is it for?\u003c\/h3\u003e\u003cp\u003eSupplement based on propolis extract, useful in case of sore throat, colds and seasonal flu disorders, with soothing action on the mucous membranes of the oral cavity; strawberry flavor and alcohol-free formulation, also suitable for children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Propolis Spray HD Strawberry 30ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003ePurified water. Poloxamer. Propolis d.e. 4:1. Preservative: potassium sorbate. Sweetener: sucralose, glycerinised ammonium, natural strawberry flavor (1.1%).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMEDIA ANALYSIS\u003c\/h2\u003e\n\u003ch3\u003eWhat does Dr.Tili Propolis Spray HD Strawberry 30ml contain?\u003c\/h3\u003e\u003cp\u003ePropolis d.e.: 100 mg.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Propolis Spray HD Strawberry 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e2 sprays of Propolis Spray HD Strawberry 3 times a day. any sediments are considered normal, shake well before use\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Propolis Spray HD Strawberry 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eDo not exceed the indicated intake quantities. Supplements are not intended as substitutes for a varied, balanced diet and a healthy lifestyle. The product is contraindicated in subjects predisposed to allergies, in particular to pollen and bee products, and in atopic or asthmatic subjects. Do not use during pregnancy. Keep out of reach of children under 3 years.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Propolis Spray HD Strawberry 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e30ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207819702387,"sku":"975044239","price":11.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/tilab-srl-propoli-spray-hd-fragola-30ml-dr-tili-farmacia-dottor-tili-1213792876.jpg?v=1767123910"},{"product_id":"propoli-spray-hd-limone-30ml-dr-tili","title":"Propolis Spray HD Lemon 30ml Dr.Tili","description":"\u003cp data-mce-fragment=\"1\"\u003e\u003cimg height=\"125\" width=\"125\" alt=\"Supplement made in Italy\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" style=\"float: none;\" data-mce-style=\"float: none;\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" alt=\"gluten-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" alt=\"lactose-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" alt=\"vegan supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e  \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003ePropoli Spray HD Lemon is a supplement based on a titrated phytotherapeutic extract of propolis. Useful in case of \u003cstrong\u003esore throat, cold, seasonal flu symptoms and inflammation of the oral cavity\u003c\/strong\u003e. The particular formulation of Propolis Spray guarantees the stability of the active ingredient over time. His \u003cstrong\u003eparticular density\u003c\/strong\u003e improves the\u003cstrong\u003eadhesion of the substance to the mucous membranes\u003c\/strong\u003e for a prolonged action. Its excellent \u003cstrong\u003elemon flavour\u003c\/strong\u003e and the \u003cstrong\u003ealcohol-free formulation\u003c\/strong\u003e they make it \u003cstrong\u003esuitable for children\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003ePropolis is a natural substance produced by bees to insulate hive cells. It thus limits the entry of air, water, bacteria, viruses and pathogens. It appears as a gummy, sticky and water-insoluble resin. It can be made up of over 200 different compounds including \u003cstrong\u003eresins, wax, essential oils, pollen, flavonoids, organic compounds, mineral salts, vitamins\u003c\/strong\u003e and other elements. Its composition depends on the type of vegetation from which the bees obtain the starting material to synthesize it.\u003c\/p\u003e\n\u003cp\u003eProperties are attributed to propolis \u003cstrong\u003enatural antiviral and antibacterial\u003c\/strong\u003e, anti-inflammatory and immunostimulant, due in particular to the presence of \u003cstrong\u003eflavonoids\u003c\/strong\u003e (Galangina and Pinocembrina). Propolis is traditionally considered a \u003cstrong\u003enatural antibiotic\u003c\/strong\u003e which can inhibit the ability of bacteria to reproduce e \u003cstrong\u003enaturally disinfect the mucous membranes and oral cavity\u003c\/strong\u003e. It proves useful in case of \u003cstrong\u003eburning in the throat\u003c\/strong\u003e and inflammation of the upper respiratory tract such as pharyngitis, laryngitis. Propolis is also a \u003cstrong\u003enatural antiviral\u003c\/strong\u003e useful against viruses that cause the common seasonal flu.\u003cbr\u003eIndicated in case of: sore throat, flu, cold, pharyngitis, laryngitis, burning throat.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Propolis Spray HD Lemon 30ml Dr.Tili? What is it for?\u003c\/h3\u003e\u003cp\u003eSupplement based on propolis extract, useful in case of sore throat, colds and seasonal flu disorders, with soothing action on the mucous membranes of the oral cavity; lemon flavor and alcohol-free formulation, also suitable for children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Propolis Spray HD Lemon 30ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003ePurified water. Poloxamer. Propolis d.e. 4:1. Preservative: potassium sorbate. Sweetener: sucralose, glycerinized ammonium, lemon natural flavor (1.1%).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMEDIA ANALYSIS\u003c\/h2\u003e\n\u003ch3\u003eWhat does Dr.Tili Propolis Spray HD Lemon 30ml contain?\u003c\/h3\u003e\u003cp\u003ePropolis d.e.: 100 mg.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Propolis Spray HD Lemon 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e2 sprays of Propolis Spray HD Lemon 3 times a day, any sediments are considered normal, shake well before use\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Propolis Spray HD Lemon 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eDo not exceed the indicated intake quantities. Supplements are not intended as substitutes for a varied, balanced diet and a healthy lifestyle. The product is contraindicated in subjects predisposed to allergies, in particular to pollen and bee products, and in atopic or asthmatic subjects. Do not use during pregnancy. Keep out of reach of children under 3 years.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Propolis Spray HD Lemon 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e30ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207819767923,"sku":"975044177","price":11.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/tilab-srl-propoli-spray-hd-limone-30ml-dr-tili-farmacia-dottor-tili-1213792863.jpg?v=1767124007"},{"product_id":"propoli-gocce-essenziali-dr-tili","title":"Propolis Essential Drops 50ml Dr.Tili","description":"\u003cp\u003e\u003cimg style=\"float: none;\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" alt=\"Supplement made in Italy\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" data-mce-style=\"float: none;\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"gluten-free supplement\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" data-mce-fragment=\"1\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"lactose-free supplement\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" data-mce-fragment=\"1\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"vegan supplement\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" data-mce-fragment=\"1\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\"\u003e\u003cspan\u003e  \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003ePropoli Gocce Essenziale is a supplement in drops based on phytotherapeutic propolis extract. Useful in case of seasonal ailments such as \u003cstrong\u003esore throat, cold and inflammation of the oral cavity\u003c\/strong\u003e. The high-titration phytotherapeutic extract of Propolis Essential Drops is rigorously stored in cobalt blue glass bottles. This preserves its quality and avoids degradation due to exposure to light. Its sweet flavor makes it pleasant and suitable for children too.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003epropolis\u003c\/strong\u003e it is a natural substance \u003cstrong\u003eantiseptic produced by bees\u003c\/strong\u003e to isolate the hive cells. It thus limits the entry of air, water, bacteria, viruses and pathogens. It appears as a gummy, sticky and water-insoluble resin. It can be made up of over 200 different compounds including resins, wax, essential oils, pollen, flavonoids, organic compounds, mineral salts, vitamins and other elements. Its composition depends on the type of vegetation from which the bees obtain the starting material to process it and for this reason it varies in color and flavour. \u003c\/p\u003e\n\u003cp\u003eThey are attributed to propolis \u003cstrong\u003enatural antiviral, antibacterial, anti-inflammatory and immunostimulant properties, \u003c\/strong\u003eall due in particular to the presence of flavonoids (Galangina and Pinocembrina). Thanks to its composition, \u003cstrong\u003epropolis is considered a natural antibiotic\u003c\/strong\u003e. It can inhibit the ability of bacteria to reproduce and naturally disinfects the mucous membranes and oral cavity. It is very useful in case of burning throat and inflammation of the upper respiratory tract such as pharyngitis, laryngitis. It is also used in case of canker sores, abscesses and gingivitis.\u003c\/p\u003e\n\u003cp\u003ePropolis is also \u003cstrong\u003ea natural antiviral useful in case of influenza and para influenza viruses\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Propolis Essential Drops 50ml Dr.Tili? What is it for?\u003c\/h3\u003e\u003cp\u003eIndicated in case of: sore throat, flu, canker sores, gingivitis, colds, pharyngitis, laryngitis, burning throat.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Propolis Essential Drops 50ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003ePurified water. Propolis d.e. soluble hrd 4:1. Sweetener: sucralose. Preservative: potassium sorbate.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMEDIA ANALYSIS\u003c\/h2\u003e\n\u003ch3\u003eWhat does Propolis Essential Drops 50ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003ePropolis: 30 mg.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Propolis Essential Drops 50ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eTake 25 gtt of Propolis Essential Drops 3 times a day.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Propolis Essential Drops 50ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eDo not exceed the indicated intake quantities. However, the product should not be used in case of liver dysfunction or disease. Do not use during pregnancy, supplements should not be intended as substitutes for a varied, balanced diet and a healthy lifestyle. Keep out of reach of children under 3 years.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Propolis Essential Drops 50ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e50ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207820685427,"sku":"973603133","price":15.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/tilab-srl-propoli-gocce-essenziali-50ml-dr-tili-farmacia-dottor-tili-1213792812.jpg?v=1767124990"},{"product_id":"aspirina-dolore-infiammazione-20-compresse-500-mg","title":"Aspirin Pain Inflammation 20 Tablets 500mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of fever and\/or mild to moderate pain, such as headache, flu syndrome, toothache, muscle pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach tablet contains 500 mg of acetylsalicylic acid. Excipients with known effect: one coated tablet contains 3.12 mmol (or 71.7 mg) sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTablet core: Colloidal silicon dioxide, Sodium carbonate. Coating: Carnauba wax, Hypromellose, Zinc stearate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to acetylsalicylic acid or other salicylates, or to any of the excipients listed in section 6.1, • history of asthma or hypersensitivity reactions (e.g. urticaria, angioedema, severe rhinitis, shock) induced by the administration of salicylates or substances with a similar action, in particular non-steroidal anti-inflammatory drugs (NSAIDs), • active peptic ulcer, • diathesis hemorrhagic, • severe renal failure (GFR\u003ci\u003e\u0026lt; 30\u003c\/i\u003e \u003ci\u003eml\/min\/ 1.73 m²\u003c\/i\u003e), • severe hepatic failure, • severe uncontrolled heart failure, • concomitant administration of methotrexate in doses exceeding 15 mg per week, for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses (see section 4.5), • concomitant administration of oral anticoagulants for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses and in patients with history of gastroduodenal ulcers (see section 4.5), • from the beginning of the 6th month of pregnancy (beyond the twenty-fourth week of amenorrhea) (see section 4.6), • children and young people under 16 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Adults and children (from 16 years onwards): 1 to 2 tablets for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose should not exceed 6 tablets. Elderly (from 65 years): 1 tablet for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose should not exceed 4 tablets. Acetylsalicylic acid should not be taken for more than 3 days (in case of fever) or 3 - 4 days (in case of pain) unless otherwise indicated by the doctor. Pediatric population: Acetylsalicylic acid should not be used in children and adolescents under 16 years of age without a medical prescription. Acetylsalicylic acid should be used with caution in patients with abnormal liver or kidney function or circulatory problems. \u003cu\u003eMethod of administration\u003c\/u\u003e For oral use. The tablets should be taken with an adequate quantity of water. To open the strip, tear from the edge at any position.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C. Store in the original packaging to protect from light and humidity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of combination with other medicinal products, to avoid any risk of overdose, check that acetylsalicylic acid is absent from the composition of these other medicines. • Reye's syndrome, a very rare and potentially fatal disease, has been described in children with symptoms of viral infections (particularly chickenpox and flu episodes) with or without taking acetylsalicylic acid. Consequently, acetylsalicylic acid should be administered to children in these conditions only after medical advice and when other measures have proven ineffective. In case of persistent vomiting, changes in consciousness or abnormal behavior, treatment with acetylsalicylic acid should be discontinued. • In case of prolonged administration of high-dose analgesics, the headache attack should not be treated with higher doses. • Regular use of analgesics, particularly a combination of analgesics, may result in permanent kidney damage, with risk of renal failure. • The medicine must be used with particular caution in the following cases: patients with mild to moderate renal function impairment (\u003ci\u003eGFR ≥ 30 to \u003c 90 ml\/min\/ 1.73 m²\u003c\/i\u003e) or patients with impaired cardiovascular circulation (e.g. renal vascular disease, congestive heart failure, volume depletion, major surgery, sepsis or major bleeding events) as acetylsalicylic acid may further increase the risk of renal impairment and acute renal failure. • In some severe forms of G6PD deficiency, high doses of acetylsalicylic acid can cause hemolysis. In case of G6PD deficiency, acetylsalicylic acid should be administered under medical supervision. • Treatment monitoring should be intensified in the following cases: • in patients with a history of gastric or duodenal ulcer, gastrointestinal bleeding, or gastritis; • in patients with renal failure; • in patients with liver failure; • in patients with asthma: the occurrence of an asthma attack, in some patients, may be linked to an allergy to non-steroidal anti-inflammatory drugs or to acetylsalicylic acid; in this case, this medicinal product is contraindicated (see section 4.3); • in patients with metrorrhagia or menorrhagia (risk of an increase in the volume and duration of the cycle). • Gastrointestinal bleeding or ulcers\/perforations may occur at any time during treatment, without necessarily having any warning signs or history in the patient. The relative risk increases in elderly subjects, in subjects with low body weight, and in patients receiving anticoagulants or platelet aggregation inhibitors (see section 4.5). In case of gastrointestinal bleeding, treatment should be stopped immediately. • Given the inhibitory effect of acetylsalicylic acid on platelet aggregation, which occurs even at very low doses and persists for several days, the patient should be aware of the risk of bleeding in the event of surgical interventions, even minor ones (e.g. tooth extraction). • In analgesic or antipyretic doses, acetylsalicylic acid inhibits the excretion of uric acid; in the doses used in rheumatology (anti-inflammatory doses), acetylsalicylic acid has a uricosuric effect. • The use of this medicine is not recommended during breastfeeding (see section 4.6). The administration of acetylsalicylic acid is not recommended with: • Oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid (≥500 mg per administration and\/or \u003c 3 g per day) and in patients without a history of gastroduodenal ulcers (see section 4.5); • Other non-steroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid (≥ 1g per administration and\/or ≥ 3g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (≥500 mg per administration and\/or \u003c 3 g per day) (see section 4.5); • Low molecular weight heparins (and related molecules) and unfractionated heparins with therapeutic doses or in elderly patients (\u003e65 years) regardless of the heparin dose, and for anti-inflammatory doses of acetylsalicylic acid (≥ 1g per administration and\/or ≥ 3g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (≥500 mg per administration and\/or \u003c 3 g per day) (see section 4.5); • Clopidogrel (beyond the approved indications for this combination in patients with acute coronary disease) (see section 4.5); • Ticlopidine (see section 4.5); • Uricosurics (see section 4.5); • Glucocorticoids (except hydrocortisone replacement therapy) for anti-inflammatory doses of acetylsalicylic acid (≥ 1g per administration and\/or ≥ 3g per day) (see section 4.5); • Pemetrexed in patients with mildly to moderately reduced renal function (creatinine clearance between 45 ml\/min and 80 ml\/min) (see section 4.5); • Anagrelide: increased risk of bleeding and decreased antithrombotic effect (see paragraph 4.5). \u003cb\u003eImportant information about some excipients\u003c\/b\u003e This medicinal product contains 71.7 mg sodium per dose equivalent to 3.6% of the WHO recommended maximum daily intake of 2 g sodium for an adult.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the following text, the following definitions apply: - anti-inflammatory doses of acetylsalicylic acid are defined as “≥ 1g per administration and\/or ≥ 3g per day”; - Analgesic or antipyretic doses of acetylsalicylic acid are defined as “≥500 mg per administration and\/or \u003c3 g per day”. Various substances give rise to interactions, due to their platelet aggregation inhibitor properties: abciximab, acetylsalicylic acid, cilostazol, clopidogrel, epoprostenol, eptifibatide, iloprost, iloprost trometamol, prasugrel, ticlopidine, Tirofiban, ticagrelor. The risk of bleeding increases with the use of multiple platelet aggregation inhibitors as well as with their use in combination with heparin or related molecules, oral anticoagulants or other thrombolytics, and must be evaluated through constant clinical monitoring. Contraindicated combinations (see section 4.3): • Methotrexate in doses higher than 15 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased toxicity of methotrexate, in particular haematological toxicity (due to reduced renal elimination of methotrexate caused by acetylsalicylic acid). • Oral anticoagulants with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid and in patients with a history of gastroduodenal ulcers: increased risk of hemorrhage. Combinations not recommended: • Oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid and in patients without a history of gastroduodenal ulcers: increased risk of haemorrhage. • Other non-steroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and haemorrhage. • Low molecular weight heparins (and related molecules) and unfractionated heparins at curative doses, or in elderly patients (≥65 years) regardless of the heparin dose, and for anti-inflammatory doses of acetylsalicylic acid or analgesic or antipyretic doses of acetylsalicylic acid: increased risk of hemorrhage (inhibition of platelet aggregation and aggression of the gastroduodenal mucosa by the acid acetylsalicylic). Another anti-inflammatory drug, or another analgesic or antipyretic should be used. • Clopidogrel (outside the approved indication for this combination in patients with acute coronary syndrome): increased risk of bleeding. If concomitant administration cannot be avoided, clinical monitoring is recommended. • Ticlopidine: increased risk of haemorrhage. If concomitant administration cannot be avoided, clinical monitoring is recommended. • Uricosurics (benzbromarone, probenecid): reduction of the uricosuric effect due to competition for the elimination of uric acid in the renal tubules. • Glucocorticoids (excluding hydrocortisone replacement therapy) for anti-inflammatory doses of acetylsalicylic acid: increased risk of bleeding. • Pemetrexed in patients with mild to moderate reduction in renal function (creatinine clearance between 45 ml\/min and 80 ml\/min); increased risk of pemetrexed toxicity (due to decreased renal elimination of pemetrexed caused by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. • Anagrelide: increased risk of hemorrhage and decreased antithrombotic effect. If concomitant administration cannot be avoided, clinical monitoring is recommended. Combinations requiring precautions for use: • Diuretics, angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, with anti-inflammatory doses of acetylsalicylic acid or with analgesic or antipyretic doses of acetylsalicylic acid: In dehydrated patients, acute renal failure may occur caused by the reduction in the glomerular filtration rate due to the decreased synthesis of renal prostaglandins. Furthermore, there may be a reduction in the antihypertensive effect. Ensure the patient is hydrated and renal function is monitored at the start of treatment. • Methotrexate in doses ≤ 15 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased toxicity of methotrexate, in particular haematological toxicity (due to reduced renal elimination of methotrexate caused by acetylsalicylic acid). Complete blood counts should be monitored weekly during the first few weeks of coadministration. Patients with reduced renal function (even mild) and elderly patients should be closely monitored. • Clopidogrel (in the approved indication for this combination in patients with acute coronary syndrome): increased risk of bleeding. Clinical monitoring is recommended. • Topical gastrointestinal treatments, antacids and activated charcoal: increased renal excretion of acetylsalicylic acid due to alkalinization of the urine. It is recommended to administer antacids and topical gastrointestinal treatments at least two hours after taking acetylsalicylic acid. • Pemetrexed in patients with normal renal function: increased risk of pemetrexed toxicity (due to decreased renal elimination of pemetrexed caused by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. Renal function should be monitored. Combinations that must be taken into consideration: • Glucocorticoids (excluding hydrocortisone replacement therapy) for analgesic and antipyretic doses of acetylsalicylic acid: increased risk of haemorrhage. • Deferasirox: with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and haemorrhage. • Low molecular weight heparins (and related molecules) and unfractionated heparins in preventive doses in patients under 65 years of age: influencing hemostasis at various levels, concomitant administration increases the risk of hemorrhage. Therefore, in patients under 65 years of age, the concomitant administration of heparins (or related molecules) in preventive doses, and of acetylsalicylic acid in any dose, should be taken into consideration combined with clinical and laboratory monitoring as needed. • Thrombolytics: increased risk of haemorrhage. • Selective Serotonin Reuptake Inhibitors (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline): increased risk of bleeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFrequencies: not known (cannot be estimated from available data) \u003cb\u003eBlood and lymphatic system disorders\u003c\/b\u003e Bleeding and tendency to haemorrhage (epistaxis, bleeding gums, purpura, etc.) with increased bleeding time. The risk of bleeding may persist for 4-8 days after stopping taking acetylsalicylic acid. It may cause an increased risk of bleeding during surgery. Intracranial and gastrointestinal hemorrhages may also occur. \u003cb\u003eImmune system disorders\u003c\/b\u003e Hypersensitivity reactions, anaphylactic reactions, asthma, angioedema \u003cb\u003eNervous system disorders\u003c\/b\u003e Headache, dizziness, sensation of hearing loss, tinnitus, usually indicating an overdose. Intracranial hemorrhage \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e Abdominal pain Occult or overt gastrointestinal bleeding (hematemesis, melena, etc.) resulting in iron deficiency anemia. The risk of bleeding is dose related. Gastric ulcers and perforations Intestinal diaphragm disease (especially in long-term treatment) \u003cb\u003eRenal and urinary disorders\u003c\/b\u003e Renal impairment and acute kidney injury have been reported \u003cb\u003eHepatobiliary disorders\u003c\/b\u003e Elevations of liver enzymes usually reversible upon discontinuation of treatment, liver damage, mainly hepatocellular in nature \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Urticaria, skin rashes \u003cb\u003eGeneral disorders \u003c\/b\u003e Reye's syndrome (see section 4.4) \u003cb\u003eReporting of side effects \u003c\/b\u003e It is important to report side effects of the medicine after authorization. This allows continued monitoring of the risk-benefit ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the Website: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOverdose can be harmful in elderly subjects and in particular in young children (therapeutic overdose or, more frequently, accidental intoxication) in which it can be fatal. \u003cb\u003eSymptoms\u003c\/b\u003e Moderate intoxication: Symptoms such as ringing in the ears, sensation of hearing loss, headache and dizziness are indicative of overdose and can be controlled by reducing the dosage. Severe intoxication: Symptoms include: Fever, hyperventilation, ketosis, respiratory alkalosis, metabolic acidosis, coma, cardiovascular collapse, respiratory failure, severe hypoglycemia. In children, overdose can be fatal starting from a single dose of 100 mg\/kg. \u003cb\u003eEmergency management\u003c\/b\u003e • Immediate transfer to a specialized hospital unit • Gastrointestinal lavage and administration of activated charcoal • Control of acid-base balance • Alkalinization of urine with monitoring of urinary pH • Hemodialysis in case of severe intoxication • Symptomatic treatment\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may have adverse effects on the course of pregnancy and\/or embryo-foetal development. Data from epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis following the use of prostaglandin synthesis inhibitors in early pregnancy. The absolute risk of cardiovascular malformations increased from no less than 1% to approximately 1.5%. The risk appears to increase with the dose and duration of treatment. In animals, it has been demonstrated that the administration of a prostaglandin synthesis inhibitor causes an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered a prostaglandin synthesis inhibitor during the organogenetic period of gestation. Unless absolutely essential, acetylsalicylic acid should not be administered during the first 24 weeks of amenorrhea. If acetylsalicylic acid is administered to women who wish to become pregnant or are pregnant during the first 24 weeks of amenorrhea, the dose should be as low as possible and the duration of treatment as short as possible. Beyond the 24th week of amenorrhea, all inhibitors of prostaglandin synthesis can expose the fetus to: • cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • renal dysfunction, which can evolve into renal failure with oligohydramniosis; In the final phase of pregnancy, the mother and newborn may experience: • Prolongation of the bleeding time, due to the inhibition of platelet aggregation which can occur even at very low doses of acetylsalicylic acid; • inhibition of uterine contractions which determines the delay or prolongation of labor. Therefore, acetylsalicylic acid is contraindicated beyond the 5th month of pregnancy (beyond 24 weeks of amenorrhea) (see section 4.3). \u003cu\u003eBreastfeeding\u003c\/u\u003e Acetylsalicylic acid passes into breast milk: therefore the use of acetylsalicylic acid is not recommended during breastfeeding (see section 4.4) Fertility There is some evidence that drugs that inhibit cyclooxygenase\/prostaglandin synthesis may cause impaired female fertility due to an effect on ovulation. This effect is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAcetylsalicylic acid has no influence on the ability to drive and use machines.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":40207823208563,"sku":"041962034","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-aspirina-dolore-infiammazione-20-compresse-500-mg-farmacia-dottor-tili-1254211176.jpg?v=1786732599"},{"product_id":"tachipirina-bambini-10-supposte-250-mg","title":"Tachipirina Children 10 Suppositories 250 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs an antipyretic: symptomatic treatment of febrile diseases such as influenza, exanthematous diseases, acute respiratory tract diseases, etc. As an analgesic: headaches, neuralgia, myalgia and other medium-level painful manifestations of various origins.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTACHIPIRINA 500 mg tablets.\u003c\/i\u003e Each tablet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 500 mg effervescent granules.\u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 12.3 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003eTACHIPIRINA 125 mg effervescent granules. \u003c\/i\u003e Each sachet contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003cu\u003eexcipients with known effects: aspartame, maltitol, 3.07 mmol sodium per sachet\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Infants 62.5 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains. \u003cu\u003eactive ingredient: paracetamol 62.5 mg\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Early Childhood 125 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 125 mg.\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Children 250 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 250 mg.\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Children 500 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 500 mg.\u003c\/u\u003e \u003ci\u003e \u003cu\u003eTACHIPIRINA Adults 1000 mg suppositories.\u003c\/u\u003e \u003c\/i\u003e Each suppository contains: \u003cu\u003eactive ingredient: paracetamol 1000 mg.\u003c\/u\u003e For the complete list of excipients, see par. 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• \u003cu\u003eTablets:\u003c\/u\u003e microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, croscarmellose sodium. • \u003cu\u003eEffervescent granules\u003c\/u\u003e: maltitol, mannitol, sodium bicarbonate, anhydrous citric acid, citrus flavouring, aspartame, sodium docusate. • \u003cu\u003eSuppositories\u003c\/u\u003e: solid semi-synthetic glycerides.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to paracetamol or to any of the excipients listed in paragraph 6.1. • Patients suffering from severe hemolytic anemia (this contraindication does not refer to the 500mg oral formulations). • Severe hepatocellular insufficiency (this contraindication does not refer to the 500mg oral formulations).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor children it is essential to respect the dosage defined according to their body weight, and therefore choose the suitable formulation. Approximate ages based on body weight are indicated for information. In adults, the maximum oral dosage is 3000 mg and rectally 4000 mg of paracetamol per day (see section 4.9). The doctor must evaluate the need for treatments for more than 3 consecutive days. The dosage schedule of Tachipirina in relation to body weight and route of administration is as follows: \u003cb\u003e500 mg tablets.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): ½ tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day (3 tablets). • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 tablet at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately between 12 and 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 doses per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e: 1 tablet at a time, to be repeated if necessary after 4 hours, without exceeding 6 doses per day. In case of severe pain or high fever, 2 tablets of 500 mg to be repeated if necessary after no less than 4 hours. \u003cb\u003e500 mg effervescent granules in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately between 12 and 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 doses per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e: 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. In case of severe pain or high fever, 2 sachets of 500 mg to be repeated if necessary after no less than 4 hours. \u003cb\u003e125 mg effervescent granules in sachets.\u003c\/b\u003e Dissolve the effervescent granules in a glass of water. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 sachet at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 sachet at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 2 sachets at a time (corresponding to 250 mg of paracetamol), to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003e62.5 mg suppositories for newborns.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 3.2 and 5 kg \u003c\/u\u003e(approximately between birth and 2 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eEarly Childhood Suppositories 125 mg. \u003c\/b\u003e • \u003cu\u003eChildren weighing between 6 and 7 kg \u003c\/u\u003e(approximately between 3 and 5 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eChildren weighing between 7 and 10 kg\u003c\/u\u003e (approximately between 6 and 19 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 administrations per day. • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 administrations per day. \u003cb\u003eSuppositories Children 250 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 11 and 12 kg\u003c\/u\u003e (approximately between 20 and 29 months): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 doses per day. • \u003cu\u003eChildren weighing between 13 and 20 kg\u003c\/u\u003e (approximately between 30 months and less than 6.5 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Children 500 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 21 and 25 kg\u003c\/u\u003e (approximately between 6.5 and less than 8 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 doses per day. • \u003cu\u003eChildren weighing between 26 and 40 kg\u003c\/u\u003e (approximately between 8 and 11 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. \u003cb\u003eSuppositories Adults of 1000 mg.\u003c\/b\u003e • \u003cu\u003eChildren weighing between 41 and 50 kg\u003c\/u\u003e (approximately between 12 and 15 years): 1 suppository at a time, to be repeated if necessary after 8 hours, without exceeding 3 doses per day. • \u003cu\u003eChildren weighing more than 50 kg\u003c\/u\u003e (approximately over 15 years): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 administrations per day. • \u003cu\u003eAdults\u003c\/u\u003e: 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day. \u003ci\u003e \u003cu\u003eRenal failure.\u003c\/u\u003e \u003c\/i\u003e In case of severe renal insufficiency (creatinine clearance less than 10 ml\/min), the interval between administrations must be at least 8 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eEffervescent tablets and granules\u003c\/u\u003e: no special precautions for storage. \u003cu\u003eSuppositories:\u003c\/u\u003e Store at a temperature not exceeding 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn rare cases of allergic reactions, administration must be suspended and appropriate treatment instituted. Use with caution in cases of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low hepatic glutathione reserves), dehydration, hypovolemia. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh\u003e9), acute hepatitis, in concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. High or prolonged doses of the product can cause even serious alterations to the kidney and blood, therefore administration to subjects with renal insufficiency must be carried out only if actually necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and kidney function and blood count. During treatment with paracetamol, before taking any other medicine, check that it does not contain the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other drug. See also par. 4.5. \u003cb\u003e \u003cu\u003eImportant information about some excipients.\u003c\/u\u003e \u003c\/b\u003e \u003cu\u003eTachipirina 125 mg effervescent granules contains\u003c\/u\u003e \u003cu\u003e:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e, is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk linked to the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e: use with caution in patients suffering from rare hereditary problems of fructose intolerance. 70.6 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 3.53% of the maximum daily intake recommended by WHO which corresponds to 2 g of sodium for an adult: to be taken into consideration in people with reduced kidney function or who follow a low-sodium diet. \u003cu\u003eTachipirina 500 mg effervescent granules contains:\u003c\/u\u003e - \u003cb\u003easpartame\u003c\/b\u003e, is a source of phenylalanine. It can be harmful in case of phenylketonuria (deficiency of the enzyme phenylalanine hydroxylase) due to the risk linked to the accumulation of the amino acid phenylalanine. - \u003cb\u003emaltitol\u003c\/b\u003e: use with caution in patients suffering from rare hereditary problems of fructose intolerance. - 283 mg of \u003cb\u003esodium\u003c\/b\u003e per sachet equivalent to 14.1% of the WHO recommended maximum daily intake which corresponds to 2 g of sodium for an adult. The maximum dose for this product is equivalent to 84.6% of the maximum daily sodium intake recommended by the WHO: to be taken into consideration in people with reduced kidney function or who follow a low-sodium diet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOral absorption of paracetamol depends on the speed of gastric emptying. Therefore, concomitant administration of drugs that slow (e.g. anticholinergics, opioids) or increase (e.g. prokinetics) the rate of gastric emptying may result in a decrease or increase in the bioavailability of the product, respectively. Concomitant administration of cholestyramine reduces the absorption of paracetamol. The simultaneous intake of paracetamol and chloramphenicol can induce an increase in the half-life of chloramphenicol, with the risk of increasing its toxicity. The concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants can induce slight variations in INR values. In these cases, more frequent monitoring of INR values ​​should be conducted during concomitant use and after its discontinuation. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). The same applies in cases of alcoholism and in patients treated with zidovudine. The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of paracetamol organized according to the MedDRA systemic and organic classification. There is insufficient data to establish the frequency of the individual effects listed.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Thrombocytopenia, leukopenia, anemia, agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Hypersensitivity reactions (urticaria, laryngeal edema, angioedema, anaphylactic shock).\u003c\/p\u003e\n\u003cp\u003eNervous system disorders: Dizziness.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Gastrointestinal reaction.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Abnormal liver function, hepatitis.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Erythema multiforme, Stevens Johnson Syndrome, Epidermal necrolysis, rash.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Acute renal failure, interstitial nephritis, hematuria, anuria.\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eThere is a risk of intoxication, especially in patients with liver disease, in cases of chronic alcoholism, in patients suffering from chronic malnutrition, and in patients receiving enzyme inducers. In these cases, overdose can be fatal.\u003c\/u\u003e \u003cu\u003eSymptoms\u003c\/u\u003e In case of accidental intake of very high doses of paracetamol, acute intoxication manifests itself with anorexia, nausea and vomiting followed by a profound deterioration of the general conditions; these symptoms typically appear within the first 24 hours. In case of overdose, paracetamol can cause hepatic cytolysis which can progress to massive and irreversible necrosis, resulting in hepatocellular failure, metabolic acidosis and encephalopathy, which can lead to coma and death. Simultaneously, an increase in the levels of hepatic transaminases, lactic dehydrogenase, and bilirubin are observed, and a reduction in prothrombin levels, which can occur in the 12-48 hours following ingestion. \u003cu\u003eTreatment\u003c\/u\u003e The measures to be adopted consist of early gastric emptying and hospitalization for the appropriate treatment, through administration, as early as possible, of N-acetylcysteine as an antidote: the dosage is 150 mg\/kg i.v. in glucose solution in 15 minutes, then 50 mg\/kg in the following 4 hours and 100 mg\/kg in the following 16 hours, for a total of 300 mg\/kg in 20 hours.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePregnancy: A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Breastfeeding: It is recommended to administer the product only in cases of actual need and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTachipirina does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207823994995,"sku":"012745042","price":6.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-tachipirina-bambini-10-supposte-250-mg-farmacia-dottor-tili-1258975883.jpg?v=1789562619"},{"product_id":"rinazina-spray-nasale-decongestionante-15ml-0-1","title":"Rinazina Decongestant Nasal Spray 15ml 0.1%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNasal decongestant during acute catarrhal rhinitis and pharyngitis, allergic rhinitis, acute sinusitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1 ml of solution contains: Active ingredient: naphazoline nitrate 1 mg \u003cu\u003eExcipients with known effects\u003c\/u\u003e: benzalkonium chloride For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRINAZINA 1 mg\/ml nasal drops, solution: sodium chloride, disodium edetate, monobasic sodium phosphate dihydrate, concentrated phosphoric acid, \u003cb\u003ebenzalkonium chloride\u003c\/b\u003e, purified water. RINAZINA 1 mg\/ml nasal spray, solution: sodium chloride, disodium edetate, monobasic sodium phosphate dihydrate, concentrated phosphoric acid, \u003cb\u003ebenzalkonium chloride\u003c\/b\u003e, balsamic aroma, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Severe heart disease and arterial hypertension. Glaucoma. Hyperthyroidism. \u003cb\u003e \u003cu\u003eThe medicine is contraindicated in children under 12 years of age.\u003c\/u\u003e \u003c\/b\u003e Do not administer during and in the two weeks following therapy with antidepressant drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eNasal drops:\u003c\/b\u003e Adults: 2-3 drops in each nostril, 2-3 times a day \u003cb\u003eNasal spray:\u003c\/b\u003e Adults: 1-2 sprays in each nostril, 2-3 times a day. \u003ci\u003ePediatric population\u003c\/i\u003e: The medicine is contraindicated in children under 12 years of age (see section 4.3). Carefully follow the recommended doses. A higher dosage of the product, even if taken topically and for a short period of time, can give rise to serious systemic effects. In the absence of a complete therapeutic response within a few days, consult your doctor; in any case, the treatment must not be continued for more than a week.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eRINAZINA 1 mg\/ml nasal spray, solution:\u003c\/i\u003e This medicinal product does not require any special storage conditions. \u003ci\u003eRINAZINA 1 mg\/ml nasal drops, solution\u003c\/i\u003e: Store below 25°C. Store upright.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse with caution in the elderly and in those with prostatic hypertrophy due to the risk of urinary retention. In patients with cardiovascular diseases, especially in hypertensive patients, the use of nasal decongestants must in any case be subject to the doctor's judgment from time to time. The prolonged use of vasoconstrictors can alter the normal function of the mucosa of the nose and paranasal sinuses, also inducing addiction to the drug. Repeating applications over a long period of time can be harmful. RINAZINA nasal drops and nasal spray contain 0.1 mg\/ml of benzalkonium chloride. Benzalkonium chloride (BAC) contained as a preservative in RINAZINA nasal drops and nasal spray can cause irritation and swelling of the nasal mucosa, especially if used for long periods. If such a reaction (persistent nasal congestion) is suspected, a medicinal product for nasal use without BAC should be used, if possible. If such medicinal products for nasal use without BAC are not available, another pharmaceutical form should be considered. May cause bronchospasm. The use, especially if prolonged, of topical products can give rise to sensitization phenomena; in this case it is necessary to interrupt the treatment and, if necessary, institute suitable therapy. Rare cases of posterior reversible encephalopathy\/reversible cerebral vasoconstriction syndrome have been reported with the use of sympathomimetic drugs, to which naphazoline also belongs. Reported symptoms include sudden onset of severe headache, nausea, vomiting and vision disturbances. Most cases improve or resolve within a few days following appropriate treatment. The use of naphazoline should be discontinued immediately and a doctor should be consulted if signs and\/or symptoms of posterior reversible encephalopathy\/reversible cerebral vasoconstriction syndrome occur.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe drug may interact with antidepressant drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product can locally cause rebound phenomena of sensitization and congestion of the mucous membranes. Due to rapid absorption of naphazoline through inflamed mucous membranes, systemic effects consisting of arterial hypertension, reflex bradycardia, headache, urination disorders may occur. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product, if accidentally ingested or if used for a long period in excessive doses, can cause toxic phenomena. It should be kept out of the reach of children as accidental ingestion can cause severe sedation. In case of overdose, arterial hypertension, tachycardia, photophobia, intense headache, chest tightness and, in children, hypothermia and severe depression of the Central Nervous System with marked sedation may appear, which require the adoption of adequate emergency measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring pregnancy and breastfeeding, RINAZINA must be used only after consulting your doctor and evaluating with him the risk\/benefit ratio in your case.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known side effects on the ability to drive or use machines.\u003c\/p\u003e","brand":"Gsk","offers":[{"title":"Default Title","offer_id":40207824191603,"sku":"000590051","price":11.59,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/glaxosmithkline-c-health-spa-rinazina-spray-nasale-decongestionante-15ml-0-1-farmacia-dottor-tili-1213792738.webp?v=1767126771"},{"product_id":"vicks-sinex-aloe-spray-nasale-15-ml","title":"Vicks Sinex Aloe Nasal Spray 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDecongestant of the nasal mucosa, especially in case of colds.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Active ingredient: oxymetazoline hydrochloride 0.0500% w\/v. 1 ml of product contains 0.5 mg of oxymetazoline hydrochloride. 1 spray (50 microlitres) contains approximately 25 micrograms of oxymetazoline hydrochloride. - Excipients with known effects: benzalkonium chloride, benzyl alcohol For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLevomenthol, sodium citrate, anhydrous citric acid, benzalkonium chloride solution, disodium edetate, eucalyptol (cineole), non-crystallizable liquid sorbitol, aloe vera, acesulfame potassium, Lcarvone, polysorbate 80, benzyl alcohol and purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1, prostatic hypertrophy, severe heart disease and arterial hypertension. Glaucoma, hyperthyroidism. Do not administer during and in the two weeks following therapy with antidepressant drugs (MAOI). Inflammation or lesions of the oral mucosa or the skin around the nostrils. The drug is contraindicated in children under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults and children over 12 years: 1-2 sprays per nostril every 8 - 12 hours, unless otherwise indicated by the doctor. Hold the bottle in a vertical position, insert its end into the nostril and press the nebulizer quickly and firmly. After application, inhale deeply with your mouth closed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse with caution in the first months of pregnancy and, due to the risk of urinary retention, in the elderly. Also use with caution in patients with angina and diabetes. If symptoms persist, a clinical reassessment must be considered; in any case, treatment must not be continued for more than 4 consecutive days to avoid a rebound effect and rhinitis phenomena induced by the drug. Carefully follow the recommended doses. Accidental ingestion may cause severe sedation. It should not be used orally. Avoid contact of the liquid with the eyes. Prolonged use of vasoconstrictors can alter the normal function of the mucosa of the nose and paranasal sinuses, also inducing addiction to the drug. Repeating applications for long periods can be harmful. The use, especially if prolonged, of topical products can give rise to sensitization phenomena; in this case it is necessary to interrupt the treatment and institute suitable therapy. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e Vicks Sinex Aloe 0.05% nebulizer solution contains benzalkonium chloride may cause bronchospasm. This medicine contains 0.01 mg of benzalkonium chloride per dose (1 spray) which is equivalent to 0.2 mg\/ml. Benzalkonium chloride can cause irritation and swelling inside the nose, especially if used for long periods. Vicks Sinex Aloe 0.05% spray solution contains benzyl alcohol. This medicine contains 0.1 mg of benzyl alcohol per dose (1 spray), equivalent to 2 mg\/ml. Benzyl alcohol can cause allergic reactions. Benzyl alcohol may cause mild local irritation\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere is the possibility of interaction between sympathomimetic amines such as oxymetazoline with anti-MAO drugs, therefore use is not recommended during or in the two weeks following treatment with anti-MAO drugs (see section 4.3). Oxymetazoline could reduce the effectiveness of beta-blocking drugs, methyl dopa or other antihypertensive drugs. Hypertension and arrhythmias may occur when tricyclic antidepressants are administered with sympathomimetic drugs such as oxymetazoline. Increased cardiovascular toxicity may occur when sympathomimetic drugs are administered concomitantly with antiparchinsonian drugs such as bromocriptines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf accidentally ingested or if used for a long period in excessive doses, the product can cause toxic phenomena. The product can locally cause sensitization phenomena and rebound congestion of the mucous membranes. In general, no serious side effects were observed. Due to rapid absorption of oxymetazoline through inflamed mucous membranes, side effects may occur divided into the following frequencies: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1000, \u003c1\/100); rare (≥1\/10000, \u003c1\/1000); very rare (\u003e1\/10000); not known (frequency cannot be estimated from the available data). \u003cb\u003e \u003cu\u003eRare:\u003c\/u\u003e \u003c\/b\u003e \u003ci\u003eEye pathologies\u003c\/i\u003e: eye irritation, discomfort or redness. \u003ci\u003eRespiratory, thoracic and mediastinal disorders\u003c\/i\u003e: discomfort or irritation of the nose, mouth or throat, sneezing. \u003cb\u003e \u003cu\u003eVery rare:\u003c\/u\u003e \u003c\/b\u003e \u003ci\u003eCardiac diseases\u003c\/i\u003e: tachycardia, palpitations, increased blood pressure, reflex bradycardia. \u003ci\u003eCentral nervous system disorders\u003c\/i\u003e: insomnia, nervousness, tremor, anxiety, agitation, irritability and headache. \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e: nausea. \u003ci\u003eRenal and urinary disorders\u003c\/i\u003e: urination disorders. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e Symptoms due to moderate or acute overdose may include mydriasis, nausea, cyanosis, fever, tachycardia, cardiac arrhythmias, hypertension, dyspnea, cardiac arrest, photophobia, headache, intense chest tightness and, in children, severe Central Nervous System depression with symptoms such as decreased body temperature, bradycardia, hypotension, apnea and loss of consciousness requiring the adoption of appropriate emergency measures. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic. In more serious cases, intubation and artificial respiration are required.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no studies on the use of the product during pregnancy and breastfeeding. Use with caution in the first months of pregnancy. Administration should only be considered if the expected benefit to the mother outweighs the risk to the baby.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo effects on the ability to drive and use machines have been observed.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":40207824322675,"sku":"023198029","price":11.88,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/procter-gamble-srl-vicks-sinex-aloe-spray-nasale-15-ml-farmacia-dottor-tili-1213792733.webp?v=1767126758"},{"product_id":"fexallegra-10-compresse-rivestite-120-mg","title":"Fexallegra 10 Coated Tablets 120 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFexallegra is indicated in adults and children from 12 years of age for the symptomatic treatment of allergic rhinitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eOne tablet contains\u003c\/u\u003e: \u003ci\u003eActive ingredient:\u003c\/i\u003e 120 mg of fexofenadine hydrochloride, equal to 112 mg of fexofenadine. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTablet core \u003c\/i\u003e microcrystalline cellulose; pregelatinized corn starch; croscarmellose sodium; magnesium stearate \u003ci\u003eFilm coating\u003c\/i\u003e hypromellose; povidone K30; titanium dioxide (E171); anhydrous colloidal silica; macrogol 400; red iron oxide (E172), yellow iron oxide (E172).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage \u003c\/u\u003e \u003ci\u003eAdults \u003c\/i\u003e The recommended dose of fexofenadine hydrochloride for adults is 120 mg once daily, before meals. Fexofenadine is a pharmacologically active metabolite of terfenadine. \u003ci\u003ePediatric population Children 12 years of age and older \u003c\/i\u003e The recommended dose of fexofenadine hydrochloride for children aged 12 years and older is 120 mg once a day, before meals. \u003ci\u003eChildren under 12 years of age \u003c\/i\u003e The efficacy and safety of fexofenadine hydrochloride 120 mg have not been studied in children under 12 years of age. In children 6 to 11 years of age: fexofenadine hydrochloride 30 mg tablets is the appropriate formulation for administration and dosing in this population. \u003ci\u003eParticular populations \u003c\/i\u003e Studies carried out in risk groups of patients (elderly, patients with renal or hepatic insufficiency) indicate that it is not necessary to adapt the dose of fexofenadine hydrochloride in these patients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eData in elderly subjects and patients with impaired renal or hepatic function are limited. Fexofenadine hydrochloride should be administered with caution to these groups of subjects (see section 4.2). Patients with previous or current cardiovascular disease should be informed that antihistamines, as a class of medicinal products, have been associated with adverse reactions such as tachycardia and palpitations (see section 4.8). \u003cu\u003eFexallegra contains sodium \u003c\/u\u003e This medicinal product contains less than 1 mmol (23 mg) sodium per tablet, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFexofenadine does not undergo hepatic biotransformation and therefore will not interact with other medicinal products at the level of hepatic mechanisms. Coadministration of fexofenadine hydrochloride and erythromycin or ketoconazole has been found to increase plasma levels of fexofenadine 2-3-fold. These alterations were not accompanied by any effect on the QT interval and were not associated with any increase in adverse reactions compared to that observed with the same medicinal products administered individually. Animal studies have shown that the increase in plasma levels of fexofenadine observed after concomitant treatment with erythromycin or ketoconazole appears to be caused by an increase in gastrointestinal absorption and a decrease in both biliary excretion and gastrointestinal secretion, respectively. No interaction was observed between fexofenadine and omeprazole. However, administration of an antacid containing aluminum and magnesium hydroxide 15 minutes before administration of fexofenadine hydrochloride resulted in a reduction in bioavailability, most likely due to binding in the gastrointestinal tract. An interval of 2 hours is advisable between the administration of fexofenadine hydrochloride and antacids containing aluminum and magnesium hydroxide.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following frequency class has been used when applicable: very common (≥ 1\/10); common (≥ 1\/100 and \u003c 1\/10); uncommon (≥ 1\/1000 and \u003c 1\/100); rare (≥ 1\/10,000 and \u003c 1\/1,000); very rare (\u003c 1\/10,000) and not known (frequency cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. In adults, the following side effects were reported in clinical trials, with an incidence similar to that observed with placebo: \u003ci\u003e \u003cu\u003eNervous system disorders.\u003c\/u\u003e \u003c\/i\u003e Common: headache, drowsiness, dizziness. \u003ci\u003e \u003cu\u003eGastrointestinal disorders.\u003c\/u\u003e \u003c\/i\u003e Common: nausea. \u003ci\u003e \u003cu\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/u\u003e \u003c\/i\u003e Uncommon: fatigue. In adults, the following side effects have been reported during post-marketing surveillance. The frequency with which they occur is not known (an estimate cannot be made based on the available data): \u003ci\u003e \u003cu\u003eImmune system disorders:\u003c\/u\u003e \u003c\/i\u003e Hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnoea, hot flushes and systemic anaphylaxis. \u003ci\u003e \u003cu\u003ePsychiatric disorders:\u003c\/u\u003e \u003c\/i\u003e Insomnia, nervousness, sleep disturbances or nightmares\/excessive dreaming (paronyria). \u003ci\u003e \u003cu\u003eCardiac disorders:\u003c\/u\u003e \u003c\/i\u003e Tachycardia, palpitations. \u003ci\u003e \u003cu\u003eGastrointestinal disorders:\u003c\/u\u003e \u003c\/i\u003e Diarrhoea. \u003ci\u003e \u003cu\u003eSkin and subcutaneous tissue disorders:\u003c\/u\u003e \u003c\/i\u003eRash, urticaria and itching. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDizziness, drowsiness, fatigue and dry mouth have been reported following overdose of fexofenadine hydrochloride. Single doses of up to 800 mg and doses of up to 690 mg twice daily for one month or 240 mg once daily for one year have been administered to healthy volunteers without resulting in clinically significant adverse reactions when compared to placebo. The maximum tolerated dose of fexofenadine hydrochloride has not been established. Standard measures to remove unabsorbed drug should be considered. Symptomatic and supportive treatment is recommended. Hemodialysis does not effectively remove fexofenadine hydrochloride from the blood.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy \u003c\/u\u003e There are no adequate data on the use of fexofenadine hydrochloride in pregnant women. Limited animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic\/foetal development, parturition or postnatal development (see section 5.3). Fexofenadine hydrochloride should not be used during pregnancy unless absolutely necessary.\u003cu\u003eBreastfeeding \u003c\/u\u003e There are no data on the concentration in breast milk after administration of fexofenadine hydrochloride. However, when terfenadine was administered to breastfeeding mothers, fexofenadine was found to pass into breast milk. Therefore the use of fexofenadine hydrochloride is not recommended during breastfeeding. \u003cu\u003eFertility \u003c\/u\u003e No data are available on the effect of fexofenadine hydrochloride on human fertility. In mice, treatment with fexofenadine hydrochloride showed no effect on fertility (see section 5.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBased on the pharmacodynamic profile and adverse reactions reported, fexofenadine hydrochloride tablets are unlikely to produce any effects on the ability to drive and use machinery. In objective tests, FEXALLEGRA was not shown to have significant effects on the function of the central nervous system. This means patients can drive or perform tasks that require concentration. However, in order to identify sensitive people who may have an unusual reaction to medicines, it is advisable to test the individual response before driving or performing complex tasks.\u003c\/p\u003e","brand":"Sanofi","offers":[{"title":"Default Title","offer_id":40207824584819,"sku":"042554042","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sanofi-fexallegra-10-compresse-rivestite-120-mg-farmacia-dottor-tili-1258975929.jpg?v=1789562590"},{"product_id":"tachifludec-limone-polvere-10-bustine","title":"Tachifludec Lemon Powder 10 Sachets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of cold and flu symptoms, including mild\/moderate pain and fever, when associated with nasal congestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach sachet contains: \u003cu\u003eactive ingredients:\u003c\/u\u003e paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equal to phenylephrine 8.2 mg). \u003cu\u003eExcipients with known effects:\u003c\/u\u003e \u003cu\u003eTACHIFLUDEC lemon flavor contains:\u003c\/u\u003e 1,817 g of \u003cb\u003esucrose\u003c\/b\u003e, 112.86 mg of \u003cb\u003esodium\u003c\/b\u003e, 6.65 mg of \u003cb\u003eglucose\u003c\/b\u003e. \u003cu\u003eTACHIFLUDEC lemon and honey flavor contains:\u003c\/u\u003e 1,892g of \u003cb\u003esucrose\u003c\/b\u003e, 135.79 mg of \u003cb\u003esodium\u003c\/b\u003e. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- TACHIFLUDEC powder for oral solution lemon flavour: \u003cb\u003esucrose\u003c\/b\u003e, anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, saccharin \u003cb\u003esodium\u003c\/b\u003e, anhydrous colloidal silica, lemon flavouring, curcumin (E100), syrup \u003cb\u003eglucose\u003c\/b\u003e dried. - TACHIFLUDEC powder for oral solution lemon and honey flavour: \u003cb\u003esucrose\u003c\/b\u003e, anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, saccharin \u003cb\u003esodium\u003c\/b\u003e, lemon flavouring, honey flavouring, caramel (E150), colloidal anhydrous silica.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Children under the age of 12. - Hypersensitivity to the active substances or to any of the excipients (listed in paragraph 6.1). - Patients taking beta-blockers. - Patients taking tricyclic antidepressants and those taking or have taken in the last 2 weeks monoamine oxidase inhibitors. - Patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who simultaneously take other sympathetic mimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants). - Patients suffering from liver or kidney failure, diabetes, hyperthyroidism, hypertension and cardiovascular diseases. - Paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those suffering from severe hemolytic anemia. - Severe hepatocellular insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cu\u003eAdults and children over 12 years old\u003c\/u\u003e: 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cu\u003eChildren under 12 years:\u003c\/u\u003e TACHIFLUDEC lemon, lemon and honey flavor is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Dissolve the contents of 1 sachet in half a glass of very hot water and, to taste, dilute with cold water to cool and sweeten as desired.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C. Store in the original container to protect the medicine from moisture and light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients should be advised not to take other medicines containing paracetamol while taking TACHIFLUDEC as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with TACHIFLUDEC. The danger of overdose is in fact greater in patients with liver problems. Invite the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatories. Caution is advised if acetaminophen is administered concurrently with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition, and other sources of glutathione deficiency (e.g., chronic alcoholism), as well as in those using maximum daily doses of acetaminophen. Close monitoring, including measurement of urinary 5-oxoproline, is recommended. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular disease (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. TACHIFLUDEC lemon flavor contains: - \u003cb\u003esodium\u003c\/b\u003e: This medicinal product contains 112.86 mg sodium per sachet equivalent to 5.64% of the maximum daily intake recommended by WHO which corresponds to 2 g sodium for an adult, to be taken into consideration in patients with reduced renal function or following a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. Patients with diabetes must take into consideration the sucrose content within TACHIFLUDEC when taking more than 2 sachets per day (sucrose \u003e 5g). - \u003cb\u003eglucose:\u003c\/b\u003e Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. TACHIFLUDEC lemon and honey flavor contains: - \u003cb\u003esodium:\u003c\/b\u003e 135.79 mg of sodium per sachet equivalent to 6.79% of the maximum daily intake recommended by WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced renal function or who follow a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. The sucrose content within TACHIFLUDEC is to be taken into consideration in people suffering from diabetes mellitus if they take more than 2 sachets per day (sucrose \u003e 5g).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e The hepatotoxic effect of paracetamol can be potentiated by the intake of other drugs active on the liver such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance the effect of coumarin anticoagulants (warfarin). Metoclopramide and domperidone can increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin as concomitant use has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Phenylephrine can antagonize the effect of beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and can potentiate the action of monoamine oxidase inhibitors (see section 4.3). The simultaneous use of phenylephrine with tricyclic antidepressants or sympathetic mimetic amines may increase the risk of cardiovascular effects. Phenylephrine can interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or heart attack, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid can increase the absorption of iron and estrogen. Ascorbic acid is metabolised to oxalate, and can potentially cause hyperoxaluria and kidney stones in patients through the crystallisation of calcium oxalate in patients who are prone to forming calcium stones. \u003ci\u003e \u003cu\u003eInterference with some laboratory tests\u003c\/u\u003e \u003c\/i\u003e The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method). Ascorbic acid can interfere in the measurement of blood and urinary parameters (e.g. urate, glucose, bilirubin, hemoglobin).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects organized according to the MedDRA System Organ classification. The frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000), not known (cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Agranulocytosis¹, leukopenia¹, thrombocytopenia¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anemia¹\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Allergic reactions1,2, hypersensitivity reactions1,2, anaphylaxis1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anaphylactic shock1,2.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Anorexia²\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Insomnia², nervousness², anxiety², restlessness², confusion², irritability²\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tremor², dizziness², headache²\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Mydriasis², acute angle-closure glaucoma²\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Tachycardia², palpitations²\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Hypertension²\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Bronchospasm1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Edema of the larynx¹\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Nausea², vomiting²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Diarrhoea¹, gastrointestinal pathology¹\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Abnormal liver function¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Liver disease¹, hepatitis¹\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Skin rash1,2, angioedema²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Toxic epidermal necrolysis¹, Steven Johnson Syndrome¹, erythema multiforme or polymorph¹\u003c\/p\u003e\n\u003cp\u003eKidney and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Aggravated renal failure¹, haematuria¹, anuria¹ urine retention²\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. ¹ Side effects associated with paracetamol ² Side effects associated with phenylephrine \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system to the site \u003cb\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/b\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eParacetamol\u003c\/i\u003e At the recommended doses, or even if you were to take the entire pack, no symptoms of paracetamol overdose should appear. However, in case of ingestion of very high doses of paracetamol (greater than 10 g), the most commonly encountered complication is liver damage, which typically occurs 12-48 hours after ingestion. \u003cu\u003eRisk factors\u003c\/u\u003e a. Long-term treatment with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's wort or other liver enzyme-inducing drugs; b. regular consumption of ethanol in quantities higher than recommended; c. glutathione depletion (e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia). \u003cu\u003eSymptoms\u003c\/u\u003e Early symptoms of paracetamol overdose in the first 24 hours are paleness, nausea, vomiting, anorexia and abdominal pain. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, liver failure may progress to encephalopathy, hemorrhage, hypoglycemia, brain edema, and death. Even in the absence of severe liver damage, acute renal failure with acute tubular necrosis, strongly suggested by flank pain, hematuria, and proteinuria can develop, even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. \u003cu\u003eTreatment\u003c\/u\u003e In the management of paracetamol overdose, immediate treatment is essential. Despite a lack of significant initial symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Management must be in accordance with treatment guidelines. If overdose has occurred within 1 hour, treatment with activated charcoal should be considered. Paracetamol plasma concentration should be measured 4 or more hours after ingestion (initial concentrations are not reliable). Treatment with N-acetylcysteine ​​can be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is achieved up to 8 hours after ingestion. The effectiveness of the antidote declines sharply after this period. If necessary, the patient should be administered N-acetylcysteine ​​intravenously, in line with the established dosing regimen. If vomiting is not a problem, oral methionine may be a suitable alternative in more remote areas, outside of hospital. Management of patients who present with severe hepatic dysfunction more than 24 hours after ingestion should be discussed with the National Poison Control Center or liver unit. \u003ci\u003ePhenylephrine\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e Symptoms of overdose caused by phenylephrine are irritability, headache and increased blood pressure. In more serious cases, confusion, hallucinations, convulsions and arrhythmias may occur. However, the amount needed to produce severe phenylephrine toxicity would be greater than that related to acetaminophen. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate. Severe hypertension should be treated with alpha blocker drugs such as phentolamine. \u003ci\u003eAscorbic acid\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e High doses of ascorbic acid (\u003e3000mg) may cause transient osmotic diarrhea and gastrointestinal effects such as nausea and abdominal discomfort. The effects of ascorbic acid overdose may be hidden by the severe liver toxicity caused by acetaminophen overdose. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePREGNANCY \u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Epidemiological studies in pregnant women have shown that there are no contraindications in the use of paracetamol when used in the recommended doses, but the administration of the preparation during pregnancy and breastfeeding must take place under the direct supervision of a doctor. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Data regarding the use of phenylephrine in pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e There are no controlled data relating to use during pregnancy. The use of ascorbic acid during pregnancy is recommended only when the benefit outweighs the risk. BREASTFEEDING \u003ci\u003e \u003cu\u003eParacetamol \u003c\/u\u003e \u003c\/i\u003e Paracetamol is excreted in breast milk but in clinically insignificant quantities. The available published data do not contraindicate its use during breastfeeding. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e No data are available regarding the excretion of phenylephrine in breast milk, nor is there information regarding the effects of phenylephrine on breast-fed infants. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid is excreted in breast milk. The effects on breast-fed infants are not known. In summary, the use of TACHIFLUDEC is not recommended during pregnancy and breastfeeding. FERTILITY There is no evidence in non-clinical studies to indicate effects of paracetamol on male and female fertility at commonly used clinical doses. The effect of phenylephrine on male and female fertility has not been studied. There is sufficient evidence indicating the importance of ascorbic acid at different levels in the reproductive process. However, no definitive human data on the clinical potential of vitamin C are available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTACHIFLUDEC does not affect the ability to drive or use machines. However, patients should be advised not to drive or operate machines if they feel dizzy.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207824814195,"sku":"034358010","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachifludec-limone-polvere-10-bustine-farmacia-dottor-tili-1213792728.webp?v=1767127487"},{"product_id":"tachifludec-limone-e-miele-polvere-10-bustine","title":"Tachifludec Lemon and Honey Powder 10 Sachets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of cold and flu symptoms, including mild\/moderate pain and fever, when associated with nasal congestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach sachet contains: \u003cu\u003eactive ingredients:\u003c\/u\u003e paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equal to phenylephrine 8.2 mg). \u003cu\u003eExcipients with known effects:\u003c\/u\u003e \u003cu\u003eTACHIFLUDEC lemon flavor contains:\u003c\/u\u003e 1,817 g of \u003cb\u003esucrose\u003c\/b\u003e, 112.86 mg of \u003cb\u003esodium\u003c\/b\u003e, 6.65 mg of \u003cb\u003eglucose\u003c\/b\u003e. \u003cu\u003eTACHIFLUDEC lemon and honey flavor contains:\u003c\/u\u003e 1,892g of \u003cb\u003esucrose\u003c\/b\u003e, 135.79 mg of \u003cb\u003esodium\u003c\/b\u003e. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- TACHIFLUDEC powder for oral solution lemon flavour: \u003cb\u003esucrose\u003c\/b\u003e, anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, saccharin \u003cb\u003esodium\u003c\/b\u003e, anhydrous colloidal silica, lemon flavouring, curcumin (E100), syrup \u003cb\u003eglucose\u003c\/b\u003e dried. - TACHIFLUDEC powder for oral solution lemon and honey flavour: \u003cb\u003esucrose\u003c\/b\u003e, anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, saccharin \u003cb\u003esodium\u003c\/b\u003e, lemon flavouring, honey flavouring, caramel (E150), colloidal anhydrous silica.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Children under the age of 12. - Hypersensitivity to the active substances or to any of the excipients (listed in paragraph 6.1). - Patients taking beta-blockers. - Patients taking tricyclic antidepressants and those taking or have taken in the last 2 weeks monoamine oxidase inhibitors. - Patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who simultaneously take other sympathetic mimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants). - Patients suffering from liver or kidney failure, diabetes, hyperthyroidism, hypertension and cardiovascular diseases. - Paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those suffering from severe hemolytic anemia. - Severe hepatocellular insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cu\u003eAdults and children over 12 years old\u003c\/u\u003e: 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cu\u003eChildren under 12 years:\u003c\/u\u003e TACHIFLUDEC lemon, lemon and honey flavor is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Dissolve the contents of 1 sachet in half a glass of very hot water and, to taste, dilute with cold water to cool and sweeten as desired.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C. Store in the original container to protect the medicine from moisture and light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients should be advised not to take other medicines containing paracetamol while taking TACHIFLUDEC as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with TACHIFLUDEC. The danger of overdose is in fact greater in patients with liver problems. Invite the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatories. Caution is advised if acetaminophen is administered concurrently with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition, and other sources of glutathione deficiency (e.g., chronic alcoholism), as well as in those using maximum daily doses of acetaminophen. Close monitoring, including measurement of urinary 5-oxoproline, is recommended. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular disease (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. TACHIFLUDEC lemon flavor contains: - \u003cb\u003esodium\u003c\/b\u003e: This medicinal product contains 112.86 mg sodium per sachet equivalent to 5.64% of the maximum daily intake recommended by WHO which corresponds to 2 g sodium for an adult, to be taken into consideration in patients with reduced renal function or following a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. Patients with diabetes must take into consideration the sucrose content within TACHIFLUDEC when taking more than 2 sachets per day (sucrose \u003e 5g). - \u003cb\u003eglucose:\u003c\/b\u003e Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. TACHIFLUDEC lemon and honey flavor contains: - \u003cb\u003esodium:\u003c\/b\u003e 135.79 mg of sodium per sachet equivalent to 6.79% of the maximum daily intake recommended by WHO which corresponds to 2 g of sodium for an adult, to be taken into consideration in patients with reduced renal function or who follow a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. The sucrose content within TACHIFLUDEC is to be taken into consideration in people suffering from diabetes mellitus if they take more than 2 sachets per day (sucrose \u003e 5g).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e The hepatotoxic effect of paracetamol can be potentiated by the intake of other drugs active on the liver such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance the effect of coumarin anticoagulants (warfarin). Metoclopramide and domperidone can increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin as concomitant use has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Phenylephrine can antagonize the effect of beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and can potentiate the action of monoamine oxidase inhibitors (see section 4.3). The simultaneous use of phenylephrine with tricyclic antidepressants or sympathetic mimetic amines may increase the risk of cardiovascular effects. Phenylephrine can interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or heart attack, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid can increase the absorption of iron and estrogen. Ascorbic acid is metabolised to oxalate, and can potentially cause hyperoxaluria and kidney stones in patients through the crystallisation of calcium oxalate in patients who are prone to forming calcium stones. \u003ci\u003e \u003cu\u003eInterference with some laboratory tests\u003c\/u\u003e \u003c\/i\u003e The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method). Ascorbic acid can interfere in the measurement of blood and urinary parameters (e.g. urate, glucose, bilirubin, hemoglobin).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects organized according to the MedDRA System Organ classification. The frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000), not known (cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Agranulocytosis¹, leukopenia¹, thrombocytopenia¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anemia¹\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Allergic reactions1,2, hypersensitivity reactions1,2, anaphylaxis1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anaphylactic shock1,2.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Anorexia²\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Insomnia², nervousness², anxiety², restlessness², confusion², irritability²\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tremor², dizziness², headache²\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Mydriasis², acute angle-closure glaucoma²\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Tachycardia², palpitations²\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Hypertension²\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Bronchospasm1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Edema of the larynx¹\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Nausea², vomiting²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Diarrhoea¹, gastrointestinal pathology¹\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Abnormal liver function¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Liver disease¹, hepatitis¹\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Skin rash1,2, angioedema²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Toxic epidermal necrolysis¹, Steven Johnson Syndrome¹, erythema multiforme or polymorph¹\u003c\/p\u003e\n\u003cp\u003eKidney and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Aggravated renal failure¹, haematuria¹, anuria¹ urine retention²\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. ¹ Side effects associated with paracetamol ² Side effects associated with phenylephrine \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system to the site \u003cb\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/b\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eParacetamol\u003c\/i\u003e At the recommended doses, or even if you were to take the entire pack, no symptoms of paracetamol overdose should appear. However, in case of ingestion of very high doses of paracetamol (greater than 10 g), the most commonly encountered complication is liver damage, which typically occurs 12-48 hours after ingestion. \u003cu\u003eRisk factors\u003c\/u\u003e a. Long-term treatment with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's wort or other liver enzyme-inducing drugs; b. regular consumption of ethanol in quantities higher than recommended; c. glutathione depletion (e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia). \u003cu\u003eSymptoms\u003c\/u\u003e Early symptoms of paracetamol overdose in the first 24 hours are paleness, nausea, vomiting, anorexia and abdominal pain. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, liver failure may progress to encephalopathy, hemorrhage, hypoglycemia, brain edema, and death. Even in the absence of severe liver damage, acute renal failure with acute tubular necrosis, strongly suggested by flank pain, hematuria, and proteinuria can develop, even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. \u003cu\u003eTreatment\u003c\/u\u003e In the management of paracetamol overdose, immediate treatment is essential. Despite a lack of significant initial symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Management must be in accordance with treatment guidelines. If overdose has occurred within 1 hour, treatment with activated charcoal should be considered. Paracetamol plasma concentration should be measured 4 or more hours after ingestion (initial concentrations are not reliable). Treatment with N-acetylcysteine ​​can be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is achieved up to 8 hours after ingestion. The effectiveness of the antidote declines sharply after this period. If necessary, the patient should be administered N-acetylcysteine ​​intravenously, in line with the established dosing regimen. If vomiting is not a problem, oral methionine may be a suitable alternative in more remote areas, outside of hospital. Management of patients who present with severe hepatic dysfunction more than 24 hours after ingestion should be discussed with the National Poison Control Center or liver unit. \u003ci\u003ePhenylephrine\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e Symptoms of overdose caused by phenylephrine are irritability, headache and increased blood pressure. In more serious cases, confusion, hallucinations, convulsions and arrhythmias may occur. However, the amount needed to produce severe phenylephrine toxicity would be greater than that related to acetaminophen. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate. Severe hypertension should be treated with alpha blocker drugs such as phentolamine. \u003ci\u003eAscorbic acid\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e High doses of ascorbic acid (\u003e3000mg) may cause transient osmotic diarrhea and gastrointestinal effects such as nausea and abdominal discomfort. The effects of ascorbic acid overdose may be hidden by the severe liver toxicity caused by acetaminophen overdose. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePREGNANCY \u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Epidemiological studies in pregnant women have shown that there are no contraindications in the use of paracetamol when used in the recommended doses, but the administration of the preparation during pregnancy and breastfeeding must take place under the direct supervision of a doctor. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Data regarding the use of phenylephrine in pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e There are no controlled data relating to use during pregnancy. The use of ascorbic acid during pregnancy is recommended only when the benefit outweighs the risk. BREASTFEEDING \u003ci\u003e \u003cu\u003eParacetamol \u003c\/u\u003e \u003c\/i\u003e Paracetamol is excreted in breast milk but in clinically insignificant quantities. The available published data do not contraindicate its use during breastfeeding. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e No data are available regarding the excretion of phenylephrine in breast milk, nor is there information regarding the effects of phenylephrine on breast-fed infants. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid is excreted in breast milk. The effects on breast-fed infants are not known. In summary, the use of TACHIFLUDEC is not recommended during pregnancy and breastfeeding. FERTILITY There is no evidence in non-clinical studies to indicate effects of paracetamol on male and female fertility at commonly used clinical doses. The effect of phenylephrine on male and female fertility has not been studied. There is sufficient evidence indicating the importance of ascorbic acid at different levels in the reproductive process. However, no definitive human data on the clinical potential of vitamin C are available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTACHIFLUDEC does not affect the ability to drive or use machines. However, patients should be advised not to drive or operate machines if they feel dizzy.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207824879731,"sku":"034358022","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachifludec-limone-e-miele-polvere-10-bustine-farmacia-dottor-tili-1213792714.jpg?v=1767127548"},{"product_id":"tachifludec-arancia-polvere-10-bustine","title":"Tachifludec Orange Powder 10 Sachets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of cold and flu symptoms, including mild\/moderate pain and fever, when associated with nasal congestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach sachet contains: \u003cu\u003eactive ingredients:\u003c\/u\u003e paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equal to phenylephrine 8.2 mg). \u003cu\u003eExcipients with known effects\u003c\/u\u003e: 2 g of \u003cb\u003esucrose\u003c\/b\u003e; 135.82 mg of \u003cb\u003esodium\u003c\/b\u003e; 33.25 mg of \u003cb\u003eglucose\u003c\/b\u003e. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSucrose\u003c\/b\u003e, anhydrous citric acid, \u003cb\u003esodium\u003c\/b\u003e citrate, corn starch, \u003cb\u003esodium\u003c\/b\u003e cyclamate, saccharin \u003cb\u003esodium\u003c\/b\u003e, colloidal anhydrous silica, blood orange flavour, curcumin (E100), syrup \u003cb\u003eglucose\u003c\/b\u003e dried.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Children under the age of 12. - Hypersensitivity to the active substances or to any of the excipients (listed in paragraph 6.1). - Patients taking beta-blockers. - Patients taking tricyclic antidepressants and those taking or have taken in the last 2 weeks monoamine oxidase inhibitors. - Patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who simultaneously take other sympathetic mimetic medicinal products (such as decongestants, appetite suppressants and amphetamine-like psychostimulants). - Patients suffering from liver or kidney failure, diabetes, hyperthyroidism, hypertension and cardiovascular diseases. - Paracetamol-based products are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those suffering from severe hemolytic anemia. - Severe hepatocellular insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cu\u003eAdults and children over 12 years:\u003c\/u\u003e 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more than 3 consecutive days without consulting your doctor. \u003ci\u003ePediatric population\u003c\/i\u003e Children under 12 years: TACHIFLUDEC orange flavor is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Dissolve the contents of a sachet in a glass of hot or cold water and sweeten to taste. Once dissolved, the medicine gives rise to a yellow opalescent solution, free of foreign particles and with an orange flavour.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C. Store in the original container to protect the medicine from moisture and light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients should be advised not to take other medicines containing paracetamol while taking TACHIFLUDEC as high doses of paracetamol may cause serious adverse reactions. Avoid alcohol consumption during treatment with TACHIFLUDEC. The danger of overdose is in fact greater in patients with liver problems. Invite the patient to contact the doctor before combining warfarin or any other drug (see also section 4.5). The use of the product is not recommended if the patient is being treated with anti-inflammatories. Caution is advised if acetaminophen is administered concurrently with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition, and other sources of glutathione deficiency (e.g., chronic alcoholism), as well as in those using maximum daily doses of acetaminophen. Close monitoring, including measurement of urinary 5-oxoproline, is recommended. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular disease (e.g. Raynaud's syndrome). Do not exceed the recommended dose and do not administer for more than 3 consecutive days. TACHIFLUDEC orange flavor contains: - \u003cb\u003esodium:\u003c\/b\u003e This medicine contains 135.82 mg sodium per sachet, equivalent to 6.79% of the maximum daily intake recommended by WHO which corresponds to 2 g sodium for an adult, to be taken into consideration in patients with reduced renal function or following a low-sodium diet. - \u003cb\u003esucrose:\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. Patients with diabetes must take into consideration the sucrose content within TACHIFLUDEC when taking more than 2 sachets per day (sucrose \u003e 5g). - \u003cb\u003eglucose:\u003c\/b\u003e Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e The hepatotoxic effect of paracetamol can be potentiated by the intake of other drugs active on the liver, such as zidovudine and isoniazid which can produce an inhibition of the metabolism of paracetamol. The administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulphate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance the effect of coumarin anticoagulants (warfarin). Metoclopramide and domperidone can increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics, respectively. Caution should be exercised when paracetamol is used concomitantly with flucloxacillin as concomitant use has been associated with high anion gap metabolic acidosis, especially in patients with risk factors (see section 4.4). \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Phenylephrine can antagonize the effect of beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and can potentiate the action of monoamine oxidase inhibitors (see section 4.3). The simultaneous use of phenylephrine with tricyclic antidepressants or sympathetic mimetic amines may increase the risk of cardiovascular effects. Phenylephrine can interact with digoxin and cardiac glycosides, increasing the risk of arrhythmia or heart attack, and with alkaloids (ergotamine and methylsergide), increasing the risk of ergotism. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid can increase the absorption of iron and estrogen. Ascorbic acid is metabolised to oxalate, and can potentially cause hyperoxaluria and kidney stones in patients through the crystallisation of calcium oxalate in patients who are prone to forming calcium stones. \u003ci\u003e \u003cu\u003eInterference with some laboratory tests\u003c\/u\u003e \u003c\/i\u003e The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method). Ascorbic acid can interfere in the measurement of blood and urinary parameters (e.g. urate, glucose, bilirubin, hemoglobin).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following are the side effects organized according to the MedDRA System Organ classification. The frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000), not known (cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Agranulocytosis¹, leukopenia¹, thrombocytopenia¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anemia¹\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Allergic reactions1,2, hypersensitivity reactions1,2, anaphylaxis1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Anaphylactic shock1, 2.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Anorexia²\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Insomnia², nervousness², anxiety², restlessness², confusion², irritability²\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tremor², dizziness², headache²\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Mydriasis², acute angle-closure glaucoma²\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Tachycardia², palpitations²\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Hypertension²\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Bronchospasm1,2.\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Edema of the larynx¹\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Side effect: Nausea², vomiting²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Diarrhoea¹, gastrointestinal pathology¹\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Abnormal liver function¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Liver disease¹, hepatitis¹\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eRare - Side effect: Skin rash1,2, angioedema²\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Toxic epidermal necrolysis¹, Steven Johnson Syndrome¹, erythema multiforme or polymorph¹\u003c\/p\u003e\n\u003cp\u003eKidney and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Side effect: Tubulointerstitial nephritis (after prolonged use of paracetamol at high doses)¹\u003c\/p\u003e\n\u003cp\u003eNot known - Side effect: Aggravated renal failure¹, haematuria¹, anuria¹ urine retention²\u003c\/p\u003e\n\u003cp\u003eVery rare cases of serious skin reactions have been reported. ¹ Side effects associated with paracetamol ² Side effects associated with phenylephrine \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system to the site \u003cb\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/b\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eParacetamol\u003c\/i\u003e At the recommended doses, or even if you were to take the entire pack, no symptoms of paracetamol overdose should appear. However, in case of ingestion of very high doses of paracetamol (greater than 10 g), the most commonly encountered complication is liver damage, which typically occurs 12-48 hours after ingestion. \u003cu\u003eRisk factors\u003c\/u\u003e a. Long-term treatment with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's wort or other liver enzyme-inducing drugs; b. regular consumption of ethanol in quantities higher than recommended; c. glutathione depletion (e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia). \u003cu\u003eSymptoms\u003c\/u\u003e Early symptoms of paracetamol overdose in the first 24 hours are paleness, nausea, vomiting, anorexia and abdominal pain. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, liver failure may progress to encephalopathy, hemorrhage, hypoglycemia, brain edema, and death. Even in the absence of severe liver damage, acute renal failure with acute tubular necrosis, strongly suggested by flank pain, hematuria, and proteinuria can develop, even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. \u003cu\u003eTreatment\u003c\/u\u003e In the management of paracetamol overdose, immediate treatment is essential. Despite a lack of significant initial symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Management must be in accordance with treatment guidelines. If overdose has occurred within 1 hour, treatment with activated charcoal should be considered. Paracetamol plasma concentration should be measured 4 or more hours after ingestion (initial concentrations are not reliable). Treatment with N-acetylcysteine ​​can be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is achieved up to 8 hours after ingestion. The effectiveness of the antidote declines sharply after this period. If necessary, the patient should be administered N-acetylcysteine ​​intravenously, in line with the established dosing regimen. If vomiting is not a problem, oral methionine may be a suitable alternative in more remote areas, outside of hospital. Management of patients who present with severe hepatic dysfunction more than 24 hours after ingestion should be discussed with the National Poison Control Center or liver unit. \u003ci\u003ePhenylephrine\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e Symptoms of overdose caused by phenylephrine are irritability, headache and increased blood pressure. In more serious cases, confusion, hallucinations, convulsions and arrhythmias may occur. However, the amount needed to produce severe phenylephrine toxicity would be greater than that related to acetaminophen. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate. Severe hypertension should be treated with alpha blocker drugs such as phentolamine. \u003ci\u003eAscorbic acid\u003c\/i\u003e \u003cu\u003eSymptoms\u003c\/u\u003e High doses of ascorbic acid (\u003e3000mg) may cause transient osmotic diarrhea and gastrointestinal effects such as nausea and abdominal discomfort. The effects of ascorbic acid overdose may be hidden by the severe liver toxicity caused by acetaminophen overdose. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be clinically appropriate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePREGNANCY \u003ci\u003e \u003cu\u003eParacetamol\u003c\/u\u003e \u003c\/i\u003e A large amount of data on pregnant women indicates neither malformation nor fetal\/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency. Epidemiological studies in pregnant women have shown that there are no contraindications in the use of paracetamol when used in the recommended doses, but the administration of the preparation during pregnancy and breastfeeding must take place under the direct supervision of a doctor. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e Data regarding the use of phenylephrine in pregnancy are limited. Vasoconstriction of the uterine vessels and reduction of blood flow to the uterus associated with the use of phenylephrine may result in fetal hypoxia. The use of phenylephrine during pregnancy should be avoided as further information is needed. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e There are no controlled data relating to use during pregnancy. The use of ascorbic acid during pregnancy is recommended only when the benefit outweighs the risk. BREASTFEEDING \u003ci\u003e \u003cu\u003eParacetamol \u003c\/u\u003e \u003c\/i\u003e Paracetamol is excreted in breast milk but in clinically insignificant quantities. The available published data do not contraindicate its use during breastfeeding. \u003ci\u003e \u003cu\u003ePhenylephrine\u003c\/u\u003e \u003c\/i\u003e No data are available regarding the excretion of phenylephrine in breast milk, nor is there information regarding the effects of phenylephrine on breast-fed infants. In the absence of available data, the use of phenylephrine should be avoided during breastfeeding. \u003ci\u003e \u003cu\u003eAscorbic acid\u003c\/u\u003e \u003c\/i\u003e Ascorbic acid is excreted in breast milk. The effects on breast-fed infants are not known. In summary, the use of TACHIFLUDEC is not recommended during pregnancy and breastfeeding. FERTILITY There is no evidence in non-clinical studies to indicate effects of paracetamol on male and female fertility at commonly used clinical doses. The effect of phenylephrine on male and female fertility has not been studied. There is sufficient evidence indicating the importance of ascorbic acid at different levels in the reproductive process. However, no definitive human data on the clinical potential of vitamin C are available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTACHIFLUDEC does not affect the ability to drive or use machines. However, patients should be advised not to drive or operate machines if they feel dizzy.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207824912499,"sku":"034358034","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/angelini-spa-tachifludec-arancia-polvere-10-bustine-farmacia-dottor-tili-1213792726.jpg?v=1767127528"},{"product_id":"tonimer-hypertonic-spray-100-ml","title":"Tonimer Hypertonic Spray 100 ml","description":"\u003cdiv\u003e\n      \u003cp\u003e\n        \u003cstrong\u003eTonimer Hypertonic Spray\u003c\/strong\u003e is a hypertonic solution based on sea water, designed to relieve nasal congestion and promote cleansing of the upper airways. Thanks to its mineral-rich composition, it helps to thin excess mucus and clear stuffy noses, improving breathing. It is suitable for both adults and children and can be used daily during periods of colds, sinusitis or allergies.\n      \u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Tonimer Hypertonic Spray 100 ml? What is it for?\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eTonimer Hypertonic Spray\u003c\/strong\u003e it is indicated for: - Reducing nasal congestion in case of colds or allergies. - Facilitate breathing by improving the fluidity of mucus. - Hydrate and cleanse the nasal mucous membranes in situations of dryness or irritation. - Suitable for use by adults and children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Tonimer Hypertonic Spray 100 ml contain?\u003c\/h3\u003e\n\u003cp\u003eMaris aqua (sea water), aqua (water).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Tonimer Hypertonic Spray 100 ml?\u003c\/h3\u003e\n\u003cp\u003eAfter removing the cap, adults and children capable of using the product independently can use it in any position.\u003cbr\u003eHowever, it is advisable to stand over the sink, keep your head tilted to one side and insert the dispenser into the upper nostril. Press on the dispenser to release the product. Repeat the identical procedure with the other nostril.\u003cbr\u003eFor newborns and small children: lay the child on his side, insert the nozzle into the upper nostril and press. Lay the baby on the other side and repeat with the other nostril.\u003cbr\u003eAfter use, clean and dry the dispenser and close the package with the appropriate cap.\u003cbr\u003eRepeat the application every 3-4 hours 2-3 times a day for 15 days, or according to medical advice.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Tonimer Hypertonic Spray 100 ml?\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor children under 6 years of age, use the product only on pediatric advice.\u003cbr\u003eDo not use in case of sensitive nasal mucosa and subject to epistaxis.\u003cbr\u003eIn case of side effects, discontinue use and consult your doctor.\u003cbr\u003eAvoid contact with eyes; if necessary, wash them with water.\u003cbr\u003ePressurized container: may burst if heated. Keep away from heat, hot surfaces, sparks, open flames or other sources of ignition. Don't smoke.\u003cbr\u003eDo not pierce or burn, even after use.\u003cbr\u003eProtect from sunlight.\u003cbr\u003eDo not expose to temperatures above 50°C\/122°F.\u003cbr\u003eKeep out of reach of children.\u003cbr\u003eDo not use other than intended.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Tonimer Hypertonic Spray 100 ml not be used and what side effects can it cause?\u003c\/h3\u003e\n\u003cp\u003eDo not use \u003cstrong\u003eTonimer Hypertonic Spray\u003c\/strong\u003e in case of hypersensitivity to one of the ingredients. Avoid use in newborns and consult a doctor in case of prolonged use or for particular conditions.\u003c\/p\u003e\n\u003cp\u003eSide effects are rare, but may include irritation or temporary dryness of the mucous membranes. In case of adverse reactions, discontinue use and consult a doctor.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Tonimer Hypertonic Spray 100 ml stored?\u003c\/h3\u003e\n\u003cp\u003eStore at a temperature not exceeding 50°C.\u003cbr\u003eValidity with intact packaging: 36 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Tonimer Hypertonic Spray 100 ml?\u003c\/h3\u003e\n\u003cp\u003e100 ml bottle\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Ganassini","offers":[{"title":"Default Title","offer_id":40207831335027,"sku":"986792265","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ganassini-tonimer-hypertonic-spray-100-ml-farmacia-dottor-tili-1254211158.jpg?v=1786732060"},{"product_id":"tonimer-lab-hypertonic-18-flaconcini-monodose","title":"Tonimer Lab Hypertonic 18 Single-Dose Vials","description":"\u003cdiv\u003e\n      \u003cp\u003e\n        \u003cstrong\u003eTonimer Lab Hypertonic\u003c\/strong\u003e is a hypertonic solution specific for the treatment of nasal congestion and hydration of the mucous membranes. Thanks to its formulation based on hypertonic sea water, it helps to decongest the nose naturally, reducing excess mucus and facilitating breathing. It is ideal for use in infants, children and adults, particularly if they have colds, sinusitis or allergies. The product is packaged in practical sterile single-dose vials, easy to use and hygienic.\n      \u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Tonimer Lab Hypertonic 18 Single-Dose Vials used? What is it for?\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eTonimer Lab Hypertonic\u003c\/strong\u003e it is indicated for: - Decongesting the nasal passages in case of colds, sinusitis or allergies. - Reduce excess mucus and improve breathing. - Hydrate and cleanse dry or irritated nasal mucous membranes. - Can be used by babies, children and adults.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Tonimer Lab Hypertonic 18 Single-Dose Vials contain?\u003c\/h3\u003e\n\u003cp\u003eMaris aqua (sea water), aqua (water).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Tonimer Lab Hypertonic 18 Single-Dose Vials?\u003c\/h3\u003e\n\u003cp\u003eBreak the upper part of the vial with a twisting motion. Lay the child on his side, insert the tip of the vial into the upper nostril and press. Lay the baby on the other side and repeat with the other nostril.\u003cbr\u003eFor children capable of using the product independently, it is recommended to position themselves over the sink, keep their head tilted to one side, insert the tip of the vial into the upper nostril and press. Repeat the identical procedure with the other nostril.\u003c\/p\u003e\n\u003cp\u003eUse half the contents of the vial in each nostril and repeat the application every 3-4 hours 2-3 times a day for 15 days or according to medical advice. In case of aerosol administration, use once or twice a day for 15 days or according to medical advice.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Tonimer Lab Hypertonic 18 Single-Dose Vials?\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot injectable.\u003cbr\u003eDo not blow your nose for 10 minutes following administration.\u003cbr\u003eDo not reuse after opening, as the product may no longer be sterile.\u003cbr\u003eKeep out of the reach and sight of children.\u003cbr\u003eIn case of side effects, discontinue use and consult your doctor.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Tonimer Lab Hypertonic 18 single-dose vials not be used and what side effects can it cause?\u003c\/h3\u003e\n\u003cp\u003eDo not use \u003cstrong\u003eTonimer Lab Hypertonic\u003c\/strong\u003e in case of hypersensitivity or allergy to one of the ingredients. Consult your doctor before use in infants or in case of pre-existing medical conditions.\u003c\/p\u003e\n\u003cbr\u003e\u003cbr\u003e\u003cp\u003eSide effects are rare, but may include irritation or temporary dryness of the nasal mucosa. If any unwanted symptoms appear, discontinue use and consult a doctor.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Tonimer Lab Hypertonic 18 Single-Dose Vials stored?\u003c\/h3\u003e\n\u003cp\u003eStore away from light and do not expose to temperatures above 40°C.\u003cbr\u003eValidity with intact packaging: 36 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Tonimer Lab Hypertonic 18 Single-Dose Vials?\u003c\/h3\u003e\n\u003cp\u003e18 single-dose vials of 5 ml\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Ganassini","offers":[{"title":"Default Title","offer_id":40207831466099,"sku":"935205551","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ganassini-tonimer-lab-hypertonic-18-flaconcini-monodose-farmacia-dottor-tili-1254211157.jpg?v=1786732032"},{"product_id":"vicks-babyrub-50-g","title":"Vicks Babyrub 50g","description":"\u003cdiv\u003e\n      \u003cp\u003e\n        \u003cstrong\u003eVicks Babyrub\u003c\/strong\u003e is an ointment designed specifically for little ones, designed to offer comfort and relief during moments of discomfort related to colds or seasonal irritations. Its delicate formulation based on natural ingredients such as aloe vera, lavender oil and rosemary, promotes a feeling of well-being and calm, helping the child to relax and sleep better. The product is dermatologically tested and safe for use in infants aged 6 months and older.\n      \u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Vicks Babyrub 50 g used? What is it for?\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eVicks Babyrub\u003c\/strong\u003e It is indicated for: - Relieving mild respiratory discomfort during colds. - Offer a calming and relaxing sensation to aid sleep. - Gently moisturize the baby's skin thanks to the presence of aloe vera.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Vicks Babyrub 50 g contain?\u003c\/h3\u003e\n\u003cp\u003ePetrolatum, Turpentine, Parfum, Paraffinum Liquidum, Cocos Nucifera Oil, Aloe Barbadensis Leaf Extract, Lavandula Angustifolia Oil, Thymol, Limonene, Linalool, Geraniol.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Vicks Babyrub 50 g?\u003c\/h3\u003e\n\u003cp\u003eGently massage the chest and belly to calm and relax the baby.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Vicks Babyrub 50 g?\u003c\/h3\u003e\n\u003cp\u003eUse only as directed. For external use only. Avoid contact with eyes. Do not apply to mouth or nostrils. Not to be used if the child is allergic to one or more components. Do not heat in: water, microwave, vaporizer or stove. Keep out of reach of children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Vicks Babyrub 50 g not be used and what side effects can it cause?\u003c\/h3\u003e\n\u003cp\u003eDo not use \u003cstrong\u003eVicks Babyrub\u003c\/strong\u003e in children under 6 months of age. Avoid contact with eyes, mouth and nostrils. Do not apply to damaged or irritated skin.\u003c\/p\u003e\n\u003cp\u003eSide effects are rare, but may include allergic reactions or skin irritation. In case of redness or irritation, discontinue use and consult a doctor.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Vicks Babyrub 50 g stored?\u003c\/h3\u003e\n\u003cp\u003eStore below 25°C.\u003cbr\u003eClose the lid of the jar after use.\u003cbr\u003eLast shelf life from the date of production, in unopened packaging: 24 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Vicks Babyrub 50 g?\u003c\/h3\u003e\n\u003cp\u003e50 g jar\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":40207831564403,"sku":"974899080","price":9.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/procter-gamble-vicks-babyrub-50-g-farmacia-dottor-tili-1254211156.jpg?v=1786731998"},{"product_id":"vicks-inalante-rinforzato-flacone-1-g","title":"Vicks Inhalant Reinforced Bottle 1 g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn colds and congestion of the nasal mucosa, it frees the stuffy nose and promotes breathing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach stick contains: 1.00 ml of medicinal liquor, absorbed onto a piece of cellulose. ACTIVE INGREDIENTS: menthol 415.4 mg, camphor 415.4 mg. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSiberian pine essential oil, methyl salicylate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Children up to 30 months of age. Children with a history of epilepsy or febrile seizures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Inhalant is contraindicated in children up to 30 months of age (see paragraph 4.3) and its use is not recommended in children under 6 years of age. Unscrew the cap and insert the tip of the nasal stick into one nostril, closing the other with a finger and inhale deeply. Repeat in each nostril several times a day. Do not exceed the recommended doses. \u003ci\u003eThe duration of treatment should not exceed 3 days.\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis product contains terpene derivatives which, in excessive doses, can cause neurological disorders such as seizures in infants and children. Vicks Inhalant is contraindicated in children up to 30 months of age and its use is not recommended in children under 6 years of age. The treatment must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003ecamphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needle, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher dose than the recommended one should not be used to avoid a greater risk of adverse reactions to the medicinal product and disorders associated with overdose (see section 4.9). The product is flammable, it must not be brought close to flames. Prolonged use may cause sensitization. In this case or in the absence of therapeutic effect, discontinue use and consult your doctor. Use the product according to the instructions. External use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVicks Inhalant must not be used concomitantly with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn general, no serious or serious side effects are expected with this product. Cases of nasal pain have been reported very rarely. Due to the presence of camphor and menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. The use, especially if prolonged, of products for topical use can cause sensitization phenomena. In this case it is necessary to interrupt the treatment and institute suitable therapy. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system reported on the website: www.agenziafarmaco.gov.it\/it\/responsabili dell'Agenzia Italiana del Farmaco.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo clinically significant cases of overdose have been reported. \u003ci\u003eIn case of accidental oral intake or incorrect administration in newborns and children there may be a risk of neurological disorders.\u003c\/i\u003e \u003ci\u003eIf necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no or limited data available on the use of camphor and menthol in pregnant women. Vicks Inhalant is not recommended during pregnancy and in women of childbearing potential who are not using contraceptive measures. \u003cu\u003eBreastfeeding\u003c\/u\u003e There is insufficient information on the excretion of camphor and menthol in breast milk. Vicks Inhalant should not be used during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":40207831597171,"sku":"003136025","price":7.42,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/procter-gamble-srl-vicks-inalante-rinforzato-flacone-1-g-farmacia-dottor-tili-1213793061.jpg?v=1767128289"},{"product_id":"isomar-spray-acqua-di-mare-e-acido-ialuronico-100ml","title":"Isomar Spray Sea Water and Hyaluronic Acid 100ml","description":"\u003cp\u003e\u003cspan style=\"text-align: justify;\" data-mce-style=\"text-align: justify;\"\u003eIsomar Spray is an isotonic and sterile solution based on \u003cstrong\u003eCinque Terre sea water and hyaluronic acid,\u003c\/strong\u003e for daily nose and ear hygiene. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eIsomar Spray Sea Water and Hyaluronic Acid is a solution suitable for \u003cstrong\u003ecolds, bronchitis, sinusitis, asthma, allergies\u003c\/strong\u003e generally also from pollen and for those who work in closed environments in the presence of dust. Indispensable for those who have suffered \u003cstrong\u003enasal interventions and for those who snore during sleep\u003c\/strong\u003e(acute and chronic bronchopathies).\u003c\/p\u003e\n\u003cp\u003eIsomar Daily Hygiene Spray is particularly recommended in pediatric age, starting from the first year of age, in pregnant women and during the breastfeeding period. With its characteristic \u003cstrong\u003efluidizing action\u003c\/strong\u003e it can be\u003cstrong\u003e used daily to increase the humidity of the nasal mucosa\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn children who have not yet fully mastered blowing their nose, it promotes greater patency of the nostrils. In adults it allows better drainage of nasal mucus. With its physiological action it is the \u003cstrong\u003eoptimal product for prolonged and frequent use for both children and adults\u003c\/strong\u003e. \u003c\/p\u003e\n\u003cp\u003eWith the \u003cstrong\u003ealternative nebulizer\u003c\/strong\u003e is indicated for \u003cstrong\u003eear cleaning and washing\u003c\/strong\u003e. It prevents the formation of earwax plugs and the accumulation of unwanted particles which could cause hearing problems. \u003cstrong\u003eIt also helps keep the auditory canal clear\u003c\/strong\u003e in the subjects \u003cstrong\u003ehearing aid wearers\u003c\/strong\u003e. The nebulization feature prevents any overpressure on the tympanic membrane.\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e2 nose and ear nebulizers.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Isomar Spray Sea Water and Hyaluronic Acid 100ml? What is it for?\u003c\/h3\u003e\u003cp\u003eSterile isotonic solution based on sea water and hyaluronic acid, indicated for the daily hygiene of the nose and ears; thanks to its fluidifying and hydrating action on the nasal mucous membranes, it is useful as an adjuvant in case of colds, sinusitis and allergies, and is also indicated in pediatric age from the first year of life, during pregnancy and during breastfeeding.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Isomar Spray Sea Water and Hyaluronic Acid 100ml contain?\u003c\/h3\u003e\u003cp\u003eIsotonic sea water.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Isomar Spray Sea Water and Hyaluronic Acid 100ml?\u003c\/h3\u003e\u003cp\u003eFor the nose: one\/two 2-second sprays per nostril. We recommend using it in a vertical position, to allow the product to flow out evenly and to obtain over 300 sprays.\u003cbr\u003eFor the ear: spray once\/twice. It can be used several times a day.\u003cbr\u003eFor those who practice underwater disciplines: use regularly before and after diving. Humidifies the nasal mucosa dried out by the mask or the compressed air from the cylinders.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Isomar Spray Sea Water and Hyaluronic Acid 100ml?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003ePressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not burn or pierce even after use.\u003cbr\u003eUse the product only for its intended use.\u003cbr\u003eKeep out of reach of children.\u003cbr\u003eFailure to check the integrity of the product could alter its functional characteristics.\u003cbr\u003eDo not use after the expiry date.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Isomar Spray Sea Water and Hyaluronic Acid 100ml?\u003c\/h3\u003e\u003cp\u003e100ml spray bottle, with 2 nose and ear sprays.\u003c\/p\u003e","brand":"Euritalia Pharma","offers":[{"title":"Default Title","offer_id":40207831728243,"sku":"906059427","price":13.3,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/euritalia-pharma-div-coswell-isomar-spray-acqua-di-mare-e-acido-ialuronico-100ml-farmacia-dottor-tili-1213793058.jpg?v=1767128351"},{"product_id":"acqua-di-sirmione-aerosol-6-flaconi-15-ml","title":"Sirmione water Aerosol 6 Bottles 15 ml","description":"\u003cp\u003e\u003cspan style=\"text-align: justify;\" data-mce-style=\"text-align: justify;\"\u003e\u003c\/span\u003eSirmione water is a\u003cstrong\u003esalsobromoiodine sulphurous thermal water \u003c\/strong\u003eexcellent for\u003cstrong\u003e dissolve mucus, clear the nose, eliminate viruses and bacteria\u003c\/strong\u003e and hydrate the nasal mucous membranes. Acqua di Sirmione 6 bottles of 15 ml is complete with nebulizer, easy to use and apply to the vials. However we recommend \u003cstrong\u003euse Sirmione Water via aerosol\u003c\/strong\u003e, to ensure optimal nebulisation and effectiveness of the product. In fact, the Sirmione water comes to the Terme di Sirmione establishments \u003cstrong\u003enormally administered by aerosol.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Acqua di Sirmione Aerosol 6 Bottles 15 ml? What is it for?\u003c\/h3\u003e\u003cp\u003eSirmione water is bacteriologically\u003cstrong\u003e pure, rich in natural mineral salts and with a characteristic and volatile sulfur smell\u003c\/strong\u003e. It can be used by both adults and children and is indicated:\u003c\/p\u003e\u003cp\u003eFor the \u003cstrong\u003edaily cleaning of the nose\u003c\/strong\u003e and nasal cavities, to deal with pollution, dust, smoke and bacteria that attack the nasal mucosa on a daily basis. For \u003cstrong\u003eimprove the hydration of the nasal mucosa\u003c\/strong\u003e and avoid dryness and irritation. Sirmione water is excellent for \u003cstrong\u003ekeep the nose free and counteract the \"stuffed nose\" naturally\u003c\/strong\u003e without altering the physiological conditions of the nasal mucosa. For cleansing the nose and nasal cavities from catarrhal secretions and for \u003cstrong\u003ethin the mucus in case of colds\u003c\/strong\u003e, thanks to the fluidizing and antiseptic action of sulphur, bromine and iodine. To assist in the treatment of nasal infections, such as \u003cstrong\u003erhinitis and sinusitis\u003c\/strong\u003e. To assist e\u003cstrong\u003e soothe the after-effects of nasal surgery\u003c\/strong\u003e and healthy paranasals.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Acqua di Sirmione Aerosol 6 Bottles 15 ml contain?\u003c\/h3\u003e\u003cp\u003eSalsobromoiodic sulphurous thermal water from Terme di Sirmione. The chemical characteristics of the water reported in the case are measured annually at the source.\u003cbr\u003eThe bottled product can present different concentrations of the different components while maintaining the natural therapeutic properties of the thermal water.\u003cbr\u003eThe possible presence of suspended particles is an intrinsic characteristic of bromine-iodic sulphurous thermal water and does not alter the quality of the product. Gluten free.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Acqua di Sirmione Aerosol 6 Bottles 15 ml?\u003c\/h3\u003e\u003cp\u003eAcqua di Sirmione 6 bottles of 15 ml can be used through a special nebulizer or through a micronized nasal shower and aerosol therapy. It is recommended to carry out at least two applications per day.\u003c\/p\u003e\u003cp\u003eWith \u003cstrong\u003enebulizing dispenser\u003c\/strong\u003e:\u003c\/p\u003e\u003cp\u003eRemove the screw cap when using. Pierce the protective seal with the nebulizer and screw it onto the bottle. Any loss of excess product is normal and may be due to an overabundance of water in the bottle. Lean your head back slightly. Gently insert the nasal nozzle into the nostril. Spray with the dispenser, making 5 to 10 sprays per nostril. Inhale deeply through your nose, to facilitate penetration and absorption of the product. The passage of a part of the product into the throat is physiological and indicates that the product has reached the depths. Repeat the operation for the other nostril. Wait about a minute before blowing your nose gently to facilitate the elimination of phlegm.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIt is recommended to take Acqua di Sirmione 6 Bottles through aerosol or nasal douche\u003c\/strong\u003e. The use of the nebulizer allows abundant hydration and dilution of mucus and phlegm in the deepest and most difficult to reach areas of the nose and throat.\u003cbr\u003e\u003cstrong\u003eWith micronized and aerosol shower devices:\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eRemove the screw cap when using. Pour the contents of a bottle of Acqua di Sirmione into the ampoule for each application. Carry out the application following the instructions of the specific equipment for your condition.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Acqua di Sirmione Aerosol 6 bottles 15 ml not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eThe product is normally well tolerated, use should be avoided in cases where individual hypersensitivity is evident. The use of the product does not affect driving or the use of machinery. There are no known contraindications for its use during pregnancy. If you have any doubts about the use of ACQUA DI SIRMIONE®, consult your doctor. For hygiene reasons, avoid using the same dispenser by more than one person. The solution is not for injection. Do not use in case of ongoing or recently concluded epistaxis. Not indicated for drinking therapy. Acqua di Sirmione has no contraindications during pregnancy.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Acqua di Sirmione Aerosol 6 bottles 15 ml stored?\u003c\/h3\u003e\u003cp\u003eStore at room temperature away from light and heat sources. Do not use the product after the expiration date. Do not use the product if the packaging is not intact.\u003cbr\u003eThe expiry date refers to the intact and correctly stored product. Do not dispose of the container in the environment after use.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Acqua di Sirmione Aerosol 6 Bottles 15 ml?\u003c\/h3\u003e\u003cp\u003e6 vials and a nebulizer dispenser\u003c\/p\u003e","brand":"Terme Di Sirmione","offers":[{"title":"Default Title","offer_id":40207831793779,"sku":"909089031","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/terme-di-sirmione-acqua-di-sirmione-aerosol-6-flaconi-15-ml-farmacia-dottor-tili-1213793039.webp?v=1767128389"},{"product_id":"argento-colloidale-puro-20-ppm-e-propoli-spray-30ml-dr-tili","title":"Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili ","description":"\u003cp\u003e\u003cimg style=\"float: none;\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" alt=\"Supplement made in Italy\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" data-mce-style=\"float: none;\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"monitored heavy metals\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Privo_di_metalli_pesanti_480x480.png?v=1668012159\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Privo_di_metalli_pesanti_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"nickel tested\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/nichel_tested_480x480.png?v=1668012159\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/nichel_tested_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"without added fragrance\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/fragrance_free_480x480.png?v=1668012159\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/fragrance_free_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"without parabens\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_parabeni_480x480.png?v=1668012159\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_parabeni_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"silicone free\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/silicon_free_480x480.png?v=1668012159\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/silicon_free_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003c\/p\u003e\nColloidal Silver 20 ppm and Propolis Spray 30ml is a unique and innovative product designed to synergistically combine the virtues of the highly titrated phytotherapeutic propolis extract with the properties of pure colloidal silver in ionic clusters. Colloidal Silver 20 ppm Propolis Spray 30ml is a product \u003cstrong\u003especific for oral use\u003c\/strong\u003e, whose particular density allows for long-lasting adhesion to the mucous membranes of the oral cavity for a long-lasting effect. Useful natural remedy in case of \u003cstrong\u003esore throat, seasonal flu, seasonal  and cold ailments.\u003c\/strong\u003e\n\u003cp\u003eObtained by dispersing very small particles of silver in water, the\u003cstrong\u003ecolloidal silver\u003c\/strong\u003e it was widely used in the treatment of the most varied infections before the advent of antibiotics. In fact, natural antibacterial, antiviral and antifungal properties are attributed to colloidal silver. This is why it is useful for \u003cstrong\u003edeeply disinfects the oral cavity \u003c\/strong\u003ein all its parts. Colloidal silver in ionic clusters, once absorbed by the body, manifests its properties \u003cstrong\u003esupporting natural immune defenses\u003c\/strong\u003e both in \u003cstrong\u003eprevention phase\u003c\/strong\u003e both during the communes \u003cstrong\u003eongoing infections\u003c\/strong\u003e.\u003cbr\u003eIt is indicated in cases of: inflammation of the oral cavity, sore throat, gingivitis, dental caries, seasonal and cold-related ailments.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003epropolis\u003c\/strong\u003e it is a natural substance produced by bees to insulate hive cells. It can be made up of over 200 different compounds including \u003cstrong\u003eresins, wax, essential oils, pollen, flavonoids, organic compounds, mineral salts, vitamins\u003c\/strong\u003e and other elements.\u003cbr\u003eProperties are attributed to propolis \u003cstrong\u003enatural antiviral and antibacterial\u003c\/strong\u003e, anti-inflammatory and immunostimulant, due in particular to the presence of \u003cstrong\u003eflavonoids\u003c\/strong\u003e (Galangina and Pinocembrina). Propolis is traditionally considered a \u003cstrong\u003enatural antibiotic\u003c\/strong\u003e which can inhibit the ability of bacteria to reproduce e \u003cstrong\u003enaturally disinfect the mucous membranes and oral cavity\u003c\/strong\u003e. It proves useful in case of \u003cstrong\u003eburning in the throat\u003c\/strong\u003e and inflammation of the upper respiratory tract such as pharyngitis, laryngitis. Propolis is also a \u003cstrong\u003enatural antiviral\u003c\/strong\u003e useful against viruses that cause the common seasonal flu.\u003cbr\u003eIndicated in case of: sore throat, flu, cold, pharyngitis, laryngitis, burning throat.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003eAqua. Propolisextract. Aloe barbadensis leaf juice. Citric acid. Maltodextrin. Xanthangum. Potassium sorbate. Rebaudiosi-de A. Colloidal silver.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eShake well before use. Two sprays of Pure Colloidal Silver ionic cluster 20 ppm Propolis Spray 30 ml several times a day on the affected areas. Helps give relief to the oral cavity.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eKeep out of reach of children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow do you store Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eStore in a cool, dry place.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e30ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207841132659,"sku":"981377803","price":13.1,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/tilab-srl-argento-colloidale-puro-20-ppm-e-propoli-spray-30ml-dr-tili-farmacia-dottor-tili-1213792720.jpg?v=1767130270"},{"product_id":"actigrip-giorno-e-notte-compresse-12-4","title":"Actigrip Day and Night Tablets 12+4","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of cold and flu symptoms.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eOne white tablet (day) contains\u003c\/u\u003e: active ingredients: paracetamol 500 mg, pseudoephedrine hydrochloride 60 mg; \u003cu\u003eOne light blue (night) coated tablet contains\u003c\/u\u003e: active ingredients: paracetamol 500 mg, diphenhydramine hydrochloride 25 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eOne white tablet (day) contains\u003c\/u\u003e: microcrystalline cellulose, pregelatinized corn starch, croscarmellose sodium, magnesium stearate, povidone, crospovidone, stearic acid. \u003cu\u003eOne light blue (night) coated tablet contains\u003c\/u\u003e: microcrystalline cellulose, corn starch, sodium starch glycolate, hydroxypropyl cellulose, pregelatinized corn starch, croscarmellose sodium, stearic acid, magnesium stearate, hypromellose, Opadry blue 02H205000 (containing propylene glycol).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1; • Children under 12 years old; • Confirmed or presumed pregnancy, breastfeeding; • Cardiovascular diseases, hypertension; • Patients with a history of stroke or predisposing risk factors; • Diabetes; • Glaucoma; • Stenosis of the gastrointestinal system; • Hyperthyroidism; • Prostatic hypertrophy, stenosis of the urogenital system; • Asthma; • In patients being treated with monoamine oxidase inhibitors (MAOIs) and in the two weeks following such treatment; • Patients with history of seizures, epilepsy. Furthermore, due to the paracetamol content, ACTIGRIP DAY \u0026 NIGHT is contraindicated in patients with manifest insufficiency of glucose-6-phosphate dehydrogenase.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults and children over 12 years of age\u003c\/i\u003e: one white tablet three times a day (in the morning, at midday and in the afternoon) plus one blue tablet in the evening before going to bed. After 3 days of continuous use without appreciable results or if high fever or other side effects appear, discontinue treatment. Do not exceed the recommended doses. \u003cu\u003eMethod of administration\u003c\/u\u003e Take the tablets orally, without chewing them.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature not exceeding 25°C. Store in the original package to protect the medicine from light and moisture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of ACTIGRIP DAY \u0026 NIGHT must be avoided in conjunction with analgesics and antipyretics. High doses or prolonged administration of paracetamol, present in the medicine or in other drugs containing paracetamol, can cause high-risk liver disease, even serious changes in the kidney and blood and other serious adverse reactions. \u003ci\u003eIn adults and children over 12 years of age\u003c\/i\u003e, the total dose of paracetamol should not exceed 4g per day. Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh \u003e 9), acute hepatitis, concomitant treatment with drugs that alter liver function, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia. In case of simultaneous treatment with anticoagulant or antiplatelet drugs, the doses of ACTIGRIP DAY \u0026 NIGHT must be reduced. \u003cu\u003eSkin safety\u003c\/u\u003e In patients treated with paracetamol, serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported very rarely. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases in the early stages of treatment. Serious skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with products containing pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules resulting from a widespread edematous erythema and localized mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules are observed, the administration of ACTIGRIP DAY \u0026 NIGHT must be stopped and appropriate measures must be taken if necessary (see section 4.8). Patients should be informed about the signs of serious skin reactions. ACTIGRIP DAY \u0026 NIGHT must be discontinued at the first appearance of skin rash or any other sign of hypersensitivity. Do not use with any other product containing diphenhydramine, including those for topical use. \u003cu\u003eCardiovascular and cerebrovascular safety\u003c\/u\u003e Patients should be informed that treatment should be suspended if the following symptoms associated with pseudoephedrine content occur: arterial hypertension, tachycardia, cardiac palpitations or arrhythmia, nausea or any neurological sign (onset or exacerbation of headache). \u003cu\u003eIschemic colitis\u003c\/u\u003e Some cases of ischemic colitis have been reported with medicines containing pseudoephedrine. If sudden abdominal pain, rectal tenesmus, rectal bleeding or other symptoms of ischemic colitis develop (see section 4.8), the use of pseudoephedrine should be discontinued and medical advice should be sought. \u003cu\u003eIschemic optic neuropathy\u003c\/u\u003e Cases of ischemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or reduction in visual acuity occurs, for example in the case of a scotoma. If symptoms persist or worsen, or if new symptoms appear, patients should stop using the medicine and consult a doctor. In the rare cases of allergic reactions, the administration of ACTIGRIP DAY \u0026 NIGHT must be suspended. Paracetamol should be used with caution in subjects with renal insufficiency or liver problems. People suffering from alcoholism should contact their doctor before taking paracetamol or other analgesics or antipyretics. Patients with the following respiratory conditions should be advised to consult a doctor before using dephenhydramine: emphysema, chronic bronchitis. The following should not take pseudoephedrine unless the doctor deems it necessary: ​​patients with reduced kidney function and patients with thyroid disease; do not use in patients suffering from hyperthyroidism (see section 4.3). Due to the paracetamol content, the administration of ACTIGRIP DAY \u0026 NIGHT can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method). For\u003cu\u003e those who carry out sporting activities\u003c\/u\u003e: the use of the drug without therapeutic necessity constitutes doping and can still result in positive anti-doping tests. ACTIGRIP DAY \u0026 NIGHT may cause drowsiness. See section 4.8 Undesirable effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe concomitant use of ACTIGRIP DAY \u0026 NIGHT with tricyclic antidepressants, sympathomimetics (for example decongestants, anorectics and amphetamine-like drugs), or with MAOIs can interfere with the catabolism of catecholamines and can occasionally cause increases in blood pressure. Acute hypertensive crises with the concomitant use of MAOIs and sympathomimetic amines have been reported in the medical literature. The effects of anticholinergic drugs (for example atropine and other psychotropic drugs) can be potentiated by the concomitant use of ACTIGRIP DAY \u0026 NIGHT. Patients should be informed that additive effects may occur with alcohol, hypnotics, sedatives and tranquilizers and should therefore not be taken at the same time. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have such an effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). The use of antihistamines simultaneously with certain ototoxic antibiotics can mask the first signs of ototoxicity, which may only reveal itself when the damage is irreversible. The habitual intake of anticonvulsant drugs or oral contraceptives can, with an enzymatic induction mechanism, accelerate the metabolism of paracetamol, decreasing the plasma concentration and increasing its elimination rate. The rate of absorption of paracetamol can be increased by the concomitant intake of metoclopramide and domperidone and decreased by cholestyramine. Treatment with probenecid can lead to a decrease in the clearance of paracetamol and an increase in its half-life in the blood. The use of the product is not recommended if the patient is being treated with antipyretics and other analgesics (NSAIDs, selective COX-2 inhibitors, corticosteroids). Due to the pseudoephedrine content, the effect of antihypertensives that interfere with sympathetic activity (e.g. methyldopa, alpha and beta blockers, debrisoquine, guanethidine, betanidine and bretylium) can be partially canceled by ACTIGRIP DAY \u0026 NIGHT, which therefore should not be taken at the same time. Anticoagulants such as warfarin and other coumarins should not be taken at the same time as ACTIGRIP DAY \u0026 NIGHT as their effect can be increased by prolonged use of paracetamol with greater risk of bleeding. Cases of high anion gap metabolic acidosis due to pyroglutamic acid (5-oxoprolinemia) have been reported with the concomitant use of therapeutic doses of paracetamol and flucloxacillin. Patients reported to be most at risk are elderly women with underlying pathological conditions such as sepsis, renal function abnormalities and malnutrition. Most patients improve after stopping one or both drugs. Before taking ACTIGRIP DAY \u0026 NIGHT, patients should ask their doctor if they are taking the antibiotic flucloxacillin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following are adverse reactions reported with a frequency ≥1%, identified in 12 randomized placebo-controlled studies, with formulations containing pseudophedrine as the single active ingredient.\u003c\/p\u003e\n\u003cp\u003eSystem Organ Class Preferred Term - Pseudophedrine60 mg single dose: (N=229). Pseudophedrine60-120 mg multiple dose: (N=496). Placebo: (N=709).\u003c\/p\u003e\n\u003cp\u003eSystem Organ Class Preferred Term - Pseudophedrine60 mg single dose: % (frequency). Pseudophedrine60-120 mg multiple dose: % (frequency). Placebo: % (frequency).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eDry mouth - Pseudophedrine60 mg single dose: \\. Pseudophedrine60-120 mg multiple dose: 3.6 (Common). Placebo: 1.0 (Common).\u003c\/p\u003e\n\u003cp\u003eNausea - Pseudophedrine60 mg single dose: 4.4 (Common). Pseudophedrine60-120 mg multiple dose: 0.2. Placebo: 1.3 (Common).\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eDizziness - Pseudophedrine60 mg single dose: 5.2 (Common). Pseudophedrine60-120 mg multiple dose: 0.4. Placebo: 2.0 (Common).\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eInsomnia - Pseudophedrine60 mg single dose: 2.2 (Common). Pseudophedrine60-120 mg multiple dose: 4.6 (Common). Placebo: 0.3.\u003c\/p\u003e\n\u003cp\u003eNervousness - Pseudophedrine60 mg single dose: 2.6 (Common). Pseudophedrine60-120 mg multiple dose: 1.8 (Common). Placebo: 0.7.\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects recorded following the intake of ACTIGRIP DAY \u0026 NIGHT. The frequency of side effects is defined using the following convention: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1,000 and \u003c1\/100); Rare (≥1\/10,000 and \u003c1\/1,000); Very rare (\u003c1\/10,000); Not known (cannot be estimated from the available data). \u003cb\u003eVery common side effects:\u003c\/b\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: abdominal or stomach pain, dyspepsia, diarrhea and vomiting, dry throat. \u003cu\u003eNervous system disorders\u003c\/u\u003e: headache, drowsiness, sedation, excitation, increased sweating, sleep disturbances. \u003cu\u003eEye pathologies\u003c\/u\u003e: impaired vision. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: skin rash, urticaria. \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e: dryness of the nose. \u003cb\u003eCommon side effects:\u003c\/b\u003e \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: itching, contact dermatitis, inflammation of the skin or mucous membranes. \u003cu\u003eCardiac diseases\u003c\/u\u003e: orthostatic\/postural hypotension, arrhythmia, tachycardia. \u003cu\u003eNervous system disorders\u003c\/u\u003e: tinnitus, ataxia, euphoria and tremors, hypotension, decreased mucous secretions. \u003cu\u003eEye pathologies\u003c\/u\u003e: diplopia, impaired vision, glaucoma, angle-closure glaucoma. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: disorders of the epigastrium. \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e: dyspnea. \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e: urinary retention. \u003cu\u003eMetabolism and nutrition disorders\u003c\/u\u003e: hyperamylasemia. \u003cu\u003eSystemic pathologies and conditions relating to the administration site\u003c\/u\u003e: fatigue, asthenia. \u003cu\u003eHepatobiliary disorders\u003c\/u\u003e: liver function disorders. \u003cb\u003eUncommon side effects:\u003c\/b\u003e \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: fixed drug eruption (FDE), erythema multiforme, exanthems. \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e: acute renal failure, interstitial nephritis, hematuria, anuria. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: constipation. \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e: sneezing, dryness of the pharynx and bronchial tree. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: photosensitization. \u003cu\u003eNervous system disorders\u003c\/u\u003e: central depression, mental confusion, disorders of cognitive function \u003cb\u003eRare side effects:\u003c\/b\u003e \u003cu\u003eEndocrine disorders\u003c\/u\u003e: hyperthyroidism. \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e: renal papillary necrosis. \u003cu\u003eNervous system disorders\u003c\/u\u003e: hallucinations and nightmares, secondary mania, anxiety, psychiatric disorders, severe headaches, decreased memory or concentration, seizures \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e: blood dyscrasias, agranulocytosis, anemia, hemolytic anemia, thrombocytopenia. \u003cu\u003eImmune system disorders\u003c\/u\u003e: anaphylactic shock, laryngeal edema. \u003cu\u003eHepatobiliary disorders\u003c\/u\u003e: hepatitis. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: pancreatitis. \u003cb\u003eVery rare side effects:\u003c\/b\u003e \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e: leukopenia, neutropenia, pancytopenia. \u003cu\u003eCardiac diseases\u003c\/u\u003e: angina, ST segment elevation, myocardial infarction, hypertension, edema. \u003cu\u003eSkin and subcutaneous tissue disorders:\u003c\/u\u003e angioedema \u003cu\u003eHepatobiliary disorders\u003c\/u\u003e: hepatotoxicity. \u003cu\u003eImmune system disorders\u003c\/u\u003e: toxic shock syndrome. \u003cb\u003eNot known side effects:\u003c\/b\u003e \u003cu\u003eNervous system disorders\u003c\/u\u003e: confusional state, irritability, agitation, abnormal coordination, paraesthesia, psychomotor hyperactivity, feeling nervous, cerebrovascular accident* \u003cu\u003eDiagnostic tests\u003c\/u\u003e: increased transaminases, increased blood pressure. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: pruritic rash, severe skin reactions, including acute generalized exanthematous pustulosis (AGEP) \u003cu\u003e(see paragraph 4.4)\u003c\/u\u003e. \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e: dysuria. \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e: chest discomfort. \u003cu\u003eCardiac diseases\u003c\/u\u003e: palpitations. \u003cu\u003eImmune system disorders\u003c\/u\u003e: hypersensitivity.\u003cu\u003ePsychiatric disorders\u003c\/u\u003e: visual hallucination. \u003cu\u003eGastrointestinal disorders: ischemic colitis* (see section 4.4)\u003c\/u\u003e. \u003cu\u003eEye disorders: Ischemic optic neuropathy\u003c\/u\u003e *adverse reactions collected during post-marketing experience with pseudoephedrine \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system at “http:\/\/www.agenziafarmaco.gov.it\/content\/comesegnalare-una-sospe tta-reazione-avversa.”.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eKeep out of reach of children. In case of overdose,\u003c\/u\u003e ask your doctor for help or contact a poison control center immediately. \u003cu\u003eParacetamol\u003c\/u\u003e In the event of an overdose, immediate treatment is essential. Despite the absence of early symptoms, gastric lavage is necessary within 4 hours of taking quantities greater than 7.5 g of paracetamol; within 48 hours the administration of oral methionine or intravenous N-acetylcysteine ​​is recommended. In the first 24 hours following overdose the following may occur: paleness, nausea, vomiting, diaphoresis, anorexia, abdominal pain and general malaise. Liver toxicity may not be evident by clinical and laboratory tests until 48-72 hours after ingestion and abnormalities in glucose metabolism and metabolic acidosis may occur. The following are clinical events associated with paracetamol overdose, which are considered to be expected, including fatal events due to fulminant hepatic failure, or its consequences. \u003cb\u003eTable n.1: Adverse drug reactions reported in cases of paracetamol overdose.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eSOC: Metabolism and nutrition disorders - Reporting of suspected adverse reactions: Anorexia.\u003c\/p\u003e\n\u003cp\u003eSOC: Gastrointestinal disorders - Reporting of suspected adverse reactions: Vomiting, nausea, abdominal discomfort.\u003c\/p\u003e\n\u003cp\u003eSOC: Hepatobiliary disorders - Reporting of suspected adverse reactions: Hepatic necrosis, acute liver failure, jaundice, hepatomegaly, liver tenderness.\u003c\/p\u003e\n\u003cp\u003eSOC: Systemic disorders and conditions relating to the administration site - Reporting of suspected adverse reactions: Pallor, hyperhidrosis, malaise.\u003c\/p\u003e\n\u003cp\u003eSOC: Investigations - Reporting of suspected adverse reactions: Blood bilirubin increased, liver enzymes increased, international normalized ratio increased, prothrombin time prolonged, blood phosphate increased, blood lactate increased.\u003c\/p\u003e\n\u003cp\u003eCardiac arrhythmias and pancreatitis have been reported. In adults and adolescents (≥ 12 years of age), liver toxicity may occur following ingestion of doses greater than 7.5 to 10 g over a period of 8 hours or less. Fatal events are infrequent (less than 3-4% of untreated cases) and have rarely been reported in cases of overdose of less than 15 g. In children (\u003c12 years), acute overdose less than 150 mg\/kg has not been associated with liver toxicity. Serious toxicity or fatal events following acute overdose in children are extremely uncommon, probably due to differences in the metabolism of paracetamol. The following clinical events are a consequence of acute liver failure and may be fatal. \u003cb\u003eTable n.2: Expected events for acute liver failure associated with paracetamol overdose\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eSOC: Infections and infestations - Reporting of suspected adverse reactions: Sepsis, fungal infection, bacterial infection.\u003c\/p\u003e\n\u003cp\u003eSOC: Blood and lymphatic system disorders - Reporting of suspected adverse reactions: Disseminated intravascular coagulation, coagulopathy, thrombocytopenia.\u003c\/p\u003e\n\u003cp\u003eSOC: Metabolism and nutrition disorders - Reporting of suspected adverse reactions: Hypoglycemia, hypophosphatemia, metabolic acidosis, lactic acidosis.\u003c\/p\u003e\n\u003cp\u003eSOC: Nervous system disorders - Reporting of suspected adverse reactions: Coma (with overdose of paracetamol or multiple drugs), encephalopathy, cerebral edema.\u003c\/p\u003e\n\u003cp\u003eSOC: Cardiac disorders - Reporting of suspected adverse reactions: Cardiomyopathy.\u003c\/p\u003e\n\u003cp\u003eSOC: Vascular disorders - Reporting of suspected adverse reactions: Hypotension.\u003c\/p\u003e\n\u003cp\u003eSOC: Respiratory, thoracic and mediastinal disorders - Reporting of suspected adverse reactions: Respiratory failure.\u003c\/p\u003e\n\u003cp\u003eSOC: Gastrointestinal disorders - Reporting of suspected adverse reactions: Pancreatitis, gastrointestinal haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSOC: Renal and urinary disorders - Reporting of suspected adverse reactions: Acute renal failure with tubular necrosis.\u003c\/p\u003e\n\u003cp\u003eSOC: Systemic disorders and conditions relating to the administration site - Reporting of suspected adverse reactions: Multi-organ failure.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePseudoephedrine\u003c\/u\u003e As with other sympathomimetic agents, symptoms of overdose may include nausea, vomiting, sympathomimetic symptoms including central nervous system stimulation, irritability, agitation, insomnia, tremors, anxiety, convulsions, palpitations, tachycardia, hypertension, reflex bradycardia, difficulty urinating, hallucinations, hypertonicity, hyperreflexia, mydriasis, hypokalemia. Other effects may include arrhythmia, hypertensive crisis, intracelebral hemorrhage, myocardial infarction, psychosis, rhabdomyolysis, intestinal ischemic infarction. If necessary, support breathing and control convulsions, perform gastric lavage and possibly catheterize the patient. In case of overdose, the pesudoephedrine contained in ACTIGRIP DAY AND NIGHT can cause a stroke. The elimination of pseudoephedrine can be accelerated by acid diuresis or dialysis. \u003cu\u003eDiphenhydramine\u003c\/u\u003e \u003ci\u003eMild to moderate symptoms of an overdose include\u003c\/i\u003e: drowsiness, hyperpyrexia and anticholinergic effects (mydriasis, hot flushes, fever, dry mouth, urinary retention, reduced borborygmus). tachycardia, mild hypertension, nausea and vomiting which are common in the presence of overdose. Agitation, confusion, and hallucinations may develop with moderate intoxication. With very high doses, and especially in children, symptoms include: excitement, insomnia, nervousness, tremors and epileptic seizures. \u003ci\u003eSerious symptoms\u003c\/i\u003e: Effects may include delirium, psychosis, seizures, coma, hypotension, cardiovascular collapse, widened QRS, and ventricular arrhythmias, including torsade de pointes, but are generally only reported in adults after large ingestions. Rhabdomyolysis and renal failure may rarely develop in patients with prolonged agitation, coma, or seizures. Death may occur due to respiratory failure or circulatory collapse. Treatment of an overdose is symptomatic and supportive. Measures to promote rapid gastric emptying (such as vomiting or gastric lavage) and, in case of acute poisoning, the intake of activated charcoal are useful. Intravenous administration of physostigmine may antagonize anticholinergic symptoms. \u003ci\u003eEmergency procedure\u003c\/i\u003e In case of taking an excessive dose of ACTIGRIP DAY \u0026 NIGHT: • take the patient immediately to hospital; • take a blood sample to determine initial plasma levels of paracetamol; • carry out gastric lavage; • acidify the urine, administering ammonium chloride to increase the elimination of pseudoephedrine. The treatment of overdose usually involves the administration, as soon as possible, of the N-Acetylcysteine ​​antidote orally or intravenously, if possible before the tenth hour after intake. Symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine is contraindicated in cases of confirmed or presumed pregnancy, and during breastfeeding. There are no adequate and controlled clinical studies in pregnant or breastfeeding women for the combination of diphenhydramine, paracetamol and pseudoephedrine. \u003cu\u003ePregnancy\u003c\/u\u003e Diphenhydramine crosses the placenta and is excreted in breast milk, but levels have not been reported. Paracetamol crosses the placenta. \u003cu\u003eBreastfeeding\u003c\/u\u003e Paracetamol, pseudoephedrine and diphenhydramine are secreted into breast milk; therefore, ACTIGRIP DAY \u0026 NIGHT is contraindicated during breastfeeding. Paracetamol is excreted in breast milk in low concentrations (0.1% to 1.85% of the dose ingested by the mother). Pseudoephedrine is distributed in breast milk; up to 0.6% of a single 60 mg dose can be detected in breast milk over a 24-hour period. No data are available on plasma protein binding in humans. Data from a study of 8 breastfeeding mothers taking 60 mg of pseudoephedrine every 6 hours suggests that approximately 4.3% of the maximum daily dose (240 mg) may be made available to the infant by the breastfeeding mother.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe blue tablets, containing diphenhydramine, an antihistamine substance, can induce drowsiness. If it occurs, driving and using machinery should be avoided.\u003c\/p\u003e","brand":"Johnson \u0026 Johnson","offers":[{"title":"Default Title","offer_id":40739996794995,"sku":"035400023","price":13.48,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/johnson-johnson-spa-actigrip-giorno-e-notte-compresse-12-4-farmacia-dottor-tili-1213792512.jpg?v=1767131190"},{"product_id":"vivin-c-20-compresse-effervescenti-330mg-200mg","title":"Vivin C 20 effervescent tablets 330mg + 200mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHeadache and toothache, neuralgia, menstrual pain, rheumatic and muscular pain. Symptomatic therapy of feverish states and flu and cold syndromes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach tablet contains: \u003cu\u003eActive ingredients\u003c\/u\u003e: acetylsalicylic acid 0.330 g, ascorbic acid 0.200 g. Excipient with known effects: sodium, sodium benzoate. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlycine, anhydrous citric acid, sodium hydrogen carbonate, sodium benzoate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVIVIN C is contraindicated in case of: Hypersensitivity to the active ingredients, (acetylsalicylic acid and ascorbic acid) or to other analgesics (painkillers)\/antipyretics (antipyretics)\/non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients listed in paragraph 6.1; Hemorrhagic diathesis; Gastropathies (e.g. gastro-duodenal ulcer); Asthma; History of gastrointestinal hemorrhage or perforation related to previous active treatment or history of recurrent peptic hemorrhage\/ulcer (two or more distinct episodes of demonstrated ulceration or bleeding); Severe kidney, heart or liver failure; Concomitant treatment with methotrexate (at doses of 15 mg\/week or more) or warfarin (see section 4.5). The use of this medicine is contraindicated in children and adolescents under 16 years of age. Dose \u003e100 mg\/day during the third trimester of pregnancy. Breastfeeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eDosage\u003c\/i\u003e. \u003ci\u003eAdults\u003c\/i\u003e: 1-2 tablets if necessary up to 3-4 times a day. Dissolve one or two VIVIN C tablets in half a glass of non-carbonated water. The product must be taken on a full stomach. Do not exceed the recommended doses. After three days of use at the maximum dose or after 5 days of continuous use, consult your doctor. Special populations. \u003ci\u003ePediatric population\u003c\/i\u003e: VIVIN C is not indicated for use in the pediatric population (see section 4.3) \u003ci\u003eElderly\u003c\/i\u003e: Elderly patients must adhere to the minimum dosages indicated above.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C. Keep the tube tightly closed to protect the medicine from moisture. For storage conditions after first opening, see paragraph 6.3.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine must not be used in children and young people under 16 years of age (see section 4.3). Cases of Reye's syndrome have been observed in children suffering from viral infections (particularly chickenpox and influenza-like conditions) and treated with acetylsalicylic acid. Reye's syndrome is a very rare, but life-threatening disease that requires immediate medical intervention. It manifests itself with persistent vomiting and signs of progressive damage to the central nervous system (drowsiness, up to the appearance of generalized convulsions and coma), signs of liver injury and hypoglycemia. G6PD deficiency, high doses of acetylsalicylic acid can cause hemolysis. In case of G6PD deficiency, acetylsalicylic acid should only be administered under medical supervision. \u003cu\u003eElderly:\u003c\/u\u003e Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal. These patients should start treatment with the lowest available dose (see section 4.2). Subjects over 70 years of age, especially in the presence of concomitant therapies, should use this medicine only after consulting a doctor. \u003cu\u003eCrohn's disease, ulcerative colitis:\u003c\/u\u003e acetylsalicylic acid, like NSAIDs in general, constitutes a risk factor for the clinical recurrence of the disease and can favor the appearance of diverticular complications such as perforation, fistulization and abscesses. It is advisable for patients with gastric and intestinal disorders or reduced renal function (mild to moderate) to consult their doctor. The use of VIVIN C should be avoided concomitantly with NSAIDs, including selective COX-2 inhibitors. Side effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms. Gastrointestinal haemorrhage, ulceration and perforation: Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported during treatment with all NSAIDs, at any time, with or without warning symptoms or previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. Patients being treated with VIVIN C should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. When gastrointestinal bleeding or ulceration occurs in patients taking VIVIN C, treatment should be stopped and not restarted without consulting the doctor. Acetylsalicylic acid and other NSAIDs may cause hypersensitivity reactions (including asthma attacks, rhinitis, angioedema or urticaria). In subjects with asthma and\/or rhinitis (with or without nasal polyposis) and\/or urticaria, reactions may be more frequent and serious. Acetylsalicylic acid modifies uric acid (in the analgesic dose acetylsalicylic acid increases uric acid by inhibiting the excretion of uric acid, at the doses used in rheumatology, acetylsalicylic acid has a uricosuric effect). Caution should be used in patients taking concomitant medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, selective serotonin reuptake inhibitor (SSRI) anticoagulants, or antiplatelet agents such as aspirin (acetylsalicylic acid 50 mg to 375 mg daily). Low molecular weight heparins and fractionated heparins (see section 4.5). In diabetic patients treated with sulfonylureas, for example, salicylics can increase the hypoglycaemic effect of sulfonylureas. (see paragraph 4.5). Caution is required in patients with a history of hypertension and\/or heart failure since, in association with therapy with acetylsalicylic acid, as with other NSAIDs, water retention and edema have been reported. The risk is greater in subjects treated with diuretics. The medicine is contraindicated in severe renal, cardiac or hepatic insufficiency (see section 4.3). The sodium content per effervescent tablet (485 mg) must be taken into consideration in the case of a low-sodium\/low-salt diet in patients with heart failure, high blood pressure and renal failure. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. VIVIN C should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cu\u003eSurgery\u003c\/u\u003e: If you have to undergo surgery (even a small one, for example tooth extractions) and in the previous days you have used acetylsalicylic acid or another NSAID, there is an increased risk of bleeding and the surgeon should be informed due to the possible effects on coagulation. Subjects with a habit of drinking large quantities of alcohol are more exposed to the risk of gastrointestinal lesions (bleeding in particular) (see section 4.5). \u003cu\u003eMetrorrhagia or menorrhagia:\u003c\/u\u003e the simultaneous intake of acetylsalicylic acid may increase the risk of greater intensity and duration of bleeding. \u003cu\u003ePregnancy and breastfeeding (see section 4.6). \u003c\/u\u003e This medicinal product contains 485 mg sodium per tablet equivalent to 24.25% of the WHO recommended maximum daily intake of 2 g sodium per adult. This medicine contains 48 mg sodium benzoate per tablet equivalent to 48 mg \/ 3500mg.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eThe following interactions should be taken into consideration when prescribing VIVIN C:\u003c\/b\u003e \u003cu\u003eMethotrexate\u003c\/u\u003e (doses greater than or equal to 15 mg\/week): increase in plasma levels and toxicity of methotrexate; the risk of toxic effects is greater if renal function is compromised. Avoid concomitant use (see section 4.3). The administration of acetylsalicylic acid, therefore, can potentiate the side effects of methotrexate and the effects and secondary manifestations of all non-steroidal antirheumatic drugs. \u003cu\u003eAnalgesics:\u003c\/u\u003e avoid concomitant administration of other salicylates or other NSAIDs (including topical formulations) due to increased risk of serious side effects. \u003cu\u003eCorticosteroids:\u003c\/u\u003e increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4). \u003cu\u003eAnticoagulants\u003c\/u\u003e: increased risk of bleeding due to inhibition of thrombocytes, risk of lesions of the duodenal mucosa, potentiation of the pharmacological effect and displacement of oral anticoagulants from their binding sites with plasma proteins (see section 4.4). \u003cu\u003eWarfarin:\u003c\/u\u003e serious increase in the risk of hemorrhage due to enhancement of the anticoagulant effect. Avoid concomitant use (see section 4.3) \u003cu\u003eLow molecular weight heparins and unfractionated heparins:\u003c\/u\u003e the joint use of medicines that act at different levels of haemostasis increases the risk of bleeding. \u003cu\u003eAntiplatelet agents \u003c\/u\u003e(e.g. clopidogrel and dipyridamole) and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). \u003cu\u003eAnagrelide\u003c\/u\u003e: increased risk of hemorrhage and decreased antithrombotic effect. If concomitant administration cannot be avoided, clinical monitoring is recommended. \u003cu\u003ePemetrexed\u003c\/u\u003e in patients with mild to moderate reduction in renal function (creatinine clearance between 45 ml\/min and 80 ml\/min); increased risk of pemetrexed toxicity (due to decreased renal elimination of pemetrexed caused by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. \u003cu\u003eAntidiabetics \u003c\/u\u003e(e.g. insulin and oral hypoglycemics): increased hypoglycemic effect; \u003cu\u003eDiuretics and antihypertensives\u003c\/u\u003e: NSAIDs may reduce the antihypertensive effects of diuretics and other antihypertensive agents. As with other NSAIDs, concomitant administration of acetylsalicylic acid with antihypertensives (e.g. ACE inhibitors) or diuretics increases the risk of acute renal failure due to reduced glomerular filtration due to reduced renal synthesis of prostaglandins. \u003cu\u003eValproic acid\u003c\/u\u003e: Acetylsalicylic acid has been reported to reduce the binding of valproate to serum albumin, thereby increasing its steady-state free plasma concentrations. \u003cu\u003eUrine alkalizers\u003c\/u\u003e (e.g. antacids, citrates): antacids taken at the same time as other drugs can reduce their absorption; the excretion of acetylsalicylic acid increases in alkalinized urine. \u003cu\u003eDigoxin and lithium\u003c\/u\u003e: acetylsalicylic acid significantly reduces the renal excretion of digoxin and lithium, resulting in an increase in their plasma concentrations. \u003cu\u003eCarbonic anhydrase inhibitors\u003c\/u\u003e (acetazolamide): reduced elimination of acetazolamide which can cause severe acidosis and increased central nervous system toxicity. \u003cu\u003ePhenytoin\u003c\/u\u003e: increased effect of phenytoin \u003cu\u003eMetoclopramide and domperidone\u003c\/u\u003e: increase in the effect of acetylsalicylic acid due to an increase in the speed of absorption. \u003cu\u003eUricosurics\u003c\/u\u003e (e.g. probenecid and sulfinpyrazone): decrease in the uricosuric effect. \u003cu\u003eChickenpox vaccine\u003c\/u\u003e: It is recommended not to administer salicylates to patients who have received chickenpox vaccination for a period of six weeks after vaccination. Cases of Reye's syndrome have occurred following the use of salicylates during chickenpox infection. \u003cu\u003eZafirlukast\u003c\/u\u003e: increased plasma concentration of zafirlukast. \u003cu\u003eAlcohol\u003c\/u\u003e: increased risk of intestinal bleeding. At doses greater than 2 g per day of vitamin C, ascorbic acid may interfere with the following tests: creatinine and glucose measurements in blood and urine. Metamizole may reduce the effect of acetylsalicylic acid on platelet aggregation, if taken simultaneously. Therefore, this combination should be used with caution in patients taking low-dose aspirin for cardioprotection.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eGastrointestinal disorders:\u003c\/u\u003e \u003c\/i\u003e The most commonly observed adverse events are gastrointestinal in nature. Most side effects are dependent on both the dose and duration of treatment. After administration of VIVIN C the following have been reported: - nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4); - peptic ulcer, even perforated; - Gastrointestinal bleeding, which can be manifest (hematemesis, melena) and sometimes fatal, or occult and cause iron deficiency anemia. Such bleeding is more frequent with increasing dosage, particularly in elderly patients (see section 4.4). - Less frequently, gastritis has been observed. \u003cb\u003eCardiac diseases\u003c\/b\u003e: - Edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e: - Bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. \u003cb\u003ePathologies of the blood and lymphatic system\u003c\/b\u003e: - Hemorrhagic syndromes (epistaxis, gingival hemorrhages, thrombocytopenia, purpura) with increased bleeding time. This effect persists for 4-8 days after stopping the administration of acetylsalicylic acid. It causes bleeding risk in patients undergoing surgery. - High doses of vitamin C (\u003e1g) can increase hemolysis in patients with G6PD-dehydrogenase deficiency in the form of chronic hemolysis \u003cb\u003eImmune system disorders\u003c\/b\u003e: - Hypersensitivity reactions: angioedema, Quincke's edema, urticaria, erythema, asthma, anaphylactic reactions. \u003cb\u003eNervous system disorders\u003c\/b\u003e: - Ringing in the ears; - Sensation of reduced hearing; - Headache, dizziness, usually a sign of overdose. \u003cb\u003ePregnancy, puerperium and perinatal conditions\u003c\/b\u003e: - Delayed birth. \u003cb\u003eRenal and urinary disorders\u003c\/b\u003e: - High doses of vitamin C (\u003e1g) can promote the formation of oxalate and uric acid stones in some individuals. \u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e: Rhinitis, dyspnea. Rarely bronchospasm, asthma attacks. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eToxicity from salicylates (a dosage exceeding 100 mg\/kg\/day for 2 consecutive days can induce toxicity) can be the consequence of a chronic intake of excessive doses, or of acute overdose, potentially dangerous for life and which also includes accidental ingestion in children. Overdose in children can be fatal from 100 mg\/kg\/day in a single dose. Symptoms:- \u003cu\u003eModerate intoxication\u003c\/u\u003e: Ringing in the ear, a feeling of reduced hearing acuity, headache, dizziness are the hallmarks of overdose and can be controlled by reducing the dosage. - \u003cu\u003eSevere poisoning\u003c\/u\u003e: Symptoms include fever, hyperventilation, ketosis, respiratory alkalosis, metabolic acidosis, coma, cardiovascular collapse, respiratory failure, severe hypoglycemia. Emergency guidance: - Immediate transfer to a specialized hospital, - gastric lavage and repeated administration of activated charcoal, - control of acid-base balance, - forced alkaline diuresis to obtain a urinary pH between 7.5 and 8, possibility of hemodialysis in severe poisoning, - compensate for dehydration with adequate fluid intake - symptomatic supportive treatment. In case of overdose, contact a poison control center or the nearest hospital immediately. Acetylsalicylic acid is dialysable.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Low doses (up to 100 mg\/day): Clinical studies indicate that doses up to 100 mg\/day can be considered safe limited to use in obstetrics, which requires specialist monitoring. -Doses of 100-500 mg\/day: There are insufficient clinical data relating to the use of doses higher than 100 mg\/day up to 500 mg\/day. Therefore, the recommendations below for doses of 500 mg\/day and above also apply to this dosage range. -Doses of 500 mg\/day and above: Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations was increased from less than 1% to approximately 1.5%. It has been estimated that the risk increases with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, acetylsalicylic acid should not be administered unless strictly necessary. If acetylsalicylic acid is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to: • cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • renal dysfunction, which can progress to renal failure with oligo-hydramnios. The mother and newborn, at the end of pregnancy, are exposed to: • possible prolongation of bleeding time and anti-aggregating effect which can occur even at very low doses; • inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, acetylsalicylic acid at doses \u003e 100 mg\/day is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e: Acetylsalicylic acid passes into breast milk in small quantities: VIVIN C should not be taken during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable.\u003c\/p\u003e","brand":"Menarini","offers":[{"title":"Default Title","offer_id":46466422800711,"sku":"020096020","price":10.14,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/a-menarini-ind-farm-riun-srl-vivin-c-20-compresse-effervescenti-330mg-200mg-farmacia-dottor-tili-1213792499.jpg?v=1767112330"},{"product_id":"narhinel-soluzione-fisiologica-neonati-20-fiale-5ml","title":"Narhinel Newborn Physiological Solution 20 vials 5ml","description":"\u003cp\u003eNarhinel Physiological Solution is indicated for children and newborns thanks to its \u003cstrong\u003edelicate cleansing action of the nasal cavities\u003c\/strong\u003e. Narhinel Physiological Solution \u003cstrong\u003esoftens mucus\u003c\/strong\u003e and promotes its expulsion thanks to its emollient and fluidifying action. It:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eis indicated in case of \u003cstrong\u003eblocked nose, allergy, cold\u003c\/strong\u003e;\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGently wash your nasal cavities\u003c\/strong\u003e of children, infants and adults;\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003erelieves irritation\u003c\/strong\u003e and protects the mucosa from external agents;\u003c\/li\u003e\n\u003cli\u003ehelps little ones who don't yet know how to blow their nose to feel better and rest well;\u003c\/li\u003e\n\u003cli\u003eit is \u003cstrong\u003eideal for daily washing\u003c\/strong\u003e of the nasal cavities;\u003c\/li\u003e\n\u003cli\u003eis in \u003cstrong\u003esterile disposable bottles\u003c\/strong\u003e;\u003c\/li\u003e\n\u003cli\u003ecan also be used in \u003cstrong\u003eaerosol therapy\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Narhinel Physiological Solution for Newborns 20 vials 5ml used? What is it for?\u003c\/h3\u003e\u003cp\u003ePhysiological solution in sterile disposable vials, indicated for daily cleansing and washing of the nasal cavities of newborns, children and adults in case of blocked nose, allergy or cold; softens mucus by promoting its expulsion and hydrates irritated or dry nasal mucosa.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Narhinel Physiological Solution for Newborns 20 vials 5ml?\u003c\/h3\u003e\u003cp\u003eNarhinel Physiological Solution contains 0.9% sodium chloride and purified water.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Narhinel Physiological Solution for Newborns 20 vials 5ml?\u003c\/h3\u003e\u003cp\u003eNarhinel Saline solution is \u003cstrong\u003esuitable for babies, children and adults\u003c\/strong\u003e.\u003c\/p\u003e\u003cp\u003eFor newborns under 2 weeks, pediatrician advice is recommended before use.\u003c\/p\u003e\u003cp\u003eThe normal frequency of use of Narhinel Saline Solution is 2-4 times per day per nostril. Do this when hiring:\u003c\/p\u003e\u003cp\u003eBefore opening the vial, wash your hands thoroughly. Blow your nose if necessary. Separate a single vial by removing the cap. Lean your head back and insert the nozzle of the vial just behind the nostril. Press the vial carefully to obtain a few drops and with more force if more thorough cleaning is necessary. Wait a few seconds and blow your nose if necessary.\u003c\/p\u003e\u003cp\u003eFor hygienic reasons to avoid infections, the vial must be used by only one person.\u003c\/p\u003e\u003cp\u003eInstructions for use in \u003cstrong\u003eaerosol therapy of Narhinel Physiological Solution for Newborns 20 vials\u003c\/strong\u003e 5ml:\u003c\/p\u003e\u003cp\u003eIf Narhinel Saline Solution for Newborns is used alone, carefully read the instructions given by the manufacturer of the aerosol device.\u003c\/p\u003e\u003cp\u003eIf Narhinel Saline Solution for Newborns is used to dilute a medicine, carefully read the instructions in the medicine leaflet.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Narhinel Physiological Solution for Newborns 20 vials 5ml?\u003c\/h3\u003e\u003cp\u003eNarhinel Physiological Solution is stored in single-dose vials, for external use only. Do not use an open vial. Do not use the product if damaged or broken. Keep out of the reach and sight of children. Do not use the product after the expiry date indicated on the package.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eDue to its cleaning capabilities, it is recommended to use Narhinel before using another nasal product for local use (for example for colds or allergic rhinitis).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Narhinel Physiological Solution for Newborns 20 vials 5ml not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eDo not use the product if you have a known hypersensitivity to any of the ingredients.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Narhinel Physiological Solution for Newborns 20 vials 5ml be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003eIt can be used during pregnancy and breastfeeding. \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eNarhinel Saline Solution can be used during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Narhinel Physiological Solution for Newborns 20 vials 5ml stored?\u003c\/h3\u003e\u003cp\u003eStore Narhinel Saline Solution for Newborns at room temperature. Protect from heat.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Narhinel Physiological Solution for Newborns 20 vials 5ml?\u003c\/h3\u003e\u003cp\u003ePack of 20 vials of 5 ml.\u003c\/p\u003e","brand":"Gsk","offers":[{"title":"Default Title","offer_id":46466547220807,"sku":"903367148","price":3.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/glaxosmithkline-c-health-srl-narhinel-soluzione-fisiologica-neonati-20-fiale-5ml-farmacia-dottor-tili-1213792498.jpg?v=1767112428"},{"product_id":"actifed-decongestionante-12-compresse-2-5mg-60mg","title":"Actifed Decongestant 12 tablets 2.5mg + 60mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDecongestant of the nasal mucosa, especially in case of colds.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eACTIFED tablets\u003c\/b\u003e One tablet contains: • active ingredients: triprolidine hydrochloride 2.5 mg; pseudoephedrine hydrochloride 60.0 mg; • excipients with known effects: lactose. \u003cb\u003eACTIFED syrup\u003c\/b\u003e 100 ml of syrup contains: • active ingredients: triprolidine hydrochloride 0.025 g; pseudoephedrine hydrochloride 0.600 g; • excipients with known effects: sucrose, methyl parahydroxybenzoate, sunset yellow (E110), sodium benzoate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eACTIFED tablets\u003c\/u\u003e Each tablet contains: lactose; corn starch; povidone; magnesium stearate. \u003cu\u003eACTIFED syrup \u003c\/u\u003e 100 ml of syrup contains: glycerol; sucrose; methyl parahydroxybenzoate; sodium benzoate; quinoline yellow (E104); sunset yellow (E110); purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• hypersensitivity to the active substances, to other antihistamines or to any of the excipients listed in paragraph 6.1; • children under the age of 12; • Pregnancy and breastfeeding; • in patients being treated with monoamine oxidase inhibitors (MAOIs) or in the two weeks following such treatment, and in the treatment of lower respiratory tract diseases, including bronchial asthma. In such cases the concomitant use of ACTIFED may cause an increase in blood pressure or hypertensive crisis; • glaucoma, prostatic hypertrophy, bladder neck obstruction, pyloric and duodenal stenosis or other tracts of the gastrointestinal and urogenital system (due to its anticholinergic effects); • cardiovascular diseases, arterial hypertension, hyperthyroidism, epilepsy and diabetes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cb\u003eACTIFED syrup\u003c\/b\u003e The package includes a measuring cup with indicated level marks corresponding to the capacities of 5 and 10 ml. \u003ci\u003eAdults and children over 12 years old\u003c\/i\u003e: a dose of 10 ml of syrup 2 - 3 times a day. \u003cb\u003eACTIFED tablets\u003c\/b\u003e \u003ci\u003eAdults and children over 12 years old:\u003c\/i\u003e one tablet 2 - 3 times a day. \u003cb\u003eDo not exceed the recommended doses\u003c\/b\u003e. \u003cu\u003eMethod of administration \u003c\/u\u003e Oral use\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eACTIFED syrup\u003c\/u\u003e Store away from light. \u003cu\u003eACTIFED tablets \u003c\/u\u003e Store at a temperature not exceeding 25°C, in a dry place.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf symptoms persist or worsen, or if new symptoms appear, patients should stop using the medicine and consult a doctor. If symptoms do not improve within 7 days or if high fever or other side effects appear, patients should be advised to stop treatment and consult their doctor. Before taking triprolidine, patients with the following respiratory conditions such as emphysema, chronic bronchitis, or acute or chronic bronchial asthma, should be advised to consult a doctor. Triprolidine may cause drowsiness and may increase the sedative effects of substances that depress the central nervous system such as alcohol, sedatives, tranquilizers. It is necessary to inform patients that the use of alcoholic beverages should be avoided during treatment with ACTIFED and that it is advisable to consult the doctor before taking ACTIFED concomitantly with medicines that depress the central nervous system. At common therapeutic doses, antihistamines present secondary reactions that vary greatly from subject to subject and from compound to compound. For the dosage in the elderly it is necessary to consider their greater sensitivity towards antihistamines and pseudoephedrine. Although pseudoephedrine did not produce important effects on the blood pressure of normotensive subjects, ACTIFED should not be taken by patients treated with antihypertensives, tricyclic antidepressants, sympathomimetic agents, such as decongestants, anorectics, amphetamine-like agents. Rare cases of posterior reversible encephalopathy have been reported with sympathomimetic drugs, including pseudoephedrine (\u003ci\u003eposterior reversible encephalopathy\u003c\/i\u003e, PRES)\/reversible cerebral vasoconstriction syndrome (\u003ci\u003ereversible cerebral vasoconstriction syndrome\u003c\/i\u003e, RCVS). Reported symptoms include sudden onset of severe headache, nausea, vomiting, and visual disturbances. If signs or symptoms of PRES\/RCVS develop, treatment with pseudoephedrine should be discontinued and a doctor should be consulted immediately. Ischemic colitis Some cases of ischemic colitis have been reported with medicinal products containing pseudoephedrine. If sudden abdominal pain, rectal tenesmus, rectal bleeding or other symptoms of ischemic colitis develop (see section 4.8), the use of pseudoephedrine should be discontinued and medical advice should be sought. Ischemic optic neuropathy Cases of ischemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or reduction in visual acuity occurs, for example in the case of a scotoma. Skin Safety Serious skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with products containing pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules resulting from a widespread edematous erythema and localized mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema, or numerous small pustules are observed, the administration of ACTIFED should be stopped and appropriate measures taken if necessary (see section 4.8). ACTIFED should not be used by patients with severe liver disease or reduced kidney function unless the doctor deems it necessary. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e: \u003cb\u003eACTIFED syrup\u003c\/b\u003e contains: • \u003cb\u003esucrose\u003c\/b\u003e. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. This medicine contains 7 g of sucrose per dose. To be taken into consideration in people suffering from diabetes mellitus; • \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e. May cause allergic reactions (even delayed); • \u003cb\u003esunset yellow (E110)\u003c\/b\u003e. May cause allergic reactions; • 10 mg of sodium benzoate per dose (10 ml of syrup) • less than 1 mmol (23 mg) of sodium per dose (10 ml of syrup), i.e. essentially “sodium-free”. \u003cb\u003eACTIFED tablets\u003c\/b\u003e contains\u003cb\u003e lactose\u003c\/b\u003e: • Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring concomitant use of monoamine oxidase inhibitors (MAOIs) and sympathomimetic amines, acute hypertensive crises have been reported in the medical literature. Pseudoephedrine exerts a vasoconstrictor action by stimulating adrenergic receptors and releasing norepinephrine from neuronal sites. Monoamine oxidase inhibitors (MAOIs) may enhance the pressor effect of pseudoephedrine, as they prevent the metabolism of sympathomimetic amines and increase the releasable amount of norepinephrine in adrenergic nervous tissue. The effects of antihistamines are made more evident by alcohol, hypnotics, sedatives, tranquilizers, and other substances with an anticholinergic action or depressant effect on the central nervous system, which therefore should not be taken during therapy. Antihistamines can shorten the duration of action of oral anticoagulants. The use of antihistamines can mask the early signs of ototoxicity of certain antibiotics. Furazolidone causes a progressive inhibition of monoamine oxidase, so it should not be taken at the same time as ACTIFED. The effect of antihypertensives that interfere with sympathetic activity (e.g. methyldopa, alpha and beta blockers, debrisoquine, guanethidine, betanidine and bretylium) can be partially canceled out by ACTIFED, which therefore, also in this case, should not be taken at the same time.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following are adverse reactions reported with a frequency ≥1%, identified in randomized placebo-controlled studies, with formulations containing pseudophedrine as the single active ingredient: dry mouth, nausea, dizziness, insomnia and nervousness. There are no placebo-controlled clinical studies with sufficient data regarding adverse reactions for the combination of the active ingredients pseuoephedrine and triprolidine. Adverse reactions identified during post-marketing experience with pseudoephedrine, triprolidine or the combination are reported in Table 1 according to frequency categories using the following convention: § very common (≥ 1\/10); • common (≥ 1\/100 and \u003c1\/10); • uncommon (≥ 1\/1,000 and \u003c 1\/100); • rare (≥ 1\/10,000 and \u003c1\/1,000); • very rare (\u003c1\/10,000); • not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Anxiety, euphoric mood, hallucination, restlessness, visual hallucination.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eVery Rare: Headache, paraesthesia, psychomotor hyperactivity (in the pediatric population), drowsiness, tremor.\u003c\/p\u003e\n\u003cp\u003eNot known: Cerebrovascular accident*, posterior reversible encephalopathy (PRES), reversible cerebral vasoconstriction syndrome (RCVS) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eVery Rare: Arrhythmia, extrasystoles, palpitations, tachycardia.\u003c\/p\u003e\n\u003cp\u003eNot known: Myocardial infarction\/Myocardial ischemia*.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eVery Rare: Asthenia.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Epistaxis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Vomiting, abdominal discomfort.\u003c\/p\u003e\n\u003cp\u003eNot known: Ischemic colitis (see section 4.4)*.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eVery rare: Pruritus, rash, urticaria, angioedema. acute generalized exanthematous pustulosis (AGEP) (see section 4.4), angioedema.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Dysuria, urinary retention.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests.\u003c\/p\u003e\n\u003cp\u003eVery rare: Increased blood pressure.\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known: Ischemic optic neuropathy.\u003c\/p\u003e\n\u003cp\u003e*adverse reactions collected during post-marketing experience with pseudoephedrine ACTIFED can also cause dizziness, photosensitivity reaction, diarrhea, hyperviscosity of bronchial secretions, very rarely blood changes and especially in the elderly, hypotension. \u003cb\u003eReporting of suspected adverse reactions.\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioniavverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of overdosage, marked depressant (due to triprolidine) or stimulant (due to pseudoephedrine) effects on the CNS are generally observed. Effects of triprolidine: drowsiness, lethargy, respiratory depression, hypertension, hyperthermia, anticholinergic syndrome (mydriasis, flushing, fever, dry mouth, urinary retention, reduced borborygmi) tachycardia, hypotension, nausea, vomiting, agitation, confusional state, hallucinations, psychosis, convulsions, arrhythmias. Patients suffering from prolonged agitation, coma, or seizures may rarely experience rhabdomyolysis and renal failure Effects of pseudoephedrine: Overdose may cause nausea, vomiting, sympathomimetic symptoms including CNS stimulation, insomnia, mydriasis, irritability, convulsions, anxiety, agitation, hallucinations, palpitations, tachycardia, hypertension, reflex bradycardia. Other effects may include arrhythmias, hypertensive crisis, intracerebral hemorrhage, myocardial infarction, psychosis, rhabdomyolysis, hypokalemia, intestinal infarction. In children the dominant action is the exciting one with accentuated tremors, insomnia, hyperactivity and convulsions, drowsiness has also been reported. Keep out of reach of children. In case of overdose, seek medical help or contact a poison control center immediately.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eACTIFED is contraindicated during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eACTIFED may cause drowsiness; this may impair your ability to drive or use machinery. If this side effect occurs, the patient should avoid driving vehicles and using machinery.\u003c\/p\u003e","brand":"Johnson \u0026 Johnson","offers":[{"title":"Default Title","offer_id":46656369262919,"sku":"018723080","price":12.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/johnson-johnson-spa-actifed-decongestionante-12-compresse-2-5mg-60mg-farmacia-dottor-tili-1213792476.jpg?v=1767112659"},{"product_id":"aspirina-400mg-10-compresse-effervescenti-con-vitamina-c","title":"Aspirin 400mg 10 effervescent tablets with vitamin C","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic therapy of feverish states and flu and cold syndromes. Symptomatic treatment of headaches and toothaches, neuralgia, menstrual pain, rheumatic and muscular pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eASPIRIN 400 mg effervescent tablets with vitamin C One tablet contains: \u003cu\u003eactive ingredients\u003c\/u\u003e: acetylsalicylic acid 400 mg ascorbic acid (Vitamin C) 240 mg For the complete list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eexcipients\u003c\/u\u003e: monosodium citrate sodium bicarbonate sodium carbonate citric acid\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eASPIRIN tablets \u003c\/b\u003eeffervescent with vitamin C is contraindicated in case of: - hypersensitivity to the active ingredients (acetylsalicylic acid and ascorbic acid), to other analgesics (painkillers) \/ antipyretics (antipyretics) \/ non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients; - gastroduodenal ulcer; - hemorrhagic diathesis; - severe renal, cardiac or hepatic failure; - glucose-6-phosphate dehydrogenase deficiency (G6PD\/favism); - concomitant treatment with methotrexate (at doses of 15 mg\/week or more) or with warfarin (see section 4.5); - history of asthma induced by the administration of salicylates or substances with similar activity, in particular non-steroidal anti-inflammatory drugs; - last trimester of pregnancy and breastfeeding (see section 4.6); - children and young people under 16 years of age. - Nephrolithiasis or previous history of nephrolithiasis - Hyperoxaluria - Hemochromatosis\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults 1-2 tablets as a single dose, repeating, if necessary, the dose at intervals of 4-8 hours up to 3-4 times a day. Aspirin C must always be dissolved before use (1 tablet in half a glass of water). The use of the product is reserved for adult patients only. Always use the minimum effective dosage and increase it only if it is not sufficient to relieve symptoms (pain and fever). Subjects most exposed to the risk of serious side effects, who can only use the drug if prescribed by their doctor, must follow the instructions scrupulously (see section 4.4). Use the medicine for the shortest period possible. Do not take the product for more than 3 - 5 days without medical advice. Consult your doctor if symptoms persist. Take the medicine preferably after main meals or, in any case, on a full stomach. \u003cb\u003eSpecial populations\u003c\/b\u003e \u003ci\u003e \u003cu\u003e Pediatric population\u003c\/u\u003e \u003c\/i\u003e Aspirin effervescent tablets with vitamin C are not indicated for use in the pediatric population (see section 4.4). \u003ci\u003eElderly\u003c\/i\u003e In elderly patients use the minimum effective dosage. \u003ci\u003e \u003cu\u003ePatients with impaired liver function \u003c\/u\u003e \u003c\/i\u003e Acetylsalicylic acid should be used with caution in patients with impaired hepatic function (see section 4.4). \u003ci\u003e \u003cu\u003ePatients with impaired renal function \u003c\/u\u003e \u003c\/i\u003e Acetylsalicylic acid should be used with caution in patients with impaired renal function (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature below 25° C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eHypersensitivity reactions\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs may cause hypersensitivity reactions (including asthma attacks, rhinitis, angioedema or urticaria). The risk is greater in subjects who have already presented a hypersensitivity reaction in the past after the use of this type of drug (see section 4.3) and in subjects who present allergic reactions to other substances (e.g. skin reactions, itching, urticaria). In subjects with asthma and\/or rhinitis (with or without nasal polyposis) and\/or urticaria, reactions may be more frequent and serious. In rare cases, reactions can be very serious and potentially fatal. In the following cases, administration of the drug requires a doctor's prescription after careful evaluation of the risk\/benefit ratio: - \u003ci\u003eSubjects at increased risk of hypersensitivity reactions (see above)\u003c\/i\u003e - \u003ci\u003eSubjects at increased risk of gastrointestinal lesions\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs can cause serious side effects at the gastrointestinal level (bleeding, ulcer, perforation). For this reason these drugs should not be used by subjects suffering from gastrointestinal ulcers or gastrointestinal bleeding. It is prudent for those who have suffered from gastrointestinal ulcers or gastrointestinal bleeding in the past to avoid its use. The risk of gastrointestinal lesions is a dose-related effect, as gastrointestinal lesions are greater in subjects who use higher doses of acetylsalicylic acid. Even subjects with a habit of drinking large quantities of alcohol are more exposed to the risk of gastrointestinal lesions (bleeding in particular) (see paragraph 4.5). - \u003ci\u003eSubjects with coagulation defects or being treated with anticoagulants\u003c\/i\u003e In subjects suffering from coagulation defects or being treated with anticoagulants, acetylsalicylic acid and other NSAIDs can cause a serious reduction in haemostatic capacity, exposing them to the risk of haemorrhage. - \u003ci\u003eSubjects with impaired renal, cardiac or hepatic function\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs can cause a critical reduction in renal function and water retention; the risk is greater in subjects treated with diuretics. This can be especially dangerous for the elderly and for those with impaired kidney, heart or liver function. - \u003ci\u003eSubjects suffering from asthma\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs can cause an aggravation of asthma. - \u003ci\u003eGeriatric age (especially above 75 years)\u003c\/i\u003e The risk of serious side effects is greater in geriatric subjects. Individuals over the age of 70, especially in the presence of concomitant therapies, should use Aspirin only after consulting their doctor. Aspirin should not be used in the pediatric population (see section 4.3). Products containing acetylsalicylic acid should not be used in children and adolescents under 16 years of age with viral infections, regardless of the presence or absence of fever. In certain viral diseases, especially influenza A, influenza B and chickenpox, there is a risk of Reye's syndrome, a very rare but life-threatening disease that requires immediate medical intervention. The risk may be increased in case of simultaneous intake of acetylsalicylic acid, although a causal relationship has not been demonstrated. Persistent vomiting in patients with these diseases may be a sign of Reye's syndrome. - \u003ci\u003eSubjects with hyperuricemia\/gout\u003c\/i\u003e Acetylsalicylic acid can interfere with the elimination of uric acid: high doses have a uricosuric effect while (very) low doses can reduce its excretion. It should also be considered that acetylsalicylic acid and other NSAIDs can mask the symptoms of gout, delaying its diagnosis. An antagonistic effect with uricosuric drugs is also possible (see section 4.5).- \u003ci\u003eSubjects with a predisposition to calcium-oxal nephrolithiasis (kidney stones) or with recurrent nephrolithiasis\u003c\/i\u003e \u003ci\u003eAspirin effervescent tablets with vitamin C\u003c\/i\u003e: Vitamin C (ascorbic acid) should be used with caution by subjects with a predisposition to calcium-oxal nephrolithiasis (kidney stones) or with recurrent nephrolithiasis. - \u003ci\u003eCombination of drugs not recommended or requiring special precautions or dosage adjustment\u003c\/i\u003e. The use of acetylsalicylic acid in combination with some drugs may increase the risk of serious side effects (see section 4.5). Do not use acetylsalicylic acid together with another NSAID or, in any case, do not use more than one NSAID at a time. If you have to undergo surgery (even a small one, for example the extraction of a tooth) and in the previous days you have used acetylsalicylic acid or another NSAID, you must inform the surgeon due to the possible effects on coagulation. Since acetylsalicylic acid can cause gastrointestinal bleeding, this must be taken into account if it is necessary to carry out a search for occult blood. Before administering any medicine, all necessary precautions must be taken to prevent unwanted reactions; particularly important is the exclusion of previous hypersensitivity reactions to this or other medicines and the exclusion of other contraindications or conditions that may expose you to the risk of potentially serious side effects listed above. If in doubt, consult your doctor or pharmacist. Imperfect and prolonged storage of Aspirin C can cause variations in the color of the tablet which in themselves do not affect either the activity or tolerability of the active ingredient. In this case, it is still advisable to ask the pharmacy for the packaging to be replaced. The product must be taken on a full stomach. \u003cb\u003e \u003ci\u003eInformation on excipients\u003c\/i\u003e \u003c\/b\u003e This medicinal product contains 467 mg sodium per effervescent tablet equivalent to 23% of the WHO recommended maximum daily intake of 2 g sodium for an adult.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eContraindicated combinations (avoid concomitant use - see section 4.3):\u003c\/i\u003e - \u003cu\u003eMethotrexate (doses greater than or equal to 15 mg\/week)\u003c\/u\u003e: increased plasma levels and toxicity of methotrexate; the risk of toxic effects is greater if renal function is compromised. - \u003cu\u003eWarfarin:\u003c\/u\u003e serious increase in the risk of hemorrhage due to enhancement of the anticoagulant effect. \u003ci\u003eAssociations not recommended (the concomitant use of the two drugs requires a doctor's prescription after careful evaluation of the risk\/benefit ratio - see section 4.4):\u003c\/i\u003e \u003cu\u003eAntiplatelet agents:\u003c\/u\u003e increased risk of hemorrhage due to the sum of the anti-aggregating effect. \u003cu\u003eOral or parenteral thrombolytics or anticoagulants\u003c\/u\u003e: increased risk of bleeding due to enhancement of the pharmacological effect. \u003cu\u003eNSAIDs\u003c\/u\u003e (topical use excluded): increased risk of serious side effects. \u003cu\u003eMethotrexate (doses less than 15mg\/week)\u003c\/u\u003e: the increased risk of toxic effects (see above) must also be considered for treatment with methotrexate at low doses. \u003cu\u003eSelective serotonin re-uptake inhibitors (SSRIs):\u003c\/u\u003e increased risk of upper gastrointestinal bleeding due to a possible synergistic effect. \u003ci\u003eAssociations requiring particular precautions or dosage adjustment (concomitant use of the two drugs requires a doctor's prescription after careful evaluation of the risk\/benefit ratio - see section 4.4):\u003c\/i\u003e \u003cu\u003eACE inhibitors:\u003c\/u\u003e reduction of the hypotensive effect; increased risk of impaired renal function. \u003cu\u003eValproic Acid:\u003c\/u\u003e increased effect of valproic acid (risk of toxicity). \u003cu\u003eAntacids:\u003c\/u\u003e antacids taken at the same time as other drugs can reduce their absorption; the excretion of acetylsalicylic acid increases in alkalinized urine. \u003cu\u003eAntidiabetics (e.g. insulin and oral hypoglycemics)\u003c\/u\u003e: increased hypoglycemic effect; the use of acetylsalicylic acid in subjects being treated with antidiabetics must take into account the risk of inducing hypoglycemia. \u003cu\u003eDigoxin:\u003c\/u\u003e increased plasma concentration of digoxin due to decreased renal elimination. \u003cu\u003eDiuretics\u003c\/u\u003e: increased risk of nephrotoxicity of acetylsalicylic acid and other NSAIDs; reduction of the effect of diuretics. \u003cu\u003eAcetazolamide\u003c\/u\u003e: reduced elimination of acetazolamide (risk of toxicity). \u003cu\u003ePhenytoin: \u003c\/u\u003eincreased effect of phenytoin. \u003cu\u003eCorticosteroids \u003c\/u\u003e(excluding those for topical use and those used for the treatment of adrenocortical insufficiency): a) increased risk of gastrointestinal lesions; b) due to the increased elimination of salicylates induced by corticosteroids there is a reduction in plasma levels of salicylate. On the other hand, after discontinuation of corticosteroid treatment, overdose of salicylates may occur. \u003cu\u003eMetoclopramide\u003c\/u\u003e: increase in the effect of acetylsalicylic acid due to an increase in the speed of absorption. \u003cu\u003eUricosurics (e.g. probenecid, benzbromarone)\u003c\/u\u003e: decrease in the uricosuric effect. \u003cu\u003eZafirlukast\u003c\/u\u003e: increased plasma concentration of zafirlukast. Deferoxamine Aspirin effervescent tablets with vitamin C: the concomitant use of ascorbic acid can cause increased tissue toxicity of iron especially at the cardiac level and cause heart failure. Aspirin effervescent tablets with Vitamin C contain buffer systems that may reduce the effects of the thyroid hormone Levothyroxine. \u003ci\u003eAlcohol (see section 4.4)\u003c\/i\u003e The sum of the effects of alcohol and acetylsalicylic acid causes increased damage to the gastrointestinal mucosa and prolongation of bleeding time. However, it is advisable not to administer other drugs orally within 1 or 2 hours of using the product. \u003cb\u003e \u003cu\u003eInterference with clinical laboratory tests \u003c\/u\u003e \u003c\/b\u003e Vitamin C Because vitamin C is a reducing agent (i.e., an electron donor), it may cause chemical interference in laboratory tests involving oxidation-reduction reactions, such as analyzes of glucose, creatinine, carbamazepine, uric acid in urine, serum, and fecal occult blood. Vitamin C can interfere with tests that measure urine and blood glucose leading to a false reading of the results even if it has no effect on blood glucose levels.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe most frequently observed side effects affect the gastrointestinal system and can occur in approximately 4% of subjects taking acetylsalicylic acid as an analgesic-antipyretic. This percentage increases significantly in subjects at risk of gastrointestinal disorders. These disorders can be partially alleviated by taking the medicine on a full stomach. Most side effects are dependent on both the dose and duration of treatment. The side effects observed with acetylsalicylic acid are generally common to other NSAIDs. \u003cb\u003ePathologies of the blood and lymphatic system\u003c\/b\u003e Prolonged bleeding time, anemia due to gastrointestinal bleeding, reduction in platelets (thrombocytopenia) in extremely rare cases. Following hemorrhage, hemorrhagic\/iron-deficiency anemia may occur (due, for example, to occult microhemorrhages) with the related alterations in laboratory parameters and the related clinical signs and symptoms such as asthenia, pallor and hypoperfusion. \u003cb\u003eNervous system disorders\u003c\/b\u003e Headache, dizziness. Rarely: Reye's syndrome (*) Rarely to very rarely: cerebral hemorrhage, especially in patients with uncontrolled hypertension and\/or on anticoagulant therapy, which, in isolated cases, can be potentially lethal. \u003cb\u003eEar and labyrinth disorders\u003c\/b\u003e Tinnitus (buzzing\/rustling\/ringing\/ringing in the ears). \u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e Respiratory disease exacerbated by acetylsalicylic acid, asthma syndrome, rhinitis (profuse rhinorrhoea), nasal congestion (associated with hypersensitivity reactions). Epistaxis. \u003cb\u003e \u003ci\u003eCardiac diseases\u003c\/i\u003e \u003c\/b\u003e Cardiorespiratory distress (associated with hypersensitivity reactions) \u003cb\u003e \u003ci\u003eEye pathologies\u003c\/i\u003e \u003c\/b\u003e Conjunctivitis (associated with hypersensitivity reactions) \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e Gastrointestinal bleeding (occult), gastric disorders, heartburn, gastrointestinal pain, gingivorrhagia. Vomiting, diarrhoea, nausea, crampy abdominal pain (associated with hypersensitivity reactions). Rarely: gastrointestinal inflammation, gastrointestinal erosion, gastrointestinal ulceration, hematemesis (vomiting of blood or \"coffee-like\" material), melena (emission of black stools, esophagitis). Very rarely: hemorrhagic gastrointestinal ulcer and\/or gastrointestinal perforation with the related clinical signs and symptoms and alterations of laboratory parameters. Frequency not known (especially in long-term treatment): - Disease of the intestinal diaphragms. \u003cb\u003e \u003ci\u003eHepatobiliary disorders\u003c\/i\u003e \u003c\/b\u003e Rarely: hepatotoxicity (generally mild and asymptomatic hepatocellular injury) manifested by an increase in transaminases. \u003cb\u003e \u003ci\u003ePathologies of the skin and subcutaneous tissues\u003c\/i\u003e \u003c\/b\u003e Rash, edema, urticaria, pruritus, erythema, angioedema (associated with hypersensitivity reactions). \u003cb\u003e \u003ci\u003eRenal and urinary disorders\u003c\/i\u003e \u003c\/b\u003e Alteration of renal function (in the presence of conditions of altered renal hemodynamics) and acute renal injury, urogenital haemorrhages. \u003cb\u003e \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e \u003c\/b\u003e Procedural hemorrhages, hematomas. \u003cb\u003e \u003ci\u003eImmune system disorders\u003c\/i\u003e \u003c\/b\u003e Rarely: anaphylactic shock with related alterations in laboratory parameters and clinical manifestations. (*) Reye's syndrome (SdR) SdR initially manifests itself with vomiting (persistent or recurrent) and with other signs of encephalic distress of varying degrees: from listlessness, drowsiness or personality changes (irritability or aggressiveness) to disorientation, confusion or delirium up to convulsions or loss of consciousness. The variability of the clinical picture must be kept in mind: vomiting may also be absent or replaced by diarrhea. If these symptoms arise in the days immediately following a flu episode (or flu-like or chickenpox or another viral infection) during which acetylsalicylic acid or other medicines containing salicylates were administered, the doctor's attention must immediately be paid to the possibility of an SdR. \u003cu\u003e Reporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of the Italian Medicines Agency. Website: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAcetylsalicylic acid\u003c\/u\u003e Toxicity from salicylates (a dosage exceeding 100 mg\/kg\/day for 2 consecutive days can induce toxicity) can be the consequence of chronic intake of excessive doses, or of acute overdose, potentially dangerous for life and which also includes accidental ingestion in children. Chronic salicylate intoxication Poisoning\u003cb\u003e chronic\u003c\/b\u003e from salicylates can be insidious since the signs and symptoms are nonspecific. Mild chronic salicylate intoxication, or salicylism, generally occurs only following repeated use of large doses. Symptoms include dizziness, vertigo, tinnitus, deafness, sweating, nausea and vomiting, headache and confusion. These symptoms can be controlled by reducing the dosage. Tinnitus can occur at plasma concentrations between 150 and 300 micrograms\/ml, while more serious adverse events occur at concentrations above 300 micrograms\/ml. Acute salicylate intoxication The main feature of intoxication\u003cb\u003e acute\u003c\/b\u003e it is a serious alteration of the acid-base balance, which can vary with age and the severity of the intoxication; the most common presentation in children is metabolic acidosis. It is not possible to estimate the severity of poisoning from plasma concentrations alone; the absorption of acetylsalicylic acid may be delayed due to reduced gastric emptying, the formation of concretions in the stomach, or as a consequence of the ingestion of gastro-resistant preparations. The management of acetylsalicylic acid poisoning is determined by the extent, stage and clinical symptoms of the latter, and must be implemented according to conventional poisoning management techniques. The main measures to be taken consist in accelerating drug excretion and restoring electrolyte and acid-base metabolism. Due to the complex pathophysiological effects connected with salicylate poisoning, the signs and symptoms\/results of biochemical and instrumental investigations may include:\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: MILD TO MODERATE INTOXICATION - Therapeutic measures: Gastric lavage, repeated administration of activated charcoal, forced alkaline diuresis.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Tachypnoea, hyperventilation, respiratory alkalosis - Results of biochemical and instrumental investigations: Alkalemia, alkaluria. Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Sweating.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Nausea, vomiting, headache, dizziness.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: MODERATE TO SEVERE INTOXICATION - Therapeutic measures: Gastric lavage, repeated administration of activated charcoal, forced alkaline diuresis, hemodialysis in severe cases.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Respiratory alkalosis with compensatory metabolic acidosis, - Results of biochemical and instrumental investigations: Acidemia, aciduria. Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Hyperpyrexia - Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Respiratory: ranging from hyperventilation and non-cardiogenic pulmonary edema to respiratory arrest and asphyxia.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Cardiovascular: variable from arrhythmias and hypotension to cardiac arrest - Results of biochemical and instrumental investigations: E.g. alteration of blood pressure, alteration of ECG.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Loss of fluids and electrolytes: dehydration, from oliguria to renal failure - Results of biochemical and instrumental investigations: E.g. hypokalemia, hyperna–tremia, hyponatremia, impaired renal function. Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Alterations of glucose metabolism, ketosis - Results of biochemical and instrumental investigations: Hyperglycemia, hypoglycemia (especially in children) Increased levels of ketones.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Tinnitus, deafness\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Gastrointestinal: gastrointestinal bleeding, gastric ulcer.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Haematological: coagulopathy, iron deficiency anemia - Results of biochemical and instrumental investigations: E.g. prolonged PT, hypoprothrombinemia.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Neurological: toxic encephalopathy and CNS depression with manifestations ranging from lethargy and confusion to coma and convulsions. Cerebral edema.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Liver: liver damage - Results of biochemical and instrumental investigations: Increased levels of liver enzymes.\u003c\/p\u003e\n\u003cp\u003eAt high doses the following may also appear: Taste alterations. Skin rashes (acneiform, erythematous, scarlatiniform, eczematoid, desquamative, bullous, purpuric), itching. Others: conjunctivitis, anorexia, reduced visual acuity, drowsiness. Rarely: aplastic anemia, agranulocytosis, disseminated intravascular coagulation, pancytopenia, leukopenia, thrombocytopenia, eosinopenia, purpura, eosinophilia associated with drug-induced hepatotoxicity, nephrotoxicity (allergic tubulointerstitial nephritis), hematuria (presence of blood in the urine). Acute allergic reactions following the intake of acetylsalicylic acid can be treated, if necessary, with the administration of adrenaline, corticosteroids and an antihistamine. In case of overdose, contact a poison control center or the nearest hospital immediately. Acetylsalicylic acid is dialysable. \u003cu\u003eAscorbic acid\u003c\/u\u003e Aspirin 400 mg effervescent tablets with vitamin C contains ascorbic acid: Single cases of acute and chronic overdose of \u003cb\u003eascorbic acid\u003c\/b\u003e. Overdose of ascorbic acid may cause oxidative haemolysis in patients with glucose-6-phosphate dehydrogenase deficiency, disseminated intravascular coagulation and significantly elevated serum and urinary oxalate levels. Increased levels of oxalates have been shown to result in the formation of calcium oxalate deposits in dialysis patients. High doses of vitamin C may cause calcium oxalate deposits, calcium oxalate crystalluria in patients with a predisposition to crystal formation, tubulointerstitial nephropathy, and acute renal failure resulting from calcium oxalate crystals.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eFertility\u003c\/u\u003e The use of acetylsalicylic acid as well as any drug that inhibits the synthesis of prostaglandins and cyclooxygenase could interfere with fertility; female subjects and in particular women who have fertility problems or who are undergoing fertility investigations must be informed of this. \u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations was increased from less than 1% to approximately 1.5%. It has been estimated that the risk increases with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, acetylsalicylic acid should not be administered unless clearly necessary. If drugs containing acetylsalicylic acid are used by a woman trying to get pregnant, or during the first and second trimester of pregnancy, treatment should be as short as possible and the dose as low as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose: the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the unborn child, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, acetylsalicylic acid is contraindicated during the third trimester of pregnancy. \u003cu\u003e Breastfeeding\u003c\/u\u003e ASPIRIN 400 mg effervescent tablets with vitamin C is contraindicated during breastfeeding (see section 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDue to the possible onset of headache or dizziness, this medicine may impair the ability to drive and use machinery.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131203060039,"sku":"004763114","price":7.27,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-aspirina-400mg-10-compresse-effervescenti-con-vitamina-c-farmacia-dottor-tili-1213792388.jpg?v=1767132850"},{"product_id":"rinofluimucil-1-0-5-spray-nasale-soluzione-10ml","title":"Rinofluimucil 1% + 0.5% nasal spray solution 10ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Acute and subacute rhinitis, especially with mucopurulent and slowly resolving exudates. - Chronic and mucus-crusty rhinitis. - Vasomotor rhinitis. - Sinusitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of solution contains: \u003cb\u003eActive ingredients\u003c\/b\u003e N-Acetylcysteine: 1,000 g; Tuaminoheptane sulphate: 0.500 g. Excipients with known effects: benzalkonium chloride Mint flavor containing d-limonene For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzalkonium chloride, Dithiothreitol, Sodium edetate, Dibasic sodium phosphate, Monobasic sodium phosphate, Sodium hydroxide, Alcohol, Hypromellose, Sorbitol 70%, Natural mint flavor (containing d-limonene), Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients. - Cardiovascular disease, including hypertension. - Previous cerebrovascular disease, including the presence of important risk factors (due to alpha-sympathomimetic activity). - Previous convulsions. - Narrow angle glaucoma. - Hyperthyroidism. - During and in the two weeks following therapy with monoamine oxidase inhibitors (MAOIs). - Children under the age of 12. - Pheochromocytoma. - During use of other sympathomimetic agents, including other nasal decongestants. - Hypophysectomy or surgical interventions with exposure of the dura mater.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRINOFLUIMUCIL is used for applications in the nasal cavities, using the appropriate dosage dispenser (see paragraph 6.6). ADULTS: 2 sprays in each nostril 3-4 times a day. CHILDREN over 12 years: 1 spray in each nostril 3-4 times a day. Do not exceed the indicated doses. The bottle, when opened, can be used for a period not exceeding 20 days.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo details.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdminister with caution in subjects suffering from occlusive vascular disease, asthma, diabetes and in therapy with beta-blocking drugs. Rinofluimucil should be administered with caution in pediatric age and is in any case contraindicated in children under 12 years of age. Prolonged use of preparations containing vasoconstrictors can alter the normal function of the mucosa of the nose and paranasal sinuses, also inducing addiction to the drug. Repeating applications for long periods can therefore be harmful. Use the product with caution due to the risk of urinary retention in the elderly and in those with prostatic hypertrophy. The use, especially if prolonged, of topical products can give rise to sensitization phenomena: in this case it is necessary to interrupt the treatment and, if necessary, institute a suitable therapy. However, in the absence of a complete therapeutic response within a few days, consult your doctor; in any case the treatment must not be continued for more than a week. The action of the preparation can be integrated, in the doctor's opinion, with an appropriate antibacterial covering. Patients should be advised to discontinue treatment if they develop arterial hypertension, tachycardia, palpitations, heart rhythm disturbances, nausea or any neurological signs and symptoms (such as headache or worsening of existing headache). Tuaminoheptane sulfate can cause a positive anti-doping test. The preparation is not for ophthalmic use. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e: This medicine contains 0.005 mg of benzalkonium chloride in each actuation. Prolonged use may cause edema of the nasal mucosa. The mint flavoring in this medicine contains d-limonene which may cause allergic reactions. In addition to allergic reactions in patients sensitive to the allergen, non-sensitive patients may become sensitive.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDespite the poor systemic absorption of tuaminoheptane administered intranasally, the following potential interactions must be taken into consideration: - monoamine oxidase inhibitors (MAOIs), including reversible monoamine oxidase inhibitors (RIMA): increased risk of hypertensive crisis; - antihypertensives (including adrenergic neuron blockers and beta blockers): can block hypotensive effects; - cardiac glycosides: they can increase the risk of dysrhythmia; - ergot alkaloids: they can increase the risk of ergotism; - antiparkinsonian drugs: they can increase the risk of cardiovascular toxicity; - oxytocin: may increase the risk of hypertension.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSecurity Profile Summary:\u003c\/b\u003e Prolonged use can alter the normal functionality of the nasal and paranasal mucosa, causing nasal congestion and inducing addiction to the drug. \u003cb\u003eSummary table of adverse reactions:\u003c\/b\u003e Frequent administration of the preparation at higher doses can cause sympathomimetic side effects (such as increased excitability, heart palpitations, tremor, etc.). Sometimes dryness of the nose and throat, acne rashes may occur. These effects disappear completely when treatment is discontinued. The following side effects may be associated with the use of Rinofluimucil:\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Adverse reactions Frequency not known°: Hypersensitivity\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Adverse reactions Frequency not known°: anxiety*, hallucination*, delirium*.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reactions Frequency not known°: headache*, restlessness*, agitation*, insomnia*, tremor*.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Adverse reactions Frequency not known°: palpitations*, tachycardia*, arrhythmia*.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Adverse reactions Frequency not known°: Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Adverse reactions Frequency not known°: dry nose and throat*, nasal discomfort*, nasal congestion*.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reactions Frequency not known°: Nausea.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reactions Frequency not known°: Urticaria, rash.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Adverse reactions Frequency not known°: Urinary retention.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the site of administration - Adverse reactions Frequency not known°: irritability,* habituation to the drug*.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e° not known (cannot be estimated from available data)\u003c\/i\u003e * Particularly with prolonged and\/or excessive use \u003cb\u003ePediatric population:\u003c\/b\u003e The product is contraindicated in children under 12 years of age (see section 4.3). \u003cb\u003eReporting of suspected adverse reactions.\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of overdose in adults, arterial hypertension, photophobia, intense headache, chest tightness may appear. \u003cb\u003ePediatric population\u003c\/b\u003e In case of overdose, hypothermia with marked sedation may appear in children. \u003cb\u003eTreatment\u003c\/b\u003e These events require the adoption of appropriate emergency measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e: Data relating to a limited number of pregnant women exposed to N-acetylcysteine ​​have not indicated any negative effects on the pregnancy itself or on the health of the foetus\/newborn. At present, no further relevant epidemiological data are available. Animal studies with N-acetylcysteine ​​have demonstrated no direct or indirect harmful effects regarding reproductive toxicity. There are no data on exposed pregnant women or animal studies with tuaminoheptane or N-acetylcysteine ​​+ tuaminoheptane. The product is not recommended during pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e: There is no information available on the excretion of N-acetylcysteine and thyaminoheptane in breast milk. A risk to the infant cannot be excluded. The product should not be used by breastfeeding mothers. \u003cu\u003eFertility:\u003c\/u\u003e There are no animal fertility studies available with N-acetylcysteine + thyaminoheptane. Furthermore, no data on humans is available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no assumptions or evidence that the drug can change attention skills and reaction times. However, patients should be informed that effects such as hallucinations have been reported.\u003c\/p\u003e","brand":"Zambon","offers":[{"title":"Default Title","offer_id":51131205026119,"sku":"021993050","price":8.56,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zambon-italia-srl-rinofluimucil-1-0-5-spray-nasale-soluzione-10ml-farmacia-dottor-tili-1213792382.jpg?v=1767132971"},{"product_id":"zerinol-300mg-2mg-20-compresse-rivestite","title":"Zerinol 300mg + 2mg 20 coated tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of flu and cold symptoms in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne coated tablet contains: paracetamol 300 mg, chlorphenamine maleate 2 mg. Excipient with known effects: sucrose. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCorn starch; microcrystalline cellulose; povidone; magnesium stearate; carmellose sodium; talc; sucrose; jelly; macrogol 6000; calcium carbonate; water-soluble chlorophyll; gum arabic; carnauba wax.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eZerinol is contraindicated in the following cases: - hypersensitivity to paracetamol or chlorphenamine, to other antihistamines of similar chemical structure or to any of the excipients listed in paragraph 6.1; - pregnancy and breastfeeding; - patients with manifest insufficiency of glucose-6-phosphate dehydrogenase and patients suffering from severe hemolytic anemia; - severe hepatocellular insufficiency (Child-Pugh C); - glaucoma, prostatic hypertrophy, bladder neck obstruction, pyloric and duodenal stenosis or other tracts of the gastrointestinal and urogenital system, due to anticholinergic effects; - patients being treated with monoamine oxidase inhibitors (MAOIs) or in the two weeks following such treatment (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cb\u003eAdults:\u003c\/b\u003e 1 coated tablet, twice a day. \u003cb\u003ePediatric population:\u003c\/b\u003e The safety and effectiveness of Zerinol in patients under 18 years of age have not been established. \u003cu\u003eMethod of administration\u003c\/u\u003e Oral use. The tablet should be taken with water after meals. \u003cu\u003eDuration of treatment\u003c\/u\u003e Patients should be advised to contact their doctor if fever persists or symptoms do not improve after 3 days of treatment (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not administer for more than 3 consecutive days without consulting your doctor. If the fever persists for more than three days or if the symptoms do not improve and others appear within three days or are accompanied by high fever, rash, excessive amount of mucus and persistent cough, consult your doctor before continuing the administration. \u003cu\u003eParacetamol\u003c\/u\u003e During treatment with Zerinol, check that no other medicine containing paracetamol is taken at the same time, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other drug. See also paragraph 4.5. High or prolonged doses of the product can cause high-risk liver disease (see also section 4.9) and even serious alterations in the kidney and blood. In case of acute hypersensitivity reactions to paracetamol (e.g. anaphylactic shock), treatment with Zerinol should be discontinued and necessary medical measures should be implemented based on the signs and symptoms. \u003cu\u003eChlorphenamine maleate\u003c\/u\u003e At common therapeutic doses, antihistamines present secondary reactions that vary greatly from subject to subject and from compound to compound. The most frequent side effect is sedation which can manifest itself with drowsiness; Those who may drive motor vehicles or carry out operations that require integrity of the level of supervision must be warned of this (see paragraph 4.7). \u003cu\u003ePatients with renal or hepatic insufficiency\u003c\/u\u003e Administer with caution in subjects with renal or hepatic insufficiency. \u003cu\u003eElderly people\u003c\/u\u003e Particular attention should be paid when determining the dose in the elderly due to their greater sensitivity towards the drug. In elderly patients treated with antihistamines, effects such as dizziness, sedation, confusion and hypotension may be more likely to occur. Elderly patients are particularly sensitive to the anticholinergic side effects of antihistamines such as dry mouth and urinary retention (especially in men). \u003cu\u003eSucrose\u003c\/u\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or insufficiency of the sucrose-isomaltase enzyme should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eParacetamol\u003c\/u\u003e Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). Normally harmless doses of acetaminophen can cause liver damage if taken together with these drugs. The same applies to potentially hepatotoxic substances and in case of alcohol abuse. Habitual ingestion of anticonvulsant drugs or oral contraceptives can, through an enzymatic induction mechanism, accelerate the metabolism of paracetamol. The use of the product is not recommended if the patient is being treated with anti-inflammatories. Taking probenecid inhibits the binding of paracetamol to glucuronic acid, thereby reducing the clearance of paracetamol by a factor of approximately 2. Therefore, the dose of paracetamol should be reduced if administered in combination with probenecid. Cholestyramine reduces the absorption of acetaminophen if administered within 1 hour of acetaminophen administration. It is not yet possible to establish the clinical relevance of the interactions between paracetamol and oral anticoagulants. Therefore, prolonged use of paracetamol in patients being treated with oral anticoagulants is advisable only under medical supervision. Combining acetaminophen with chloramphenicol may prolong the half-life of chloramphenicol, increasing the risk of toxicity. The concomitant use of paracetamol and zidovudine increases the tendency of the latter to reduce the number of leukocytes (neutropenia). Therefore, you should only take Zerinol together with zidovudine under your doctor's supervision. Medicines that slow gastric emptying, such as propantheline, reduce the speed of absorption of paracetamol and delay the onset of its effect. However, medicines that accelerate gastric emptying, such as metoclopramide, lead to an increase in the speed of absorption. \u003cu\u003eInterference with laboratory tests\u003c\/u\u003e The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method). \u003cu\u003eChlorphenamine maleate\u003c\/u\u003e Other substances with anticholinergic action should not be taken at the same time as Zerinol, as these can cause significant interactions. The product is contraindicated in patients being treated with monoamine oxidase inhibitors (MAOIs) or in the two weeks following such treatment (see section 4.3) as these may prolong and intensify the anticholinergic and central nervous system (CNS) depressant effects of chlorphenamine maleate. The product may interact with alcohol, tricyclic antidepressants, neuroleptics or other drugs with a depressant action on the central nervous system such as barbiturates, sedatives, tranquilizers, hypnotics. These products should not be taken during therapy with Zerinol as they can cause an increase in the sedative effect. The use of antihistamines can mask the first signs of ototoxicity of certain antibiotics. Chlorphenamine inhibits the metabolism of phenytoin and may cause phenytoin toxicity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the use of Zerinol, the following side effects may occur. The frequency of these side effects cannot be estimated from the available data. \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e: - thrombocytopenia, leukopenia, anemia, agranulocytosis, pancytopenia. \u003cu\u003eImmune system disorders\u003c\/u\u003e: - hypersensitivity reactions such as angioedema, laryngeal edema, anaphylactic shock. \u003cu\u003eNervous system disorders\u003c\/u\u003e: - drowsiness, asthenia, dizziness, headache, inability to concentrate. \u003cu\u003eEye pathologies\u003c\/u\u003e: - blurred vision. \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e: - thickening of bronchial secretions. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: - dry mouth, nausea. \u003cu\u003eHepatobiliary disorders:\u003c\/u\u003e - alterations in liver function and hepatitis. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: - skin reactions of various types and severity have been reported with the use of paracetamol including cases of urticaria, erythema multiforme, very rare cases of serious skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). Photosensitization. \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e: - renal alterations (acute renal failure, interstitial nephritis, hematuria, anuria), urinary retention. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e In case of overdose, marked depressive or stimulant effects on the central nervous system, drowsiness, lethargy, respiratory depression are generally observed. In case of overdose, paracetamol, contained in Zerinol, can cause hepatic cytolysis which could evolve towards massive necrosis. \u003cu\u003eTherapy\u003c\/u\u003e N-acetylcysteine, administered in the hours immediately following ingestion of paracetamol, is effective in limiting liver damage. It is recommended to use usual measures to remove unabsorbed material from the gastrointestinal tract; keep the patient under observation by practicing supportive therapy. Further measures will depend on the severity, nature and course of clinical symptoms and should follow standard intensive care protocols.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy and breastfeeding\u003c\/u\u003e Zerinol is contraindicated during pregnancy and breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e No studies have been conducted with Zerinol to evaluate the effects on fertility in humans.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients should be warned that Zerinol may cause drowsiness. Patients who may drive vehicles or who may be carrying out operations requiring an intact state of vigilance must be warned of this.\u003c\/p\u003e","brand":"Zentiva","offers":[{"title":"Default Title","offer_id":51131216429383,"sku":"035304043","price":11.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zentiva-zerinol-300mg-2mg-20-compresse-rivestite-farmacia-dottor-tili-1258975881.jpg?v=1789561811"},{"product_id":"nurofen-influenza-e-raffreddore-200mg-30mg-12-compresse-rivestite","title":"Nurofen Cold and Flu 200mg + 30mg 12 coated tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNUROFEN FLU AND COLDS 200 mg + 30 mg Coated Tablets, is indicated in adults and adolescents over 12 years of age. Treatment of cold and flu symptoms such as nasal and sinus congestion, pain, fever, sore throat, headache.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne tablet contains: Ibuprofen 200 mg, Pseudoephedrine hydrochloride 30 mg Excipients with known effects: sodium, sunset yellow FCF (E 110). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTricalcium phosphate, sodium carboxymethylcellulose, microcrystalline cellulose, povidone, methylhydroxypropylcellulose, magnesium stearate, talc, colourants: E 104, E 110, E 171.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Patients suffering from peptic ulcer. History of gastrointestinal hemorrhage or perforation related to previous active treatments or history of recurrent hemorrhage\/peptic ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). Subjects who have previously shown hypersensitivity reactions (such as nasal polyposis, asthma, rhinitis, angioedema or urticaria) following the use of ibuprofen, acetylsalicylic acid or other analgesics, antipyretics, other non-steroidal anti-inflammatory drugs (NSAIDs). Severe kidney or liver failure. Severe heart failure (NYHA class IV) Patients with serious cardiovascular diseases, tachycardia, hypertension, angina pectoris, hyperthyroidism, diabetes, pheochromocytoma, glaucoma, prostatic syndrome. Pregnancy. Breastfeeding (see section 4.6). Children under 12 years old. Patients taking or have taken monoamine oxidase inhibitors (MAOIs) in the previous 14 days (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Only for a short period of treatment. • maximum 5 days of therapy for the adult population; • 3 days maximum therapy for the pediatric population (12-18 years). Undesirable effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see section 4.4). If the use of the medicine is necessary for more than 5 days in adults and for more than 3 days in adolescents, or in the case of worsening of symptoms, the doctor should be consulted. \u003cu\u003ePediatric population\u003c\/u\u003e: Do not administer to children under 12 years of age \u003cu\u003eAdults and adolescents over 12 years old\u003c\/u\u003e: The initial dose is 1-2 tablets per day, then, if necessary, 1-2 tablets every 4 hours. Do not exceed the dose of 6 tablets in 24 hours. \u003cu\u003eElderly\u003c\/u\u003e: No changes to the recommended dosage are required in the elderly except in patients with renal or hepatic alterations for whom it is necessary to individually adapt the dosage. \u003cu\u003eMethod of administration\u003c\/u\u003e: Oral use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on Gastrointestinal and Cardiovascular Risks). Other NSAIDs: the use of NUROFEN COLD AND FLU should be avoided in conjunction with NSAIDs, including selective COX-2 inhibitors. Avoid the simultaneous use of two or more analgesics, antipyretics, non-steroidal anti-inflammatory drugs, as this leads to an increased risk of side effects. The use of NSAIDs must be carefully evaluated in patients suffering from coagulation disorders as a reduction in coagulability is possible. The same applies to patients being treated with oral anticoagulants, due to the possibility of an enhancement of the anticoagulant effect (see also section 4.5). Gastrointestinal safety: as with all anti-inflammatories, the drug should not be taken if the patient suffers from ulcers or gastric disorders. Gastrointestinal haemorrhage, ulceration and perforation: Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported at any time during treatment with all NSAIDs, with or without warning symptoms or previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see section 4.5 below). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or haemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking NUROFEN FLU AND COLDS, treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Cardiovascular and cerebrovascular effects: caution is required (discuss with your doctor or pharmacist) before starting treatment in patients with a positive history of hypertension and\/or heart failure since fluid retention, hypertension and edema have been found in association with treatment with NSAIDs. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration and high doses (2400 mg\/day) should be avoided. Be careful consideration must also be exercised before starting long-term treatment for patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking habit), especially if high doses (2400 mg\/day) of ibuprofen are necessary. Skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases in the early stages of treatment. NUROFEN FLU AND COLDS should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Severe skin reactions: Severe skin reactions, such as acute generalized exanthematous pustulosis (PEAG), may occur with medicines containing ibuprofen and pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules resulting from a widespread edematous erythema and localized mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules are observed, the administration of Nurofen Flu and Cold should be stopped and appropriate measures taken if necessary. Respiratory disorders: bronchospasm may occur in patients with bronchial asthma or current or previous allergic diseases. Do not take the product in cases of asthma and allergy to acetylsalicylic acid unless after consulting your doctor (see paragraph 4.3). SLE and mixed connective tissue disease: in case of systemic lupus erythematosus and mixed connective tissue disease it may lead to an increased risk of aseptic meningitis (see section 4.8). Renal function: renal failure, as renal function may be impaired (see sections 4.3 and 4.8). Liver function: liver dysfunction (see sections 4.3 and 4.8). Impaired female fertility: see paragraph 4.6 regarding female fertility. To be used with caution in combination with antihypertensives including neuronal adrenergic blockers and beta blockers (see section 4.5). To be used with caution with other sympathomimetic agents such as decongestants, appetite suppressants and amphetamine psycho-stimulants (see section 4.5). To be used with caution in case of hyperexcitation. If hallucinations, restlessness or sleep disturbances occur during administration of the medicine, use of the medicine should be discontinued. Elderly: Elderly patients present a higher frequency of adverse reactions to NSAIDs, in particular gastrointestinal haemorrhage and perforation which can be fatal (see section 4.2). Pediatric population: In dehydrated adolescents there is a risk of impaired renal function. Ischemic colitis: Some cases of ischemic colitis have been reported with pseudoephedrine. If sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis develop, pseudoephedrine should be discontinued and a physician should be consulted. \u003cu\u003eIschemic optic neuropathy\u003c\/u\u003e Cases of ischemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or reduction in visual acuity occurs, for example in the case of a scotoma. \u003cu\u003eMasking of symptoms of underlying infections\u003c\/u\u003e Nurofen Flu and Cold can mask the symptoms of infection, which could delay starting appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Nurofen Flu and Cold is administered for the relief of fever or pain related to infection, monitoring of the infection is recommended. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. This medicinal product contains: • less than 1 mmol (23 mg) of \u003cb\u003esodium\u003c\/b\u003e per tablet, i.e. essentially “sodium-free”; • \u003cb\u003esunset yellow dye FCF (E 110)\u003c\/b\u003e, which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAnticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4). Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal haemorrhage (see section 4.4). Corticosteroids: increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4). The product must not be taken by patients being treated with monoamine oxidase inhibitors and for 14 days following the cessation of such treatment. The product may enhance the effect of other sympathomimetic agents, such as decongestants. The effect of pseudoephedrine could be reduced by guanethidine, reserpine and methyldopa and could be influenced by tricyclic antidepressants. In turn, pseudoephedrine may reduce the effect of guanethidine and may increase the possibility of arrhythmias in digitized patients, or in patients taking anticholinergics (including tricyclic antidepressants) or quinidine. Diuretics, ACE inhibitors and Angiotensin II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking NUROFEN FLU AND COLDS concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy. Acetylsalicylic acid: concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects (see section 4.4). Experimental data suggest that ibuprofen may competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility cannot be excluded that regular, long-term use of ibuprofen may reduce the cardioprotective effect of acetylsalicylic acid at low doses. No relevant clinical effects are considered likely following occasional use of ibuprofen (see section 5.1). Other NSAIDs including selective cyclooxygenase-2 inhibitors: concomitant use of two or more NSAIDs should be avoided as it may increase the risk of adverse events (see section 4.4). Cardiac glucosides: NSAIDs can worsen heart failure, reduce GFR (glomerular filtration rate) and plasma levels of glucosides. Lithium. There is evidence of the possibility of a potential increase in lithium levels in the blood. Methotrexate. There is evidence of the possibility of an increase in plasma levels of methotrexate. Cyclosporins: increase the risk of nephrotoxicity. Mifepristone: NSAIDs cannot be administered for 8-12 days following administration of mifepristone as NSAIDs may reduce the effect of mifepristone. Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are administered with tacrolimus. Zidovudine: Increased risk of hematological toxicity when NSAIDs are used concomitantly with Zidovudine. There is evidence of increased risk of hemarthrosis and hematoma in HIV-positive haemophilia patients if treated simultaneously with zidovudine and ibuprofen. Quinolone antibiotics: Data from animal studies indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. Ergot alkaloids (ergotamine and methysergide): increased risk of ergotism. Appetite suppressants (anorectics) and amphetamine-like psychostimulants: risk of hypertension. Oxytocin: risk of hypertension\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe list of the following side effects includes those that have been observed during treatment with ibuprofen at self-medication doses (up to a maximum of 1200mg per day) and with sympathomimetics including pseudoephedrine for short periods of administration. Side effects associated with the administration of ibuprofen and sympathomimetics such as pseudoephedrine are listed below according to system organ class and frequency. \u003ci\u003eFor the frequency of occurrence of side effects, the following expressions are used:\u003c\/i\u003e \u003ci\u003eVery common (\u003c\/i\u003e≥ \u003ci\u003e1\/10)\u003c\/i\u003e \u003ci\u003eMunicipality (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/100, \u0026lt;1\/10)\u003c\/i\u003e \u003ci\u003eUncommon (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/1000, \u0026lt;1\/100)\u003c\/i\u003e \u003ci\u003eRare (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/10.000, \u0026lt;1\/1000)\u003c\/i\u003e \u003ci\u003eVery rare (\u003c1\/10,000)\u003c\/i\u003e \u003ci\u003eNot known (frequency cannot be estimated from the available data)\u003c\/i\u003e \u003ci\u003eWithin each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/i\u003e \u003cb\u003eTable of side effects\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Uncommon. Adverse Reaction: Hypersensitivity reactions characterized by urticaria and pruritus²\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Very rare. Adverse Reaction: Hematopoietic disorders¹. Severe hypersensitivity reactions. Symptoms may be: swelling of the face, tongue and larynx, dyspnoea, tachycardia, hypotension (anaphylaxis, angioedema or severe shock).²\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse Reaction: Insomnia, anxiety, restlessness, agitation, hallucinations.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse Reaction: Headache, tremors.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Very rare. Adverse Reaction: Aseptic meningitis³\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse Reaction: Ischemic optic neuropathy.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse Reaction: Heart failure and edema4, tachycardia, chest pain, arrhythmia, palpitations.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse Reaction: Hypertension4.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Not known. Adverse Reaction: Reactivity of the respiratory system including asthma, bronchospasm or dyspnoea²\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse Reaction: Abdominal pain, nausea and dyspepsia5.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Rare. Adverse Reaction: Diarrhoea, flatulence, constipation and vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Very rare. Adverse Reaction: Peptic ulcer, gastrointestinal perforation or haemorrhage, melena, haematemesis, sometimes fatal, particularly in the elderly (see section 4.4). Ulcerative stomatitis, mouth ulcerations, gastritis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse Reaction: Dry mouth. Exacerbation of colitis and Crohn's disease (see section 4.4). Ischemic colitis.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Very rare. Adverse Reaction: Liver disorders.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse Reaction: Skin rashes ²\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Very rare. Adverse Reaction: Bullous reactions including Stevens-Johnson syndrome, erythema multiforme and Toxic Epidermal Necrolysis may occur.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse Reaction: Hyperhidrosis. Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Severe skin reactions, including acute generalized exanthematous pustulosis (PEAG). Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eMusculoskeletal system and connective tissue disorders - Frequency: Not known. Adverse Reaction: Muscle weakness.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Very rare. Adverse Reaction: Severe renal failure 6.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse Reaction: Urinary retention.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse Reaction: Irritability, thirst.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Frequency: Very rare. Adverse Reaction: Decreased hemoglobin level in the blood.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eDescription of some side effects\u003c\/b\u003e 1) Examples of hematopoietic disorders include anemia, leukopenia, thrombocytopenia, pancytopenia, and agranulocytosis. The first symptoms are fever, sore throat, superficial mouth ulcers, flu-like symptoms, severe feeling of tiredness, unexplained bleeding and bruising. 2) Hypersensitivity reactions: these reactions include a) non-specific allergic reactions and anaphylaxis, b) respiratory tract reactivity including asthma, worsening of asthma, bronchospasm or dyspnoea or c) various skin conditions such as various skin rashes, pruritus, urticaria, purpura, angioedema and very rarely bullous and exfoliative dermatitis including toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme, d) cross-reactivity reactions with pseudoephedrine 3) The pathogenesis of drug-induced aseptic meningitis is not completely known. However, the data available on aseptic meningitis related to the administration of NSAIDs leads us to think of an immune hypersensitivity reaction (due to a temporary relationship with the intake of the medicine and the disappearance of symptoms after discontinuation of treatment). Of note, individual cases of aseptic meningitis symptoms (such as stiff neck, headache, nausea, vomiting, fever and disorientation) have been observed during treatment with ibuprofen in patients with autoimmune disorders (such as systemic lupus erythematosus, mixed connective tissue disease). 4) Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day) may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4) 5) Gastrointestinal: the most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, may occur, particularly in the elderly (see section 4.4). 6) Especially during long treatments, associated with an increase in serum urea and edema. Also includes papillary necrosis. Gastrointestinal intolerance, bleeding, sweating, dizziness, precordial pain, difficulty urinating and insomnia may occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioniavverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e Nausea, vomiting, abdominal pain and more rarely diarrhea may occur. Tinnitus, headaches and gastrointestinal bleeding may also occur. In more severe cases of poisoning, central nervous system toxicity is observed, manifested by dizziness, drowsiness, occasionally excitation and disorientation or coma. Occasionally patients develop seizures. In cases of severe poisoning, metabolic acidosis and a prolongation of the prothrombin time\/INR may occur, probably caused by interference with the action of coagulation factors present in the circulation. Acute renal failure, liver damage and respiratory depression may also occur. In asthmatic subjects, asthma exacerbation may occur. As with other sympathomimetics, an excessive dose of pseudoephedrine can cause symptoms related to central nervous system disorders and cardiovascular stimulation, including\u003cb\u003e:\u003c\/b\u003e irritability, restlessness, tremors, thirst, blurred vision, anxiety anxiety, insomnia, fever, sweating, exophthalmos, hallucinations, muscle weakness\u003cb\u003e,\u003c\/b\u003e palpitations, convulsions, urinary retention, hypertension, difficulty urinating, nausea, vomiting, tachycardia and cardiac arrhythmias. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be symptomatic and supportive, particularly of the cardiovascular and respiratory systems, and must include maintaining a patent airway and monitoring cardiac function and vital signs until the patient is stabilized. Oral administration of activated charcoal should be considered if the patient presents within 1 hour of ingesting a potentially toxic quantity. If necessary, corrective intervention of serum electrolytes should be used. Seizures should be treated with intravenous benzodiazepines if they are frequent or prolonged. Administer bronchodilators in case of asthma. The elimination of pseudoephedrine can be accelerated by acid diuresis or dialysis. Hypertensive phenomena can be treated with IV alpha receptor blocking drugs. Cardiac arrhythmias may require the use of beta-adrenergic blocking agents after administration of alpha-adrenergic blockers. Hyperexcitability and hallucinations can be treated with chlorpromazine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product should not be used during pregnancy and breastfeeding. \u003cb\u003ePregnancy:\u003c\/b\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligo-hydramnios; The mother and newborn, at the end of pregnancy, are exposed to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. There is the possibility of an association between the onset of fetal anomalies and taking pseudoephedrine in the first trimester of pregnancy. \u003cb\u003eBreastfeeding:\u003c\/b\u003e Although ibuprofen is present in breast milk in very low concentrations, pseudoephedrine is secreted into milk in significant quantities; for this reason the product must not be used during breastfeeding. \u003cb\u003eFertility:\u003c\/b\u003e As with other NSAIDs, the use of NUROFEN FLU AND COLDS can alter female fertility due to its effect on ovulation. It is therefore not recommended in women wishing to conceive.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131232026951,"sku":"034246013","price":11.53,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-nurofen-influenza-e-raffreddore-200mg-30mg-12-compresse-rivestite-farmacia-dottor-tili-1213792327.jpg?v=1767143169"},{"product_id":"nurofen-influenza-e-raffreddore-200mg-30mg-24-compresse-rivestite","title":"Nurofen Cold and Flu 200mg + 30mg 24 coated tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNUROFEN FLU AND COLDS 200 mg + 30 mg Coated Tablets, is indicated in adults and adolescents over 12 years of age. Treatment of cold and flu symptoms such as nasal and sinus congestion, pain, fever, sore throat, headache.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne tablet contains: Ibuprofen 200 mg, Pseudoephedrine hydrochloride 30 mg Excipients with known effects: sodium, sunset yellow FCF (E 110). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTricalcium phosphate, sodium carboxymethylcellulose, microcrystalline cellulose, povidone, methylhydroxypropylcellulose, magnesium stearate, talc, colourants: E 104, E 110, E 171.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Patients suffering from peptic ulcer. History of gastrointestinal hemorrhage or perforation related to previous active treatments or history of recurrent hemorrhage\/peptic ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). Subjects who have previously shown hypersensitivity reactions (such as nasal polyposis, asthma, rhinitis, angioedema or urticaria) following the use of ibuprofen, acetylsalicylic acid or other analgesics, antipyretics, other non-steroidal anti-inflammatory drugs (NSAIDs). Severe kidney or liver failure. Severe heart failure (NYHA class IV) Patients with serious cardiovascular diseases, tachycardia, hypertension, angina pectoris, hyperthyroidism, diabetes, pheochromocytoma, glaucoma, prostatic syndrome. Pregnancy. Breastfeeding (see section 4.6). Children under 12 years old. Patients taking or have taken monoamine oxidase inhibitors (MAOIs) in the previous 14 days (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Only for a short period of treatment. • maximum 5 days of therapy for the adult population; • 3 days maximum therapy for the pediatric population (12-18 years). Undesirable effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see section 4.4). If the use of the medicine is necessary for more than 5 days in adults and for more than 3 days in adolescents, or in the case of worsening of symptoms, the doctor should be consulted. \u003cu\u003ePediatric population\u003c\/u\u003e: Do not administer to children under 12 years of age \u003cu\u003eAdults and adolescents over 12 years old\u003c\/u\u003e: The initial dose is 1-2 tablets per day, then, if necessary, 1-2 tablets every 4 hours. Do not exceed the dose of 6 tablets in 24 hours. \u003cu\u003eElderly\u003c\/u\u003e: No changes to the recommended dosage are required in the elderly except in patients with renal or hepatic alterations for whom it is necessary to individually adapt the dosage. \u003cu\u003eMethod of administration\u003c\/u\u003e: Oral use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on Gastrointestinal and Cardiovascular Risks). Other NSAIDs: the use of NUROFEN COLD AND FLU should be avoided in conjunction with NSAIDs, including selective COX-2 inhibitors. Avoid the simultaneous use of two or more analgesics, antipyretics, non-steroidal anti-inflammatory drugs, as this leads to an increased risk of side effects. The use of NSAIDs must be carefully evaluated in patients suffering from coagulation disorders as a reduction in coagulability is possible. The same applies to patients being treated with oral anticoagulants, due to the possibility of an enhancement of the anticoagulant effect (see also section 4.5). Gastrointestinal safety: as with all anti-inflammatories, the drug should not be taken if the patient suffers from ulcers or gastric disorders. Gastrointestinal haemorrhage, ulceration and perforation: Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported at any time during treatment with all NSAIDs, with or without warning symptoms or previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see section 4.5 below). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or haemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking NUROFEN FLU AND COLDS, treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Cardiovascular and cerebrovascular effects: caution is required (discuss with your doctor or pharmacist) before starting treatment in patients with a positive history of hypertension and\/or heart failure since fluid retention, hypertension and edema have been found in association with treatment with NSAIDs. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration and high doses (2400 mg\/day) should be avoided. Be careful consideration must also be exercised before starting long-term treatment for patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking habit), especially if high doses (2400 mg\/day) of ibuprofen are necessary. Skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases in the early stages of treatment. NUROFEN FLU AND COLDS should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Severe skin reactions: Severe skin reactions, such as acute generalized exanthematous pustulosis (PEAG), may occur with medicines containing ibuprofen and pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules resulting from a widespread edematous erythema and localized mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules are observed, the administration of Nurofen Flu and Cold should be stopped and appropriate measures taken if necessary. Respiratory disorders: bronchospasm may occur in patients with bronchial asthma or current or previous allergic diseases. Do not take the product in cases of asthma and allergy to acetylsalicylic acid unless after consulting your doctor (see paragraph 4.3). SLE and mixed connective tissue disease: in case of systemic lupus erythematosus and mixed connective tissue disease it may lead to an increased risk of aseptic meningitis (see section 4.8). Renal function: renal failure, as renal function may be impaired (see sections 4.3 and 4.8). Liver function: liver dysfunction (see sections 4.3 and 4.8). Impaired female fertility: see paragraph 4.6 regarding female fertility. To be used with caution in combination with antihypertensives including neuronal adrenergic blockers and beta blockers (see section 4.5). To be used with caution with other sympathomimetic agents such as decongestants, appetite suppressants and amphetamine psycho-stimulants (see section 4.5). To be used with caution in case of hyperexcitation. If hallucinations, restlessness or sleep disturbances occur during administration of the medicine, use of the medicine should be discontinued. Elderly: Elderly patients present a higher frequency of adverse reactions to NSAIDs, in particular gastrointestinal haemorrhage and perforation which can be fatal (see section 4.2). Pediatric population: In dehydrated adolescents there is a risk of impaired renal function. Ischemic colitis: Some cases of ischemic colitis have been reported with pseudoephedrine. If sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis develop, pseudoephedrine should be discontinued and a physician should be consulted. \u003cu\u003eIschemic optic neuropathy\u003c\/u\u003e Cases of ischemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or reduction in visual acuity occurs, for example in the case of a scotoma. \u003cu\u003eMasking of symptoms of underlying infections\u003c\/u\u003e Nurofen Flu and Cold can mask the symptoms of infection, which could delay starting appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Nurofen Flu and Cold is administered for the relief of fever or pain related to infection, monitoring of the infection is recommended. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. This medicinal product contains: • less than 1 mmol (23 mg) of \u003cb\u003esodium\u003c\/b\u003e per tablet, i.e. essentially “sodium-free”; • \u003cb\u003esunset yellow dye FCF (E 110)\u003c\/b\u003e, which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAnticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4). Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal haemorrhage (see section 4.4). Corticosteroids: increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4). The product must not be taken by patients being treated with monoamine oxidase inhibitors and for 14 days following the cessation of such treatment. The product may enhance the effect of other sympathomimetic agents, such as decongestants. The effect of pseudoephedrine could be reduced by guanethidine, reserpine and methyldopa and could be influenced by tricyclic antidepressants. In turn, pseudoephedrine may reduce the effect of guanethidine and may increase the possibility of arrhythmias in digitized patients, or in patients taking anticholinergics (including tricyclic antidepressants) or quinidine. Diuretics, ACE inhibitors and Angiotensin II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking NUROFEN FLU AND COLDS concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy. Acetylsalicylic acid: concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects (see section 4.4). Experimental data suggest that ibuprofen may competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility cannot be excluded that regular, long-term use of ibuprofen may reduce the cardioprotective effect of acetylsalicylic acid at low doses. No relevant clinical effects are considered likely following occasional use of ibuprofen (see section 5.1). Other NSAIDs including selective cyclooxygenase-2 inhibitors: concomitant use of two or more NSAIDs should be avoided as it may increase the risk of adverse events (see section 4.4). Cardiac glucosides: NSAIDs can worsen heart failure, reduce GFR (glomerular filtration rate) and plasma levels of glucosides. Lithium. There is evidence of the possibility of a potential increase in lithium levels in the blood. Methotrexate. There is evidence of the possibility of an increase in plasma levels of methotrexate. Cyclosporins: increase the risk of nephrotoxicity. Mifepristone: NSAIDs cannot be administered for 8-12 days following administration of mifepristone as NSAIDs may reduce the effect of mifepristone. Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are administered with tacrolimus. Zidovudine: Increased risk of hematological toxicity when NSAIDs are used concomitantly with Zidovudine. There is evidence of increased risk of hemarthrosis and hematoma in HIV-positive haemophilia patients if treated simultaneously with zidovudine and ibuprofen. Quinolone antibiotics: Data from animal studies indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. Ergot alkaloids (ergotamine and methysergide): increased risk of ergotism. Appetite suppressants (anorectics) and amphetamine-like psychostimulants: risk of hypertension. Oxytocin: risk of hypertension\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe list of the following side effects includes those that have been observed during treatment with ibuprofen at self-medication doses (up to a maximum of 1200mg per day) and with sympathomimetics including pseudoephedrine for short periods of administration. Side effects associated with the administration of ibuprofen and sympathomimetics such as pseudoephedrine are listed below according to system organ class and frequency. \u003ci\u003eFor the frequency of occurrence of side effects, the following expressions are used:\u003c\/i\u003e \u003ci\u003eVery common (\u003c\/i\u003e≥ \u003ci\u003e1\/10)\u003c\/i\u003e \u003ci\u003eMunicipality (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/100, \u0026lt;1\/10)\u003c\/i\u003e \u003ci\u003eUncommon (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/1000, \u0026lt;1\/100)\u003c\/i\u003e \u003ci\u003eRare (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/10.000, \u0026lt;1\/1000)\u003c\/i\u003e \u003ci\u003eVery rare (\u003c1\/10,000)\u003c\/i\u003e \u003ci\u003eNot known (frequency cannot be estimated from the available data)\u003c\/i\u003e \u003ci\u003eWithin each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/i\u003e \u003cb\u003eTable of side effects\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Uncommon. Adverse Reaction: Hypersensitivity reactions characterized by urticaria and pruritus²\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Very rare. Adverse Reaction: Hematopoietic disorders¹. Severe hypersensitivity reactions. Symptoms may be: swelling of the face, tongue and larynx, dyspnoea, tachycardia, hypotension (anaphylaxis, angioedema or severe shock).²\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse Reaction: Insomnia, anxiety, restlessness, agitation, hallucinations.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse Reaction: Headache, tremors.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Very rare. Adverse Reaction: Aseptic meningitis³\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse Reaction: Ischemic optic neuropathy.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse Reaction: Heart failure and edema4, tachycardia, chest pain, arrhythmia, palpitations.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse Reaction: Hypertension4.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Not known. Adverse Reaction: Reactivity of the respiratory system including asthma, bronchospasm or dyspnoea²\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse Reaction: Abdominal pain, nausea and dyspepsia5.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Rare. Adverse Reaction: Diarrhoea, flatulence, constipation and vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Very rare. Adverse Reaction: Peptic ulcer, gastrointestinal perforation or haemorrhage, melena, haematemesis, sometimes fatal, particularly in the elderly (see section 4.4). Ulcerative stomatitis, mouth ulcerations, gastritis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse Reaction: Dry mouth. Exacerbation of colitis and Crohn's disease (see section 4.4). Ischemic colitis.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Very rare. Adverse Reaction: Liver disorders.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse Reaction: Skin rashes ²\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Very rare. Adverse Reaction: Bullous reactions including Stevens-Johnson syndrome, erythema multiforme and Toxic Epidermal Necrolysis may occur.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse Reaction: Hyperhidrosis. Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Severe skin reactions, including acute generalized exanthematous pustulosis (PEAG). Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eMusculoskeletal system and connective tissue disorders - Frequency: Not known. Adverse Reaction: Muscle weakness.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Very rare. Adverse Reaction: Severe renal failure 6.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse Reaction: Urinary retention.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse Reaction: Irritability, thirst.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Frequency: Very rare. Adverse Reaction: Decreased hemoglobin level in the blood.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eDescription of some side effects\u003c\/b\u003e 1) Examples of hematopoietic disorders include anemia, leukopenia, thrombocytopenia, pancytopenia, and agranulocytosis. The first symptoms are fever, sore throat, superficial mouth ulcers, flu-like symptoms, severe feeling of tiredness, unexplained bleeding and bruising. 2) Hypersensitivity reactions: these reactions include a) non-specific allergic reactions and anaphylaxis, b) respiratory tract reactivity including asthma, worsening of asthma, bronchospasm or dyspnoea or c) various skin conditions such as various skin rashes, pruritus, urticaria, purpura, angioedema and very rarely bullous and exfoliative dermatitis including toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme, d) cross-reactivity reactions with pseudoephedrine 3) The pathogenesis of drug-induced aseptic meningitis is not completely known. However, the data available on aseptic meningitis related to the administration of NSAIDs leads us to think of an immune hypersensitivity reaction (due to a temporary relationship with the intake of the medicine and the disappearance of symptoms after discontinuation of treatment). Of note, individual cases of aseptic meningitis symptoms (such as stiff neck, headache, nausea, vomiting, fever and disorientation) have been observed during treatment with ibuprofen in patients with autoimmune disorders (such as systemic lupus erythematosus, mixed connective tissue disease). 4) Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day) may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4) 5) Gastrointestinal: the most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, may occur, particularly in the elderly (see section 4.4). 6) Especially during long treatments, associated with an increase in serum urea and edema. Also includes papillary necrosis. Gastrointestinal intolerance, bleeding, sweating, dizziness, precordial pain, difficulty urinating and insomnia may occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioniavverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e Nausea, vomiting, abdominal pain and more rarely diarrhea may occur. Tinnitus, headaches and gastrointestinal bleeding may also occur. In more severe cases of poisoning, central nervous system toxicity is observed, manifested by dizziness, drowsiness, occasionally excitation and disorientation or coma. Occasionally patients develop seizures. In cases of severe poisoning, metabolic acidosis and a prolongation of the prothrombin time\/INR may occur, probably caused by interference with the action of coagulation factors present in the circulation. Acute renal failure, liver damage and respiratory depression may also occur. In asthmatic subjects, asthma exacerbation may occur. As with other sympathomimetics, an excessive dose of pseudoephedrine can cause symptoms related to central nervous system disorders and cardiovascular stimulation, including\u003cb\u003e:\u003c\/b\u003e irritability, restlessness, tremors, thirst, blurred vision, anxiety anxiety, insomnia, fever, sweating, exophthalmos, hallucinations, muscle weakness\u003cb\u003e,\u003c\/b\u003e palpitations, convulsions, urinary retention, hypertension, difficulty urinating, nausea, vomiting, tachycardia and cardiac arrhythmias. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be symptomatic and supportive, particularly of the cardiovascular and respiratory systems, and must include maintaining a patent airway and monitoring cardiac function and vital signs until the patient is stabilized. Oral administration of activated charcoal should be considered if the patient presents within 1 hour of ingesting a potentially toxic quantity. If necessary, corrective intervention of serum electrolytes should be used. Seizures should be treated with intravenous benzodiazepines if they are frequent or prolonged. Administer bronchodilators in case of asthma. The elimination of pseudoephedrine can be accelerated by acid diuresis or dialysis. Hypertensive phenomena can be treated with IV alpha receptor blocking drugs. Cardiac arrhythmias may require the use of beta-adrenergic blocking agents after administration of alpha-adrenergic blockers. Hyperexcitability and hallucinations can be treated with chlorpromazine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product should not be used during pregnancy and breastfeeding. \u003cb\u003ePregnancy:\u003c\/b\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligo-hydramnios; The mother and newborn, at the end of pregnancy, are exposed to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. There is the possibility of an association between the onset of fetal anomalies and taking pseudoephedrine in the first trimester of pregnancy. \u003cb\u003eBreastfeeding:\u003c\/b\u003e Although ibuprofen is present in breast milk in very low concentrations, pseudoephedrine is secreted into milk in significant quantities; for this reason the product must not be used during breastfeeding. \u003cb\u003eFertility:\u003c\/b\u003e As with other NSAIDs, the use of NUROFEN FLU AND COLDS can alter female fertility due to its effect on ovulation. It is therefore not recommended in women wishing to conceive.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131252539719,"sku":"034246025","price":18.51,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-nurofen-influenza-e-raffreddore-200mg-30mg-24-compresse-rivestite-farmacia-dottor-tili-1213792309.jpg?v=1767143529"},{"product_id":"vicks-flu-tripla-azione-500mg-200mg-10mg-10-bustine-polvere-per-soluzione-orale","title":"Vicks Flu Triple Action 500mg\/200mg\/10mg 10 sachets powder for oral solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term symptomatic treatment of mild to moderate pain, fever, nasal congestion with expectorant effect in case of wet cough, associated with colds, chills and flu.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne sachet contains: 500 mg of paracetamol 200 mg of guaifenesin 10 mg of phenylephrine hydrochloride Excipients: Sucrose 2000 mg Aspartame 6 mg Sodium 157 mg For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSucrose Citric acid Tartaric acid Sodium cyclamate Sodium citrate Aspartame (E951) Acesulfame potassium (E950) Menthol powder Lemon flavor Lemon juice flavor Quinoline yellow (E104)\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to paracetamol, guaifenesin, phenylephrine hydrochloride or to any of the excipients. Severe hepatic or renal impairment Hypertension Hyperthyroidism Diabetes Heart disease. Angle-closure glaucoma Porphyria Use in patients who are taking tricyclic antidepressants Use in patients who are taking, or who have taken in the previous 2 weeks, monoamine oxidase inhibitors (MAOIs). Use in patients who are taking beta-blocking drugs. Use in patients who are taking other sympathomimetic drugs. Children under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDissolve the contents of one sachet in a medium-sized cup and add hot, non-boiling water (approximately 250 ml). Allow to cool to a drinkable temperature. Adults and children from 12 years of age: one sachetRepeat every four hours according to the indications, without exceeding four doses (sachets) within 24 hours. Do not administer to children under 12 years of age without medical advice. Do not administer to patients with hepatic impairment or severe renal impairment (see section 4.3). Consult your doctor if symptoms persist for more than 3 days.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProlonged use of the product is not recommended. Patients should be advised not to take other products containing paracetamol or containing the same active ingredients as this preparation. Patients should also be advised to avoid the concomitant use of alcohol, other decongestant products or cough or cold products. The doctor or pharmacist is required to verify that preparations containing sympathomimetics are not administered simultaneously through multiple routes, i.e. orally and topically (nasal, auricular and ocular preparations). This medicine should only be recommended in the presence of all symptoms (pain and\/or fever, nasal congestion and bronchial cough). The risks related to overdose are greater in patients with non-cirrhotic alcoholic liver disease. Use with caution in patients taking digitalis, beta-adrenergic blockers, methyldopa or other antihypertensive agents (see section 4.5). Use with caution in patients with prostatic hypertrophy as they are potentially subject to urinary retention. Products containing sympathomimetics should be used with great care in patients taking phenothiazines. Use in patients with Raynaud's phenomenon. Consult your doctor before use in case of persistent or chronic cough such as that manifested by smoking, asthma, chronic bronchitis or emphysema. Contains sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrasisomaltase insufficiency should not take this medicine. Contains 157 mg sodium per dose. To be taken into consideration in people with reduced kidney function or who follow a low sodium diet. Contains aspartame (E951). This medicine contains a source of phenylalanine. It may be harmful to you if you suffer from phenylketonuria.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe hepatotoxicity of paracetamol can be potentiated by excessive alcohol intake. The rate of absorption of paracetamol can be increased with metoclopramide or domperidone and the absorption reduced with cholestyramine. Substances that induce hepatic microsomal enzymes, such as alcohol, barbiturates, monoamine oxidase inhibitors and tricyclic antidepressants, may increase the hepatotoxicity of paracetamol, particularly following overdosage. Isoniazid reduces the elimination of paracetamol, with possible enhancement of its activity and\/or toxicity, through the inhibition of its metabolism in the liver. Probenecid causes a halving of the elimination of paracetamol, inhibiting its binding with glucuronic acid. A reduction in paracetamol should be considered if probenecid is being taken. Regular use of paracetamol may reduce the metabolism of Zidovudine (increasing the risk of neutropenia). Interactions between sympathomimetic amines, such as phenylephrine, and monoamine oxidase inhibitors cause hypertensive effects. Phenylephrine may interact negatively with sympathomimetic agents and may reduce the effectiveness of beta-blocking drugs, methyldopa and other antihypertensive drugs (see section 4.4). The conditions in which these drugs are taken constitute contraindications to the use of the product. The anticoagulant effect of warfarin and other coumarin drugs can be enhanced by regular and prolonged intake of paracetamol, with an increased risk of bleeding; doses taken occasionally have no significant effects. Drug interactions have been reported between acetaminophen and several other drugs. Such interactions are considered unlikely to be clinically significant in temporary use and in accordance with the suggested dosing regimen. Salicylates\/aspirin can prolong the elimination (t ½) of paracetamol. Paracetamol may decrease the bioequivalence of lamotrigine, with a possible decrease in its effect, due to a possible increase in its metabolism in the liver. It is possible that digitalis may sensitize the myocardium to sympathomimetic-like effects. Paracetamol can alter the uric acid phosphotungstate test and the blood sugar test.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe incidence of side effects is usually classified as follows: Very common (\u003e10) Common (\u003e1\/100 to \u003c1\/10) Uncommon (\u003e1\/1000 to \u003c1\/100) Rare (\u003e1\/10,000 to \u003c1\/1000) Very rare (\u003c1\/10,000) Not known (the incidence cannot be classified from the available data) Cardiac disorders: Phenylephrine may be rarely associated with tachycardia (≥1\/10,000 to ≤1 in 1000). Blood and lymphatic system disorders: very rarely (\u003c1 in 10,000) blood dyscrasias such as thrombocytopenia, agranulocytosis, hemolytic anemia, neutropenia, leukopenia and pancytopenia have been reported following the intake of paracetamol, although there may not be a causal relationship. Nervous system disorders: As with other sympathomimetic amines, insomnia, nervousness, tremor, anxiety, restlessness, confusion, irritability and headache may occur rarely (≥1\/10,000 to ≤1 in 1000). It is also known that guaifenesin can rarely (≥1\/10,000 to ≤1 in 1000) cause headache and dizziness. Gastrointestinal disorders: Anorexia, nausea and vomiting are common with sympathomimetics (≥1 in 100 to ≤1 in 10) and may occur with phenylephrine. Gastrointestinal disorders, nausea, vomiting, and diarrhea are the most common side effects associated with guaifenesin, but occur rarely (≥1\/10,000 to ≤1 in 1000). The gastrointestinal effects of paracetamol are very rare but cases of acute pancreatitis have been reported following ingestion of higher than normal doses. Renal and urinary disorders: Interstitial nephritis has been reported randomly after prolonged use of high doses of paracetamol. Skin and subcutaneous tissue disorders: hypersensitivity, including skin rash, and urticaria may rarely occur following the intake of paracetamol (from ≥1\/10,000 to ≤1 in 1000). Vascular disorders: following the intake of phenylephrine, increased blood pressure associated with headache, vomiting and palpitations may rarely occur (from ≥1\/10,000 to ≤1 in 1000). Immune system disorders: Rare cases (≥1\/10,000 to ≤1 in 1000) of allergic or hypersensitivity reactions have been reported following intake of both phenylephrine and paracetamol, including skin rashes, urticaria, anaphylaxis and bronchospasm. Hepatobiliary disorders: rarely (≥ 1\/10,000 to ≤ 1\/1000), abnormalities in liver function tests (increased liver transaminases).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePARACETAMOL There is a risk of poisoning particularly in elderly patients, young children, in patients with liver disease, in chronic alcoholics, in patients with chronic malnutrition. In these cases, an overdose can be fatal. In adults, a quantity of paracetamol equal to or greater than 10 g can cause liver damage. If the patient has one of the risk factors (see below), ingesting 5 g or more of paracetamol may cause liver damage. Risk factors If the patient: a) is on prolonged therapy with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. John's wort or other liver enzyme-inducing drugs, or b) regularly takes ethanol in excess of recommended amounts, or c) has a glutathione deficiency, e.g. in case of eating disorders, cystic fibrosis, HIV infection, inanition, cachexia. Symptoms The symptoms of paracetamol overdose that appear in the first 24 hours are paleness, nausea, vomiting, anorexia and abdominal pain. Liver damage may appear 12–48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In cases of severe poisoning, liver failure may progress to encephalopathy, hemorrhage, hypoglycemia, brain edema, and death. Even in the absence of severe liver damage, acute renal failure with acute tubular necrosis may occur, which is highly likely if accompanied by low back pain, hematuria, and proteinuria. Cases of cardiac arrhythmia and pancreatitis have been reported. Treatment In case of paracetamol overdose it is essential to treat the patient immediately. Even in the absence of significant initial symptoms, the patient must be urgently transferred to hospital. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Patient treatment must be carried out in compliance with current guidelines. If no more than an hour has passed since the overdose was taken, treatment with activated charcoal may be considered. The plasma concentration of paracetamol must be measured no earlier than 4 hours after ingestion (plasma concentrations measured at earlier times are not reliable). Within 24 hours of ingesting paracetamol the patient can be treated with N-acetylcysteine; however, the maximum protective effect is obtained within 8 hours of ingestion. After this time, the effectiveness of the antidote decreases drastically. If necessary, the patient should be administered N-acetylcysteine ​​intravenously, in line with the established dosing schedule. If vomiting is not a problem and the patient is away from the hospital, taking oral methionine can be a valid alternative. Treatment of patients with severe hepatic dysfunction presenting within 24 hours of ingestion should be discussed with the poison control center or hepatology department. Phenylephrine hydrochloride Symptoms of phenylephrine overdose include irritability, headache, arterial hypertension, reflex bradycardia and arrhythmias. Hypertension must be treated with an alpha-blocker such as phentolamine IV. The reduction in blood pressure can increase, as a reflex mechanism, the heart rate but, if necessary, this can be facilitated by taking atropine. GUAIFENESIN Mild to moderate overdose may cause dizziness and gastrointestinal disturbances. Very high doses can produce excitation, confusion and respiratory depression. Urinary stones have been reported in patients consuming large quantities of guaifenesin-containing preparations. Treatment is symptomatic and includes gastric lavage and general supportive measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEpidemiological studies on pregnant women have demonstrated the absence of negative effects due to the use of paracetamol in the recommended dosages; however, pregnant patients are required to follow their doctor's instructions regarding the use of the drug. Paracetamol is excreted in breast milk, although not in clinically significant quantities. The available published data do not report contraindications regarding breastfeeding. Data on the use of phenylephrine in pregnancy are limited. Vasoconstriction of the uterine vessels and reduction in uterine blood flow associated with the use of phenylephrine may cause fetal hypoxia. Until further information is available, taking phenylephrine during pregnancy should be avoided, except when your doctor deems it essential. There are no data available regarding the possible release of phenylephrine into breast milk nor are there any reports regarding the effects of phenylephrine on breast-fed infants. Until further data become available, taking phenylephrine during breastfeeding should be avoided, except when your doctor deems it essential. The safety of guaifenesin during pregnancy and breastfeeding has not yet been fully defined. During pregnancy, the product must be taken only when the doctor deems it essential.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed. When carrying out these activities, the possibility of adverse events, such as dizziness and confusion, must be considered.\u003c\/p\u003e","brand":"Procter \u0026 Gamble","offers":[{"title":"Default Title","offer_id":51131272331591,"sku":"039773027","price":9.43,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/procter-gamble-srl-vicks-flu-tripla-azione-500mg-200mg-10mg-10-bustine-polvere-per-soluzione-orale-farmacia-dottor-tili-1213792260.jpg?v=1767133270"},{"product_id":"isomar-spray-decongestionante-con-acido-ialuronico","title":"Isomar decongestant spray with hyaluronic acid","description":"\u003cp\u003eIsomar decongestant spray with hyaluronic acid is an innovative hypertonic solution, designed to offer immediate and long-lasting relief from stuffy nose. Thanks to its formulation based on \u003cstrong\u003ehypertonic sea water\u003c\/strong\u003e e \u003cstrong\u003ehyaluronic acid\u003c\/strong\u003e, this spray is ideal for those suffering from allergic rhinitis, sinusitis or colds. The natural salt concentration of sea water, around 3%, promotes a decongestant action by osmosis, helping to drain nasal secretions delicately and effectively.\u003c\/p\u003e\n\u003cp\u003eHyaluronic acid, known for its hydrating properties, keeps the nasal mucosa soft and well hydrated, reducing the risk of dryness and microlesions that can occur during episodes of severe congestion. This makes Isomar decongestant spray particularly suitable for frequent use, without inducing habituation, and also safe during pregnancy.\u003c\/p\u003e\n\u003cp\u003eFree of preservatives and colourants, Isomar spray is a \u003cstrong\u003emedical device\u003c\/strong\u003e which guarantees optimal nasal hygiene for adults and children. Its natural and delicate formulation makes it a precious ally for those looking for an effective and safe product for the well-being of the respiratory tract. \u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Isomar decongestant spray with hyaluronic acid used? What is it for?\u003c\/h3\u003e\u003cp\u003eNasal spray based on hypertonic sea water and hyaluronic acid, indicated for the relief of stuffy nose in case of allergic rhinitis, sinusitis or cold; the decongestant action by osmosis promotes the drainage of nasal secretions, while hyaluronic acid hydrates the mucosa.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Isomar decongestant spray with hyaluronic acid contain?\u003c\/h3\u003e\u003cp\u003eHypertonic sea water (Natural salt concentration of sea water around 3%), sodium hyaluronate.\u003cbr\u003eInert propellant gas: nitrogen.\u003cbr\u003eIt contains neither preservatives nor colourants.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Isomar decongestant spray with hyaluronic acid?\u003c\/h3\u003e\u003cp\u003eApply the nose regulator to the cylinder. Spray one\/two 2-second sprays into each nostril, wait a few seconds for the solution to drip slightly and blow your nose. To better reach all the recesses of the nasal septum and therefore have greater and rapid cleansing, we recommend using the bottle vertically. To facilitate use in children, even in a lying position, the product can also be used in a horizontal or upside-down position.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Isomar decongestant spray with hyaluronic acid?\u003c\/h3\u003e\u003cp\u003eValidity with intact packaging: 60 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Isomar decongestant spray with hyaluronic acid stored?\u003c\/h3\u003e\u003cp\u003eValidity with intact packaging: 60 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Isomar decongestant spray with hyaluronic acid?\u003c\/h3\u003e\u003cp\u003e100 ml bottle.\u003c\/p\u003e","brand":"Euritalia Pharma","offers":[{"title":"Default Title","offer_id":51131273838919,"sku":"927143925","price":14.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/euritalia-pharma-div-coswell-isomar-spray-decongestionante-con-acido-ialuronico-farmacia-dottor-tili-1213792266.jpg?v=1767133330"},{"product_id":"zerinolflu-20-compresse-effervescenti","title":"ZerinolFlu 20 effervescent tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of flu and cold symptoms in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne effervescent tablet contains: paracetamol 300 mg, chlorphenamine maleate 2 mg, sodium ascorbate 280 mg corresponding to ascorbic acid (vitamin C) 250 mg. Excipients with known effects: aspartame, sodium, sorbitol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAnhydrous citric acid, sodium bicarbonate, sodium carbonate, sorbitol, povidone, dimethicone, aspartame, orange flavor, lemon flavor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eZerinolflu is contraindicated in the following cases: - hypersensitivity to paracetamol, chlorphenamine or ascorbic acid, to any of the excipients listed in paragraph 6.1 or to other substances closely related from a chemical point of view, in particular antihistamines with a chemical structure similar to chlorphenamine; - pregnancy and breastfeeding; - patients with manifest insufficiency of glucose-6-phosphate dehydrogenase and patients suffering from severe hemolytic anemia; - severe hepatocellular insufficiency (Child-Pugh C); - glaucoma, prostatic hypertrophy, bladder neck obstruction, pyloric and duodenal stenosis or other tracts of the gastrointestinal and urogenital system, due to anticholinergic effects; - patients being treated with monoamine oxidase inhibitors (MAOIs) or in the two weeks following such treatment (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cb\u003eAdults:\u003c\/b\u003e 1 effervescent tablet twice a day. \u003cb\u003ePediatric population: \u003c\/b\u003eThe safety and effectiveness of Zerinolflu in patients under 18 years of age have not been established. \u003cu\u003eMethod of administration\u003c\/u\u003e Oral use. The effervescent tablet should be dissolved in approximately half a glass of water. The medicine should be taken after meals. \u003cu\u003eDuration of treatment\u003c\/u\u003e Patients should be advised to contact their doctor if fever persists or symptoms do not improve after 3 days of treatment (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not administer for more than 3 consecutive days without consulting your doctor. If the fever persists for more than three days or if the symptoms do not improve and others appear within three days or are accompanied by high fever, rash, excessive amount of mucus and persistent cough, consult your doctor before continuing the administration. \u003cu\u003eParacetamol\u003c\/u\u003e During treatment with Zerinolflu, check that no other medicine containing paracetamol is taken at the same time, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other drug. See also paragraph 4.5. High or prolonged doses of the product can cause high-risk liver disease (see also section 4.9) and even serious alterations in the kidney and blood. In case of acute hypersensitivity reactions to paracetamol (e.g. anaphylactic shock), treatment with Zerinolflu should be discontinued and necessary medical measures should be implemented based on the signs and symptoms. \u003cu\u003eChlorphenamine maleate\u003c\/u\u003e At common therapeutic doses, antihistamines present secondary reactions that vary greatly from subject to subject and from compound to compound. The most frequent side effect is sedation which can manifest itself with drowsiness; Those who may drive motor vehicles or carry out operations that require integrity of the level of supervision must be warned of this (see paragraph 4.7). \u003cu\u003eAscorbic acid\u003c\/u\u003e Ascorbic acid (vitamin C) should be used with caution by subjects who suffer, or have suffered in the past, from nephrolithiasis (kidney stones) and by those suffering from G6PD (Glucose-6-phosphate dehydrogenase) deficiency, hemochromatosis, thalassemia or sideroblastic anemia. \u003cu\u003ePatients with renal or hepatic insufficiency\u003c\/u\u003e Administer with caution in subjects with renal or hepatic insufficiency. \u003cu\u003eElderly\u003c\/u\u003e Particular attention should be paid when determining the dose in the elderly due to their greater sensitivity towards the drug. In elderly patients treated with antihistamines, effects such as dizziness, sedation, confusion and hypotension may be more likely to occur. Elderly patients are particularly sensitive to the anticholinergic side effects of antihistamines such as dry mouth and urinary retention (especially in men). \u003cu\u003eZerinolflu effervescent tablets contains\u003c\/u\u003e: \u003cu\u003eAspartame\u003c\/u\u003e This medicine contains a source of phenylalanine. It can be harmful if affected by phenylketonuria (lack of the enzyme phenylalanine hydroxylase). \u003cu\u003eSorbitol\u003c\/u\u003e Patients with rare hereditary problems of fructose intolerance should not take this medicine. \u003cu\u003eSodium\u003c\/u\u003e One effervescent tablet contains 14.83 mmol sodium. To be taken into consideration in patients with reduced renal function or who follow a low sodium diet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eParacetamol\u003c\/u\u003e Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). Normally harmless doses of acetaminophen can cause liver damage if taken together with these drugs. The same applies to potentially hepatotoxic substances and in case of alcohol abuse. Habitual ingestion of anticonvulsant drugs or oral contraceptives can, through an enzymatic induction mechanism, accelerate the metabolism of paracetamol. The use of the product is not recommended if the patient is being treated with anti-inflammatories. Taking probenecid inhibits the binding of paracetamol to glucuronic acid, thereby reducing the clearance of paracetamol by a factor of approximately 2. Therefore, the dose of paracetamol should be reduced if administered in combination with probenecid. Cholestyramine reduces the absorption of paracetamol if administered within 1 hour of taking paracetamol. It is not yet possible to establish the clinical relevance of the interactions between paracetamol and oral anticoagulants. Therefore, prolonged use of paracetamol in patients being treated with oral anticoagulants is advisable only under medical supervision. Combining acetaminophen with chloramphenicol may prolong the half-life of chloramphenicol, increasing the risk of toxicity. The concomitant use of paracetamol and zidovudine increases the tendency of the latter to reduce the number of leukocytes (neutropenia). Therefore, you should take Zerinolflu together with zidovudine only under your doctor's supervision. Medicines that slow gastric emptying, such as propantheline, reduce the speed of absorption of paracetamol and delay the onset of its effect. However, medicines that accelerate gastric emptying, such as metoclopramide, lead to an increase in the speed of absorption. \u003cu\u003eInterference with laboratory tests\u003c\/u\u003e The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method). \u003cu\u003eChlorphenamine maleate\u003c\/u\u003e Other substances with anticholinergic action should not be taken at the same time as Zerinolflu, as these can cause significant interactions. The product is contraindicated in patients being treated with monoamine oxidase inhibitors (MAOIs) or in the two weeks following such treatment (see section 4.3) as these may prolong and intensify the anticholinergic and central nervous system (CNS) depressant effects of chlorphenamine maleate. The product may interact with alcohol, tricyclic antidepressants, neuroleptics or other drugs with a depressant action on the central nervous system such as barbiturates, sedatives, tranquilizers, hypnotics. These products should not be taken during therapy with Zerinolflu as they can cause an increase in the sedative effect. Like all preparations containing antihistamines, Zerinolflu can mask the first signs of ototoxicity of certain antibiotics. Chlorphenamine inhibits the metabolism of phenytoin and may cause phenytoin toxicity. \u003cu\u003eAscorbic acid\u003c\/u\u003e Ascorbic acid (vitamin C) reduces amphetamine levels by inhibiting gastrointestinal absorption. Vitamin C increases the bioavailability of iron by chelation with deferoxamine. Estrogens can increase the elimination of vitamin C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the use of Zerinolflu, the side effects indicated below may occur. The frequency of these side effects cannot be estimated from the available data. \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e: - thrombocytopenia, leukopenia, anemia, agranulocytosis, pancytopenia. \u003cu\u003eImmune system disorders\u003c\/u\u003e: - hypersensitivity reactions such as angioedema, laryngeal edema, anaphylactic shock. \u003cu\u003eNervous system disorders\u003c\/u\u003e: - drowsiness, asthenia, dizziness, headache, inability to concentrate. \u003cu\u003eEye pathologies\u003c\/u\u003e: - blurred vision. \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e: - thickening of bronchial secretions. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: - dry mouth, nausea. \u003cu\u003eHepatobiliary disorders\u003c\/u\u003e: - alterations in liver function and hepatitis. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: - skin reactions of various types and severity have been reported with the use of paracetamol including cases of urticaria, erythema multiforme, very rare cases of serious skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). Photosensitization. \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e: - renal alterations (acute renal failure, interstitial nephritis, hematuria, anuria), urinary retention. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e In case of overdose, marked depressive or stimulant effects on the central nervous system, drowsiness, lethargy, respiratory depression are generally observed. In case of overdose, the paracetamol contained in Zerinolflu can cause hepatic cytolysis which could evolve towards massive necrosis. \u003cu\u003eTherapy\u003c\/u\u003e N-acetylcysteine, administered in the hours immediately following ingestion of paracetamol, is effective in limiting liver damage. It is recommended to use the usual measures to remove unabsorbed material from the gastrointestinal tract by inducing vomiting or possibly by gastric lavage; keep the patient under observation by practicing supportive therapy. Further measures will depend on the severity, nature and course of clinical symptoms and should follow standard intensive care protocols.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy and breastfeeding\u003c\/u\u003e Zerinolflu is contraindicated during pregnancy and breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e No studies have been conducted with Zerinolflu to evaluate the effects on fertility in humans.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients should be warned that Zerinolflu may cause drowsiness. Those who drive vehicles or carry out operations requiring the integrity of the state of vigilance must be aware of this.\u003c\/p\u003e","brand":"Zentiva","offers":[{"title":"Default Title","offer_id":51131278360903,"sku":"035191030","price":15.62,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zentiva-italia-srl-zerinolflu-20-compresse-effervescenti-farmacia-dottor-tili-1213792255.jpg?v=1767133590"},{"product_id":"rinopanteina-unguento-10g","title":"Rinopanteina ointment 10g","description":"\u003cp\u003e\u003cstrong\u003eRhinopantheine ointment 10g\u003c\/strong\u003e is a medical device formulated to offer effective \u003cstrong\u003elubrication and hydration of the nasal mucosa\u003c\/strong\u003e. This product is particularly suitable for those who suffer from \u003cstrong\u003edryness and atrophy of the nasal mucosa\u003c\/strong\u003e, conditions that can be caused by environmental factors, use of nasal sprays, aerosol therapy or pathologies such as medicated or allergic rhinitis. Furthermore, Rhinopanteina is a valid support in \u003cstrong\u003ereepithelialization process\u003c\/strong\u003e post-surgery, helping to reduce crusting and improve nasal comfort.\u003c\/p\u003e\n\n\u003cp\u003eThanks to its formulation enriched with \u003cstrong\u003eVitamin A palmitate\u003c\/strong\u003e, \u003cstrong\u003eD-panthenol\u003c\/strong\u003e e \u003cstrong\u003ehyaluronic acid\u003c\/strong\u003e, Rhinopanteina ointment 10g promotes tissue regeneration and helps keep the nasal mucosa soft and protected. It is particularly useful for reducing the consequences of \u003cstrong\u003eepistaxis\u003c\/strong\u003e, even of traumatic origin, and to facilitate endoscopic examinations and tamponade maneuvers. Additionally, the ointment is effective in preventing and treating cracking caused by cooling of the perinasal areas.\u003c\/p\u003e\n\n\u003cp\u003eRhinopanteina ointment 10g is a precious ally for those looking for a reliable and quality product for the well-being of their nose, guaranteeing an adjuvant action in repair processes and long-lasting comfort. Its formulation is designed to offer simple application and proven effectiveness, making it an indispensable product for those who want to take care of their nasal health.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Rhinopanteina ointment 10g used? What is it for?\u003c\/h3\u003e\u003cp\u003eMedical device based on Vitamin A palmitate, D-panthenol and hyaluronic acid, indicated for the lubrication and hydration of the nasal mucosa in case of dryness or atrophy; promotes re-epithelization after surgical interventions and helps reduce the consequences of epistaxis, even of traumatic origin.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Rhinopantheine Ointment 10g contain?\u003c\/h3\u003e\u003cp\u003eVitamin A Palmitate (0.05%), D-Panthenol (5.0%), Avena Sativa Protein Hydrolysate, Hyaluronic Acid Sodium Salt (0.10%), Ceteareth-20, Sodium Benzoate, BHA, Vaseline Oil, White Vaseline, Purified Water.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Rhinopanteina ointment 10g?\u003c\/h3\u003e\u003cp\u003eApply a small amount of ointment one to three times a day and gently massage the wings of the nose to promote its diffusion.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Rhinopanteina ointment 10g?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eDo not use the product in case of known hypersensitivity to the components of the product.\u003cbr\u003eIn case of adverse reactions, discontinue use of the product and consult your doctor.\u003cbr\u003eDo not use the product if the packaging is not intact or has been tampered with. Tampering and\/or lack of integrity of the packaging could compromise the safety requirements of the product itself.\u003cbr\u003eDo not use this product after the expiry date stated on the package.\u003cbr\u003eClose the container tightly after use.\u003cbr\u003eKeep Rhinopantheine out of the sight and reach of children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Rhinopanteina ointment 10g stored?\u003c\/h3\u003e\u003cp\u003eStore the product between 15°C and 25°C.\u003cbr\u003eAt low temperatures, the drops can take on a semi-solid consistency without any deterioration in product quality. Simply shake the product and keep it at room temperature (not lower than 15°C) so that it regains its original consistency.\u003cbr\u003eThe expiry date indicated refers to the product in intact packaging, correctly stored.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Rhinopanteina ointment 10g?\u003c\/h3\u003e\u003cp\u003e10 g tube.\u003c\/p\u003e","brand":"Dmg Italia","offers":[{"title":"Default Title","offer_id":51131282063687,"sku":"909971398","price":11.4,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/dmg-italia-rinopanteina-unguento-10g-farmacia-dottor-tili-1258975839.jpg?v=1789561721"},{"product_id":"rinazina-aquamarina-spray-nasale-ipertonico","title":"Rinazine Aquamarina hypertonic nasal spray","description":"\u003cp\u003eThe \u003cstrong\u003eRinazine Aquamarina hypertonic nasal spray\u003c\/strong\u003e is an innovative medical device designed to offer quick and natural relief from nasal congestion. Formulated with \u003cstrong\u003ehypertonic sea water\u003c\/strong\u003e, this spray uses the osmotic effect to reduce the swelling of the nasal mucosa, making breathing easier. Enriched with \u003cstrong\u003eEucalyptus essential oil\u003c\/strong\u003e and wild mint extract, the product not only decongests, but also offers a pleasant sensation of freshness.\u003c\/p\u003e\n\n\u003cp\u003eIdeal for those who suffer from \u003cstrong\u003ecolds\u003c\/strong\u003e e \u003cstrong\u003erhinosinusitis\u003c\/strong\u003e, Rinazine Aquamarina acts with a \u003cstrong\u003etriple action\u003c\/strong\u003e: decongestant, purifying and hydrating. Its natural formulation, free of medicines and propellant gases, makes it suitable for daily use by adults and children aged 6 and over. Thanks to the mechanical action of the spray, it helps to remove viruses and bacteria, helping to keep the nasal cavities clean and protected.\u003c\/p\u003e\n\n\u003cp\u003eThe Rinazine Aquamarina hypertonic nasal spray is a precious ally for those looking for an effective and natural remedy against nasal congestion, guaranteeing a \u003cstrong\u003enasal relief\u003c\/strong\u003e immediate and lasting. Its preservative-free formulation ensures safe and delicate use, respecting the natural physiology of the respiratory tract.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Rinazine Aquamarina hypertonic nasal spray used? What is it for?\u003c\/h3\u003e\u003cp\u003eMedical device based on hypertonic sea water with eucalyptus essential oil and wild mint extract, indicated for rapid relief from nasal congestion in cases of colds and rhinosinusitis; the osmotic action reduces the swelling of the mucous membranes, facilitating breathing, for adults and children from 6 years old.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Rinazine Aquamarina hypertonic nasal spray contain?\u003c\/h3\u003e\u003cp\u003eSea water (hypertonic with a salt concentration of 2.2%).\u003cbr\u003eExcipients: Eucalyptus globulus essential oil, menthol extracted from Mentha arvensis.\u003cbr\u003eWithout preservatives. Without propellant gases.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Rinazine Aquamarina hypertonic nasal spray?\u003c\/h3\u003e\u003cp\u003eFor children aged 6 years and older and adults: 2-3 sprays in each nostril up to 6 times a day.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Rinazine Aquamarina hypertonic nasal spray?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eDo not use during pregnancy, breastfeeding, in case of allergy to any of the ingredients and in children under 6 years.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Rinazine Aquamarina hypertonic nasal spray stored?\u003c\/h3\u003e\u003cp\u003eKeep the product out of the reach and sight of children. Do not use the product after the expiry date or 6 months after opening. Store in the original packaging.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Rinazine Aquamarina hypertonic nasal spray?\u003c\/h3\u003e\u003cp\u003e20 ml pre-measured nasal spray\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51131297300807,"sku":"971101136","price":10.46,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-rinazina-aquamarina-spray-nasale-ipertonico-farmacia-dottor-tili-1213792201.jpg?v=1767127049"},{"product_id":"momentact-400mg-8-bustine-sospensione-orale-10ml","title":"Momentact 400mg 8 sachets oral suspension 10ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMomentact is indicated in adults and adolescents over 12 years of age. Pain of various origins and nature (headache, toothache, neuralgia, osteo-articular and muscular pain, menstrual pain). Adjuvant in the symptomatic treatment of fever and flu.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: ibuprofen 400 mg. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: \u003cb\u003esucrose\u003c\/b\u003e, \u003cb\u003esucrose\u003c\/b\u003e monopalmitate, of\u003cb\u003esodium\u003c\/b\u003e edetate dihydrate, \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e, \u003cb\u003epropyl parahydroxybenzoate\u003c\/b\u003e. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCetyl alcohol, \u003cb\u003esucrose\u003c\/b\u003e, xanthan gum, \u003cb\u003esucrose\u003c\/b\u003e monopalmitate, colloidal anhydrous silica, citric acid monohydrate, disodium edetate dihydrate, \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e, simethicone emulsion, \u003cb\u003eparahydroxybe propyl\u003cu\u003en\u003c\/u\u003ezoato\u003c\/b\u003e, blood orange flavour, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance (ibuprofen), to acetylsalicylic acid, to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients listed in paragraph 6.1. • Children under the age of 12. • Third trimester of pregnancy and breastfeeding (see section 4.6). • Active or severe gastroduodenal ulcer or other gastropathies. • History of gastrointestinal hemorrhage or perforation related to previous active treatment or history of recurrent peptic hemorrhage\/ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). • Severe hepatic or renal insufficiency. • Severe heart failure (NYHA class IV). • Severe dehydration (caused by vomiting, diarrhea or insufficient fluid intake).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cb\u003eAdults and adolescents\u003c\/b\u003e of equal age or older\u003cb\u003e at 12 years old:\u003c\/b\u003e 1 sachet 2-3 times a day. Do not exceed the dose of 1200 mg (3 single-dose sachets) per day. If the use of the medicine is necessary for more than 3 days in adolescents aged 12 years or older, or in the case of worsening of symptoms, the doctor should be consulted. Do not exceed the recommended doses. Elderly patients must adhere to the minimum dosages indicated above (see section 4.4). Side effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see section 4.4). \u003ci\u003eRenal impairment\u003c\/i\u003e: In patients with mild or moderate reduction in renal function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and renal function should be monitored. \u003ci\u003eHepatic impairment\u003c\/i\u003e: In patients with mild or moderate reduction in liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms and liver function should be monitored. Momentact is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePediatric population\u003c\/i\u003e Momentact is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e You can take Momentact on an empty stomach. In subjects with gastric tolerability problems, it is preferable to take the medicine on a full stomach.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• In asthmatic patients the product must be used with caution, following medical evaluation. • The use of Momentact, like any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. • The administration of Momentact should be suspended in women who have fertility problems or who are undergoing fertility investigations. • Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). • Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). \u003cu\u003e• Cardiovascular and cerebrovascular effects\u003c\/u\u003e Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration must also be exercised before starting patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking habit) on long-term treatment, especially if high doses (2400 mg\/day) of ibuprofen are necessary. Caution is required before starting treatment in patients with a history of hypertension and\/or heart failure since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. NSAIDs can reduce the effect of diuretics and other antihypertensive drugs (see section 4.5). \u003cu\u003e• Gastrointestinal haemorrhage, ulceration and perforation\u003c\/u\u003e The use of Momentact should be avoided concomitantly with NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors due to an increased risk of ulceration or bleeding (see section 4.5). Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported during treatment with all NSAIDs at any time, with or without warning symptoms or previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal haemorrhage) particularly in the initial stages of treatment. Carefully monitor patients taking concomitant medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors, or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking Momentact, treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). \u003cu\u003e• Renal effects\u003c\/u\u003e When initiating treatment with ibuprofen, caution should be exercised in patients with considerable dehydration. Ibuprofen may cause water and sodium, potassium retention in patients who have never suffered from kidney disease due to its effects on renal perfusion. This may cause edema or heart failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other renal pathological changes. In general, the habitual use of analgesics, especially combinations of different analgesic active ingredients, can lead to permanent kidney damage, with the risk of onset of renal failure (analgesic nephropathy). Renal toxicity has been reported in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. The administration of NSAIDs in these patients can lead to a dose-dependent reduction in the formation of prostaglandins and, as a secondary effect, in renal blood flow which can quickly lead to renal decompensation. The patients most at risk of these reactions are those with reduced renal function, heart failure, liver dysfunction, the elderly and all those patients taking diuretics and ACE inhibitors. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. In dehydrated adolescents there is a risk of impaired renal function. In case of prolonged use, monitor renal function, particularly in cases of diffuse lupus erythematosus. \u003cu\u003e• Dermatological effects\u003c\/u\u003e Severe skin reactions some of\u003cu\u003el\u003c\/u\u003ewhich fatalities, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Momentact should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity as well as if visual disturbances or persistent signs of liver dysfunction occur. \u003cu\u003e• Respiratory disorders\u003c\/u\u003e Momentact should be prescribed with caution in patients with bronchial asthma, chronic rhinitis, nasal polyps, sinusitis or current or previous allergic diseases because bronchospasm, urticaria and angioedema may occur. The same applies to those subjects who have experienced bronchospasm after the use of acetylsalicylic acid or other NSAIDs. \u003cu\u003e• Hypersensitivity reactions\u003c\/u\u003e Analgesics, antipyretics, NSAIDs can cause potentially serious hypersensitivity reactions (anaphylactoid reactions), even in subjects not previously exposed to this type of drugs. The risk of hypersensitivity reactions after taking ibuprofen is greater in subjects who have experienced such reactions after the use of other analgesics, antipyretics, NSAIDs and in subjects with bronchial hyperreactivity (asthma), hay fever, nasal polyposis or chronic obstructive respiratory diseases or previous episodes of angioedema (see sections 4.3 and 4.8). Hypersensitivity reactions may present in the form of asthma attacks (so-called analgesic asthma), Quincke's edema or urticaria. Severe hypersensitivity reactions (e.g. anaphylactic shock) have been observed rarely. At the first signs of hypersensitivity reaction after administration of ibuprofen, treatment should be discontinued. Medically assisted measures must be initiated by specialized medical personnel, in line with the symptoms. \u003cu\u003e• Reduced cardiac, renal and hepatic function\u003c\/u\u003e Particular caution must be taken when treating patients with reduced cardiac, hepatic or renal function since the use of NSAIDs may cause a deterioration of renal function. The usual concomitant use of different painkillers can further increase this risk. In patients with reduced cardiac, hepatic or renal function it is advisable to use the lowest effective dose for the shortest period of treatment and periodic monitoring of clinical and laboratory parameters, especially in case of prolonged treatment. \u003cu\u003e• Hematological effects\u003c\/u\u003e Ibuprofen, like other NSAIDs, can inhibit platelet aggregation and has shown evidence of prolonging bleeding time in healthy subjects. Therefore, patients with coagulation defects or on anticoagulant therapy should be carefully observed. \u003cu\u003e• Aseptic meningitis \u003c\/u\u003e On rare occasions, symptoms of aseptic meningitis have been observed in patients treated with ibuprofen. Although this is more likely to occur in patients with systemic lupus erythematosus and related connective tissue disorders, it has also been observed in patients without concomitant chronic diseases (see section 4.8). • Since ocular alterations have been detected during animal studies with NSAIDs, it is recommended, in case of prolonged treatments, to carry out periodic ophthalmological checks. • Alcohol consumption should be avoided as it can intensify the side effects of NSAIDs, especially those affecting the gastrointestinal tract or central nervous system. Ibuprofen may mask the signs or symptoms of infection (fever, pain, and swelling). \u003cu\u003eImportant information about some excipients\u003c\/u\u003e • Momentact contains: \u003cb\u003ePropyl and methyl parahydroxybenzoate\u003c\/b\u003e: can cause allergic reactions (even delayed) \u003cb\u003eSucrose\u003c\/b\u003e: Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. \u003cb\u003eSodium:\u003c\/b\u003e This medicinal product contains less than 1 mmol (23mg) sodium per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Ibuprofen (like other NSAIDs) should be taken with caution in combination with the substances listed below. • Corticosteroids: increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4). • Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin or heparin (see section 4.4). In case of concomitant treatment, monitoring of coagulation status is recommended. • \u003ci\u003eAcetylsalicylic acid:\u003c\/i\u003e Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects. Experimental data suggest that ibuprofen can competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility cannot be excluded that regular, long-term use of ibuprofen may reduce the cardioprotective effect of acetylsalicylic acid at low doses. No relevant clinical effects are considered likely following occasional use of ibuprofen (see section 5.1). • Cyclooxygenase-2 (COX-2) inhibitors and other NSAIDs: these substances may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). It is advisable not to combine ibuprofen with acetylsalicylic acid or other NSAIDs, including selective COX-2 inhibitors, due to potential additive effect (see section 4.4) • Anti-aggregating agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4). • Diuretics, ACE inhibitors (such as captopril), beta blockers and angiotensin II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of NSAID-associated nephrotoxicity. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Momentact concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and monitoring of renal function should be considered after initiation of concomitant therapy and thereafter. • Phenytoin and lithium: concomitant administration of ibuprofen and phenytoin or lithium preparations may result in reduced elimination of these medicines with consequent increase in their plasma levels with the possibility of reaching the toxic threshold. If this combination is deemed necessary, monitoring of plasma levels of phenytoin and lithium is recommended in order to adapt the dosage during simultaneous treatment with ibuprofen. • Methotrexate: NSAIDs may inhibit the tubular secretion of methotrexate and some metabolic interactions may occur resulting in reduced clearance of methotrexate and increased risk of toxicity. • Moclobemide: increases the effect of ibuprofen. • Aminoglycosides: NSAIDs may decrease the excretion of increased aminoglycosides\u003cu\u003et\u003c\/u\u003eresulting in toxicity.• Cardiac glycosides: NSAIDs can exacerbate heart failure, reduce the glomerular filtration rate and increase plasma levels of cardiac glycosides. Monitoring of serum glycoside levels is recommended. • Cholestyramine: the concomitant administration of ibuprofen and cholestyramine can reduce the absorption of ibuprofen from the gastrointestinal tract. However, the clinical relevance of this interaction is unknown. • Ciclosporin: concomitant administration of ciclosporin and some NSAIDs causes an increased risk of renal damage. This effect cannot be excluded for the combination of ciclosporin and ibuprofen. • Plant extracts: Ginkgo Biloba may increase the risk of bleeding in association with NSAIDs. • Mifepristone: due to the anti-prostaglandin properties of NSAIDs, their use after the administration of mifepristone may lead to a reduction in the effect of mifepristone. Limited evidence suggests that co-administration of NSAIDs and prostaglandins on the same day does not adversely influence the effects of mifepristone or prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of the medicinal product on pregnancy termination. • Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. • Sulfonylureas: NSAIDs can increase the hypoglycemic effect of sulfonylureas. In the case of simultaneous treatment, monitoring of blood glucose levels is recommended. • Tacrolimus: co-administration of NSAIDs and tacrolimus may lead to an increased risk of nephrotoxicity. • Zidovudine: there is evidence of an increased risk of haemarthrosis and hematoma in HIV-positive haemophiliac patients in simultaneous treatment with Zidovudine and other NSAIDs. A haematological examination is recommended 1-2 weeks after starting treatment. • Ritonavir: may cause an increase in plasma concentrations of NSAIDs. • Probenecid: slows down the excretion of ibuprofen, with possible increase in its plasma concentrations. • CYP2C9 inhibitors: Concomitant administration of ibuprofen and CYP2C9 inhibitors may slow the elimination of ibuprofen (CYP2C9 substrate) resulting in increased ibuprofen exposure. In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased exposure to S(+)ibuprofen by approximately 80% to 100% was observed. Reduction of the ibuprofen dose should be considered in cases of coadministration with strong CYP2C9 inhibitors, particularly when high doses of ibuprofen are administered with voriconazole or fluconazole • Alcohol, bisphosphonates and oxypentifylline (pentoxyfylline): may potentiate gastrointestinal side effects and the risk of bleeding and ulcers. • Baclofen: high toxicity of baclofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe side effects observed with ibuprofen are generally common to other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and are reported below using the following convention: Very common (≥1\/10), Common (≥1\/100, \u003c 1\/10), Uncommon (≥ 1\/ 1,000, \u003c1\/100), Rare (≥1\/10,000, \u003c 1\/1,000), Very rare (\u003c1\/10,000), Not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eInfections and infestations: Uncommon Rhinitis*.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations: Rare Aseptic meningitis* Exacerbation of infection-related inflammation (e.g. development of necrotizing fasciitis).\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Rare leukopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, inhibition of platelet aggregation.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Uncommon Hypersensitivity reactions: various types of skin rash, urticaria, pruritus, purpura, angioedema, exanthema, bronchospasm, dyspnoea, asthmatic attack (sometimes with hypotension).\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Rare Lupus erythematosus syndrome.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Very rare Severe hypersensitivity reactions: severe asthma, face edema, tongue edema, laryngeal edema, airway edema with bronchospasm, dyspnoea, tachycardia, anaphylaxis, exfoliative and bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Not known nonspecific allergic reaction and anaphylaxis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders: Uncommon Insomnia, anxiety.\u003c\/p\u003e\n\u003cp\u003eRare Depression, confusional state, hallucinations.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders: Common Dizziness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders: Uncommon Paraesthesia, drowsiness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders: Rare Optic neuritis.\u003c\/p\u003e\n\u003cp\u003eEye disorders: Uncommon Visual disturbances.\u003c\/p\u003e\n\u003cp\u003eEye disorders: Rare Ocular changes resulting in visual disturbances, toxic optic neuropathy.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders: Uncommon Impaired hearing, tinnitus, vertigo.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders: Very rare Palpitations, heart failure, myocardial infarction, acute pulmonary edema.\u003c\/p\u003e\n\u003cp\u003eVascular disorders: Very rare Hypertension.\u003c\/p\u003e\n\u003cp\u003eVascular disorders: Not known Stroke **.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders: Uncommon Bronchospasm, dyspnoea, apnoea.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Uncommon Gastritis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Very rare Pancreatitis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Rare Gastrointestinal perforation.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Not known Peptic ulcer, gastrointestinal haemorrhage. Sensation of heaviness in the stomach, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, epigastric pain, heartburn, abdominal pain, melena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Uncommon Abnormal liver function, hepatitis, jaundice.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Very rare Hepatic failure.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Uncommon Allergic skin rash (erythema) Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Very rare Bullous dermatitis including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme. Skin infection and soft tissue disease**.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Not known Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Uncommon Abnormal renal function, toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Rare Hyperazotemia.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site: Common Malaise, fatigue.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site: Rare Edema.\u003c\/p\u003e\n\u003cp\u003eInvestigations: Rare Increased transaminases, increased alkaline phosphatase, decreased hemoglobin, decreased hematocrit, prolonged bleeding time, decreased blood calcium, increased blood uric acid.\u003c\/p\u003e\n\u003cp\u003e*Rhinitis and aseptic meningitis have been observed especially in patients with pre-existing autoimmune disorders (such as systemic lupus erythematosus and mixed connective tissue disease) with symptoms of neck stiffness, headache, nausea, vomiting, fever or disorientation (see section 4.4). Exacerbation of infection-related inflammation has been described (e.g. development of necrotizing fasciitis). ** Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4). *** Serious skin infections and soft tissue disorders can occur during chickenpox infection. \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eToxicity\u003c\/u\u003e Signs and symptoms of toxicity were generally not observed at doses below 100 mg\/kg in children or adults. However, in some cases supportive treatment may be necessary. Children have been observed to exhibit signs and symptoms of toxicity after ingesting ibuprofen at doses of 400 mg\/kg or greater. \u003cu\u003eSymptoms\u003c\/u\u003e Most patients who have ingested significant amounts of ibuprofen will experience symptoms within 4 to 6 hours. The most commonly reported overdose symptoms include: nausea, vomiting, abdominal pain, lethargy, and drowsiness. Central nervous system (CNS) effects include headache, tinnitus, dizziness, seizures, and loss of consciousness. Nystagmus, hypothermia, renal effects, gastrointestinal bleeding, coma, apnea, diarrhea and CNS and respiratory depression have also been reported rarely. Disorientation, arousal, fainting and cardiovascular toxicity including hypotension, bradycardia and tachycardia have been reported. In cases of significant overdose, renal failure and liver damage are possible. In cases of severe poisoning, metabolic acidosis may occur \u003cu\u003eTreatment\u003c\/u\u003e There is no specific antidote for ibuprofen overdose. In case of overdose, symptomatic and supportive treatment is therefore indicated. Particular attention is due to the control of blood pressure, acid-base balance and any gastrointestinal bleeding. Administration of activated charcoal should be considered within one hour of ingesting a potentially toxic quantity. Alternatively, in adults, gastric lavage should be considered within one hour of ingesting a potentially life-threatening overdose. Adequate diuresis must be ensured and renal and hepatic functions must be closely monitored. The patient must remain under observation for at least four hours following ingestion of a potentially toxic amount of drug. Any occurrence of frequent or prolonged convulsions should be treated with intravenous diazepam. Depending on the patient's clinical condition, other support measures may be necessary. For more information, contact your local poison control center.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo-foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, Momentact should not be administered unless strictly necessary. If Momentact is used by a woman trying to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. \u003cb\u003e \u003cu\u003e During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to\u003c\/u\u003e:\u003c\/b\u003e - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; \u003cb\u003e \u003cu\u003e At the end of pregnancy, all inhibitors of prostaglandin synthesis can expose the mother and newborn to:\u003c\/u\u003e \u003c\/b\u003e - possible prolongation of bleeding time, and anti-aggregating effect which may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Momentact is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding \u003c\/u\u003e Ibuprofen is excreted in breast milk, but at therapeutic doses during short-term treatment, the risk of influencing the newborn appears unlikely. If, however, the treatment is longer term, early weaning should be considered. NSAIDs should be avoided during breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e The use of Ibuprofen may compromise female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulty conceiving or who are under investigation for infertility, discontinuation of ibuprofen treatment should be considered.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAs a rule, the use of ibuprofen does not alter the ability to drive and use machinery. However, patients whose activity requires vigilance should use caution if they notice drowsiness, dizziness or depression during ibuprofen therapy.\u003c\/p\u003e","brand":"Angelini Pharma","offers":[{"title":"Default Title","offer_id":51131297661255,"sku":"035618077","price":10.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momentact-400mg-8-bustine-sospensione-orale-10ml-farmacia-dottor-tili-1213792184.jpg?v=1767127109"},{"product_id":"fomentil-10-compresse-per-suffumigi","title":"Fomentil 10 tablets for fumigations","description":"\u003cp\u003eFomentil 10 fumigation tablets is a \u003cstrong\u003emedical device\u003c\/strong\u003e Class I, designed to provide relief to the respiratory tract through inhalation of vapors. These non-sterile tablets are ideal for those suffering from \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003esinusitis\u003c\/strong\u003e, \u003cstrong\u003ebronchitis\u003c\/strong\u003e and other inflammations of the respiratory system. Thanks to their formulation, Fomentil acts as an effective \u003cstrong\u003edecongestant\u003c\/strong\u003e, helping to clear the airways and fluidize catarrhal secretions, which are then naturally expelled through coughing.\u003c\/p\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Fomentil 10 fumigation tablets used? What is it for?\u003c\/h3\u003e\u003cp\u003eFomentil 10 fumigation tablets is a \u003cstrong\u003emedical device\u003c\/strong\u003e Class I, designed to provide relief to the respiratory tract through inhalation of vapors. These non-sterile tablets are ideal for those suffering from \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003esinusitis\u003c\/strong\u003e, \u003cstrong\u003ebronchitis\u003c\/strong\u003e and other inflammations of the respiratory system. Thanks to their formulation, Fomentil acts as an effective \u003cstrong\u003edecongestant\u003c\/strong\u003e, helping to clear the airways and fluidize catarrhal secretions, which are then naturally expelled through coughing.\u003c\/p\u003e\u003cp\u003eThe product exploits the beneficial properties of \u003cstrong\u003ementhol\u003c\/strong\u003e and of the\u003cstrong\u003eeucalyptus\u003c\/strong\u003e, which, combined with water vapor, help to decongest the respiratory tract, offering an immediate sense of relief. Fomentil is particularly useful in the presence of \u003cstrong\u003emucosal hypersecretion\u003c\/strong\u003e, acting as an adjuvant in treatments aimed at restoring the normal functioning of the respiratory tract. Its action is also indicated for conditions of \u003cstrong\u003erhinitis\u003c\/strong\u003e, \u003cstrong\u003epharyngitis\u003c\/strong\u003e e \u003cstrong\u003elaryngitis\u003c\/strong\u003e, protecting the nasal and oropharyngeal mucosa.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Fomentil 10 fumigation tablets contain?\u003c\/h3\u003e\u003cp\u003eSodium Bicarbonate, Tartaric Acid, Microcrystalline Cellulose, Bentonite, Glyceryl Distearate, Silica Colloidal Hydrated, Polyvinylpyrrolidone, Talc, Magnesium Stearate, Flavor (Eucaliptus Globulus Leaf Oil, Lavandula Angustifolia Oil, Thymus Vulgaris Flower\/Leaf Oil, Menthol).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Fomentil 10 fumigation tablets?\u003c\/h3\u003e\u003cp\u003eDissolve 1-2 tablets in approximately half a liter of boiling water and breathe the vapors for 3-4 minutes, collecting them using a special vapor inhaler or with your hands. Repeat this operation 3-4 times a day.\u003cbr\u003eThe water must be boiling for the tablet to dissolve completely. Break the tablets to facilitate their dissolution.\u003cbr\u003eDo not cover your head with a cloth while inhaling and be careful to keep your face at a distance of about 40 cm to prevent the hot water vapor from irritating the skin.\u003cbr\u003eFor children over 30 months: place a basin with boiling water near the child's bed and dissolve 3-4 tablets in it, one at a time. The duration of fumigation treatment should not exceed 3 days.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Fomentil 10 fumigation tablets?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eRead the leaflet carefully. Do not use if package is open or damaged. The product should not be used for children under 30 months of age. Do not administer in case of already known hypersensitivity to the components. For external use, do not swallow the tablets or drink the solution. Use only for fumigations and inhalations. Avoid contact with eyes. There are no known interactions with other products and\/or medicines, however in case of concomitant therapy for the respiratory tract, wait at least 30 minutes between the use of Fomentil and the other treatment. Fomentil is not recommended during pregnancy and in women of childbearing potential who are not using contraceptive measures. Fomentil should not be used during breastfeeding. It is important to report the appearance of side effects to your doctor or pharmacist. Keep out of the sight and reach of children and anyone who may accidentally ingest the tablet or solution. A higher dose than recommended should not be used. Consult your doctor if you suffer from chronic respiratory diseases.\u003cbr\u003eDo not use the product after the expiry date indicated on the package. Do not dispose of in the environment after use.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Fomentil 10 fumigation tablets stored?\u003c\/h3\u003e\u003cp\u003eStore the product in the original packaging, away from direct light and heat, at room temperature.\u003cbr\u003eThe expiry date refers to the intact product, correctly stored.\u003cbr\u003eValidity with intact packaging: 36 months.\u003cbr\u003eValidity after first opening: 18 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Fomentil 10 fumigation tablets?\u003c\/h3\u003e\u003cp\u003eTube of 10 tablets.\u003c\/p\u003e","brand":"Sit Laboratorio Farmaceutico","offers":[{"title":"Default Title","offer_id":51131304640839,"sku":"935558039","price":8.84,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sit-laboratorio-farmac-srl-fomentil-10-compresse-per-suffumigi-farmacia-dottor-tili-1213792163.jpg?v=1767134710"},{"product_id":"nurofencaps-400mg-10-capsule-molli","title":"Nurofencaps 400mg 10 soft capsules","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine is indicated in adults, children and adolescents weighing more than 40 kg (from 12 years of age) for the short-term symptomatic treatment of mild to moderate pain, such as headache, menstrual pain, toothache and pain associated with the common cold.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach capsule contains Ibuprofen 400 mg Excipients with known effects: Sorbitol (E420) 36.6 mg\/capsule; Ponceau 4R (E124) 0.79 mg\/capsule. For the full list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eFilling\u003c\/u\u003e: Macrogol 600, Potassium hydroxide, Purified water. \u003cu\u003eGelatin casing\u003c\/u\u003e: Jelly, \u003cb\u003eLiquid Sorbitol (E420)\u003c\/b\u003e, \u003cb\u003ePonceau 4R (E124)\u003c\/b\u003e. \u003cu\u003eInk\u003c\/u\u003e: Titanium dioxide (E171), Propylene glycol, Hypromellose (E464). \u003cu\u003eProcess aids\u003c\/u\u003e: Triglycerides (medium chain), Lecithin (E322).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Patients who have experienced hypersensitivity reactions (such as bronchospasm, asthma, rhinitis, angioedema or urticaria) associated with the use of acetylsalicylic acid (ASA) or other non-steroidal anti-inflammatory products (NSAIDs). • History of gastrointestinal bleeding or perforation related to previous NSAID treatment • Patients with current peptic ulcer\/haemorrhage or history of recurrent peptic ulcer\/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). • Patients with severe hepatic, renal or cardiac insufficiency (NYHA Class IV). See also section 4.4 • Patients with cerebrovascular bleeding or other active bleeding. • Patients with unclear hematopoiesis disorders. • Patients with severe dehydration (caused by vomiting, diarrhea or insufficient fluid intake) • During the last trimester of pregnancy (see section 4.6). • Adolescents weighing less than 40 kg or children under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Only for a short period of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see section 4.4). \u003cu\u003eAdults, children and adolescents weighing more than 40 kg (from 12 years of age)\u003c\/u\u003e. The initial dose is one capsule to be taken with water. Then, if necessary, one capsule every 6 hours. Do not exceed the dose of 3 capsules (1200 mg) in 24 hours. If the use of the medicine is necessary for more than 3 days in adolescents or in the case of worsening of symptoms, the doctor should be consulted. If in adults it is necessary to administer the product for more than 3 days in case of fever and 4 days for the treatment of pain, or if the symptoms worsen, consult your doctor. The onset of the effect of Nurofencaps may be delayed if the medicine is taken shortly after eating. If this occurs, do not take a higher dose of Nurofencaps than recommended in section 4.2 (dosage) or wait for the necessary time to elapse between one administration and another. \u003cb\u003eSpecial populations\u003c\/b\u003e \u003cu\u003eElderly\u003c\/u\u003e: No special dose adjustment is required. Due to the possible adverse effect profile (see section 4.4) elderly people should be monitored with particular attention. \u003cu\u003eRenal failure\u003c\/u\u003e No dose reduction is required in patients with mild to moderate renal impairment (for patients with severe renal impairment see section 4.3). \u003cu\u003eHepatic failure (see section 5.2)\u003c\/u\u003e No dose reduction is required in patients with mild to moderate hepatic impairment (for patients with severe hepatic impairment see section 4.3). \u003cu\u003eChildren and adolescents\u003c\/u\u003e For use in children and adolescents see section 4.3. \u003cu\u003eMethod of administration\u003c\/u\u003e For oral use. The capsules should not be chewed. It is recommended that patients with gastric sensitivity problems take Nurofencaps on a full stomach.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C. Store in the original package to protect the medicine from moisture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see below for gastrointestinal and cardiovascular risks). Caution is required in patients with the following conditions, which may worsen: • systemic lupus erythematosus and mixed connective tissue disease - for increased risk of aseptic meningitis (see section 4.8) • congenital disorders of porphyrin metabolism (e.g. Acute Intermittent Porphyria) • gastrointestinal disorders and chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease (see section 4.8) • hypertension and\/or heart failure (see sections 4.3 and 4.8) • renal failure, as renal function may be impaired (see sections 4.3 and 4.8) • liver dysfunction (see sections 4.3 and 4.8) • immediately after major surgery • In patients who experience allergic reactions to other substances, as they are at higher risk of developing hypersensitivity reactions even when using Nurofencaps • In patients suffering from hay fever, nasal polyps, respiratory disorders chronic obstructive disorders, or who have a history of allergic diseases, as there is an increased risk for these patients of developing allergic reactions. These can manifest themselves in the form of asthma attacks (so-called \"analgesic asthma\"), Quincke's edema or urticaria. \u003cu\u003eMasking of symptoms of underlying infections\u003c\/u\u003e Nurofencaps may mask the symptoms of infection, which could delay the initiation of appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Nurofencaps is administered for the relief of fever or pain related to infection, monitoring of the infection is advised. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. \u003cu\u003eGastrointestinal (GI) safety\u003c\/u\u003e: Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, increases the risk of adverse reactions (see section 4.5) and should be avoided. \u003cu\u003eElderly\u003c\/u\u003e: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). \u003cu\u003eGastrointestinal bleeding, ulceration and perforation\u003c\/u\u003e: Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported during treatment with all NSAIDs at any time, with or without warning symptoms or previous history of serious gastrointestinal events. When gastrointestinal bleeding or ulceration occurs following administration of ibuprofen, treatment should be discontinued. In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see section 4.5). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding), particularly in the initial stages of treatment. Caution should be advised in patients taking concomitant medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors (SSRIs) or antiplatelet agents such as acetylsalicylic acid (see section 4.5). NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). \u003cu\u003eSevere skin reactions\u003c\/u\u003e: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of the reaction occurs in most cases within the first month of treatment. Acute generalized exanthematous pustulosis (PEAG) has been reported in connection with ibuprofen-containing medicinal products. Nurofencaps should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity. Chickenpox can exceptionally cause serious infectious complications to the skin and soft tissues. It is advisable to avoid using Nurofencaps in case of chickenpox. \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e: Before starting treatment in patients with a history of hypertension and\/or heart failure, caution is required (consult your doctor or pharmacist) since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg per day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤1200 mg per day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration must also be exercised before starting patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking habit) on long-term treatment, especially if high doses (2400 mg\/day) of ibuprofen are necessary. \u003cu\u003eOther considerations\u003c\/u\u003e Severe acute hypersensitivity reactions (e.g. anaphylactic shock) are observed very rarely. At the first signs of hypersensitivity reaction after administration\/taking of Nurofencaps, therapy should be discontinued. The medical aid measures required based on the symptoms must be undertaken by specialized personnel. Ibuprofen, the active ingredient in Nurofencaps, can temporarily inhibit the function of platelets (thrombocyte aggregation), therefore it is recommended to carefully monitor patients with coagulation disorders. In case of prolonged administration of Nurofencaps, regular monitoring of liver values, renal function and blood counts is required. Prolonged use of any type of pain reliever for headaches can worsen symptoms. If this situation occurs or is suspected, the doctor should be consulted and treatment should be suspended. The diagnosis of headache due to medication abuse (\u003ci\u003emedication overuse headache -MOH\u003c\/i\u003e) should be suspected in patients who experience frequent or daily headaches despite or because of regular use of headache medications. The habitual use of analgesics, especially combinations of different analgesic active ingredients, can lead to permanent kidney damage with the risk of onset of renal failure (analgesic nephropathy). This risk may be increased by salt loss and dehydration. Side effects related to the active ingredient, in particular those relating to the gastrointestinal tract or central nervous system, may be increased by taking NSAIDs in combination with alcohol. There is some evidence that medicinal products that inhibit cyclooxygenase\/prostaglandin synthesis may cause impairment of female fertility through effect on ovulation. This effect is reversible after discontinuation of treatment. (see section 4.6). In dehydrated children and adolescents there is a risk of impaired kidney function. This medicine contains \u003cb\u003esorbitol\u003c\/b\u003e: Patients suffering from rare hereditary problems of fructose intolerance should not take this medicine. This medicine contains \u003cb\u003ePonceau 4R (E124)\u003c\/b\u003e. May cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAcetylsalicylic acid (low dose)\u003c\/u\u003e. Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects. Experimental data suggest that ibuprofen can competitively inhibit the effects of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility cannot be excluded that regular, long-term use of ibuprofen may reduce the cardioprotective effect of acetylsalicylic acid at low doses. No relevant clinical effects are considered likely following occasional use of ibuprofen (see section 5.1). \u003cu\u003eOther NSAIDs including selective cyclooxygenase-2 inhibitors\u003c\/u\u003e. Concomitant administration of several NSAIDs may increase the risk of gastrointestinal ulcers and bleeding due to the synergistic effect. The concomitant use of ibuprofen with other NSAIDs should therefore be avoided (see section 4.4) \u003cu\u003eDigoxin. Phenytoin, Lithium\u003c\/u\u003e. The simultaneous use of Nurofencaps with digoxin, phenytoin or lithium. may increase serum levels of these medicines. With correct use (maximum for 4 days) it is not usually necessary to control the levels of lithium, dioxin, phenytoin in the serum. \u003cu\u003eCorticosteroids\u003c\/u\u003e. Corticosteroids may increase the risk of adverse reactions, especially of the gastrointestinal tract (gastrointestinal ulceration or haemorrhage) (see section 4.3) \u003cu\u003eAntiplatelet agents and selective serotonin reuptake inhibitors (SSRIs)\u003c\/u\u003e: Increased risk of gastrointestinal bleeding (see section 4.4). \u003cu\u003eAnticoagulants\u003c\/u\u003e. NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4) \u003cu\u003eProbenecid and sulfinpyrazone\u003c\/u\u003e. Medicines containing probenecid or sulfinpyrazone may delay the excretion of ibuprofen \u003cu\u003eDiuretics, ACE inhibitors and Angiotensin II antagonists\u003c\/u\u003e. NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor, a beta-blocker or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and monitoring of renal function should be considered after initiation of concomitant therapy, and periodically thereafter \u003cu\u003ePotassium-sparing diuretics\u003c\/u\u003e. Co-administration of Nurofencaps and potassium-sparing diuretics may cause hyperkalemia. \u003cu\u003eMethotrexate\u003c\/u\u003e. Administration of Nurofencaps in the 24 hours before and after the administration of methotrexate may lead to an increase in plasma levels of methotrexate and an increase in its toxic effects. \u003cu\u003eCyclosporine\u003c\/u\u003e. Coadministration with some nonsteroidal anti-inflammatory drugs increases the risk of liver injury from cyclosporine. This effect cannot also be excluded for the association of ciclosporin with ibuprofen. \u003cu\u003eTacrolimus\u003c\/u\u003e. the risk of nephrotoxicity increases if the two medicines are administered simultaneously. \u003cu\u003eZidovudine\u003c\/u\u003e. There is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophilia patients if treated simultaneously with zidovudine and ibuprofen. There is a risk of increased haematological toxicity when NSAIDs are administered with zidovudine. \u003cu\u003eSulfonylureas\u003c\/u\u003e Clinical investigations have highlighted interactions between non-steroidal anti-inflammatory drugs and anti-diabetics (Sulfonylureas). Although no interactions between antidiabetics and ibuprofen have been described so far, it is recommended to monitor plasma glucose levels as a precaution in case of co-administration. \u003cu\u003eQuinolone antibiotics\u003c\/u\u003e Experimental animal data indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of having seizures. \u003cu\u003eMifepristone\u003c\/u\u003e: NSAIDs should not be used for 8-12 days after administration of Mifepristone as NSAIDs may reduce the effect of Mifepristone. \u003cu\u003eCYP2C9 inhibitors\u003c\/u\u003e: Concomitant administration of ibuprofen and CYP2C9 inhibitors may potentiate exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), increased exposure to S(+)-ibuprofen by approximately 80% to 100% was observed. Ibuprofen dose reduction should be considered when potent CYP2C9 inhibitors are administered concomitantly, particularly when high-dose ibuprofen is administered with voriconazole and fluconazole.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe list of the following side effects includes all side effects that have been recognized during treatment with ibuprofen, even those observed during prolonged high-dose therapy in patients with rheumatism. The frequencies reported, which extend beyond reports of very rare side effects, refer to short periods of treatment for daily doses up to a maximum of 1200 mg of ibuprofen for oral pharmaceutical forms and up to a maximum of 1800 mg for suppositories. It should be taken into account that the following adverse reactions are predominantly dose-dependent and vary from individual to individual. The most commonly observed adverse reactions are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, may occur, particularly in the elderly (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease have been reported following administration of ibuprofen (see section 4.4). Less frequently, gastritis was observed. In particular, the risk of gastrointestinal bleeding depends on the dosage and duration of treatment. Edema, hypertension and heart failure have been reported in association with NSAID treatment. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4). Hypersensitivity reactions have been reported and may manifest as: (a) non-specific allergic reactions and anaphylaxis; (b) respiratory tract reactivity, such as asthma, aggravated asthma, bronchospasm, dyspnea; (c) various skin reactions, such as pruritus, urticaria, angioedema and more rarely bullous and exfoliative dermatoses (including epidermal necrolysis and erythema multiforme). The patient should be informed to immediately inform the doctor and stop taking Nurofencaps if any of the above-mentioned adverse reactions occur. Please note that for each frequency group, side effects are presented in order of decreasing seriousness:\u003c\/p\u003e\n\u003cp\u003eVery common (≥1\/10).\u003c\/p\u003e\n\u003cp\u003eCommon (≥1\/100, \u003c1\/10).\u003c\/p\u003e\n\u003cp\u003eUncommon (≥1\/1,000, \u003c1\/100).\u003c\/p\u003e\n\u003cp\u003eRare (≥1\/10,000, \u003c1\/1,000).\u003c\/p\u003e\n\u003cp\u003eVery rare (\u003c1\/10,000).\u003c\/p\u003e\n\u003cp\u003eNot known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations.\u003c\/b\u003e Very rare: Exacerbation of infection-related inflammation (e.g. development of necrotizing fasciitis) has been described with the use of non-steroidal anti-inflammatory drugs. This is potentially associated with the mechanism of action of nonsteroidal anti-inflammatory drugs. If signs of infection appear or worsen while using Nurofencaps, the patient is recommended to contact a doctor immediately. The possible indication for anti-infective\/antibiotic therapy must be evaluated. Symptoms of aseptic meningitis such as stiff neck, headache, nausea, vomiting, fever or disorientation have been observed during treatment with ibuprofen. Patients with autoimmune disorders (systemic lupus erythematosus, mixed connective tissue disease) appear to be predisposed. \u003cb\u003ePathologies of the blood and lymphatic system\u003c\/b\u003e. Very rare: haematopoietic disorders (anaemia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis). The first manifestations may be: fever, sore throat, superficial ulcers of the oral cavity, flu-like symptoms, severe fatigue, nasal and skin bleeding. In these cases the patient must be informed to immediately suspend therapy, to avoid taking any analgesic or antipyretic self-medication medicines and to consult the doctor. For prolonged therapy the blood count must be checked regularly. \u003cb\u003eImmune system disorders (hypersensitivity)\u003c\/b\u003e. Uncommon: hypersensitivity reactions with urticaria and itching, as well as asthma attacks (possibly with fall in blood pressure). Very rare: severe generalized hypersensitivity reactions. Symptoms may be: swelling of the face, tongue and larynx, dyspnea, tachycardia, hypotension (anaphylaxis, angioedema or severe shock). Exacerbation of asthma and bronchospasm. \u003cb\u003ePsychiatric disorders\u003c\/b\u003e. Very rare: psychotic reactions, depression. \u003cb\u003eNervous system disorders\u003c\/b\u003e. Uncommon: central nervous system disorders such as headache, dizziness, drowsiness, agitation, irritability or tiredness. \u003cb\u003eEye pathologies\u003c\/b\u003e. Uncommon: visual disturbances. \u003cb\u003eEar and labyrinth disorders\u003c\/b\u003e. Rare: tinnitus, hearing impairment. \u003cb\u003eCardiac diseases\u003c\/b\u003e. Very rare: palpitations, heart failure, myocardial infarction. \u003cb\u003eVascular pathologies\u003c\/b\u003e. Very rare: arterial hypertension, vasculitis. \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e. Common: gastrointestinal disorders such as dyspepsia, heartburn, abdominal pain, nausea, vomiting, flatulence, diarrhea, constipation and slight gastrointestinal blood loss which in exceptional cases can cause anemia; Uncommon: Gastrointestinal ulcers, potentially with perforation and gastrointestinal bleeding. Ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4), gastritis; Very rare: esophagitis, pancreatitis, formation of diaphragmatic-like intestinal strictures. The patient should be advised to discontinue the medicinal product and seek immediate medical attention if severe upper abdominal pain, melena or haematemesis occurs. \u003cb\u003eHepatobiliary disorders\u003c\/b\u003e. Very rare: liver dysfunction, liver damage, especially following long-term treatment, liver failure, acute hepatitis. \u003cb\u003ePathologies of the skin and subcutaneous tissue.\u003c\/b\u003e Uncommon: various skin rashes; Very rare: bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome), alopecia. In exceptional cases, serious skin infections and soft tissue complications may occur during a chickenpox infection (see also “Infections and infestations”). Not known: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Acute generalized exanthematous pustulosis (PEAG). Photosensitivity reactions. \u003cb\u003eRenal and urinary disorders\u003c\/b\u003e. Rare: Kidney tissue damage (papillary necrosis) and high concentrations of uric acid in the blood may rarely occur. High concentrations of urea in the blood; Very rare: edema formation, particularly in patients with arterial hypertension or renal failure, nephrotic syndrome, interstitial nephritis which may be accompanied by acute renal failure. Kidney function should therefore be checked regularly. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse. \u003cu\u003eDiagnostic tests\u003c\/u\u003e. Rare: decreased hemoglobin levels.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn adults and adolescents there is no obvious dose-response effect. The half-life in case of overdose is 1.5-3 hours. \u003cu\u003eSymptoms\u003c\/u\u003e Most patients who have ingested clinically relevant quantities of NSAIDs present exclusively nausea, vomiting, epigastric pain, or more rarely diarrhea. You may also experience tinnitus, headache, and gastrointestinal bleeding. In more severe cases of poisoning, central nervous system toxicity is observed, manifested by dizziness, drowsiness, occasionally excitation and disorientation or coma. Occasionally patients develop seizures. In severe cases of poisoning, metabolic acidosis and a prolongation of the prothrombin time\/INR may occur, probably caused by interference with the action of coagulation factors present in the circulation. Acute renal failure and liver damage may also occur. In asthmatic subjects, asthma exacerbation may occur. \u003cu\u003eTreatment\u003c\/u\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until the patient is stabilized. Oral administration of activated charcoal should be considered if the patient presents within 1 hour of ingesting a potentially toxic quantity. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators in case of asthma. There is no specific antidote available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Data obtained from epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor during the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk is thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, ibuprofen should not be administered unless strictly necessary. When used by women about to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be as low and as short as possible, respectively. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligohydramniosis; the mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, ibuprofen is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Ibuprofen and its metabolites can pass in low concentrations into breast milk. No dangerous effects for newborns are known to date, therefore for short treatments with the recommended dose for pain and fever, interruption of breastfeeding is generally not necessary. \u003cu\u003eFertility\u003c\/u\u003e There is some evidence that drugs that inhibit cyclooxygenase\/prostaglandin synthesis may cause impairment of female fertility with an effect on ovulation. This is reversible upon discontinuation of treatment (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients who experience dizziness, drowsiness, vertigo or visual disturbances during ibuprofen therapy should avoid driving or using machinery. For a single administration or short periods of treatment, ibuprofen does not normally require the adoption of any special precautions. These effects are even more enhanced in case of concomitant alcohol intake.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131308933447,"sku":"041860053","price":10.51,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-nurofencaps-400mg-10-capsule-molli-farmacia-dottor-tili-1213792149.jpg?v=1767135149"},{"product_id":"nurofen-200mg-24-compresse-rivestite","title":"Nurofen 200mg 24 coated tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePain of various kinds: headache, toothache, neuralgia, muscular and osteoarticular pain, menstrual pain. Adjuvant in the symptomatic treatment of feverish and flu states. Nurofen is indicated in adults and adolescents over 12 years of age\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e200 mg coated tablets: each tablet contains 200 mg of ibuprofen 400 mg coated tablets: each tablet contains 400 mg of ibuprofen Excipients with known effects: Each 200 mg coated tablet contains: - 116.1 mg of sucrose, equivalent to approximately 0.34 mmol - 17.34 mg of sodium, equivalent to approximately 0.75 mmol Each 400 mg coated tablet contains: - 232.2 mg, equivalent to approximately 0.68 mmol - 34.69 mg sodium, equivalent to approximately 1.51 mmol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eNurofen 200 mg coated tablets\u003c\/b\u003e Croscarmellose sodium, \u003cb\u003esodium\u003c\/b\u003e lauryl sulfate, \u003cb\u003esodium\u003c\/b\u003e citrate, stearic acid, colloidal anhydrous silica, carmellose \u003cb\u003esodium\u003c\/b\u003e, talc, dried atomized gum arabic, \u003cb\u003esucrose\u003c\/b\u003e, titanium dioxide, macrogol 6000, ink (shellac, black iron oxide E172, propylene glycol E1520). \u003cb\u003eNurofen 400 mg coated tablets\u003c\/b\u003e Croscarmellose \u003cb\u003esodium\u003c\/b\u003e, \u003cb\u003esodium\u003c\/b\u003e lauryl sulfate, \u003cb\u003esodium\u003c\/b\u003e citrate, stearic acid, colloidal anhydrous silica, carmellose \u003cb\u003esodium\u003c\/b\u003e, talc, dried atomized gum arabic, \u003cb\u003esucrose\u003c\/b\u003e, titanium dioxide, macrogol 6000, ink (shellac, red iron oxide (E 172), propylene glycol (E1520), ammonium hydroxide (E527), simethicone).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients, listed in paragraph 6.1. Patients who have previously experienced hypersensitivity reactions (e.g. bronchospasm, asthma, rhinitis, angioedema or urticaria) following the use of ibuprofen, acetylsalicylic acid, or other non-steroidal anti-inflammatory products (NSAIDs). Patients with severe hepatic or renal impairment (see section 4.4). Severe heart failure (NYHA class IV) Patients with a history of gastrointestinal bleeding or perforation, related to previous NSAID therapy. Patients with current or previous recurrent peptic ulcers\/haemorrhages (two or more distinct episodes of proven ulceration or bleeding). During the last trimester of pregnancy (see section 4.6). Children under 12 years old. Before or after cardiac surgery.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage \u003c\/u\u003e Only for a short period of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see section 4.4). If symptoms persist or worsen after a short period of treatment, consult your doctor. If the use of the medicine is necessary for more than 3 days in adolescents, or in the case of worsening of symptoms, the doctor should be consulted. \u003cb\u003e \u003cu\u003eNUROFEN 200 mg coated tablets\u003c\/u\u003e \u003c\/b\u003e \u003cb\u003e Pediatric population:\u003c\/b\u003e Do not administer to children under 12 years of age.\u003cb\u003eAdults and adolescents over 12 years old\u003c\/b\u003e: 1-2 tablets, 2-3 times a day. The interval between doses should not be less than 4 hours. Do not exceed a dose of 1200 mg (6 tablets) in 24 hours. \u003cb\u003eElderly\u003c\/b\u003e: No changes to the dosage schedule are required. \u003cb\u003e \u003cu\u003eNUROFEN 400 mg coated tablets\u003c\/u\u003e \u003c\/b\u003e \u003cb\u003ePediatric population:\u003c\/b\u003e Do not administer to children under 12 years of age.\u003cb\u003eAdults and adolescents over 12 years old\u003c\/b\u003e One tablet 2-3 times a day. The interval between doses should not be less than 4 hours. Do not exceed a dose of 1200 mg (3 tablets) in 24 hours. \u003cb\u003eElderly:\u003c\/b\u003e No changes to the dosage schedule are required. \u003cu\u003eMethod of administration \u003c\/u\u003e Oral use Patients with gastric sensitivity problems are advised to take Nurofen on a full stomach.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNurofen 400 mg coated tablets: store at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution is required in patients with coagulation defects. Side effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see gastrointestinal and cardiovascular risks below). \u003cb\u003eElderly\u003c\/b\u003e: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2). \u003cb\u003ePediatric population\u003c\/b\u003e: in dehydrated adolescents there is a risk of impaired renal function. \u003cb\u003eRespiratory disorders\u003c\/b\u003e: bronchospasm may occur in patients with bronchial asthma or current or previous allergic diseases. \u003cb\u003eOther NSAIDs\u003c\/b\u003e: The use of Nurofen should be avoided concomitantly with other NSAIDs, including selective cyclooxygenase-2 inhibitors. (see paragraph 4.5) \u003cb\u003eSLE and mixed connective tissue disease\u003c\/b\u003e Systemic lupus erythematosus and with mixed connective tissue disease due to increased risk of aseptic meningitis (see section 4.8); \u003cb\u003eCardiovascular and cerebrovascular effects\u003c\/b\u003e: caution is required (discuss with your doctor or pharmacist) before starting treatment in patients with a positive history of hypertension and\/or heart failure since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration and high doses (2400 mg\/day) should be avoided. Careful consideration must also be exercised before starting long-term treatment for patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking habit), especially if high doses (2400 mg\/day) of ibuprofen are necessary. \u003cb\u003eLiver or kidney function:\u003c\/b\u003e • renal failure, as renal function may be compromised (see sections 4.3 and 4.8). In general, the habitual use of analgesics, especially combinations of different analgesic active ingredients, can lead to permanent kidney damage with the risk of the onset of renal failure (analgesic nephropathy). • liver dysfunction (see sections 4.3 and 4.8). Particular caution should be taken when treating patients with reduced hepatic or renal function. In such patients it is advisable to resort to periodic monitoring of clinical and laboratory parameters, especially in case of prolonged treatment. \u003cb\u003eCompromised female fertility\u003c\/b\u003e: Administration of Nurofen should be avoided in women planning pregnancy (see section 4.6). \u003cb\u003eGastrointestinal safety\u003c\/b\u003e: NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported during treatment with all NSAIDs at any time, with or without warning symptoms or previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. The concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see section 4.5). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal haemorrhage) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking Nurofen, treatment should be discontinued. \u003cb\u003eSevere skin reactions:\u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of the reaction occurs in most cases within the first month of treatment. Acute generalized exanthematous pustulosis (PEAG) has been reported in connection with ibuprofen-containing medicinal products. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003eMasking of symptoms of underlying infections\u003c\/b\u003e: Nurofen may mask the symptoms of infection, which may delay the initiation of appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Nurofen is given for the relief of fever or pain related to infection, monitoring of the infection is advised. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. \u003cb\u003eOther:\u003c\/b\u003e during prolonged treatments with analgesic medicinal products at doses higher than those indicated, headaches may occur which must not be treated with higher doses of the product. Alcohol consumption should be avoided as it can intensify the side effects of NSAIDs, especially those affecting the gastrointestinal tract or central nervous system. At the first signs of hypersensitivity reaction after administration of ibuprofen, treatment should be discontinued. Medically assisted measures must be initiated by specialized medical personnel, in line with the symptoms. Acid ibuprofen can cause a prolongation of the bleeding time by reversibly inhibiting the aggregation of platelets. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003cu\u003eNurofen\u003c\/u\u003e contains sucrose: patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. \u003cu\u003eNurofen 200 mg coated tablets\u003c\/u\u003e contains sodium: this medicine contains less than 1 mmol (23 mg) sodium per tablet (17.34 mg), i.e. essentially 'sodium-free' and just over 1 mmol (23 mg) sodium per 2 tablets (34.68 mg), equivalent to 1.73% of the maximum daily intake recommended by the WHO which corresponds to 2 g sodium for an adult. \u003cu\u003eNurofen 400 mg coated tablets contain sodium\u003c\/u\u003e: This medicine contains 34.69 mg sodium per tablet, equivalent to 1.73% of the WHO recommended maximum daily intake of 2 g sodium for an adult.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIbuprofen should be avoided in association with: - Acetylsalicylic acid: concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects (see section 4.4). Experimental data suggest that ibuprofen can competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility cannot be excluded that regular, long-term use of ibuprofen may reduce the cardioprotective effect of acetylsalicylic acid at low doses. No relevant clinical effects are considered likely following occasional use of ibuprofen (see section 5.1). - Other NSAIDs including selective cyclooxygenase-2 inhibitors: the concomitant use of two or more NSAIDs should be avoided as they may increase the risk of adverse reactions affecting the gastrointestinal tract (see section 4.4). Ibuprofen (like other NSAIDs) should be used with caution in association with: - Corticosteroids: increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4) - Anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4) - Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal haemorrhage (see section 4.4). - Antihypertensives (ACE inhibitors and Angiotensin II Antagonists), diuretics and beta blockers: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking a coxib (such as Nurofen) concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and at regular intervals thereafter. Diuretics may increase the risk of NSAID nephrotoxicity. - Cardiac glycosides: NSAIDs can worsen heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides. - Lithium. There are demonstrations of the possibility of a potential increase in lithium levels in the blood, with the possibility of reaching the toxic threshold. If this combination is necessary, monitor lithium levels in order to adapt the lithium dosage during simultaneous treatment with ibuprofen. - Methotrexate. There is evidence of the possibility of an increase in plasma levels of methotrexate. - Cyclosporins: increase the risk of nephrotoxicity. - Mifepristone: NSAIDs should not be taken for 8-12 days after administration of Mifepristone as NSAIDs may reduce the effects of Mifepristone. - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered with Tacrolimus. - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with Zidovudine. There is evidence of an increased risk of haemarthrosis and haematoma in HIV-positive haemophilia patients if treated simultaneously with zidovudine and ibuprofen. - Antibiotics quinolones: Data from animal studies indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. - Alcohol, bisphosphonates and pentoxifylline: can potentiate gastrointestinal side effects and the risk of bleeding and ulcers. - Baclofen: high toxicity of baclofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe list of the following side effects includes side effects that have been observed during treatment with ibuprofen at self-medication doses (up to a maximum of 1200mg per day). In case of chronic conditions, additional side effects may occur during long-term treatment. The side effects associated with the administration of ibuprofen are listed below according to system organ classification and frequency. \u003ci\u003eFor the frequency of occurrence of side effects, the following expressions are used:\u003c\/i\u003e \u003ci\u003eVery common (\u003c\/i\u003e≥ \u003ci\u003e1\/10)\u003c\/i\u003e; \u003ci\u003eMunicipality (\u003c\/i\u003e≥ \u003ci\u003e1\/100, \u0026lt;1\/10)\u003c\/i\u003e; \u003ci\u003eUncommon (\u003c\/i\u003e≥ \u003ci\u003e1\/1000, \u0026lt;1\/100)\u003c\/i\u003e; \u003ci\u003eRare (\u003c\/i\u003e≥ \u003ci\u003e1\/10.000, \u0026lt;1\/1000)\u003c\/i\u003e; \u003ci\u003eVery rare (\u003c1\/10,000)\u003c\/i\u003e; \u003ci\u003eNot known (frequency cannot be estimated from the available data)\u003c\/i\u003e. \u003ci\u003eWithin each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Very Rare. Adverse Reaction: Hematopoietic disorders¹\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Uncommon. Adverse Reaction: Hypersensitivity reactions including urticaria and pruritus²\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Very Rare. Adverse Reaction: Severe hypersensitivity reactions including swelling of the face, tongue and throat, dyspnoea, tachycardia, hypotension (anaphylaxis, angioedema or severe shock)²\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse Reaction: Headache, dizziness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Rare. Adverse Reaction: Cerebrovascular accident9.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Very rare. Adverse Reaction: Aseptic meningitis³\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Very Rare. Adverse Reaction: Visual disturbances.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Very rare. Adverse Reaction: Heart failure and edema4.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Very rare. Adverse Reaction: Hypertension4.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Not known. Adverse Reaction: Respiratory tract reactivity including asthma, worsening of asthma, bronchospasm or dyspnea.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse Reaction: Dyspepsia, abdominal pain and nausea5.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Rare. Adverse Reaction: Diarrhoea, flatulence, constipation and vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Very rare. Adverse Reaction: Peptic ulcers, gastrointestinal perforation or hemorrhage, melena, hematemesis6, ulcerative stomatitis, gastritis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse Reaction: Exacerbation of colitis and Crohn's disease7, pancreatitis.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Rare. Adverse Reaction: Hepatotoxicity\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Very rare. Adverse Reaction: Liver disorders, especially following long-term treatment, hepatitis, jaundice.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse Reaction: Skin rashes².\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Very rare. Adverse Reaction: Erythema multiforme, bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.²\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse Reaction: Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalized exanthematous pustulosis (PEAG), photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Very rare. Adverse Reaction: Acute renal failure8, hematuria, nephritis, nephrotic syndrome9.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Frequency: Rare. Adverse Reaction: Increased transaminases, increased alkaline phosphatase, decreased hematocrit, prolonged bleeding time, decreased blood calcium, increased uric acid.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Frequency: Very rare. Adverse Reaction: Decreased hemoglobin level in the blood.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eDescription of some side effects\u003c\/b\u003e \u003csup\u003e1\u003c\/sup\u003e Examples include anemia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis). The first manifestations are: fever, sore throat, superficial ulcers of the oral cavity, flu-like symptoms, severe fatigue, bruises and unexplained bleeding. ² Hypersensitivity reactions: these reactions may include a) non-specific allergic reactions and anaphylaxis, b) respiratory tract reactivity including asthma, worsening of asthma, bronchospasm or dyspnoea or c) various skin conditions such as various skin rashes, pruritus, urticaria, purpura, angioedema and very rarely bullous and exfoliative dermatitis including toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. ³ The pathogenesis of drug-induced aseptic meningitis is not completely understood. However, the data available on aseptic meningitis related to the administration of NSAIDs leads us to think of an immune hypersensitivity reaction (due to a temporary relationship with the intake of the medicine and the disappearance of symptoms after discontinuation of treatment). Of note, individual cases of aseptic meningitis symptoms (such as stiff neck, headache, nausea, vomiting, fever and disorientation) have been observed during treatment with ibuprofen in patients with autoimmune disorders (such as systemic lupus erythematosus, mixed connective tissue disease). \u003csup\u003e4\u003c\/sup\u003e Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day) may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4) \u003csup\u003e5\u003c\/sup\u003e The most commonly observed adverse reactions are gastrointestinal in nature. \u003csup\u003e6\u003c\/sup\u003e sometimes fatal, particularly in the elderly \u003csup\u003e7\u003c\/sup\u003e see paragraph 4.4 \u003csup\u003e8\u003c\/sup\u003e particularly following long-term treatment, associated with increased serum urea concentrations. Decreased urea excretion and edema. Also includes papillary necrosis \u003csup\u003e9\u003c\/sup\u003e reported as an effect of NSAID class \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioniavverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eToxicity \u003c\/u\u003e Signs and symptoms of toxicity were generally not observed at doses below 100 mg\/kg in children or adults. However, in some cases supportive treatment may be necessary. Children have been observed to exhibit signs and symptoms of toxicity after ingesting ibuprofen at doses of 400 mg\/kg or greater. \u003cu\u003eSymptoms \u003c\/u\u003e Most patients who have ingested significant amounts of ibuprofen will experience symptoms within 4 to 6 hours. The most commonly reported overdose symptoms include: nausea, vomiting, abdominal pain, lethargy, and drowsiness. Central nervous system (CNS) effects include headache, tinnitus, dizziness, seizures, and loss of consciousness. Nystagmus, metabolic acidosis, hypothermia, renal effects, gastrointestinal bleeding, coma, apnea, diarrhea and depression of the CNS and respiratory system, blurring of vision have also been reported rarely. Disorientation, arousal, fainting and cardiovascular toxicity including hypotension, bradycardia and tachycardia have been reported. In cases of significant overdose, renal failure and liver damage are possible. In cases of severe poisoning, metabolic acidosis and a prolongation of the prothrombin time\/INR may occur, probably caused by interference with the action of coagulation factors present in the circulation. In asthmatic subjects, asthma exacerbation may occur. \u003cu\u003eTreatment \u003c\/u\u003e There is no specific antidote for ibuprofen overdose. In case of overdose, symptomatic and supportive treatment is therefore indicated and must include maintaining a patent airway and monitoring cardiac function and vital signs until the patient is stabilised. Particular attention is due to the control of blood pressure, acid-base balance and any gastrointestinal bleeding. Administration of activated charcoal should be considered within one hour of ingesting a potentially toxic quantity. Alternatively, in adults, gastric lavage should be considered within one hour of ingestion of a potentially life-threatening overdose. Adequate diuresis must be ensured and renal and hepatic functions must be closely monitored. The patient must remain under observation for at least four hours following ingestion of a potentially toxic amount of drug. Any occurrence of frequent or prolonged convulsions should be treated with intravenous diazepam. If ibuprofen has already been absorbed, alkaline substances should be administered to promote excretion of the acidic ibuprofen in the urine. Administer bronchodilators in case of asthma. Depending on the patient's clinical condition, other support measures may be necessary. For more information, contact your local poison control center.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can negatively affect the pregnant woman and\/or embryo\/foetal development. Data obtained from epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor during early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk is thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. From the 20th\u003csup\u003ea\u003c\/sup\u003e week of pregnancy onwards, the use of ibuprofen could cause oligohydramnios resulting from fetal renal dysfunction. This condition may be experienced shortly after starting treatment and is usually reversible upon discontinuation of treatment. Additionally, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester, most of which resolved after treatment was discontinued. Therefore, during the first and second trimester of pregnancy ibuprofen should not be administered unless strictly necessary. If ibuprofen is used by a woman planning pregnancy, or during the first and second trimester of pregnancy, the lowest possible dose should be used for the shortest possible time. Following exposure to ibuprofen for several days from the 20th\u003csup\u003ea\u003c\/sup\u003e week of gestation onwards, antenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered. In case of oligohydramnios or constriction of the ductus arteriosus, treatment with ibuprofen should be discontinued. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (premature constriction\/closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction (see above); the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Nurofen is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3). \u003cu\u003eBreastfeeding \u003c\/u\u003e Ibuprofen and its metabolites can pass in low concentrations into breast milk. No dangerous effects for newborns are known to date, therefore for short treatments with the recommended dose for pain and fever, interruption of breastfeeding is generally not necessary. \u003cu\u003eFertility \u003c\/u\u003e There is evidence that medicinal products that inhibit the synthesis of cyclooxygenase\/prostaglandins can cause a weakening of female fertility by affecting ovulation. This effect is reversible after discontinuation of treatment. The administration of Nurofen should be suspended in women who have fertility problems or who are undergoing fertility investigations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor short periods of treatment, Nurofen has no or negligible influence on the ability to drive and use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131311653191,"sku":"025634041","price":11.53,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-nurofen-200mg-24-compresse-rivestite-farmacia-dottor-tili-1213792139.jpg?v=1767135310"},{"product_id":"rinoway-doccia-irrigazione-nasale","title":"Rinoway nasal irrigation shower","description":"\u003cp\u003eThe \u003cstrong\u003eRinoway nasal irrigation shower\u003c\/strong\u003e is a medical device designed to improve the hygiene and health of the upper respiratory tract. Ideal for those who suffer from \u003cstrong\u003esinusitis\u003c\/strong\u003e, \u003cstrong\u003eallergic rhinitis\u003c\/strong\u003e or cold, this tool uses a \u003cstrong\u003esaline solution\u003c\/strong\u003e to carry out an effective nasal wash, removing allergens and excess mucus. Its structure in \u003cstrong\u003esturdy plastic\u003c\/strong\u003e guarantees long life and resistance to daily use.\u003c\/p\u003e\n\n\u003cp\u003eThanks to its ability to perform gentle but effective nasal irrigation, the Rinoway nasal shower helps keep the nasal cavities clean, improving the \u003cstrong\u003ebreathing\u003c\/strong\u003e and reducing congestion. It is particularly useful for those who live in environments with a high presence of \u003cstrong\u003eallergens\u003c\/strong\u003e or air pollutants. Regular use of this device can help prevent infection \u003cstrong\u003eupper respiratory tract\u003c\/strong\u003e and improve general well-being.\u003c\/p\u003e\n\n\u003cp\u003eThe Rinoway nasal shower is compatible with \u003cstrong\u003eisotonic salts\u003c\/strong\u003e e \u003cstrong\u003ehypertonic salts\u003c\/strong\u003e, offering flexibility in treating different nasal conditions. Its ergonomic design and \u003cstrong\u003enebulizer\u003c\/strong\u003e integrated facilitate the application of the solution, making the cleaning process simple and comfortable. Perfect for home use, the Rinoway nasal irrigation shower is an indispensable ally for those who want to maintain optimal nasal hygiene and improve the quality of their breathing.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Rinoway nasal irrigation douche? What is it for?\u003c\/h3\u003e\u003cp\u003eMedical device for washing the upper respiratory tract using saline solution, indicated in cases of sinusitis, allergic rhinitis or colds; helps remove allergens and excess mucus, promoting breathing and cleaning the nasal cavities.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Rinoway nasal irrigation douche contain?\u003c\/h3\u003e\u003cp\u003eSodium chloride, sodium bicarbonate, panthenol (vitamin B5), hyaluronic acid sodium salt.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Rinoway nasal irrigation shower?\u003c\/h3\u003e\u003cp\u003eTo be used with isotonic or hypertonic saline solutions, depending on the problem.\u003cbr\u003ePressure mode: for a strong wash. Drain mode: for slower, gentler watering.\u003cbr\u003eFor children the nebulizer nozzle can be used.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Rinoway nasal irrigation shower?\u003c\/h3\u003e\u003cp\u003eDo not use in case of known hypersensitivity to the product components. In case of adverse reactions, discontinue use of the product and consult your doctor. Close the container tightly after use. Do not use the product after the expiry date indicated on the packaging. Do not use the product if the packaging or bottle is not intact. Keep out of reach of children. Avoid contact with eyes. Do not inject. Do not ingest. Do not dispose of the bottle in the environment after use. Avoid promiscuous use of the product. Store at a temperature not exceeding 30°C and away from heat sources. Validity with intact packaging: 24 months. Post-opening validity: 90 days.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Rinoway nasal irrigation shower?\u003c\/h3\u003e\u003cp\u003eAvailable in packs of 15, 30 or 60 sachets of 2.25 g. With nebulizer.\u003c\/p\u003e","brand":"Envicon Medical","offers":[{"title":"Default Title","offer_id":51131313586503,"sku":"932720978","price":16.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/envicon-medical-rinoway-doccia-irrigazione-nasale-farmacia-dottor-tili-1258975938.jpg?v=1789561602"},{"product_id":"isomar-flaconcini-decongestionanti-20x5ml","title":"Isomar decongestant vials 20x5ml","description":"\u003cp\u003e\u003cstrong\u003eIsomar decongestant vials 20x5ml\u003c\/strong\u003e is a hypertonic solution based on pure sea water, designed to offer a natural decongestant action on the nasal mucous membranes. Thanks to its formulation, this medical device is ideal for freeing the nose from excess mucus through an osmosis process, making it particularly suitable for use in aerosol therapy. The hypertonic saline solution, with a higher salt concentration than body fluids, promotes the drainage of secretions, helping to reduce airway edema and improve breathing.\u003c\/p\u003e\n\n\u003cp\u003eThese single-dose vials are suitable for both adults and children, offering a practical and hygienic option for daily nasal hygiene. They are particularly useful in cases of allergic rhinitis, sinusitis and colds, helping to keep the nasal cavities clean and free from obstructions. Regular use of \u003cstrong\u003eIsomar decongestant vials\u003c\/strong\u003e can help improve respiratory comfort, especially during periods of intense nasal congestion.\u003c\/p\u003e\n\n\u003cp\u003ePackaged in handy 5ml vials, these nasal decongestants are easy to use and transport, ensuring quick and effective relief wherever you are. Their hypertonic seawater-based formulation is free of preservatives and colorants, ensuring a delicate and safe treatment for the nasal mucous membranes. Choose \u003cstrong\u003eIsomar decongestant vials\u003c\/strong\u003e for a natural decongestant action and optimal respiratory well-being.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Isomar decongestant vials 20x5ml? What is it for?\u003c\/h3\u003e\u003cp\u003eHypertonic solution based on sea water, medical device indicated for the decongestion of nasal mucous membranes and the drainage of secretions in case of colds, allergic rhinitis or sinusitis; can also be used in aerosol therapy for adults and children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Isomar decongestant vials 20x5ml contain?\u003c\/h3\u003e\u003cp\u003eSterile hypertonic seawater.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Isomar decongestant vials 20x5ml?\u003c\/h3\u003e\u003cp\u003eUse up to a maximum of 3 times a day and for no longer than 2 weeks of treatment. Prolonged use could cause dehydration of the nasal mucosa.\u003cbr\u003eOpen the sealed vial by twisting the cap. Introduce the single-dose vial into the nostrils of the lying child. Press the vial until the desired dose comes out. For children able to use Isomar Decongestant Vials alone and for adults, alternately introduce the vial into the nostrils, pressing each time, with the head up, inhaling and closing the other nostril with the finger.\u003cbr\u003eFor aerosol therapy: insert the liquid into the aerosol device following the instructions for use on the device.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Isomar decongestant vials 20x5ml?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eDo not use Isomar Decongestant Vials in infants under 6 months of age. Do not use in case of nosebleeds.\u003cbr\u003eSterile, non-injectable solution. Do not use in conjunction with other topical treatments. Do not use the same single-dose bottle for both nasal hygiene and aerosol therapy. Do not mix with other solutions. Keep the vial out of the reach of children. After opening, the vial should be used immediately and discarded after use. Failure to check the integrity of the vial could alter the functional characteristics of the product. Do not use beyond the expiry date. Do not dispose of empty bottles in the environment. In aerosol therapy it is recommended to alternate the application of Isomar Decongestant Vials with pharmacological treatments. In some cases the product may be minimally irritating.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Isomar 20x5ml decongestant vials stored?\u003c\/h3\u003e\u003cp\u003eStore in a dry place, away from heat sources at a temperature below 25°C.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Isomar 20x5ml decongestant vials?\u003c\/h3\u003e\u003cp\u003e20 single-dose vials of 5 ml.\u003c\/p\u003e","brand":"Euritalia Pharma","offers":[{"title":"Default Title","offer_id":51131318174023,"sku":"984177927","price":9.77,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/euritalia-pharma-div-coswell-isomar-flaconcini-decongestionanti-20x5ml-farmacia-dottor-tili-1213792103.jpg?v=1767136151"},{"product_id":"pic-soluzione-fisiologica-20-flaconcini-5ml","title":"Pic physiological solution 20 vials 5ml","description":"\u003cp\u003eThe \u003cstrong\u003ePic saline solution 20 vials 5ml\u003c\/strong\u003e It is a versatile and indispensable product for daily health care. This sterile saline solution is designed to offer a wide range of applications, making it ideal for the whole family, including adults and children. Each 5 ml single-dose vial is composed of an isotonic mixture of \u003cstrong\u003esodium chloride\u003c\/strong\u003e e \u003cstrong\u003epurified water\u003c\/strong\u003e, ensuring safe and practical use.\u003c\/p\u003e\n\n\u003cp\u003ePerfect for \u003cstrong\u003edilution of drugs\u003c\/strong\u003e intended for\u003cstrong\u003eaerosol therapy\u003c\/strong\u003e, Pic saline is also an excellent choice for \u003cstrong\u003enasal cleaning\u003c\/strong\u003e. It helps humidify the nasal mucous membranes, alleviating the symptoms of \u003cstrong\u003enasal congestion\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e e \u003cstrong\u003eallergies\u003c\/strong\u003e. Furthermore, it is suitable for\u003cstrong\u003eocular hygiene\u003c\/strong\u003e, particularly useful in case of the onset of conjunctivitis or for newborns with obstruction of the tear duct.\u003c\/p\u003e\n\n\u003cp\u003eThanks to its format in disposable vials, the Pic physiological solution offers maximum \u003cstrong\u003epracticality\u003c\/strong\u003e e \u003cstrong\u003esafety\u003c\/strong\u003e of use, eliminating the risk of contamination. This product is a precious ally for maintaining optimal hygiene and daily well-being, effectively supporting the needs of the whole family.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Pic saline solution 20 vials 5ml? What is it for?\u003c\/h3\u003e\u003cp\u003eSterile single-dose physiological solution (sodium chloride and purified water), indicated for nasal cleaning and hygiene, useful for relieving nasal congestion linked to colds or allergies, for diluting aerosol therapy drugs and for ocular hygiene, even in the case of the onset of conjunctivitis or obstruction of the lacrimal duct in newborns.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Pic saline solution 20 vials 5ml contain?\u003c\/h3\u003e\u003cp\u003eThe solution is composed of sodium chloride and purified water. It is a sterile physiological solution always ready for use, packaged in disposable vials.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Pic saline solution 20 vials 5ml?\u003c\/h3\u003e\u003cp\u003ePic physiological solution is indicated for diluting drugs for aerosol therapy, for cleaning the nose in adults and children, and for humidifying the nasal mucous membranes. It is also used for the external hygiene of the eyes in case of the onset of conjunctivitis and in newborns in case of obstruction of the lacrimal duct.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Pic saline solution 20 vials 5ml?\u003c\/h3\u003e\u003cp\u003eUse the product following the instructions of your doctor or pharmacist. Do not use if the packaging is damaged. Keep out of reach of children. Store in a cool, dry place, away from heat sources. Do not use after the expiry date indicated on the package.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Pic saline solution 20 vials 5ml?\u003c\/h3\u003e\u003cp\u003epack of 10 vials of 2 ml and 10 ml and pack of 20 vials of 5 ml\u003c\/p\u003e","brand":"Pic Solution","offers":[{"title":"Default Title","offer_id":51131329216839,"sku":"912071370","price":9.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/pikdare-spa-pic-soluzione-fisiologica-20-flaconcini-5ml-farmacia-dottor-tili-1213792074.jpg?v=1767136873"},{"product_id":"breathe-right-balsamici-10-pezzi","title":"Breathe Right balsamic 10 pieces","description":"\u003cp\u003eI \u003cstrong\u003eBreathe Right balsamics 10 pieces\u003c\/strong\u003e are innovative nasal patches designed to offer immediate relief from nasal congestion. Thanks to \u003cstrong\u003ebalsamic aromas\u003c\/strong\u003e, these patches help open the nasal passages without the use of medications, making them ideal for those looking for a natural alternative to relieve a stuffy nose. Perfect for those who suffer from \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003eallergies\u003c\/strong\u003e or has a \u003cstrong\u003edeviated nasal septum\u003c\/strong\u003e, Breathe Right patches improve airflow, making breathing easier.\u003c\/p\u003e\n\n\u003cp\u003eTheirs \u003cstrong\u003eanatomical shape\u003c\/strong\u003e and the special adhesive guarantee optimal adhesion, while the disposable design ensures impeccable hygiene. Can also be used to reduce \u003cstrong\u003esnore\u003c\/strong\u003e, these patches are a \u003cstrong\u003emedical device\u003c\/strong\u003e safe and practical for outdoor use. The package contains 10 pieces, offering a convenient option for those who need quick and effective relief from nasal congestion.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Breathe Right balsamic 10 pieces? What is it for?\u003c\/h3\u003e\u003cp\u003eNasal patch medical device with balsamic aromas, indicated for the relief of nasal congestion linked to colds, allergies or deviated nasal septum; improves airflow and can also be used to reduce snoring.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Breathe Right balsamic 10 pieces contain?\u003c\/h3\u003e\u003cp\u003eBreathe Right balsamic patches are made with hypoallergenic materials and contain balsamic aromas for a refreshing effect. They do not contain medicines.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Breathe Right balsamic 10 pieces?\u003c\/h3\u003e\u003cp\u003eApply the nasal patch to the clean, dry skin of the nose. Make sure the ends of the patch are positioned correctly to ensure optimal adhesion. Use one patch nightly or as needed to relieve nasal congestion.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Breathe Right balsamic 10 pieces?\u003c\/h3\u003e\u003cp\u003eDo not use on irritated or injured skin. If irritation or allergic reaction occurs, discontinue use and consult a doctor. Keep out of reach of children. Store in a cool, dry place.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Breathe Right balsamic 10 pieces?\u003c\/h3\u003e\u003cp\u003ePack of 10 pieces\u003c\/p\u003e","brand":"Efas","offers":[{"title":"Default Title","offer_id":51131334033735,"sku":"982483529","price":9.03,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/e-fa-s-spa-breathe-right-balsamici-10-pezzi-farmacia-dottor-tili-1213792053.jpg?v=1767137291"},{"product_id":"zerinolflu-12-compresse-effervescenti","title":"ZerinolFlu 12 effervescent tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of flu and cold symptoms in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne effervescent tablet contains: paracetamol 300 mg, chlorphenamine maleate 2 mg, sodium ascorbate 280 mg corresponding to ascorbic acid (vitamin C) 250 mg. Excipients with known effects: aspartame, sodium, sorbitol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAnhydrous citric acid, sodium bicarbonate, sodium carbonate, sorbitol, povidone, dimethicone, aspartame, orange flavor, lemon flavor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eZerinolflu is contraindicated in the following cases: - hypersensitivity to paracetamol, chlorphenamine or ascorbic acid, to any of the excipients listed in paragraph 6.1 or to other substances closely related from a chemical point of view, in particular antihistamines with a chemical structure similar to chlorphenamine; - pregnancy and breastfeeding; - patients with manifest insufficiency of glucose-6-phosphate dehydrogenase and patients suffering from severe hemolytic anemia; - severe hepatocellular insufficiency (Child-Pugh C); - glaucoma, prostatic hypertrophy, bladder neck obstruction, pyloric and duodenal stenosis or other tracts of the gastrointestinal and urogenital system, due to anticholinergic effects; - patients being treated with monoamine oxidase inhibitors (MAOIs) or in the two weeks following such treatment (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cb\u003eAdults:\u003c\/b\u003e 1 effervescent tablet twice a day. \u003cb\u003ePediatric population: \u003c\/b\u003eThe safety and effectiveness of Zerinolflu in patients under 18 years of age have not been established. \u003cu\u003eMethod of administration\u003c\/u\u003e Oral use. The effervescent tablet should be dissolved in approximately half a glass of water. The medicine must be taken after meals. \u003cu\u003eDuration of treatment\u003c\/u\u003e Patients should be advised to contact their doctor if fever persists or symptoms do not improve after 3 days of treatment (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not administer for more than 3 consecutive days without consulting your doctor. If the fever persists for more than three days or if the symptoms do not improve and others appear within three days or are accompanied by high fever, rash, excessive amount of mucus and persistent cough, consult your doctor before continuing the administration. \u003cu\u003eParacetamol\u003c\/u\u003e During treatment with Zerinolflu, check that no other medicine containing paracetamol is taken at the same time, since if paracetamol is taken in high doses, serious adverse reactions may occur. Invite the patient to contact the doctor before combining any other drug. See also paragraph 4.5. High or prolonged doses of the product can cause high-risk liver disease (see also section 4.9) and even serious alterations in the kidney and blood. In case of acute hypersensitivity reactions to paracetamol (e.g. anaphylactic shock), treatment with Zerinolflu should be discontinued and necessary medical measures should be implemented based on the signs and symptoms. \u003cu\u003eChlorphenamine maleate\u003c\/u\u003e At common therapeutic doses, antihistamines present secondary reactions that vary greatly from subject to subject and from compound to compound. The most frequent side effect is sedation which can manifest itself with drowsiness; Those who may drive motor vehicles or carry out operations that require integrity of the level of supervision must be warned of this (see paragraph 4.7). \u003cu\u003eAscorbic acid\u003c\/u\u003e Ascorbic acid (vitamin C) should be used with caution by subjects who suffer, or have suffered in the past, from nephrolithiasis (kidney stones) and by those suffering from G6PD (Glucose-6-phosphate dehydrogenase) deficiency, hemochromatosis, thalassemia or sideroblastic anemia. \u003cu\u003ePatients with renal or hepatic insufficiency\u003c\/u\u003e Administer with caution in subjects with renal or hepatic insufficiency. \u003cu\u003eElderly\u003c\/u\u003e Particular attention should be paid when determining the dose in the elderly due to their greater sensitivity towards the drug. In elderly patients treated with antihistamines, effects such as dizziness, sedation, confusion and hypotension may be more likely to occur. Elderly patients are particularly sensitive to the anticholinergic side effects of antihistamines such as dry mouth and urinary retention (especially in men). \u003cu\u003eZerinolflu effervescent tablets contains\u003c\/u\u003e: \u003cu\u003eAspartame\u003c\/u\u003e This medicine contains a source of phenylalanine. It can be harmful if affected by phenylketonuria (lack of the enzyme phenylalanine hydroxylase). \u003cu\u003eSorbitol\u003c\/u\u003e Patients with rare hereditary problems of fructose intolerance should not take this medicine. \u003cu\u003eSodium\u003c\/u\u003e One effervescent tablet contains 14.83 mmol sodium. To be taken into consideration in patients with reduced renal function or who follow a low sodium diet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eParacetamol\u003c\/u\u003e Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). Normally harmless doses of acetaminophen can cause liver damage if taken together with these drugs. The same applies to potentially hepatotoxic substances and in case of alcohol abuse. Habitual ingestion of anticonvulsant drugs or oral contraceptives can, through an enzymatic induction mechanism, accelerate the metabolism of paracetamol. The use of the product is not recommended if the patient is being treated with anti-inflammatories. Taking probenecid inhibits the binding of paracetamol to glucuronic acid, thereby reducing the clearance of paracetamol by a factor of approximately 2. Therefore, the dose of paracetamol should be reduced if administered in combination with probenecid. Cholestyramine reduces the absorption of paracetamol if administered within 1 hour of taking paracetamol. It is not yet possible to establish the clinical relevance of the interactions between paracetamol and oral anticoagulants. Therefore, prolonged use of paracetamol in patients being treated with oral anticoagulants is advisable only under medical supervision. Combining acetaminophen with chloramphenicol may prolong the half-life of chloramphenicol, increasing the risk of toxicity. The concomitant use of paracetamol and zidovudine increases the tendency of the latter to reduce the number of leukocytes (neutropenia). Therefore, you should take Zerinolflu together with zidovudine only under your doctor's supervision. Medicines that slow gastric emptying, such as propantheline, reduce the speed of absorption of paracetamol and delay the onset of its effect. However, medicines that accelerate gastric emptying, such as metoclopramide, lead to an increase in the speed of absorption. \u003cu\u003eInterference with laboratory tests\u003c\/u\u003e The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method). \u003cu\u003eChlorphenamine maleate\u003c\/u\u003e Other substances with anticholinergic action should not be taken at the same time as Zerinolflu, as these can cause significant interactions. The product is contraindicated in patients being treated with monoamine oxidase inhibitors (MAOIs) or in the two weeks following such treatment (see section 4.3) as these may prolong and intensify the anticholinergic and central nervous system (CNS) depressant effects of chlorphenamine maleate. The product may interact with alcohol, tricyclic antidepressants, neuroleptics or other drugs with a depressant action on the central nervous system such as barbiturates, sedatives, tranquilizers, hypnotics. These products should not be taken during therapy with Zerinolflu as they can cause an increase in the sedative effect. Like all preparations containing antihistamines, Zerinolflu can mask the first signs of ototoxicity of certain antibiotics. Chlorphenamine inhibits the metabolism of phenytoin and may cause phenytoin toxicity. \u003cu\u003eAscorbic acid\u003c\/u\u003e Ascorbic acid (vitamin C) reduces amphetamine levels by inhibiting gastrointestinal absorption. Vitamin C increases the bioavailability of iron by chelation with deferoxamine. Estrogens can increase the elimination of vitamin C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the use of Zerinolflu, the side effects indicated below may occur. The frequency of these side effects cannot be estimated from the available data. \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e: - thrombocytopenia, leukopenia, anemia, agranulocytosis, pancytopenia. \u003cu\u003eImmune system disorders\u003c\/u\u003e: - hypersensitivity reactions such as angioedema, laryngeal edema, anaphylactic shock. \u003cu\u003eNervous system disorders\u003c\/u\u003e: - drowsiness, asthenia, dizziness, headache, inability to concentrate. \u003cu\u003eEye pathologies\u003c\/u\u003e: - blurred vision. \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e: - thickening of bronchial secretions. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: - dry mouth, nausea. \u003cu\u003eHepatobiliary disorders\u003c\/u\u003e: - alterations in liver function and hepatitis. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: - skin reactions of various types and severity have been reported with the use of paracetamol including cases of urticaria, erythema multiforme, very rare cases of serious skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP). Photosensitization. \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e: - renal alterations (acute renal failure, interstitial nephritis, hematuria, anuria), urinary retention. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e In case of overdose, marked depressive or stimulant effects on the central nervous system, drowsiness, lethargy, respiratory depression are generally observed. In case of overdose, the paracetamol contained in Zerinolflu can cause hepatic cytolysis which could evolve towards massive necrosis. \u003cu\u003eTherapy\u003c\/u\u003e N-acetylcysteine, administered in the hours immediately following ingestion of paracetamol, is effective in limiting liver damage. It is recommended to use the usual measures to remove unabsorbed material from the gastrointestinal tract by inducing vomiting or possibly by gastric lavage; keep the patient under observation by practicing supportive therapy. Further measures will depend on the severity, nature and course of clinical symptoms and should follow standard intensive care protocols.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy and breastfeeding\u003c\/u\u003e Zerinolflu is contraindicated during pregnancy and breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e No studies have been conducted with Zerinolflu to evaluate the effects on fertility in humans.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients should be warned that Zerinolflu may cause drowsiness. Those who drive vehicles or carry out operations requiring the integrity of the state of vigilance must be aware of this.\u003c\/p\u003e","brand":"Zentiva","offers":[{"title":"Default Title","offer_id":51131338064199,"sku":"035191028","price":10.64,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zentiva-italia-srl-zerinolflu-12-compresse-effervescenti-farmacia-dottor-tili-1213792017.jpg?v=1767148650"},{"product_id":"momenxsin-200mg-30mg-12-compresse-rivestite","title":"Momenxsin 200mg\/30mg 12 coated tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of nasal congestion associated with acute rhinosinusitis of suspected viral origin with headache and\/or fever. Momenxsin is indicated in adults and adolescents aged 15 years and older.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach film-coated tablet contains 200 mg of ibuprofen and 30 mg of pseudoephedrine hydrochloride. \u003cu\u003eExcipient with known effects:\u003c\/u\u003e sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eTablet core:\u003c\/u\u003e Microcrystalline cellulose; Calcium hydrogen phosphate anhydrous; Croscarmellose sodium\u003cb\u003e;\u003c\/b\u003e Corn starch; Colloidal anhydrous silica; Magnesium stearate. \u003cu\u003eTablet coating:\u003c\/u\u003e Hypromellose; Macrogol 400; Talc; Titanium dioxide (E171); Yellow iron oxide (E172).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to ibuprofen, pseudoephedrine hydrochloride or to any of the excipients listed in paragraph 6.1; • Patients under 15 years of age; • Women in the third trimester of pregnancy (see section 4.6); • Breastfeeding women (see section 4.6); • Patients with a history of hypersensitivity reactions (for example bronchospasm, asthma, rhinitis, angioedema or urticaria) associated with acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs); • History of gastrointestinal bleeding or perforation associated with previous NSAID therapy; • Current or past recurrent peptic hemorrhage\/ulcer (at least two distinct episodes of demonstrated ulceration or bleeding); • Cerebrovascular or other bleeding; • Hematopoietic abnormalities of unknown origin; • Severe liver failure; • Severe renal failure; • Severe heart failure; • Severe cardiovascular disorders, coronary heart disease (heart disease, hypertension, angina pectoris), tachycardia, hyperthyroidism, diabetes, pheochromocytoma; • History of stroke or presence of risk factors for stroke (due to the α-–sympathomimetic activity of pseudoephedrine hydrochloride); • Risk of closed-angle glaucoma; • Risk of urinary retention related to urethroprostatic disorders; • History of myocardial infarction; • History of seizures; • Systemic lupus erythematosus; • Concomitant use of other vasoconstrictors such as nasal decongestants, administered orally or nasally (e.g. phenylpropanolamine, phenylephrine and ephedrine), and methylphenidate (see section 4.5); • Concomitant use of non-selective monoamine oxidase inhibitors (MAOIs) (iproniazid) (see section 4.5) or use of monoamine oxidase inhibitors in the last two weeks.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage.\u003c\/u\u003e \u003ci\u003eAdults and adolescents aged 15 years and older\u003c\/i\u003e: 1 tablet (equivalent to 200 mg of ibuprofen and 30 mg of pseudoephedrine hydrochloride) every 6 hours if necessary. In case of more intense symptoms, 2 tablets (equivalent to 400 mg of ibuprofen and 60 mg of pseudoephedrine hydrochloride) every 6 hours if necessary, up to a maximum total daily dose of 6 tablets (equivalent to 1200 mg of ibuprofen and 180 mg of pseudoephedrine hydrochloride). Do not exceed the maximum total daily dose of 6 tablets (equivalent to 1200 mg of ibuprofen and 180 mg of pseudoephedrine hydrochloride). For short-term use. \u003cb\u003eIf symptoms worsen, consult a doctor. The maximum duration of treatment is 4 days for adults and 3 days for adolescents aged 15 years and older.\u003c\/b\u003e In cases where symptoms consist predominantly of pain\/fever or nasal congestion, administration of a product containing a single active ingredient is preferable. \u003ci\u003eSide effects can be contained by using the lowest effective dose for the shortest time necessary to control symptoms (see section 4.4).\u003c\/i\u003e\u003ci\u003ePediatric population\u003c\/i\u003e: Momenxsin is contraindicated in pediatric patients under 15 years of age (see section 4.3). \u003cu\u003eMethod of administration:\u003c\/u\u003e For oral use. The tablets should be swallowed whole and not chewed, with a glass of water, preferably during meals.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConcomitant use of Momenxsin and other NSAIDs, including selective cyclooxygenase (COX)-2 inhibitors, should be avoided. Side effects can be reduced by using for the shortest possible time the minimum effective dose necessary to control symptoms (see the paragraphs \"Gastrointestinal effects\" and \"Cardiovascular and cerebrovascular effects\" below). If symptoms persist beyond the maximum recommended duration of treatment with this medicine (4 days for adults and 3 days for adolescents), the measures to be implemented should be re-evaluated, in particular the possible usefulness of antibiotic treatment. Acute rhinosinusitis of suspected viral origin is defined as a series of bilateral rhinological symptoms of moderate intensity, dominated by nasal congestion with severe or purulent rhinorrhea, occurring in an epidemic context. The purulent appearance of rhinorrhea is common and does not systematically correspond to bacterial superinfection. Pain in the paranasal sinuses in the first days of the disease is associated with congestion of the related mucosa (acute congestive rhinosinusitis) and in most cases resolves spontaneously. In case of acute bacterial sinusitis, the use of antibiotic therapy is justified. \u003cb\u003e \u003ci\u003eSpecial warnings regarding pseudoephedrine hydrochloride\u003c\/i\u003e: \u003c\/b\u003e • The dosage, the maximum recommended duration of treatment (4 days for adults and 3 days for adolescents) and contraindications must be strictly respected (see section 4.8); • Patients must be informed that treatment must be suspended if hypertension, tachycardia, palpitations, cardiac arrhythmias, nausea or any neurological signs appear, such as the onset or worsening of headache; • Ischemic colitis Some cases of ischemic colitis have been reported with pseudoephedrine. If sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis develop, pseudoephedrine should be discontinued and a physician should be consulted. \u003ci\u003eSevere skin reactions:\u003c\/i\u003e Serious skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with products containing pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules resulting from a widespread edematous erythema and localized mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules are observed, the administration of Momenxsin should be stopped and appropriate measures taken if necessary. Before using this medicine, patients should consult their doctor if they have: • hypertension, heart disease, hyperthyroidism, psychosis or diabetes; • concomitant use of anti-migraine drugs, in particular vasoconstrictors based on ergot alkaloids (due to the α-sympathomimetic activity of pseudoephedrine); • mixed connective tissue disease: increased risk of aseptic meningitis (see section 4.8); • neurological symptoms such as convulsive seizures, hallucinations, behavioral disorders, agitation and insomnia have been described following the administration of systemic vasoconstrictors, especially during feverish episodes or in cases of overdose. Such symptoms have been reported more commonly in the pediatric population. It is therefore advisable to: • avoid administering Momenxsin in association with drugs that can lower the epileptogenic threshold, such as terpene derivatives, clobutinol, atropine-like substances and local anaesthetics, or in the presence of a history of convulsive seizures; • strictly adhere, in all cases, to the recommended dosage and inform patients about the risks of overdose if Momenxsin is taken concomitantly with other medicinal products containing vasoconstrictors. Patients with urethroprostatic disorders are more susceptible to developing symptoms such as dysuria and urinary retention. Elderly patients may be more sensitive to central nervous system (CNS) effects. \u003cb\u003e \u003ci\u003ePrecautions for use relating to pseudoephedrine hydrochloride\u003c\/i\u003e: \u003c\/b\u003e • In patients who are to undergo a planned surgical operation in which the use of halogenated volatile anesthetics is expected, it is preferable to suspend treatment with Momenxsin several days before the operation, in consideration of the risk of acute hypertension (see section 4.5); • Athletes should be informed that treatment with pseudoephedrine hydrochloride may result in positive doping tests. \u003cu\u003eInterferences with serological tests: \u003c\/u\u003e Pseudoephedrine may potentially reduce iobenguane i-131 uptake in neuroendocrine tumors, thus interfering with scintigraphy. \u003cb\u003e \u003ci\u003eSpecial warnings regarding ibuprofen\u003c\/i\u003e: \u003c\/b\u003e In patients suffering from bronchial asthma or allergic diseases or with a history of such diseases, bronchospasm may occur. In case of asthma, the product must not be taken without first consulting a doctor (see section 4.3). Patients suffering from asthma associated with chronic rhinitis, chronic sinusitis and\/or nasal polyposis are exposed to a greater risk of allergic reactions if they take acetylsalicylic acid and\/or NSAIDs. Administration of Momenxsin may trigger an acute asthma attack, particularly in some patients allergic to acetylsalicylic acid or an NSAID (see section 4.3). Prolonged use of any type of painkiller for headache can cause it to get worse. Where this situation is encountered or suspected, medical advice should be sought and treatment discontinued. The diagnosis of medication overuse headache (MOH) should be suspected in patients who experience frequent or daily headaches despite (or because of) regular use of headache medications. Before using this medicine, patients suffering from blood clotting disorders should consult their doctor.\u003ci\u003e \u003cu\u003eGastrointestinal effects: \u003c\/u\u003e \u003c\/i\u003e Gastrointestinal haemorrhage, ulceration or perforation, sometimes fatal, have been reported at any stage of treatment with the use of all NSAIDs, with or without warning symptoms or previous gastrointestinal events. The risk of gastrointestinal haemorrhage, ulceration or perforation, sometimes fatal, increases with higher doses of NSAIDs, in patients with a history of ulcer, particularly if complicated by bleeding or perforation (see section 4.3) and in the elderly. These patients should start treatment with the lowest available dose. For these patients and for those taking concomitant treatment with low doses of acetylsalicylic acid or other medicinal products that may increase the risk of gastrointestinal events, combination therapy with gastroprotectants (e.g. misoprostol or proton pump inhibitors) should be considered (see below and section 4.5). Patients with a history of gastrointestinal toxicity, especially elderly patients, should report any unusual abdominal symptoms (particularly gastrointestinal bleeding), especially in the initial stages of treatment. Particular caution is advised in patients receiving concomitant treatment with drugs that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors (SSRIs) or antiplatelet agents such as acetylsalicylic acid (see section 4.5). Treatment with Momenxsin must be stopped immediately in case of gastrointestinal bleeding or ulceration. NSAIDs should be administered with caution to patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease), because these conditions could be exacerbated (see section 4.8). In case of concomitant alcohol intake, the use of NSAIDs may increase side effects related to the active ingredient, in particular those affecting the gastrointestinal tract or central nervous system. \u003ci\u003e \u003cu\u003eCardiovascular and cerebrovascular effects: \u003c\/u\u003e \u003c\/i\u003e The following conditions are subject to contraindications due to the presence of pseudoephedrine hydrochloride (see section 4.3): severe cardiovascular disorders, coronary heart disease (cardiopathy, hypertension, angina pectoris), tachycardia, hyperthyroidism, diabetes, pheochromocytoma, history of stroke or presence of risk factors for stroke, history of myocardial infarction. Clinical studies suggest that the use of ibuprofen, particularly at high doses (2400 mg\/day), may be associated with a slight increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low-dose ibuprofen (e.g. ≤ 1200 mg\/day) is associated with an increased risk of arterial thrombotic events. Patients suffering from uncontrolled hypertension, heart failure (NYHA II-III), established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disorders should be treated with ibuprofen only after careful evaluation and high doses (2400 mg\/day) should be avoided. Careful evaluation must also be carried out before patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) undertake long-term treatment, particularly if high doses of ibuprofen (2400 mg\/day) are required. \u003ci\u003e \u003cu\u003eSevere skin reactions:\u003c\/u\u003e \u003c\/i\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be at higher risk for these reactions: the onset of the reaction occurs in most cases within the first month of treatment. Severe skin reactions, such as acute generalized exanthematous pustulosis (PEAG), may occur with medicines containing ibuprofen and pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules resulting from a widespread edematous erythema and localized mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules are observed, as well as the appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, the administration of Momenxsin must be discontinued and appropriate measures must be taken if necessary. \u003ci\u003eMasking symptoms of underlying infections:\u003c\/i\u003e Momenxsin may mask the symptoms of infection, which could delay the initiation of appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Momenxsin is administered for the relief of fever or pain related to infection, monitoring of the infection is recommended. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. \u003cb\u003e \u003ci\u003ePrecautions for use relating to ibuprofen:\u003c\/i\u003e \u003c\/b\u003e • Elderly: the pharmacokinetics of ibuprofen are not modified by age, therefore dosage adjustments are not necessary in the elderly. However, elderly patients should be carefully monitored, as they are more sensitive to NSAID-related side effects, especially gastrointestinal bleeding and perforation, which can be fatal; • Caution and special monitoring are required when ibuprofen is administered to patients with a history of gastrointestinal diseases (such as peptic ulcer, hiatal hernia or gastrointestinal haemorrhage); • In the initial stages of treatment, careful monitoring of urine output and renal function is necessary in patients with heart failure, in patients with chronic impairment of renal or hepatic function, in patients taking diuretics, in patients hypovolemic due to major surgery and, in particular, in elderly patients. Dehydrated adolescents are at risk of kidney damage; • In case of visual disturbances during treatment, the patient must undergo a complete ophthalmological examination. \u003ci\u003e \u003cu\u003eImportant information about some excipients.\u003c\/u\u003e \u003c\/i\u003e Momenxsin contains:- \u003cb\u003eSodium:\u003c\/b\u003e This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNon-selective MAOIs (iproniazid) - Possible reaction: Paroxysmal hypertension and hyperthermia, which can be fatal. Due to the long duration of action of MAOIs, this interaction may occur up to 15 days after discontinuation of the MAOI.\u003c\/p\u003e\n\u003cp\u003eOther sympathomimetics or vasoconstrictors with indirect action administered orally or nasally, α-sympathomimetic drugs, phenylpropanolamine, phenylephrine, ephedrine, methylphenidate - Possible reaction: Risk of vasoconstriction and\/or hypertensive crisis.\u003c\/p\u003e\n\u003cp\u003eReversible monoamine oxidase A (RIMA) inhibitors, linezolid, dopaminergic ergot alkaloids, vasoconstrictor ergot alkaloids - Possible reaction: Risk of vasoconstriction and\/or hypertensive crisis.\u003c\/p\u003e\n\u003cp\u003eHalogenated volatile anesthetics - Possible reaction: Acute perioperative hypertension. If you have scheduled surgery, stop taking Momenxsin several days in advance.\u003c\/p\u003e\n\u003cp\u003eGuanethidine, reserpine and methyldopa - Possible reaction: The effect of pseudoephedrine may be attenuated.\u003c\/p\u003e\n\u003cp\u003eTricyclic antidepressants - Possible reaction: The effect of pseudoephedrine may be attenuated or enhanced.\u003c\/p\u003e\n\u003cp\u003eDigitalis, quinidine or tricyclic antidepressants - Possible reaction: Increased frequency of arrhythmias.\u003c\/p\u003e\n\u003cp\u003eOther NSAIDs, including salicylates and selective COX-2 inhibitors - Possible reaction: Concomitant administration of several NSAIDs could increase the risk of gastrointestinal bleeding and ulcers due to a synergistic effect. Therefore, the concomitant use of ibuprofen with other NSAIDs should be avoided (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eDigoxin - Possible reaction: The concomitant use of Momenxsin with digoxin-based preparations could increase the serum levels of the latter. With proper use (maximum 4 days), monitoring of serum digoxin levels is generally not necessary.\u003c\/p\u003e\n\u003cp\u003eCorticosteroids - Possible reaction: Corticosteroids could increase the risk of adverse reactions, particularly affecting the gastrointestinal tract (gastrointestinal haemorrhage or ulceration) (see section 4.3).\u003c\/p\u003e\n\u003cp\u003eAntiplatelet agents - Possible reaction: Increased risk of gastrointestinal bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAcetylsalicylic acid - Possible reaction: Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased adverse effects. Experimental data suggest that ibuprofen may cause competitive inhibition of the effect of low-dose acetylsalicylic acid on platelet aggregation when the two medicines are taken simultaneously. Despite doubts regarding the applicability of these data to clinical situations, the possibility that long-term regular use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effects are considered likely following occasional use of ibuprofen (see section 5.1).\u003c\/p\u003e\n\u003cp\u003eAnticoagulants (e.g. warfarin, ticlopidine, clopidogrel, Tirofiban, eptifibatide, abciximab, iloprost) - Possible reaction: NSAIDs such as ibuprofen may potentiate the effects of anticoagulants (see section 4.4).\u003c\/p\u003e\n\u003cp\u003ePhenytoin - Possible reaction: Concomitant use of Momenxsin with phenytoin-based preparations could increase serum levels of the latter. With proper use (maximum 4 days), monitoring of phenytoin serum levels is generally not necessary.\u003c\/p\u003e\n\u003cp\u003eSelective serotonin reuptake inhibitors (SSRIs) - Possible reaction: Increased risk of gastrointestinal bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eLithium - Possible reaction: The concomitant use of Momenxsin with lithium-based preparations could increase serum levels of the latter. With proper use (maximum 4 days), monitoring of serum lithium levels is generally not necessary.\u003c\/p\u003e\n\u003cp\u003eProbenecid and sulfinpyrazone - Possible reaction: Medicines containing probenecid or sulfinpyrazone may delay the excretion of ibuprofen.\u003c\/p\u003e\n\u003cp\u003eDiuretics, ACE inhibitors, beta blockers and angiotensin II antagonists - Possible reaction: NSAIDs could reduce the effect of diuretics and other antihypertensive medicines. In some patients with impaired renal function (e.g. dehydrated patients or elderly patients with impaired renal function), concomitant administration of ACE inhibitors, beta-blockers or angiotensin II antagonists and agents that inhibit cyclo-oxygenase could lead to further deterioration of renal function, including possible acute renal failure which is usually reversible. Therefore, this combination must be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter.\u003c\/p\u003e\n\u003cp\u003ePotassium-sparing diuretics - Possible reaction: Concomitant administration of Momenxsin and potassium-sparing diuretics may cause hyperkalemia (monitoring of serum potassium levels is recommended).\u003c\/p\u003e\n\u003cp\u003eMethotrexate - Possible reaction: Administration of Momenxsin in the 24 hours before or after taking methotrexate may increase its concentrations and toxic effects.\u003c\/p\u003e\n\u003cp\u003eCiclosporin - Possible reaction: The risk of cyclosporine-induced renal damage is increased by concomitant use of some non-steroidal anti-inflammatory drugs. This effect cannot be excluded even in the case of simultaneous intake of ciclosporin and ibuprofen.\u003c\/p\u003e\n\u003cp\u003eTacrolimus - Possible reaction: The risk of nephrotoxicity increases if the two medicines are administered simultaneously.\u003c\/p\u003e\n\u003cp\u003eZidovudine - Possible reaction: There is evidence of an increased risk of hemarthrosis and hematoma in HIV (+) hemophiliac patients receiving concomitant treatment with zidovudine and ibuprofen.\u003c\/p\u003e\n\u003cp\u003eSulfonylureas - Possible reaction: Clinical research has demonstrated the existence of interactions between nonsteroidal anti-inflammatory drugs and antidiabetics (sulfonylureas). Although no interactions between ibuprofen and sulphonylureas have been described so far, in case of concomitant use of these two drugs it is advisable, as a precaution, to check blood sugar values.\u003c\/p\u003e\n\u003cp\u003eQuinolone antibiotics - Possible reaction: Animal studies indicate that NSAIDs may increase the risk of seizures associated with the use of quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of experiencing seizures.\u003c\/p\u003e\n\u003cp\u003eHeparins; gingko biloba - Possible reaction: Increased risk of bleeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe most commonly observed ibuprofen-related adverse reactions are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal bleeding, even fatal, may occur, particularly in the elderly (see section 4.4). Following its administration, nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease have been reported (see section 4.4 Special warnings and precautions for use). Gastritis was detected less frequently. In general, the risk of experiencing adverse reactions (in particular serious gastrointestinal complications) increases with increasing dose and duration of treatment. Hypersensitivity reactions have been reported following treatment with ibuprofen, which may include: (a) nonspecific allergic reactions and anaphylaxis; (b) airway reactivity, including asthma, aggravated asthma, bronchospasm, or dyspnea; (c) various skin disorders, including various types of skin rashes, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatoses (including epidermal necrolysis and erythema multiforme). In patients with existing autoimmune disorders (such as systemic lupus erythematosus or mixed connective tissue disease), isolated cases of symptoms of aseptic meningitis, such as stiff neck, headache, nausea, vomiting, fever or disorientation have been observed during treatment with ibuprofen. Edema, hypertension and heart failure have been reported in association with the intake of NSAIDs. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a slight increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4). The list of adverse reactions reported below refers to reactions occurring with ibuprofen and pseudoephedrine hydrochloride at the doses contained in over-the-counter drugs, for short-term use. In the treatment of chronic conditions, additional adverse reactions may occur during long-term treatment. Patients should be advised to immediately stop taking Momenxsin and consult a doctor in case of a serious adverse reaction to the drug. very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eInfections and infestations: Ibuprofen Very rare Exacerbation of inflammation of an infectious nature (e.g. necrotizing fasciitis), aseptic meningitis (neck stiffness, headache, nausea, vomiting, fever or disorientation) in patients suffering from pre-existing autoimmune diseases (systemic lupus erythematosus (SLE), mixed connective tissue disease).\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Ibuprofen Very rare Hematopoietic disorders (anaemia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis).\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Ibuprofen Uncommon Hypersensitivity reactions with urticaria, itching and asthma attacks (with drop in blood pressure).\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Ibuprofen and Pseudoephedrine hydrochloride Very rare Severe generalized hypersensitivity reactions, the signs of which may be facial edema, angioedema, dyspnoea, tachycardia, reduction in blood pressure, anaphylactic shock.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders: Ibuprofen Very rare Psychotic reactions, depression.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders: Pseudoephedrine hydrochloride Not known Agitation, hallucinations, anxiety, abnormal behavior, insomnia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders: Ibuprofen Uncommon Central nervous system disorders, such as headache, dizziness, insomnia, agitation, irritability or tiredness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders: Pseudoephedrine hydrochloride Rare Insomnia, nervousness, anxiety, restlessness, tremors, hallucinations.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders: Pseudoephedrine hydrochloride Not known Haemorrhagic stroke, ischemic stroke, convulsions, headache.\u003c\/p\u003e\n\u003cp\u003eEye disorders: Ibuprofen Uncommon Visual disturbances.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders: Ibuprofen Rare Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders: Ibuprofen Very rare Palpitations, heart failure, myocardial infarction.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders: Pseudoephedrine hydrochloride Not known Palpitations, tachycardia, chest pain, arrhythmia.\u003c\/p\u003e\n\u003cp\u003eVascular disorders: Ibuprofen Very rare Arterial hypertension.\u003c\/p\u003e\n\u003cp\u003eVascular disorders: Pseudoephedrine hydrochloride Not known Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders: Pseudoephedrine hydrochloride Rare Exacerbation of asthma or hypersensitivity reaction with bronchospasm.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Ibuprofen Common Gastrointestinal discomfort, dyspepsia, abdominal pain, nausea, vomiting, flatulence, diarrhoea, constipation, mild gastrointestinal bleeding which in rare cases leads to anemia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Ibuprofen Uncommon Gastrointestinal ulcers in some cases associated with bleeding and\/or perforation, gastritis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Ibuprofen Very rare Esophagitis, pancreatitis, diaphragm-like intestinal stenosis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Pseudoephedrine hydrochloride Not known Dry mouth, thirst, nausea, vomiting, ischemic colitis.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Ibuprofen Very rare Liver dysfunction, liver damage, especially in case of prolonged therapy, liver failure, acute hepatitis.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Ibuprofen Uncommon Various skin rashes.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Ibuprofen Very rare Bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome), alopecia, severe skin infections and soft tissue complications in case of chickenpox infection.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Ibuprofen Not known Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) Acute generalized exanthematous pustulosis (AGEP).\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Pseudoephedrine hydrochloride Not known Rash, urticaria, pruritus, hyperhidrosis, severe skin reactions including acute generalized exanthematous pustulosis (AGEP).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Ibuprofen Rare Damage to renal tissue (papillary necrosis) and high concentrations of uric acid in the blood.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Ibuprofen Very rare Increased serum creatinine, edema (particularly in patients suffering from arterial hypertension or renal failure), nephrotic syndrome, interstitial nephritis, acute renal failure.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Pseudoephedrine hydrochloride Not known Difficulty in urination.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eReporting of suspected adverse reactions:\u003c\/u\u003e \u003c\/i\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system: at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe clinical effects of overdose are more likely due to the presence of pseudoephedrine hydrochloride in this product, rather than ibuprofen. The effects are not clearly related to the dose taken due to the different sensitivity of various individuals to the sympathomimetic properties. \u003ci\u003eSymptoms due to the sympathomimetic effect \u003c\/i\u003e CNS depression: e.g. sedation, apnoea, cyanosis, coma. CNS stimulation (more likely in children): e.g. insomnia, hallucinations, convulsions, tremors. In addition to the symptoms already mentioned as side effects, the following symptoms may occur: hypertensive crisis, cardiac arrhythmias, muscle weakness and tension, euphoria, excitement, thirst, chest pain, dizziness, tinnitus, ataxia, blurred vision, hypotension. \u003ci\u003eSymptoms related to ibuprofen (in addition to the gastrointestinal and neurological ones already mentioned as side effects) \u003c\/i\u003e Drowsiness, nystagmus, tinnitus, hypotension, loss of consciousness. In cases of severe poisoning, metabolic acidosis may occur. \u003ci\u003eTherapeutic measures \u003c\/i\u003e There are no specific antidotes available. If the patient presents within an hour of taking a potentially toxic amount of medication, oral activated charcoal may be considered. An electrolyte check and an ECG are also necessary. In case of symptomatic cardiovascular instability and\/or electrolyte imbalance, symptomatic treatment should be initiated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy.\u003c\/u\u003e \u003ci\u003ePseudoephedrine hydrochloride:\u003c\/i\u003e Animal studies have demonstrated reproductive toxicity (see section 5.3). The use of pseudoephedrine hydrochloride reduces the mother's uterine blood flow, but clinical data regarding the effects on pregnancy are insufficient. \u003ci\u003eIbuprofen\u003c\/i\u003e: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryonic\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis following the use of prostaglandin synthesis inhibitors in the early stages of pregnancy. The risk is believed to increase proportionally to the dose and duration of therapy. It has been shown that in animals the administration of a prostaglandin synthesis inhibitor causes an increase in pre- and post-implantation losses and embryonic\/fetal lethality. Furthermore, an increased incidence of various malformations, including cardiovascular ones, has been reported in animals administered a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of pregnancy, ibuprofen should not be administered unless strictly necessary. If a woman who is trying to conceive or is in the first or second trimester of pregnancy must take ibuprofen, the dose and duration of treatment should be kept as low as possible. \u003cu\u003eDuring the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to:\u003c\/u\u003e - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligohydramnios; \u003cu\u003ethe mother and child, at the end of pregnancy: \u003c\/u\u003e - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delay or prolongation of labor. Consequently, this medicine is: contraindicated in the third trimester of pregnancy and should only be administered where strictly necessary in the first and second trimesters. \u003cu\u003eBreastfeeding:\u003c\/u\u003e The need to take measures during breastfeeding arises from the presence of pseudoephedrine hydrochloride in the formulation of the medicine: pseudoephedrine hydrochloride is excreted in breast milk. Taking into account the potential cardiovascular and neurological effects of vasoconstrictors, taking this medicine is contraindicated during breastfeeding. \u003cu\u003eFertility: \u003c\/u\u003e There is evidence that cyclooxygenase\/prostaglandin synthesis inhibitors may impair female fertility by affecting ovulation. The effect is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMomenxsin has minor or moderate influence on the ability to drive and use machines. Patients who experience dizziness, hallucinations, unusual headaches, and impaired vision or hearing should avoid driving or using machinery. Generally, a single administration or the use of this medicine for short periods does not require the adoption of any particular precautions.\u003c\/p\u003e","brand":"Angelini Pharma","offers":[{"title":"Default Title","offer_id":51131350778183,"sku":"043682020","price":9.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momenxsin-200mg-30mg-12-compresse-rivestite-farmacia-dottor-tili-1213791971.jpg?v=1767149890"},{"product_id":"actifed-decongestionante-1mg-ml-spray-nasale-soluzione-10ml","title":"Actifed decongestant 1mg\/ml nasal spray solution 10ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary symptomatic treatment of nasal congestion due to rhinitis or sinusitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eXylometazoline hydrochloride 1 mg in 1 ml of solution: Each spray-dose (140mcl) contains 140 mcg of xylometazoline hydrochloride. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium hyaluronate, Sorbitol (E420), Glycerol (E422), Sodium dihydrogen phosphate dihydrate, Disodium phosphate dihydrate, Sodium chloride, Water for injections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eACTIFED DECONGESTANT must not be used: - in patients with hypersensitivity to the active ingredient or to any of the excipients listed in paragraph 6.1; - in patients with high intraocular pressure, particularly in the presence of narrow-angle glaucoma; - in patients with \"dry\" inflammation of the nasal mucosa (\u003ci\u003eDry rhinitis\u003c\/i\u003e); - in children under 12 years of age; - after transsphenoidal hypophysectomy or other transnasal\/transoral surgery with exposure of the dura mater; - in patients being treated with monoamine oxidase inhibitors (MAOIs) or who have used these drugs in the previous 2 weeks, or in patients taking other medicinal products with potential hypertensive effect; - in patients with atrophic or vasomotor rhinitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor nasal use. \u003cu\u003eAdults and children over 12 years old\u003c\/u\u003e: One spray in each nostril no more than three times a day. This medicine must be used for a maximum of 7 days, unless otherwise prescribed by a doctor. To minimize the risk of infection, the product should not be used by more than one person and the nozzle should be cleaned after each use. \u003cb\u003eChildren\u003c\/b\u003e: ACTIFED DECONGESTANT is contraindicated in children under 12 years of age (see paragraph 4.3). \u003cb\u003eElderly\u003c\/b\u003e: Same dosage as adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eXylometazoline, like other medicines belonging to the same pharmacological category, should be administered with caution in patients with a marked reaction to sympathomimetic substances. The use of substances of this type can cause a series of disorders in such patients, such as insomnia, dizziness, tremors, arrhythmia or increased blood pressure. Particular caution is necessary in the case of patients suffering from cardiovascular diseases, hypertension, hyperthyroidism or diabetes, as well as in the case of patients with prostatic hypertrophy and pheochromocytoma. Patients with long QT syndrome treated with xylometazoline may be at increased risk of serious ventricular arrhythmias. In case of prolonged treatment with xylometazoline, the reappearance of the symptoms of rhinitis and edema of the mucous membrane is sometimes observed upon discontinuation of therapy. In these cases, it may also be the so-called \"rebound\" phenomenon caused by the medicine itself, which progresses to chronic edema and atrophy of the nasal mucosa (\u003ci\u003eRhinitis medicamentosa and Rhinitis sicca)\u003c\/i\u003e. To avoid this, the duration of treatment should be as short as possible (see section 4.2). Nasal and paranasal inflammations of bacterial origin must be treated appropriately. For the treatment of allergic rhinitis, this product can only be used temporarily as supportive therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of the product is not recommended in conjunction with tricyclic or tetracyclic antidepressant drugs or monoamine oxidase inhibitor drugs (MAOI), or within two weeks following the use of MAO inhibitors.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe most frequently reported side effects of this medicine are tingling or burning of the nose and throat and dryness of the nasal mucosa. Based on their frequency, side effects have been divided into the following categories: Very common ≥1\/10; Common ≥1\/100 to \u003c1\/10; Uncommon ≥1\/1000 to \u003c1\/100; Rare ≥1\/10,000 to \u003c1\/1000; Very rare \u003c1\/10,000 including isolated reports; Not known, frequency cannot be estimated from the available data.\u003c\/p\u003e\n\u003cp\u003eImmune System Disorders - Rare: Systemic allergic reactions.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Rare: Nervousness, insomnia.\u003c\/p\u003e\n\u003cp\u003eNervous system pathology - Rare: Headache, dizziness.\u003c\/p\u003e\n\u003cp\u003eEye disorders - Rare: Transient visual disturbances.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Rare: Palpitation.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Rare: Increased blood pressure.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Common: Tingling and burning of the nose and throat and dryness of the nasal mucosa. Uncommon: Epistaxis. Not known: Rebound effect.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Rare: Nausea.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBeing an imidazoline, systemic overdose of xylometazoline can cause a wide range of symptoms referable to cardiac and nervous system stimulation or depression. Cases of overdose are mainly linked to the use of the medicine in children. Reported symptoms of intoxication include severe paralysis of the central nervous system, sedation, dry mouth and sweating, as well as symptoms caused by stimulation of the sympathetic nervous system (tachycardia, irregular pulse and increased blood pressure). One drop (single dose) of the adult preparation xylometazoline (1 mg\/ml) administered intranasally caused a 4-hour coma in a 15-day-old infant. During follow-up, the newborn completely recovered. Treatment of intoxication is nosotropic and may include administration of charcoal, gastric lavage, and oxygen inhalation. To reduce blood pressure, 5 mg of phentolamine in saline solution is administered slowly intravenously or 100 mg orally. If necessary, antipyretics and anticonvulsants are administered. The use of vasopressors is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no data regarding the trans-placental passage of xylometazoline, nor its secretion into breast milk. Due to the potential systemic effect of vascular constriction, this medicine should not be used during pregnancy. During breastfeeding, this medicine should be used with caution as it is not known whether or not the active ingredient is transferred into breast milk.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhen used correctly, xylometazoline is not known to have any influence on the ability to drive or use machinery.\u003c\/p\u003e","brand":"Johnson \u0026 Johnson","offers":[{"title":"Default Title","offer_id":51131354153287,"sku":"040282016","price":10.43,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/johnson-johnson-spa-actifed-decongestionante-1mg-ml-spray-nasale-soluzione-10ml-farmacia-dottor-tili-1213791917.jpg?v=1767141070"},{"product_id":"sedo-calcio-soluzione-100ml","title":"Sedo Calcium solution 100ml","description":"\u003cp\u003e\u003cstrong\u003eSedo Calcium solution 100ml\u003c\/strong\u003e is an innovative product designed to keep the upper respiratory tract clean through the mechanical removal of catarrhal secretions. Thanks to its unique formulation, this solution not only lubricates and cleans the oropharyngeal cavity, but also creates a protective film that offers a barrier against irritants such as fine dust, smoke and smog. This makes it especially useful during times of flu and colds, when the airways are most vulnerable.\u003c\/p\u003e\n\n\u003cp\u003eThe composition of \u003cstrong\u003eSedo Football\u003c\/strong\u003e includes ingredients such as glycerin, sucrose, sodium benzoate, calcium lactate, EDTA, menthol, anise essence and cinnamon, which work synergistically to ensure effective and gentle action. Menthol and anise and cinnamon essences give the solution a pleasant and refreshing aroma, improving the experience of use.\u003c\/p\u003e\n\n\u003cp\u003eIdeal for \u003cstrong\u003efumigate\u003c\/strong\u003e, steam inhalations and gargles, Sedo Calcio solution 100ml is a precious ally for those looking for a natural and safe method to relieve the symptoms of congested airways. Its versatility makes it suitable for different modes of use, offering quick and long-lasting relief. Available in a handy 100ml bottle, it is perfect for home use and easy to take with you wherever you go.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Sedo Calcium solution 100ml? What is it for?\u003c\/h3\u003e\u003cp\u003eSolution for cleaning and lubricating the oropharyngeal cavity and upper respiratory tract, indicated for the mechanical removal of catarrhal secretions; it forms a protective film against fine dust, smoke and smog, particularly useful during periods of flu and colds.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Sedo Calcium solution 100ml contain?\u003c\/h3\u003e\u003cp\u003eGlycerin, sucrose, sodium benzoate, calcium lactate, EDTA, menthol, anise essence, cinnamon essence, purified water.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Sedo Calcium solution 100ml?\u003c\/h3\u003e\u003cp\u003e- Fuments\/fumigations: the prepared solution must not be used for subsequent applications.\u003cbr\u003eAdults: dilute three tablespoons of calcium sedum in 1 liter of hot water, inhale the vapors for about 5 minutes; maximum four applications daily.\u003cbr\u003e- Steam inhalations:\u003cbr\u003eAdults: three tablespoons of sedo calcium diluted in 500 ml of hot water; maximum two applications daily.\u003cbr\u003e- Gargling:\u003cbr\u003eAdults: one tablespoon in half a glass of water; maximum four\/five applications daily.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Sedo Calcium solution 100ml?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eDo not use the product without first diluting it. Do not use if hypersensitive or allergic to any of the components. Contact a doctor if there is hypersensitivity to the components. Keep out of reach of children. Avoid contact with eyes. In case of accidental contact, wash eyes with plenty of water. Do not ingest. Do not use for more than 3 consecutive days. Do not administer to children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Sedo Calcium solution 100ml stored?\u003c\/h3\u003e\u003cp\u003eStore at room temperature, in a cool, dry place and away from heat sources. Do not use the device after the expiry date indicated on the packaging. The expiry date refers to the product in intact packaging, correctly stored.\u003cbr\u003eValidity with intact packaging: 36 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Sedo Calcium solution 100ml?\u003c\/h3\u003e\u003cp\u003e100 ml bottle.\u003c\/p\u003e","brand":"Deca Laboratorio Chimico","offers":[{"title":"Default Title","offer_id":51131362935111,"sku":"938989288","price":16.84,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/deca-laboratorio-chimico-srl-sedo-calcio-soluzione-100ml-farmacia-dottor-tili-1213791925.jpg?v=1767141730"},{"product_id":"breathe-right-classici-grandi-30-pezzi","title":"Breathe Right Classic Large 30 Pieces","description":"\u003cp\u003eI \u003cstrong\u003eBreathe Right classics large 30 pieces\u003c\/strong\u003e are nasal patches designed to offer immediate relief from nasal congestion, improving breathing and reducing snoring. These patches, ideal for adults with larger noses, use advanced technology that gently widens the nasal passages, allowing for an increase in airflow by up to 31%. They are particularly effective in cases of allergies, colds or deviated nasal septum, offering optimal comfort without the use of medicines.\u003c\/p\u003e\n\n\u003cp\u003eMade as single-use medical devices, Breathe Right patches feature a secure adhesive and an anatomical shape that fits perfectly to the nose, ensuring comfortable application and gentle removal. Their transparency makes them discreet, allowing them to be used at any time of the day or during the night for a more peaceful rest. Thanks to their effectiveness, these patches are a practical and non-invasive solution for those looking to improve the quality of their daily breathing.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Breathe Right Classic Large 30 Pieces? What is it for?\u003c\/h3\u003e\u003cp\u003eNasal patch, disposable medical device, indicated for the relief of nasal congestion and to improve breathing by reducing snoring; It works by delicately widening the nasal passages, being useful in case of allergies, colds or deviated nasal septum, without the use of medicines.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Breathe Right classic large 30 pieces?\u003c\/h3\u003e\u003cp\u003eRemove the oiled film that protects the glue. Make the patch adhere perfectly to the wings of the nose (at the root), pressing lightly on the sides of the device with your fingers. To remove: moisten the patch with warm water and gently remove by lifting the adhesive starting from the flaps.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Breathe Right Classic Large 30 Pieces?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eNasal patches are not indicated in cases of nasal polyposis, deviation of the nasal septum, tonsillar\/adenoid hypertrophy and sleep apnea. Adult nasal plasters are contraindicated for children. Read the information leaflet contained inside the package carefully before use. The product is not indicated in patients allergic to latex.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Breathe Right classic large 30 pieces not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eNasal patches are not indicated in cases of nasal polyposis, deviation of the nasal septum, tonsillar\/adenoid hypertrophy and sleep apnea. Adult nasal plasters are contraindicated for children. Read the information leaflet contained inside the package carefully before use. The product is not indicated in patients allergic to latex.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Breathe Right Classics Large 30 Pieces?\u003c\/h3\u003e\u003cp\u003ePack of 30 standard classic nasal plasters.\u003c\/p\u003e","brand":"Efas","offers":[{"title":"Default Title","offer_id":51131366900039,"sku":"982483582","price":23.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/e-fa-s-spa-breathe-right-classici-grandi-30-pezzi-farmacia-dottor-tili-1213791899.jpg?v=1767150148"},{"product_id":"actigrip-2-5mg-60mg-500mg-12-compresse","title":"Actigrip 2.5mg\/60mg\/500mg 12 tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of cold symptoms characterized by nasal obstruction, watery rhinorrhea, headache and\/or fever.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach tablet contains: • \u003ci\u003e \u003cu\u003eactive ingredients:\u003c\/u\u003e \u003c\/i\u003e triprolidine hydrochloride 2.5 mg (triprolidine free base 2.091 mg); pseudoephedrine hydrochloride 60.0 mg (pseudoephedrine free base 49.154 mg); paracetamol 500.0 mg; For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach tablet contains: pregelatinized corn starch, povidone, crospovidone, stearic acid, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substances, to other antihistamines or to any of the excipients listed in paragraph 6.1. • Children under the age of 12. • During pregnancy and breastfeeding (see section 4.6). • Patients being treated with monoamine oxidase inhibitors (MAOIs) or in the two weeks following such treatment. In such cases the concomitant use of Actigrip can cause an increase in blood pressure or hypertensive crisis (see section 4.5) and in the treatment of lower respiratory tract diseases, including bronchial asthma. • The association with indirect sympathomimetic drugs, alpha sympathetic mimetics (orally and\/or nasally) (see section 4.5 Interactions with other medicinal products and other forms of interaction). • Due to its anticholinergic effects, do not use in case of glaucoma, prostatic hypertrophy, obstruction of the bladder neck, pyloric and duodenal stenosis or other tracts of the gastrointestinal and urogenital system. • Patients with pre-existing cardiovascular disease, particularly those with coronary heart disease, hypertension and thyroid disease. • In patients with a history of stroke or who have risk factors for stroke, due to the alphasympathomimetic activity of the vasoconstrictor, § Epilepsy. • Diabetes. • Severe liver and kidney disease. • Paracetamol-based medicines are contraindicated in patients with manifest glucose-6-phosphate dehydrogenase insufficiency and in those suffering from severe hemolytic anemia. • Severe hepatocellular failure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage.\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: one tablet 2 - 3 times a day, for a maximum of 5 days of therapy. \u003ci\u003ePediatric population (children over 12 years old up to 18 years old)\u003c\/i\u003e: one tablet 2 - 3 times a day, for a maximum of 3 days of therapy. \u003cb\u003eDo not exceed the recommended doses\u003c\/b\u003e; in particular elderly patients must adhere to the minimum dosages indicated above. \u003cu\u003eMethod of administration:\u003c\/u\u003e Take the tablets orally. The medicine must be taken on a full stomach.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in a dry place, at a temperature not exceeding 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of Actigrip should be avoided if you are already using any other medicine containing paracetamol. People suffering from alcoholism should contact their doctor before taking paracetamol. Patients with liver disease should consult their doctor before taking Actigrip. Migraine patients treated with ergotamine alkaloid vasoconstrictors should consult their doctor before taking Actigrip (see section 4.5). In patients treated with paracetamol, serious skin reactions such as acute generalized exanthematous pustulosis (PEAG), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported very rarely. Patients should be informed of the signs of serious skin reactions and use should be discontinued at the first signs of skin rash or any other sign of hypersensitivity. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases in the early stages of treatment. Serious skin reactions such as acute generalized exanthematous pustulosis (AGEP) have been reported very rarely with products containing pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules resulting from a widespread edematous erythema and localized mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as formation of numerous small pustules with or without pyrexia or erythema are observed, administration of ACTIGRIP should be discontinued (see section 4.8). If fever persists for more than three days or if symptoms do not improve or others appear within five days or are accompanied by high fever, rash, excessive amount of mucus and persistent cough, consult your doctor before continuing administration. Due to the presence of pseudoephedrine, patients must be informed that treatment must be discontinued in the event of: hypertension, tachycardia, palpitations or cardiac arrhythmia, nausea or any neurological signs (such as the appearance or exacerbation of headache). If sudden abdominal pain, rectal bleeding or other symptoms of ischemic colitis develop (see section 4.8), pseudoephedrine should be discontinued and medical advice should be sought. Ischemic optic neuropathy: Cases of ischemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or reduction in visual acuity occurs, for example in the case of a scotoma. The use of antihistamines can mask the first signs of ototoxicity of certain antibiotics. Patients with respiratory conditions such as emphysema and chronic bronchitis should be advised to consult a doctor before using triprolidine. May cause drowsiness (see section 4.8). Triprolidine may increase the sedative effects of substances that depress the central nervous system such as alcohol, sedatives, tranquilizers (see section 4.5). It is necessary to inform patients that the use of alcoholic beverages should be avoided during treatment with Actigrip and that it is advisable to consult the doctor before taking Actigrip concomitantly with medicines that depress the central nervous system. Patients with reduced kidney function should not take Actigrip unless advised by their doctor. High or prolonged doses of the medicine can cause high-risk liver disease and even serious changes in the kidney and blood. In case of renal and hepatocellular insufficiency, use only if clearly necessary and under direct medical supervision. During treatment with paracetamol before taking any other medicine, check that it does not contains the same active ingredient, since if paracetamol is taken in high doses, serious adverse reactions may occur. Overdose can lead to liver damage. Careful medical supervision is therefore necessary for both adults and children even if no obvious signs or symptoms appear. Invite the patient to contact the doctor before combining any other drug (see section 4.5). The use of the medicine is not recommended if the patient is being treated with anti-inflammatory drugs. \u003ci\u003eSpecial populations:\u003c\/i\u003e Consult your doctor to determine the dose in the elderly due to their greater sensitivity towards the drug.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAnticoagulant drugs (e.g. warfarin)\u003c\/i\u003e: Concomitant use of paracetamol with oral anticoagulants may lead to slight changes in INR values. In this case, patients should seek advice from their doctor or pharmacist before using Actigrip if they are already taking blood-thinning medications, such as warfarin or other coumarin derivatives. \u003ci\u003eMonoamine oxidase inhibitors (MAOIs)\u003c\/i\u003e: Pseudoephedrine exerts its vasoconstrictor properties by stimulating adrenergic receptors and promoting the release of norepinephrine from neuronal sites. Because MAOIs impair the metabolism of sympathomimetic amines by increasing the availability of releasable norepinephrine in the nervous system, they may potentiate the pressor effect of pseudoephedrine. Cases of acute hypertensive crises due to the concomitant use of MAOIs and sympathomimetic amines have been reported in the literature. \u003ci\u003eSubstances that depress the CNS (Alcohol, sedatives, tranquilizers)\u003c\/i\u003e: The medicine may interact with alcohol, tricyclic antidepressants, neuroleptics or other drugs with a depressant action on the central nervous system such as barbiturates, sedatives, tranquilizers, hypnotics which should not be taken during therapy. Related to the presence of pseudoephedrine, associations with indirect sympathomimetics (ephedrine, methylphenidate, phenylephrine) and oral and\/or nasal alpha sympathomimetics (naphazoline, oxymetazoline, phenylephrine, tetrizoline, tramazoline, tuaminoheptane) are contraindicated due to the possible risk of vasoconstriction and\/or hypertensive crisis (see section 4.3 \"Contraindications\"). Concomitant administration of dopaminergic ergot alkaloids (bromocriptine, cabergoline, lisuride, pergolide) and vasoconstrictor ergot alkaloids (dihydroergotamine, ergotamine, methylergometrine) can induce vasoconstriction and\/or hypertensive crisis. Likewise, antihypertensives, oral hypoglycemics, metoclopramide, other substances with anticholinergic action should not be taken at the same time as ACTIGRIP, as they could cause significant interactions. Associations requiring precautions for use: Halogenated anesthetic gases: risk of perioperative hypertensive crisis. It is advisable to stop treatment with ACTIGRIP a few days before a scheduled surgery. Furazolidone causes progressive inhibition of monoamine oxidase, so it should not be taken at the same time as ACTIGRIP. The effect of antihypertensives that interfere with sympathetic activity (e.g. methyldopa, alpha and beta blockers, debrisoquine, guanethidine, betanidine and bretylium) can be partially canceled out by ACTIGRIP, which therefore, also in this case, should not be taken at the same time. The habitual ingestion of anticonvulsant drugs or oral contraceptives can, through an enzymatic induction mechanism, accelerate the metabolism of paracetamol. Use with extreme caution and under strict control during chronic treatment with drugs that can cause the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutetimide, phenobarbital, carbamazepine). The administration of paracetamol can interfere with the determination of uric acid (using the phosphotungstic acid method) and with that of blood sugar (using the glucose-oxidase-peroxidase method).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eData from clinical trials\u003c\/i\u003e: \u003c\/b\u003e There are insufficient data to report adverse reactions from randomized placebo-controlled studies for the combination of parcetamol, pseudoephedrine and triprolidine. The following are adverse reactions reported with a frequency ≥1%, identified in randomized placebo-controlled studies: - with formulations containing pseudophedrine as the single active substance: dry mouth, nausea, dizziness, insomnia and nervousness; - with formulations containing paracetamol and pseudoephedrine: nervousness. \u003cb\u003e \u003ci\u003eData from post-marketing experience\u003c\/i\u003e: \u003c\/b\u003e The following are adverse events identified during post-marketing experience with paracetamol, pseudoephedrine, the combination of pseudoephedrine and triprolidine, the combination of pseudoephedrine and paracetamol, or the combination of paracetamol, pseudoephedrine and triprolidine. Adverse reactions are reported in Table 1 according to frequency categories using the following convention: Very common (≥ 1\/10); Common (≥ 1\/100, \u003c1\/10); Uncommon (≥ 1\/1,000, \u003c 1\/100); Rare (≥1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000); Not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: anxiety, nervousness, restlessness, visual hallucination, insomnia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: convulsions, dizziness, excitation, headache (especially in the elderly), cerebrovascular accident.\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: Palpitations, myocardial infarction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: Epistaxis.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: pruritus, urticaria, acute generalized exanthematous pustulosis, rash, severe skin reactions, including cases of erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis, photosensitization.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: Dysuria, urinary retention.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: Ischemic colitis.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: increased blood pressure.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: - Adverse reactions: hypersensitivity reactions, anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: Ischemic optic neuropathy.\u003c\/p\u003e\n\u003cp\u003eSide effects related to the presence of Paracetamol: \u003cb\u003eSkin and subcutaneous tissue disorders:\u003c\/b\u003e itchy skin rash, angioedema. \u003cb\u003eSystemic disorders and conditions relating to the administration site:\u003c\/b\u003e asthenia. \u003cb\u003ePathologies of the blood and lymphatic system\u003c\/b\u003e: thrombocytopenia, leukopenia, neutropenia, anemia, agranulocytosis. \u003cb\u003eHepatobiliary disorders:\u003c\/b\u003e liver function disorders, hepatitis. \u003cb\u003eRenal and urinary disorders\u003c\/b\u003e: kidney alterations, acute renal failure, interstitial nephritis, hematuria. \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e: dry mouth, abdominal discomfort, constipation, nausea, vomiting, diarrhea. \u003cb\u003e Diagnostic tests\u003c\/b\u003e: increase in transaminases*. \u003csup\u003e*\u003c\/sup\u003ea slight increase in transaminase levels may occur in some patients taking recommended dosages of acetaminophen. These cases are not accompanied by liver failure and generally resolve with the continuation or suspension of paracetamol therapy. Side effects related to the presence of Pseudoephedrine: \u003cb\u003ePsychiatric disorders:\u003c\/b\u003e hallucinations. \u003cb\u003eNervous system disorders:\u003c\/b\u003e paresthesia, psychomotor hyperactivity, tremors, cerebrovascular accident. \u003cb\u003eCardiac disorders:\u003c\/b\u003e arrhythmia, tachycardia, myocardial infarction. \u003cb\u003eSkin and subcutaneous tissue disorders:\u003c\/b\u003e angioedema. \u003cb\u003eSystemic disorders and conditions relating to the administration site:\u003c\/b\u003e sweating. \u003cb\u003eGastrointestinal Pathologies:\u003c\/b\u003e ischemic colitis. Side effects related to the presence of Triprolidine: \u003cb\u003ePsychiatric disorders:\u003c\/b\u003e euphoria. \u003cb\u003eNervous system disorders:\u003c\/b\u003e drowsiness. \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e: dry mouth, abdominal discomfort, constipation, nausea, vomiting, diarrhea. \u003cb\u003eCardiac diseases\u003c\/b\u003e: hypotension (especially in the elderly). \u003cb\u003eRespiratory, thoracic and mediastinal disorders:\u003c\/b\u003e increased hyperviscosity of bronchial secretions. \u003cb\u003eEye disorders:\u003c\/b\u003e acute attack of angle-closure glaucoma, mydriasis, blurred vision. In isolated cases, hemorrhagic stroke has occurred in patients who used drugs containing pseudoephedrine. Notably, these cerebrovascular accidents have occurred during overdose, misuse and\/or in patients with vascular risk factors. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of pseudoephedrine overdose, nausea, vomiting, marked depressive or stimulant effects on the central nervous system, insomnia, tremors, mydriasis, anxiety, agitation, hallucinations, palpitations, tachycardia, reflex bradycardia, drowsiness, lethargy, respiratory depression, hypertension, irritability, convulsions are generally observed. Other effects may concern dysrhythmia, hypertensive crisis, intracerebral hemorrhage, myocardial infarction, psychosis, rhabdomyolysis, hypocalemia and ischemic infarction of the intestine. In children the dominant action is the exciting one with accentuated tremors, drowsiness, insomnia, hyperactivity and convulsions. Pallor, anorexia, nausea and vomiting are frequently the first signs of paracetamol overdose. Hepatic necrosis is a complication related to paracetamol overdose. Liver enzymes may become elevated and prothrombin time prolonged for 12 to 48 hours but clinical signs may not appear until the 6th day after ingestion. Alcohol may potentiate the hepatoxicity of acetaminophen overdose and may have contributed to acute pancreatitis in a patient who had taken excessive amounts of acetaminophen. In case of overdose, paracetamol, contained in ACTIGRIP, can cause hepatic cytolysis and can evolve towards massive and irreversible necrosis. Keep out of reach of children. In case of overdose, seek medical help or contact a poison control center immediately. \u003cb\u003eManagement\u003c\/b\u003e • Immediate transfer of the patient to hospital. • Taking a plasma sample to determine the initial dosage of paracetamol. • Rapid evacuation of the ingested product through gastric lavage. • Acidify the urine by administering ammonium chloride (to increase the elimination of pseudoephedrine). • Usually the treatment of overdose includes the administration of the antidote N-acetylcysteine ​​intravenously or orally as soon as possible and, if possible, before the tenth hour. • Symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eACTIGRIP is contraindicated during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt common therapeutic doses, antihistamines present secondary reactions that vary greatly from subject to subject and from compound to compound. The most frequent secondary effect is sedation which can manifest itself with drowsiness, of which those who can drive motor vehicles or carry out operations that require an intact level of vigilance must be warned.\u003c\/p\u003e","brand":"Johnson \u0026 Johnson","offers":[{"title":"Default Title","offer_id":51131372208455,"sku":"024823080","price":11.77,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/johnson-johnson-spa-actigrip-2-5mg-60mg-500mg-12-compresse-farmacia-dottor-tili-1213791873.jpg?v=1767137627"},{"product_id":"aspirina-400mg-granulato-effervescente-con-vitamina-c-10-bustine-10g","title":"Aspirin 400mg effervescent granules with vitamin C 10 sachets 10g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic therapy of feverish states and flu and cold syndromes. Symptomatic treatment of headaches and toothaches, neuralgia, menstrual pain, rheumatic and muscular pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne sachet contains: \u003cu\u003eactive ingredients\u003c\/u\u003e: acetylsalicylic acid: 400 mg; ascorbic acid (vitamin C): 240 mg. Excipients: sucrose, sicovit (E110). For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCitric acid; monobasic sodium citrate; sodium bicarbonate; sodium carbonate; orange concentrate; powdered orange flavouring; saccharin E 110; sucrose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eASPIRIN effervescent granules with vitamin C is contraindicated in case of: - hypersensitivity to active ingredients (acetylsalicylic acid and ascorbic acid), to other analgesics (painkillers)\/antipyretics (antipyretics) \/ non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients; - gastroduodenal ulcer; - hemorrhagic diathesis; - Severe renal, cardiac or hepatic insufficiency - glucose -6-phosphate dehydrogenase deficiency (G6PD\/favism); - concomitant treatment with methotrexate (at doses of 15 mg\/week or more) or with warfarin (see section 4.5); - history of asthma induced by the administration of salicylates or substances with similar activity, in particular non-steroidal anti-inflammatory drugs; - last trimester of pregnancy and breastfeeding (see section 4.6); - children and young people under the age of 16; - Nephrolithiasis or previous history of nephrolithiasis; - Hyperoxaluria; - Hemochromatosis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults Pour the contents of the sachet into half a glass of water, or more. Mix with a teaspoon. Before drinking, wait for the slight effervescence to cease. 1 sachet repeating, if necessary, the dose at intervals of 4-8 hours up to 3-4 times a day. The use of the product is reserved for adult patients only. Always use the minimum effective dosage and increase it only if it is not sufficient to relieve symptoms (pain and fever). Subjects most exposed to the risk of serious side effects, who can only use the drug if prescribed by their doctor, must follow the instructions scrupulously (see section 4.4). Do not take the product for more than 3-5 days without your doctor's advice. Consult your doctor if symptoms persist. Use the medicine for the shortest period possible. Take the medicine preferably after main meals or, in any case, on a full stomach. \u003cb\u003eSpecial populations\u003c\/b\u003e \u003cb\u003e \u003ci\u003e \u003cu\u003ePediatric population\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Effervescent granulated aspirin with vitamin C is not indicated for use in the pediatric population (see section 4.4). \u003cb\u003e \u003ci\u003e \u003cu\u003eElderly\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e In elderly patients use the minimum effective dosage \u003cb\u003e \u003ci\u003e \u003cu\u003ePatients with impaired liver function \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Acetylsalicylic acid should be used with caution in patients with impaired hepatic function (see section 4.4). \u003cb\u003e \u003ci\u003e \u003cu\u003ePatients with impaired renal function \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Acetylsalicylic acid should be used with caution in patients with impaired renal function (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eHypersensitivity reactions\u003c\/b\u003e Acetylsalicylic acid and other NSAIDs may cause hypersensitivity reactions (including asthma attacks, rhinitis, angioedema or urticaria). The risk is greater in subjects who have already presented a hypersensitivity reaction in the past after the use of this type of drug (see section 4.3) and in subjects who present allergic reactions to other substances (e.g. skin reactions, itching, urticaria). In subjects with asthma and\/or rhinitis (with or without nasal polyposis) and\/or urticaria the reactions may be more frequent and serious. In rare cases, reactions can be very serious and potentially fatal. In the following cases, administration of the drug requires a doctor's prescription after careful evaluation of the risk\/benefit ratio: - \u003ci\u003eSubjects at increased risk of hypersensitivity reactions (see above)\u003c\/i\u003e - \u003ci\u003eSubjects at increased risk of gastrointestinal lesions\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs can cause serious side effects at the gastrointestinal level (bleeding, ulcer, perforation). For this reason these drugs should not be used by subjects suffering from gastrointestinal ulcers or gastrointestinal bleeding. It is prudent for those who have suffered from gastrointestinal ulcers or gastrointestinal bleeding in the past to avoid its use. The risk of gastrointestinal lesions is a dose-related effect, as gastrointestinal lesions are greater in subjects who use higher doses of acetylsalicylic acid. Even subjects with a habit of drinking large quantities of alcohol are more exposed to the risk of gastrointestinal lesions (bleeding in particular) (see section 4.5). - \u003ci\u003eSubjects with coagulation defects or being treated with anticoagulants\u003c\/i\u003e In subjects suffering from coagulation defects or being treated with anticoagulants, acetylsalicylic acid and other NSAIDs can cause a serious reduction in haemostatic capacity, exposing them to the risk of haemorrhage. - \u003ci\u003eSubjects with impaired renal, cardiac or hepatic function\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs can cause a critical reduction in renal function and water retention; the risk is greater in subjects treated with diuretics. This can be especially dangerous for the elderly and for those with impaired kidney, heart or liver function. - \u003ci\u003eSubjects suffering from asthma\u003c\/i\u003e Acetylsalicylic acid and other NSAIDs can cause an aggravation of asthma. - \u003ci\u003eGeriatric age (especially above 75 years)\u003c\/i\u003e The risk of serious side effects is greater in geriatric subjects. Subjects over the age of 70, especially in the presence of concomitant therapies, should use Aspirin 400 mg effervescent granules only after consulting their doctor. Aspirin 400mg effervescent granules must not be used in the pediatric population (see section 4.3). Products containing acetylsalicylic acid should not be used in children and adolescents under 16 years of age with viral infections, regardless of the presence or absence of fever. In certain viral diseases, especially influenza A, influenza B and chickenpox, there is a risk of Reye's syndrome, a very rare but life-threatening disease that requires immediate medical intervention. The risk may be increased in case of simultaneous intake of acetylsalicylic acid, although a causal relationship has not been demonstrated. Persistent vomiting in patients with these diseases may be a sign of Reye's syndrome. - \u003ci\u003eSubjects with hyperuricemia\/gout\u003c\/i\u003e Acetylsalicylic acid can interfere with the elimination of uric acid: high doses have a uricosuric effect while (very) low doses can reduce its excretion. It should also be considered that acetylsalicylic acid and other NSAIDs can mask the symptoms of gout, delaying its diagnosis. An antagonistic effect with uricosuric drugs is also possible (see section 4.5).- \u003ci\u003eSubjects with a predisposition to calcium-oxal nephrolithiasis (kidney stones) or with recurrent nephrolithiasis\u003c\/i\u003e Vitamin C (ascorbic acid) should be used with caution by subjects with a predisposition to calcium-oxal nephrolithiasis (kidney stones) or with recurrent nephrolithiasis. - \u003ci\u003eCombination of drugs not recommended or requiring special precautions or dosage adjustment\u003c\/i\u003e. The use of acetylsalicylic acid in combination with some drugs may increase the risk of serious side effects (see section 4.5). Do not use acetylsalicylic acid together with another NSAID or, in any case, do not use more than one NSAID at a time. \u003ci\u003eSodium\u003c\/i\u003e This medicine contains 469 mg sodium per sachet equivalent to 23% of the WHO recommended maximum daily intake of 2 g sodium for an adult. \u003ci\u003eSucrose\u003c\/i\u003e This medicine contains 5.6 g of sucrose per sachet. To be taken into consideration in people suffering from diabetes mellitus. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. \u003ci\u003eYellow orange dye (E 110)\u003c\/i\u003e May cause allergic reactions. If you have to undergo surgery (even a small one, for example the extraction of a tooth) and in the previous days you have used acetylsalicylic acid or another NSAID, you must inform the surgeon due to the possible effects on coagulation. Since acetylsalicylic acid can cause gastrointestinal bleeding, this must be taken into account if it is necessary to carry out a search for occult blood. Before administering any medicine, all necessary precautions must be taken to prevent unwanted reactions; particularly important is the exclusion of previous hypersensitivity reactions to this or other medicines and the exclusion of other contraindications or conditions that may expose you to the risk of potentially serious side effects listed above. If in doubt, consult your doctor or pharmacist. The product must be taken on a full stomach.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eContraindicated associations\u003ci\u003e (avoid concomitant use - see section 4.3)\u003c\/i\u003e - \u003cu\u003eMethotrexate (doses greater than or equal to 15 mg\/week): \u003c\/u\u003eincreased plasma levels and toxicity of methotrexate; the risk of toxic effects is greater if renal function is compromised. - \u003cu\u003eWarfarin:\u003c\/u\u003e serious increase in the risk of hemorrhage due to enhancement of the anticoagulant effect. Associations not recommended (the concomitant use of the two drugs requires a doctor's prescription after careful evaluation of the risk\/benefit ratio - see section 4.4) \u003cu\u003eAntiplatelet agents: \u003c\/u\u003eincreased risk of hemorrhage due to the sum of the anti-aggregating effect. \u003cu\u003eThrombolytics\u003c\/u\u003e or \u003cu\u003eOral or parenteral anticoagulants:\u003c\/u\u003e increased risk of hemorrhage due to enhancement of the pharmacological effect. \u003cu\u003eNSAIDs\u003c\/u\u003e (topical use excluded): increased risk of serious side effects. \u003cu\u003eMethotrexate (doses less than 15mg\/week): \u003c\/u\u003ethe increased risk of toxic effects (see above) must also be considered for treatment with methotrexate at low doses. \u003cu\u003eSelective serotonin re-uptake inhibitors (SSRIs):\u003c\/u\u003e increased risk of upper gastrointestinal bleeding due to a possible synergistic effect. Associations requiring particular precautions or dosage adjustment (concomitant use of the two drugs requires a doctor's prescription after careful evaluation of the risk\/benefit ratio - see section 4.4) \u003cu\u003eACE inhibitors: \u003c\/u\u003ereduction of the hypotensive effect; increased risk of impaired renal function. \u003cu\u003eValproic Acid: \u003c\/u\u003eincreased effect of valproic acid (risk of toxicity). \u003cu\u003eAntacids:\u003c\/u\u003e antacids taken at the same time as other drugs can reduce their absorption; the excretion of acetylsalicylic acid increases in alkalinized urine. \u003cu\u003eAntidiabetics (e.g. insulin and oral hypoglycemics)\u003c\/u\u003e: increased hypoglycemic effect; the use of acetylsalicylic acid in subjects being treated with antidiabetics must take into account the risk of inducing hypoglycemia. \u003cu\u003eDigoxin:\u003c\/u\u003e increased plasma concentration of digoxin due to decreased renal elimination. \u003cu\u003eDiuretics\u003c\/u\u003e: increased risk of nephrotoxicity of acetylsalicylic acid and other NSAIDs; reduction of the effect of diuretics. \u003cu\u003eAcetazolamide\u003c\/u\u003e: reduced elimination of acetazolamide (risk of toxicity) \u003cu\u003ePhenytoin: \u003c\/u\u003eincreased effect of phenytoin. \u003cu\u003eCorticosteroids \u003c\/u\u003e(excluding those for topical use and those used for the treatment of adrenocortical insufficiency): a) increased risk of gastrointestinal lesions; b) due to the increased elimination of salicylates induced by corticosteroids, there is a reduction in plasma levels of salicylate. Conversely, after interruption of corticosteroid treatment, overdose of salicylates may occur. \u003cu\u003eMetoclopramide: \u003c\/u\u003eincrease in the effect of acetylsalicylic acid due to an increase in the speed of absorption. \u003cu\u003eUricosurics (e.g. probenecid, benzbromarone): \u003c\/u\u003edecrease in the uricosuric effect. \u003cu\u003eZafirlukast: \u003c\/u\u003eincreased plasma concentration of zafirlukast. Deferoxamine: concomitant use of ascorbic acid can cause increased tissue toxicity of iron, especially at the cardiac level, and cause heart failure. Aspirin 400mg effervescent granules contains buffer systems that could reduce the effects of the thyroid hormone Levothyroxine. \u003cb\u003eAlcohol (see section 4.4)\u003c\/b\u003e The sum of the effects of alcohol and acetylsalicylic acid causes increased damage to the gastrointestinal mucosa and prolongation of bleeding time. However, it is advisable not to administer other drugs orally within 1 or 2 hours of using the product. \u003cb\u003e \u003cu\u003eInterference with clinical laboratory tests \u003c\/u\u003e \u003c\/b\u003e Vitamin C Because vitamin C is a reducing agent (i.e., an electron donor), it may cause chemical interference in laboratory tests involving oxidation-reduction reactions, such as analyzes of glucose, creatinine, carbamazepine, uric acid in urine, serum, and fecal occult blood. Vitamin C can interfere with tests that measure urine and blood glucose leading to a false reading of the results even if it has no effect on blood glucose levels.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe most frequently observed side effects affect the gastrointestinal system and can occur in approximately 4% of subjects taking acetylsalicylic acid as an analgesic-antipyretic. This percentage increases significantly in subjects at risk of gastrointestinal disorders. These disorders can be partially alleviated by taking the medicine on a full stomach. Most side effects are dependent on both the dose and duration of treatment. The side effects observed with acetylsalicylic acid are generally common to other NSAIDs. \u003cb\u003ePathologies of the blood and lymphatic system\u003c\/b\u003e: prolonged bleeding time, haemorrhage from gastrointestinal bleeding, reduction in platelets (thrombocytopenia) in extremely rare cases. Following hemorrhage, hemorrhagic\/iron-deficiency anemia may occur (due, for example, to occult microhemorrhages) with the related alterations in laboratory parameters and the related clinical signs and symptoms such as asthenia, pallor and hypoperfusion. \u003cb\u003eNervous system disorders\u003c\/b\u003e: headache, dizziness. Rarely: Reye's syndrome (*). Rarely to very rarely: cerebral hemorrhage, especially in patients with uncontrolled hypertension and\/or on anticoagulant therapy which, in isolated cases, can be potentially lethal. \u003cb\u003eEar and labyrinth disorders\u003c\/b\u003e: tinnitus (buzzing\/rustling\/ringing\/ringing in the ears). \u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e: respiratory disease exacerbated by acetylsalicylic acid, asthma syndrome, rhinitis (profuse rhinorrhoea), nasal congestion (associated with hypersensitivity reactions). Epistaxis. \u003cb\u003e \u003ci\u003eCardiac diseases\u003c\/i\u003e \u003c\/b\u003e: cardiorespiratory distress (associated with hypersensitivity reactions). \u003cb\u003e \u003ci\u003eEye pathologies\u003c\/i\u003e \u003c\/b\u003e: conjunctivitis (associated with hypersensitivity reactions). \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e: gastrointestinal bleeding (occult), gastric disorders, heartburn, gastrointestinal pain, gingivorrhagia. Vomiting, diarrhoea, nausea, abdominal pain, cramps (associated with hypersensitivity reactions). Rarely: gastrointestinal inflammation, gastrointestinal erosion, gastrointestinal ulceration, hematemesis (vomiting of blood or \"coffee-like\" material), melena (emission of black stools, esophagitis). Very rarely: hemorrhagic gastrointestinal ulcer and\/or gastrointestinal perforation with the related clinical signs and symptoms and alterations of laboratory parameters. Frequency not known (especially in long-term treatment): - Disease of the intestinal diaphragms. \u003cb\u003e \u003ci\u003eHepatobiliary disorders\u003c\/i\u003e \u003c\/b\u003e: rarely: hepatotoxicity (hepatocellular injury generally mild and asymptomatic) manifested by an increase in transaminases. \u003cb\u003e \u003ci\u003ePathologies of the skin and subcutaneous tissues\u003c\/i\u003e \u003c\/b\u003e:rash, edema, urticaria, pruritus, erythema, angioedema (associated with hypersensitivity reactions). \u003cb\u003e \u003ci\u003eRenal and urinary disorders\u003c\/i\u003e \u003c\/b\u003e: alteration of renal function (in the presence of conditions of altered renal hemodynamics) and acute renal injury, urogenital haemorrhages. \u003cb\u003e \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e \u003c\/b\u003e: procedural hemorrhages, hematomas. \u003cb\u003e \u003ci\u003eImmune system disorders\u003c\/i\u003e \u003c\/b\u003e: rarely: anaphylactic shock with related alterations in laboratory parameters and clinical manifestations. (*) Reye's syndrome (SdR) SdR initially manifests itself with vomiting (persistent or recurrent) and with other signs of encephalic distress of varying degrees: from listlessness, drowsiness or personality changes (irritability or aggressiveness) to disorientation, confusion or delirium up to convulsions or loss of consciousness. The variability of the clinical picture must be kept in mind: vomiting may also be absent or replaced by diarrhea. If these symptoms arise in the days immediately following a flu episode (or flu-like or chickenpox or another viral infection) during which acetylsalicylic acid or other medicines containing salicylates were administered, the doctor's attention must immediately be paid to the possibility of an SdR. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Website: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAcetylsalicylic acid\u003c\/u\u003e Toxicity from salicylates (a dosage exceeding 100 mg\/kg\/day for 2 consecutive days can induce toxicity) can be the consequence of chronic intake of excessive doses, or of acute overdose, potentially dangerous for life and which also includes accidental ingestion in children. \u003cu\u003eChronic salicylate intoxication\u003c\/u\u003e The poisoning\u003cb\u003e chronic\u003c\/b\u003e from salicylates can be insidious since the signs and symptoms are nonspecific. Mild chronic salicylate intoxication, or salicylism, generally occurs only following repeated use of large doses. Symptoms include dizziness, vertigo, tinnitus, deafness, sweating, nausea and vomiting, headache and confusion. These symptoms can be controlled by reducing the dosage. Tinnitus can occur at plasma concentrations between 150 and 300 micrograms\/ml, while more serious adverse events occur at concentrations above 300 micrograms\/ml. \u003cu\u003eAcute salicylate intoxication\u003c\/u\u003e The main feature of intoxication\u003cb\u003e acute\u003c\/b\u003e it is a serious alteration of the acid-base balance, which can vary with age and the severity of the intoxication; the most common presentation in children is metabolic acidosis. It is not possible to estimate the severity of poisoning from plasma concentrations alone; the absorption of acetylsalicylic acid may be delayed due to reduced gastric emptying, the formation of concretions in the stomach, or as a consequence of the ingestion of gastro-resistant preparations. The management of acetylsalicylic acid poisoning is determined by the extent, stage and clinical symptoms of the latter, and must be implemented according to conventional poisoning management techniques. The main measures to be taken consist in accelerating drug excretion and restoring electrolyte and acid-base metabolism. Due to the complex pathophysiological effects connected with salicylate poisoning, the signs and symptoms\/results of biochemical and instrumental investigations may include:\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: MILD TO MODERATE INTOXICATION - Therapeutic measures: Gastric lavage, repeated administration of activated charcoal, forced alkaline diuresis.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Tachypnoea, hyperventilation, respiratory alkalosis - Results of biochemical and instrumental investigations: Alkalemia, alkaluria. Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Sweating.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Nausea, vomiting, headache, dizziness.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: MODERATE TO SEVERE INTOXICATION - Therapeutic measures: Gastric lavage, repeated administration of activated charcoal, forced alkaline diuresis, hemodialysis in severe cases.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Respiratory alkalosis with compensatory metabolic acidosis, - Results of biochemical and instrumental investigations: Acidemia, aciduria. Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Hyperpyrexia - Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Respiratory: ranging from hyperventilation and non-cardiogenic pulmonary edema to respiratory arrest and asphyxia.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Cardiovascular: variable from arrhythmias and hypotension to cardiac arrest - Results of biochemical and instrumental investigations: E.g. alteration of blood pressure, alteration of ECG.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Loss of fluids and electrolytes: dehydration, from oliguria to renal failure - Results of biochemical and instrumental investigations: E.g. hypokalemia, hyperna–tremia, hyponatremia, impaired renal function. Therapeutic measures: Fluid and electrolyte management.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Alterations of glucose metabolism, ketosis - Results of biochemical and instrumental investigations: Hyperglycemia, hypoglycemia (especially in children) Increased levels of ketones.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Tinnitus, deafness\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Gastrointestinal: gastrointestinal bleeding, gastric ulcer.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Haematological: coagulopathy, iron deficiency anemia - Results of biochemical and instrumental investigations: E.g. prolonged PT, hypoprothrombinemia.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Neurological: toxic encephalopathy and CNS depression with manifestations ranging from lethargy and confusion to coma and convulsions. Cerebral edema.\u003c\/p\u003e\n\u003cp\u003eSigns and symptoms: Liver: liver damage - Results of biochemical and instrumental investigations: Increased levels of liver enzymes.\u003c\/p\u003e\n\u003cp\u003eAt high doses the following may also appear: Taste alterations. Skin rashes (acneiform, erythematous, scarlatiniform, eczematoid, desquamative, bullous, purpuric), itching. Others: Conjunctivitis, anorexia, reduced visual acuity, drowsiness. \u003cb\u003eRarely: aplastic anemia, agranulocytosis, disseminated intravascular coagulation, pancytopenia, leukopenia, thrombocytopenia, eosinopenia, purpura, eosinophilia associated with drug-induced hepatotoxicity, nephrotoxicity (allergic tubulointerstitial nephritis), hematuria (presence of blood in the urine).\u003c\/b\u003e Acute allergic reactions following the intake of acetylsalicyc acid can be treated, if necessary, with the administration of adrenaline, corticosteroids and an antihistamine. In case of overdose, contact a poison control center or the nearest hospital immediately. Acetylsalicylic acid is dialyzable. \u003cu\u003eAscorbic acid\u003c\/u\u003e Single cases of acute and chronic overdose of \u003cb\u003eascorbic acid\u003c\/b\u003e. Overdose of ascorbic acid may cause oxidative haemolysis in patients with glucose-6-phosphate dehydrogenase deficiency, disseminated intravascular coagulation and significantly elevated serum and urinary oxalate levels. Increased levels of oxalates have been shown to result in the formation of calcium oxalate deposits in dialysis patients. High doses of vitamin C may cause calcium oxalate deposits, calcium oxalate crystalluria in patients with a predisposition to crystal formation, tubulointerstitial nephropathy, and acute renal failure resulting from calcium oxalate crystals.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eFertility\u003c\/u\u003e The use of acetylsalicylic acid as well as any drug that inhibits the synthesis of prostaglandins and cyclooxygenase could interfere with fertility; female subjects and in particular women who have fertility problems or who are undergoing fertility investigations must be informed of this. \u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations was increased from less than 1% to approximately 1.5%. It has been estimated that the risk increases with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, acetylsalicylic acid should not be administered unless clearly necessary. If drugs containing acetylsalicylic acid are used by a woman trying to get pregnant, or during the first and second trimester of pregnancy, treatment should be as short as possible and the dose as low as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose: the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the unborn child, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, acetylsalicylic acid is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e ASPIRIN effervescent granules with vitamin C is contraindicated during breastfeeding (see section 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDue to the possible onset of headache or dizziness, this medicine may impair the ability to drive and use machinery.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131377090887,"sku":"004763153","price":7.6,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-aspirina-400mg-granulato-effervescente-con-vitamina-c-10-bustine-10g-farmacia-dottor-tili-1213791853.jpg?v=1767140651"},{"product_id":"viscoflu-10-flaconcini-5ml","title":"Viscoflu 10 vials 5ml","description":"\u003cp\u003eThe \u003cstrong\u003eViscoflu 10 vials 5ml\u003c\/strong\u003e is a disposable medical device designed for the treatment of respiratory tract diseases characterized by dense and viscous hypersecretion. This sterile hypertonic saline solution is particularly suitable for conditions such as \u003cstrong\u003eacute bronchitis\u003c\/strong\u003e, \u003cstrong\u003echronic bronchitis\u003c\/strong\u003e and its exacerbations, \u003cstrong\u003epulmonary emphysema\u003c\/strong\u003e, \u003cstrong\u003emucoviscidosis\u003c\/strong\u003e, \u003cstrong\u003ebronchiectasis\u003c\/strong\u003e, \u003cstrong\u003erhinosinusitis\u003c\/strong\u003e e \u003cstrong\u003emidsecretory otitis\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThanks to its formulation, Viscoflu can be used in different ways to ensure effective therapeutic action. It can be \u003cstrong\u003enebulized\u003c\/strong\u003e with aerosol devices for inhalation, allowing the solution to directly reach the bronchial district. Furthermore, it is possible to instill it directly to wash the nasal and ear cavities, or at an endobronchial level via permanent tubes or a bronchoscope.\u003c\/p\u003e\n\n\u003cp\u003eThe composition of Viscoflu includes \u003cstrong\u003eN-acetylcysteine\u003c\/strong\u003e (300 mg) e \u003cstrong\u003esodium chloride\u003c\/strong\u003e (150 mg), supported by excipients such as sodium hydroxide, sodium edetate and water for injections. This combination of ingredients is designed to thin secretions, facilitating their expulsion and improving breathing.\u003c\/p\u003e\n\n\u003cp\u003eThe product is packaged in practical 5 ml vials, with a total of 10 vials per pack, ensuring simple and hygienic use. Viscoflu is an ideal solution for those looking for an effective and targeted treatment for respiratory problems, supported by the quality and reliability of \u003cstrong\u003ePharma Line Srl\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Viscoflu 10 vials 5ml used? What is it for?\u003c\/h3\u003e\u003cp\u003eDisposable sterile hypertonic saline solution (medical device), indicated as an adjuvant in respiratory tract diseases with dense and viscous hypersecretion (acute and chronic bronchitis, pulmonary emphysema, mucoviscidosis, bronchiectasis, rhinosinusitis, midsecretory otitis); it can be nebulized by aerosol or used for nasal and ear washes.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Viscoflu 10 vials 5ml contain?\u003c\/h3\u003e\u003cp\u003eN-acetylcysteine ​​(300 mg), Sodium chloride (150 mg).\u003cbr\u003eExcipients: sodium hydroxide, sodium edetate, water for injections.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Viscoflu 10 vials 5ml?\u003c\/h3\u003e\u003cp\u003eSterile solution which can be:\u003cbr\u003e- Nebulized with aerosol devices to be inhaled in order to reach the bronchial district.\u003cbr\u003e- Instilled directly for washing the nasal and ear cavities.\u003cbr\u003e- Instilled endobronchially via permanent tubes, bronchoscope, etc.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Viscoflu 10 vials 5ml?\u003c\/h3\u003e\u003cp\u003ePack containing 10 vials of 5 ml\u003c\/p\u003e","brand":"Pharma Line","offers":[{"title":"Default Title","offer_id":51131378368839,"sku":"934038276","price":14.06,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/pharma-line-srl-viscoflu-10-flaconcini-5ml-farmacia-dottor-tili-1213791721.jpg?v=1767140890"},{"product_id":"argotone-0-12-spray-nasale","title":"Argotone 0-12 nasal spray","description":"\u003cp\u003eArgotone 0-12 nasal spray is a \u003cstrong\u003emedical device\u003c\/strong\u003e designed to provide relief to children with problems \u003cstrong\u003estuffy nose\u003c\/strong\u003e and symptoms from \u003cstrong\u003ecold\u003c\/strong\u003e. This nasal spray is particularly suitable for the treatment of \u003cstrong\u003einflammation\u003c\/strong\u003e of the nasal cavities, even of bacterial origin, thanks to its action \u003cstrong\u003efluidizing\u003c\/strong\u003e e \u003cstrong\u003edecongestant\u003c\/strong\u003e. Its unique formulation, enriched with \u003cstrong\u003ecolloidal silver\u003c\/strong\u003e, helps cleanse and fluidize nasal secretions, improving breathing and tubal ventilation.\u003c\/p\u003e\n\u003cp\u003eArgotone 0-12 is ideal for children, thanks to its delicate and free composition \u003cstrong\u003egluten\u003c\/strong\u003e e \u003cstrong\u003elactose\u003c\/strong\u003e. Ingredients like \u003cstrong\u003ecarboxymethyl-betaglucan\u003c\/strong\u003e and the \u003cstrong\u003epotassium sorbate\u003c\/strong\u003e they help keep the nasal cavities clean and free, while the strawberry aroma makes the application more pleasant for the little ones. This nasal spray is a precious ally during flu and flu conditions \u003cstrong\u003erhinitis\u003c\/strong\u003e, offering an action \u003cstrong\u003eantiseptic\u003c\/strong\u003e e \u003cstrong\u003eanti-inflammatory\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eProduced by \u003cstrong\u003eDompé Farmaceutici\u003c\/strong\u003e, Argotone 0-12 is available in a practical 20 ml bottle with nebulizer, easy to use and take with you.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Argotone 0-12 nasal spray used? What is it for?\u003c\/h3\u003e\u003cp\u003eNasal spray (medical device) based on colloidal silver, indicated for children with stuffy nose and cold symptoms, even in the presence of inflammation of the nasal cavities of bacterial origin; cleanses and fluidizes nasal secretions, improving breathing.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Argotone 0-12 nasal spray contain?\u003c\/h3\u003e\u003cp\u003eCarboxymethyl-betaglucan, colloidal silver, potassium sorbate, sorbic acid, sodium benzoate, sodium N-hydroxymethylglycinate, strawberry flavor, monobasic sodium phosphate, dibasic sodium phosphate, purified water.\u003c\/p\u003e\u003cp\u003eWithout \u003cstrong\u003egluten\u003c\/strong\u003e, without \u003cstrong\u003elactose\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Argotone 0-12 nasal spray?\u003c\/h3\u003e\u003cp\u003eTo prepare the bottle, remove the cap from the nebulizer pump and without placing it on any surface to avoid contamination, insert it into the bottle.\u003cbr\u003eCarry out 1-2 sprays 2-3 times a day up to a maximum of 7 days. The product can also be used in the presence of small lesions of the skin around the nostrils or of the nasal mucosa.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Argotone 0-12 nasal spray?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eDo not use in case of known hypersensitivity to the product components. In case of adverse reactions, discontinue use of the product and consult your doctor. Close the container tightly after use. Do not use the product after the expiry date indicated on the package. Do not use the product if the packaging or bottle is not intact. Keep out of reach of children. Avoid contact with eyes. Do not inject. Do not ingest. Do not dispose of the bottle in the environment after use. Avoid promiscuous use of the product.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Argotone 0-12 nasal spray stored?\u003c\/h3\u003e\u003cp\u003eStore at a temperature not exceeding 30°C and away from heat sources.\u003cbr\u003eValidity with intact packaging: 24 months.\u003cbr\u003ePost-opening validity: 90 days.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Argotone 0-12 nasal spray?\u003c\/h3\u003e\u003cp\u003e20 ml bottle with nebulizer.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":51131381907783,"sku":"981996008","price":12.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/dompe-farmaceutici-spa-argotone-0-12-spray-nasale-farmacia-dottor-tili-1213791711.jpg?v=1767144191"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/collections\/Frame_53_33.svg?v=1784273774","url":"https:\/\/www.dottortili.com\/en\/collections\/medicines-and-sprays-for-colds-and-stuffed-noses.oembed","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}